annual report saw substantial progress accelerate new product sales growth strengthen pharmaceuticals vaccines consumer healthcare businessesb gsk annual report strategic report governance remuneration financial statements investor information overview made substantial progress accelerate new product sales growth integrate new businesses vaccines consumer healthcare restructure global pharmaceuticals business progress means group well positioned return core earnings growth sir andrew witty chief executive officer performance summary bn bn bn bn group turnover total operating profit core operating profit cash dividends paid cerup cer cera cerdown proformaa cer proformaa bn p p new product salesb total earnings per share core earnings per share markets operating primarily cer primarily new commercial model reflecting impact reflecting shortterm dilution transaction gains novartis transactiona st potential new medicines potential file estimated internal access medicine vaccines profiled rd assets regulators rate return rd index event potential firstinclassc footnotes use number adjusted measures report performance business described include core results cer growth rates proforma cer growth rates reconciliation total results core results set b new products defined pharmaceuticals relvarbreo ellipta anoro ellipta incruse ellipta arnuity ellipta eperzantanzeum nucala tivicay triumeq vaccines menveo bexsero shingrix yet approved c gsk rd event november front cover story innovation heart katherine pictured left one team scientists continuing develop nucala almost years focused rd including nine distinct patient studies nucala monoclonal antibody stops il binding receptor surface eosinophils people asthma eosinophils type white blood cell cause inflammation lungs making difficult breathe increasing risk asthma attacks european us regulatory approvals nucala firstinclass approved targeted biologic therapy people eosinophilicdriven severe asthma consolidates gsks leading global position respiratory medicine katherine gsk senior scientist stevenage ukgsk annual report strategic report governance remuneration financial statements investor information contents gsk mission strategic report improve quality human investor proposition business chairmans statement life enabling people ceos statement global marketplace feel better live longer business model strategic priorities performed approach risk pharmaceuticals vaccines consumer healthcare responsible business group financial review governance remuneration board corporate executive team board governance corporate governance framework committee reports audit risk nominations corporate responsibility remuneration report chairmans annual statement annual report remuneration remuneration policy summary find wwwgskcom financial statements directors statement responsibilities independent auditors report financial statements notes financial statements financial statements glaxosmithkline plc prepared uk gaap cautionary statement regarding forwardlooking statements groups reports filed furnished us securities exchange commission sec including document investor information written information released oral statements made public future behalf group may quarterly trend contain forwardlooking statements forwardlooking statements give groups current expectations forecasts future events investor identify statements fact relate strictly historical current five year record facts use words anticipate estimate expect intend project plan believe words product development pipeline terms similar meaning connection discussion future operating financial performance particular product competition include statements relating future actions prospective products product approvals future performance results current anticipated products sales efforts expenses outcome contingencies legal proceedings intellectual property financial results accordance legal regulatory obligations including uk listing risk factors rules disclosure transparency rules financial conduct authority group undertakes obligation update forwardlooking statements whether result new information future events otherwise share capital share price reader however consult additional disclosures group may make documents dividends publishes andor files sec readers wherever located take note disclosures accordingly assurance given particular expectation met shareholders cautioned place financial calendar undue reliance forwardlooking statements annual general meeting forwardlooking statements subject assumptions inherent risks uncertainties many relate factors tax information shareholders beyond groups control precise estimate group cautions investors number important factors shareholder services including document could cause actual results differ materially expressed implied forwardlooking statement factors include limited discussed risk factors pages contacts annual report forwardlooking statements made behalf group speak us law regulation date made based upon knowledge information available directors date group companies annual report glossary terms expectations targets regarding future performance also read together assumptions related outlook inside back cover number adjusted measures used report performance business measures defined reconciliation core results total results set gsk annual report strategic report governance remuneration financial statements investor information investor proposition gsk scienceled global healthcare company aims deliver growth improving returns shareholders development innovative pharmaceutical vaccine consumer healthcare products three worldleading businesses broad range pharmaceuticals vaccines consumer healthcare growth drivers global presence access bn bn bn increasing demand healthcare turnover turnover turnover leadership key comprehensive one world 's therapeutic areas vaccines portfolio leading global consumer including respiratory industry healthcare companies hiv retail sales strong rd innovation around new potential medicines rd underpins vaccines pipeline businesses vaccines respiratory rare diseases profiled rd eventb diseases research focused six core therapy areas believe potentially firstinclass immuno hivinfectious oncology inflammation diseases potential file assets b gsk rd event november bn bn efficient global operating model adjusted free cash flow excluding incremental annual cost focused costs funded divestmentsc savings delivered optimising operations bn bn restructuring investments net proceeds disposals annual cost savings modernisation generated expected end improve profitability bn efficiency reduction net debt c excluding legal payments also noncore billion annual savings restructuring integration costs initial achieved december tax payments sale oncology businessgsk annual report strategic report governance remuneration financial statements investor information bn earnings core eps percentage presence annual revenues growth expected markets expected new reach double digits pharmaceutical cer vaccine product sales bn sales achieved mediumterm outlook group grow core eps midtohigh single digitsg cagr five investor event may years cerh gsk outlined series expectations performance five year period see inside back cover returns ordinary dividend p per share special dividend estimated internal partner rate return organisations around world p per share rd investment including academic institutions billion novartis publicprivate partnerships transaction proceeds pharmaceutical biotechnology companies expect pay ordinary dividend p per share time supply customer trust key new pharmaceutical gsk respiratory product introduction vaccines usf launches across markets e legacy gsk brands f customer trust rankings demonstrated unique visitors gsk gsk annual customer value survey hcp digital portals customers g investor event may gsk consumer healthcare outlined series expectations performance five year period supply average service see inside back cover levels otif h expected compound annual growth rate time full e cagr using base year see inside back cover gsk annual report strategic report governance remuneration financial statements investor information business focused research development innovative pharmaceutical medicines vaccines consumer healthcare products businesses strategy pharmaceuticals vaccines strategy designed generate consumer healthcare businesses sustainable sales earnings growth generated turnover billion improved returns shareholders three strategic priorities business benefits gsk 's global research development commercial infrastructure integrated supply grow balanced business networks innovative rd significant product portfolio capable rd innovation underpins global presence delivering sustainable sales growth businesses partner see business model companies academic research develop deliver organisations around world r ead businesses opposite high quality innovative products enabling us increase pages offer valuable improvements understanding new areas science treatment patients consumers global presence share risk development healthcare providers significant global presence deep portfolio innovation employees simplify way operate focused across six core areas markets network manufacturing reduce complexity increase efficiency scientific research development sites large rd centres uk free resources reinvest hiv infectious diseases oncology us belgium china elsewhere business return immunoinflammation vaccines shareholders wherever see respiratory rare diseases attractive returns profiled around new potential balanced geographies medicines vaccines turnover region responsible business believe potential responsible business central firstinclass means may offer strategy deliver success benefits beyond current standards important achieve care cases could radically work underpinned values transform patients treated patient focus integrity respect people transparency read rd pages read strategic priorities us approach responsible europe business pages international potential file assets assets profiled balanced businesses expect group turnover phase iii starts phase ii starts estimated internal rate return rd investment pharmaceuticals vaccines bn consumer healthcare core rd expenditure core rd expenditure allocation bn pharmaceuticals vaccines consumer healthcare gsk annual report strategic report governance remuneration financial statements investor information pharmaceuticals vaccines consumer healthcare pharmaceuticals business develops vaccines business one consumer healthcare business makes medicines treat broad largest world developing develops markets products range acute chronic diseases producing distributing million wellness oral health nutrition leading global positions vaccines every day people across skin health portfolio respiratory disease hiv world broad portfolio worlds trusted best portfolio innovative established paediatric adolescent adult selling brands include sensodyne medicines travel vaccines voltaren horlicks panadol read pages read pages read pages bn bn bn total turnover total turnover total turnover group turnover group turnover group turnover sales therapy area sales category sales category respiratory rotavirus wellness cardiovascular metabolic urology pneumococcal oral health immunoinflammation flu nutrition oncology meningitis skin health pharmaceuticals tdap established products hepatitis hiv viiv healthcare representing sales prior disposal tetanus diphtheria acellular pertussis oncology business unit novartis march gsk annual report strategic report governance remuneration financial statements investor information strategic report governance remuneration financial statements investor information chairmans statement group made good progress delivering strategy outlook set shareholders may group declared pleased report group highlights ordinary dividend pence per share demonstrated strength multiple areas special dividend pence governance review work overseen audit risk committee current level annual dividend remuneration committee pence exceeds cash flows p p operated accordance binding businesses however board remuneration policy approved said expects maintain level shareholders remuneration payment p ordinary dividend special report found important years change dividend p period longterm impact cash flow pleased welcome two decline seretideadvair new independent nonexecutive directors become clearer benefit board vindi banga dr jesse first letter shareholders cash generation growth recently goodman senior independent pleased report group made launched products expansion director designate scientific good progress delivering strategy vaccines consumer businesses medical expert respectively pleased outlook set shareholders reduced restructuring expenditure contributions made may already boards deliberations good progress made clear element groups strategy development companys operating sir christopher gent retired deal decline sales model rd pipeline board chairman may seretideadvair best important longterm health years helm gsk stood part last decade biggest company board encouraged time tom de swaan source profits group level innovation companys jing ulrich longserving non considerable challenge however pipeline novel assets development executive directors dr stephanie burns investments made new across six core therapy areas sir deryck maughan dr daniel pharmaceutical vaccine products podolsky retire planned priority board manage seeing effective transition agm may completing succession executive management groups portfolio nine years service hans wijers also nearly years decided seek reelection agm also important group secure ceo sir andrew indicated year greatly appreciated sales benefits cost synergies board intention retire dedication experience wealth resulting recent novartis company early board knowledge insights brought transaction successfully agreed retire march board deliberations years completed board closely culmination years service board monitoring integration new service leadership gsk businesses acquired vaccines industry thank andrew closing behalf board would consumer healthcare clear formally tremendous dedication like thank sir andrew executive management made substantial contribution next year meantime team commitment progress board start formal search performance successor consider internal external candidates role philip hampton chairmangsk annual report strategic report governance remuneration financial statements investor information strategic report governance remuneration financial statements investor information ceos statement progress made strongly positions group deliver medium term outlook set investors may last year return core earnings growth last two years launched restructuring modernising highlights number new pharmaceutical vaccine business products sales group ahead schedule reached billion performance integration restructuring programmes driven continued excellent uptake realised billion bn hiv launches tivicay triumeq incremental annual cost savings growing momentum new respiratory well track deliver billion portfolio relvarbreo anoro incruse savings end group turnover significant contributions newly modernising business cer cer proforma acquired meningitis vaccines bexsero making significant changes menveo commercial model already bn new product sales changed compensate sales offsetting declines seretideadvair representatives beginning sales around january stopped paying external new product sales peak doctors speak products industry firsts time also saw strong performance investing significantly bn consumer healthcare business medical expertise developing new sales proforma digital capabilities improve driven number key brands including interactions physicians incremental annual cost savings sensodyne allergy treatment flonase integration restructuring switched prescription status outlook overthecounter us progress made strongly positions group deliver strong rd innovation mediumterm outlook set marked progress rd organisation continued deliver investors may last year return strategy creating balanced group significant innovation group core earnings growth three world leading business key milestone approval us pharmaceuticals vaccines consumer europe nucala first biologic finally year ever would healthcare clear aim deliver growth treatment severe asthma also like thank employees improving returns shareholders successfully gained approval malaria extraordinary energy passion tenacity vaccine first vaccine parasite year completed major part transaction novartis made good since group received progress integrate new businesses approvals new molecular entities consumer healthcare vaccines nmes november profiled restructure pharmaceuticals business around new potential medicines time sales new vaccines believe could products dramatically accelerated firstinclass trading performance next two years expect see sir andrew witty group sales rose proforma significant development milestones chief executive officer billion despite trading conditions number assets including filings remaining challenging number vaccine shingles shingrix markets core earnings per share sirukumab rheumatoid arthritis pence cer ahead triple combination therapy chronic guidance year total earnings per obstructive pulmonary disease copd share pence rise addition expect continued progress reflecting significant gains mid late stage pipeline core transaction therapy areas respiratory immuno inflammation hiv vaccines oncology footnote bn savings achieved december bn come next two years gsk annual report strategic report governance remuneration financial statements investor information global marketplace global healthcare marketplace experiencing significant change uneven economic recovery farreaching global trends evolving commercial environment particularly pricing transform sector global healthcare market developed economies ageing global economy remained fragile populations improvements macroeconomic overall growth falling medical technology adding social trends reflecting slower pressure healthcare budgets growth certain emerging economies changing societal attitudes also oilexporting countries shaping healthcare environment despite unsettled economic people taking increasingly population growth background global pharmaceuticals active role managing ageing populations market continued grow global sales health creating demand lifestyle changes billion period january healthcare products september billion finally heightened geopolitical nine months uncertainty several key regions longterm economic growth north america remained largest likely impact certain healthcare markets emerging markets pharmaceuticals market beyond share global sales europe represented gsk 's group three world leading asia pacific relatively static businesses pharmaceuticals vaccines rapid scientific emerging markets fell consumer healthcare global technological advances japan presence means well positioned respond opportunities see global vaccines market grew around billion expected strategic response opposite political instability continue growing around per year pricing market access fragmentation represent around billion b pressure public debate industrys approach pricing continued consumer healthcare markets increase key markets increased expectations gsk operates estimated worth particularly us alongside transparency billion projected many healthcare systems focusing high standards grow annually next assess value medicines businesses five yearsc formal health technology assessments evaluated implications htas continuing grow importance business possible exit japan us new assessment climate change united kingdom european processes piloted resource depletion union view advantages established systems europe continue uk remaining part eu present challenges delay launch group would continue easy restrict patient populations however access significant economic bloc successful market access negotiations global competition able operate within established innovative valueadding products talent harmonised regulatory approval system continued countries continue benefit eu advocacy demonstrating continued willingness international trade discussions however pay treatments meet genuine unmet uk leaving eu would create patient needs saw aggressive formulary uncertainty add complexity wide price negotiations exclusions range business activities highlycharged public debate competing products shortterm disruption likely plans pricing increased influence value place mitigate effects assessments likely continue public commentary issue currently believe would beyond continue create able capture complexities pricing material adverse impact uncertainty industry increased structures confidential discounts groups results financial position collaboration different stakeholders creating lack transparency many key deliver mutually acceptable stakeholders including policy makers global societal trends pricing access solutions presidential election candidates payers impacting healthcare providers patients called pricing us emerging markets longterm economic reform expect pricing growth increasing expectations healthcare healthcare landscape us continues focus policy debates us provision changing diets lifestyles see substantial change strong focus beyond increasing demand healthcare continuing expand healthcare coverage products across life stages especially controlling costs areas high growth footnotes treat chronic conditions including time us government international monetary fund world economic respiratory cardiovascular disease implementing policies shift payment outlook adjusting lower commodity prices october demand expected grow significantly away traditional feeforservice faster markets coming arrangements towards approaches b e ov l u e p jh ua nr em w orld preview outlook years mature economies intended increase competition c internal forecasts based nicholas hall create funding challenges incentivising efficiency quality euromonitorgsk annual report strategic report governance remuneration financial statements investor information opportunities challenges healthcare sector rising living standards ageing populations leading growing demand healthcare particularly emerging markets changing lifestyles leading changing disease burdens global scientific advances create opportunity healthcare innovation marketplace payer concern cost value leading pressure pricing demand differentiated products expectation high standards behaviour healthcare companies strategic response three worldleading businesses global sustainable pricing leading responsible created group three world aim improve returns rd business approach leading businesses pharmaceuticals innovation striking balance responsible business vaccines consumer healthcare price volume generation fundamental gsk strategic presence markets priorities us business actively working payers provides access global demand important financial results policymakers physicians others healthcare aims deliver growth deliver led industry solutions address concerns improving returns shareholders access medicines data transparency cost healthcare realising evolving commercial model read pages maximising value patients ensure patients ' interests come first providers innovators creating innovative products centre discussion read rd innovation underpins businesses focused six core therapy read areas scientific understanding help deliver significant medical advances patients read pages gsk annual report strategic report governance remuneration financial statements investor information global marketplace continued regulatory environment provisions introduced growing population prescription medicines vaccines period time depending highly regulated ensure patients country agreement ratified users access safe effective us congress medicines us food eu also concluded bilateral bn people drug administration fda approves new agreements markets region medicines approved novel vietnam medicines highest improve regulatory environment number approvals across enhance patient access key medicines pharmaceutical industry since vaccines number trade bn year olds healthcare landscape continues agreements negotiation undergo substantial change much transpacific trade investment stronger focus improving quality partnership eujapan fta controlling costs fda responding challenges working markets availability intellectual bn people outside industry advance alternative approaches property rights particularly patents data us europe help reduce time cost protection may limited developing new medicines particularly difficult enforce developed world generics include amongst others markets example india brazil use biomarkers real world data argentina implemented new babies considering practices restrict europe european medicines availability patents addition agency ema regulates new medicines countries considering widespread issued positive opinions use compulsory licensing medicines containing new active substances vaccines biological products europe ema continued efforts help currently face degree generic given significant public funding accelerate patient access valuable competition largely healthcare european countries new medicines included progressing products research required pressure government budgets continued adaptive pathways pilot proposals difficult product complex create challenges industry launch new scheme boost innovation quality dependent technical market grew primarily due called prime priority medicines manufacturing processes compared use new highpriced medicines small molecule medicines japan new medicines hepatitis c putting ever greater constraints received approval along first intellectual property protections healthcare budgets inequality access two regenerative cell based medicine available consumer healthcare medicines european products one developed products importance countries within patient populations jcr pharmaceuticals partner effectiveness different consumer well affordability remain significant gsk six products obtained first healthcare products also covered issues despite much debate issue designations sakigake fasttrack national regulation regarding testing medicines affordability particular review system introduced approval manufacturing labelling affordability member states lower promote early development marketing advertising products gdp practical challenges remain regulatory application japan ahead strong reliance brand loyalty significant reform medicines pricing rest world trade mark protection create protect access value time especially emerging intellectual property patent japan markets protection developments strong focus pricing ensure reasonable return competition japan government implementing investment researchbased healthcare gsk operates highly competitive new approach mitigate fiscal burden companies rely protection dynamic marketplace saw rapid associated medicines annual intellectual property patents consolidation within sector response sales billion yen regulatory data exclusivity rights significant market pressure exceeded significantly sales forecast industry mergers acquisitions agreed government launch patent expiry early loss patent pharma medical biotech sector hit lead availability generic emerging markets new record transactions version product often governments across emerging market reaching billion globally billion cheaper generic manufacturer regions continue seek ways improve deals sector typically incur significant rd costs access healthcare us alonee consumer healthcare developed markets generics rapidly time manage healthcare expenditure market also remains highly competitive capture large share market market several high profile deals countries dependent oil may look erosion may less emerging markets limit spending health result agreement reached significant decrease oil prices transpacific partnership giving countries diverse ghana china footnotes inter alia five years data exclusivity india looking expand mergermarket global regional population covered governmentfunded nonbiologic pharmaceutical products biologics additional health schemes increases e mergermarket global regional three years equivalent protection opportunities high volume tenders also impacts pricinggsk annual report strategic report governance remuneration financial statements investor information business model success depends ability research develop innovative healthcare products make accessible many people possible deliver mission must align business model designed well lead profitable inputs behind strategic priorities deliver range outputs patients sustainable performance turn harness primary inputs set shareholders society addition allows us generate value returns strengthen ability make products direct benefits patients consumers shareholders enables us satisfy unmet needs offer cost effective shareholders successful business reinvest business healthcare options customers help build strong societies make increase access vaccines medicines direct indirect contributions consumer healthcare products countries operates tax employment charitable support inputs businesses operations outputs unmet medical needs pharmaceuticals rd healthcare benefits discovering patients developing innovative consumers scientific healthcare products technological expertise sustainable sales growth macro socioeconomic vaccines manufacturing environment making distributing returns shareholders quality products financial resources around world benefits society including tax collaborations consumer healthcare commercialisation employment partnerships distribution charitable support improving access people products profits cashflow culture generation reinvestment gsk annual report strategic report governance remuneration financial statements investor information strategic priorities strategy designed generate improved sales earnings growth sustainable returns shareholders benefits patients consumers strategic strategic priorities progress novartis transaction completed grow significantly strengthening vaccines consumer healthcare businesses strong performance new balanced business pharmaceutical vaccine products create balanced business billion sales product portfolio capable delivering sustainable sales earnings growth successful otc launch flonase centred three businesses allergy relief us pharmaceuticals vaccines consumer healthcare read pages launch us nucala eosinophilic deliver asthma approval europe positive phase iii data shingrix products value candidate shingles vaccine research develop high quality filed first gene therapy rare disease innovative products offer valuable adascid europe improvements treatment patients consumers healthcare providers read pages integration restructuring cost savings simplify track pharmaceuticals consumer operating model healthcare markets live gsks global erp transform operate reduce system since first 'go live ' august complexity increase efficiency free consumer healthcare supply achieved average resources reinvest elsewhere service levels otif time full business return shareholders wherever see attractive time supply key new returns pharmaceutical product introduction launches across markets read pages legacy gsk brands responsible malaria candidate vaccine rtss business received positive opinion european regulators responsible business central continued transform commercial strategy deliver model drive growth build trust success important reshaping relationships achieve healthcare professionals implementing new sales force ensure values embedded compensation approach culture decision making help us better meet expectations society read pages gsk annual report strategic report governance remuneration financial statements investor information key challenges performance future priorities continued pricing pressure deliver earnings guidance bn us europe core eps percentage growth reach double digits cer changes us market dynamics impacting speed uptake new group turnover drive sales new products meet product launches target billion annual turnover p slowing emerging market economies group core eps midtohigh single digit cagr growth cer basis read global five year period marketplace pages core earnings per share investor event may gsk reconciliation total results core outlined series expectations results set performance five year period see inside back cover ensure continued focus rd file approval key products including delivery ongoing restructuring shingrix benlysta subcutaneous programme including site rationalisation sirukumab closed triple eu integration novartis ' vaccines new potential medicines vaccines pipeline pipeline profiled rd event deliver phase iii starts phase ii starts summit study show statistically gsk rd event november significant mortality benefit relvar complete integration bms pipeline breo ellipta copd patients hiv medicines estimated internal rate return rd investment complexity integrating deliver incremental annual savings employees consumer healthcare bn billion billion vaccines businesses bringing total billion annual savings end rolling new systems eg erp incremental annual cost savings scale across many markets continue streamline product portfolio delivered reduce complexity formulations transfer marketed oncology products novartis packaging formats embed common processes platforms read approach risk integrate reporting systems following pages global reduction number pharmaceuticals novartis transaction marketplace pages pack variants baseline billion savings achieved december reducing value chain carbon emissions support delivery malaria demand products high vaccine notforprofit price carbon footprint ventolin key partnerships increasing dow jones sustainability index score continue enhance governance strengthening valuesbased culture compliance quality encouraging reporting st proactive risk management concerns qualityled culture change programme transform led access medicine continue improve leadership commercial model index since effectiveness quality talent gsk annual report strategic report governance remuneration financial statements investor information performed measure performance number key performance indicators remuneration executives based many group turnover bn performed turnover reported basis proforma proforma basis higher sales hiv vaccines consumer healthcare growth cer partly offset lower global pharmaceutical sales reported proforma excluding divestments completed new pharmaceutical bn vaccine product performance definition new products identified investor event expected deliver least billion sales per annum growth growth cer basis target cer expected reached two years earlier performed sales new products billion represented pharmaceutical vaccines turnover sdnedivid sdnedivid sdnedivid pharmaceuticals turnover bn performed turnover reported basis proforma growth hiv products primarily tivicay triumeq offset growth cer continued decline seretideadvair sales due price pressure reported increased generic competition proforma excluding divestments completed vaccines turnover bn consumer healthcare bn turnover performed turnover reported performed basis proforma turnover grew reported business benefited basis proforma newly acquired meningitis portfolio growth cer business benefited sales growth cer proforma growth driven newly acquired products strong rotarix flulaval reported particularly voltaren otrivin reported boostrix sales us proforma theraflu proforma growth proforma bexsero sales europe predominantly driven oral us health wellness categories excluding divestments completed cash returned bn shareholders performed gsk returned billion shareholders dividends returned billion shareholders billion dividends billion share repurchasesgsk annual report strategic report governance remuneration financial statements investor information total operating bn core operating bn profit margin profit margina performed definition total operating profit core results exclude number items billion excluding currency total results full definition core effects total operating margin growth results found growth cer increased percentage points reconciliation total results cer reported primarily reflecting core results provided higher profits disposal performed proforma oncology business assets partly offset increase core operating profit billion excluding currency effects contingent consideration liability core operating margin declined payable relation viiv healthcare result higher sales outlook percentage points primarily g r b ui sav ii nc c ea sy sta mn fd io x l l aor fi wu tem rn e g thq e h nen ocd vh ah ri ng tigh se e sr r imefl pe ac ct ti n og f ta h e n op ar rc tie sn tt ra ag ne ap co ti ot n transaction excluding divestments completed total earnings per share p core earnings per sharea p performed definition total earnings per share core results exclude number items p compared p total results full definition core primarily reflecting increased results found business asset disposal gains growth reconciliation total results growth partly offset increase core results provided contingent consideration liability cer cer performed payable relation viiv healthcare core eps decreased primarily result higher sales outlook reflecting shortterm dilution tivicay triumeq novartis transaction impact continuing transition pharmaceuticals business particularly respiratory excluding divestments completed free cash flowa bn net debt bn definition definition calculations free cash flow net debt comprises bank loans adjusted free cash flow described overdrafts obligations finance reconciliations leases commercial paper provided growth bonds issued gsk less cash performed na liquid investments f exre ce lu c da ins gh lo eu gt afl l sw et w tlea ms e n ts pb ail yli mon e n b tsu h tho ew n w ete p p roe cr efo er dm e frd om disposal restructuring costs initial tax oncology business payments oncology disposal assets enabled us accelerate free cash flow billion restructuring integration compared billion programmes return billion decline reflected initial impact cash shareholders dividends novartis transaction lower reduce net debt billion operating profits free cash flow excluding payments legal costs restructuring tax oncology disposal footnote w e use number adjusted measures report performance business described include core results used management planning reporting purposes may directly comparable similarly described measures used companies gsk annual report strategic report governance remuneration financial statements investor information approach risk rigorous consistent risk management processes systems help us assure integrity business operations effective risk management key principal risk sustainable business success established risk management framework definition coupled internal controls helps us maintain focus managing principal risks affecting business principal risks listed table opposite believe could cause patient safety results differ materially expected failure appropriately collect review follow report adverse events historical results also risks potential sources act relevant findings timely manner may significantly impact strategic priorities grow deliver simplify corporate executive team review intellectual property principal risks annually fourth quarter failure appropriately secure protect intellectual property rights assure appropriateness following year agreed consolidate reporting descriptions number principal risks align product quality managed across business failure comply current good manufacturing practices cgmp consolidated list reported opposite inadequate controls governance quality supply chain covering within table summarised supplier standards manufacturing distribution products define risk assessment change risk assessment based external financial control reporting environment operate failure comply current tax law incurring significant losses due business operations impact treasury activities failure report accurate financial information compliance internal controls severity risk accounting standards applicable legislation failure maintain adequate period risk exposure continually governance oversight thirdparty relationships reviewed senior management therefore subject change result internal external factors future events antibribery corruption abac otherwise full details definition failure prevent gsk employees third parties complying abac context potential impact mitigating principles standards well applicable legislation activities see pages progress established global risk management office help drive best practices commercialisation standards across business remit failure execute business strategies manage competitive opportunities includes standardising methodology threats effectively accordance letter spirit legal industry managing principal risks identifying company requirements significant emerging risks business continued evolve antibribery corruption team enhanced research practices resourcing focus remit failure adequately conduct ethical sound preclinical clinical research includes third party oversight tpo also addition failure engage scientific activities consistent letter commissioned external assessors evaluate spirit law industry groups requirements highest risk suppliers distributors building efforts enhanced environment health safety sustainability ehss standardised approach regional failure manage ehss risks line objectives policies reviews internal controls relevant laws regulations pharmaceuticals business first assessed using new approach annual reviews enable us confirm information protection company standards local laws failure protect maintain access critical sensitive computer systems regulations understood adhered information take place businesses viability statement sets assessment prospects group crisis continuity management next three years made inability recover sustain critical operations including key supply chains reference amongst things following disruption respond crisis incident timely manner principal risks managedgsk annual report strategic report governance remuneration financial statements investor information manage risk assessment change risk increased risk change risk decreased risk chief medical officer leads large global safety pharmacovigilance team maintains global policies guide employees risk remains paramount focus us mature rigorous controls place manage global patents group continually analyses changes patent laws regulations ensures incorporated processes continued focus ensuring robust effective processes place meant assessment risk changed chief product quality officer accountable quality management system including implementation associated policies leading global network quality councils view risk continued escalate due increased regulations sanctions across companies sector response significantly invested reinforced strengthened quality culture organisation chief financial officer group financial controller oversee internal controls relating financial information reporting tax treasury introduced additional resources monitoring ensure robust financial controls maintained effectively managing risks initial phase integrating former novartis businesses control reporting framework implemented ongoing transformation upgrade financial systems processes continued additional risk mitigation introduced amending programme timelines ongoing system upgrades extensive global abac programme policy procedure includes training employees whilst risk remained significant gsk continuous improvements compliance training programmes well review reduction presence number 'high risk ' markets manage bribery corruption risk exposure presented global business operations single global standard promotional marketing activities gsk products employees including third parties acting behalf must comply introduced changes engage healthcare providers implemented new sales force incentive model globally believe decreased level risk business also structured provide access fast growing demand healthcare balanced exposure future changes industry environment governance systems controls oversee clinical trial research use biological samples data integrity key systems continued focus regulatory inspections place established quality assurance programmes ensuring continued adherence regulatory requirements global ehss standards support clear policies employees trained believe overall management ehss risk remains effective gsk reducing risk employee harm traditional enterprise disruption categories process safety high risk chemical manufacturing facilities chief information security officer oversees global information policy programme regularly assesses changes monitoring internal systems external environment believe risk increased major companies year including due prominence external threats internally continue invest improving capabilities technological solutions counter threat crisis continuity management ccm governance board supported team ccm experts ensure critical business operations plans place potential disruptions business continue risk established governance boards within businesses continue learn plan activations enabling us continue drive improvements programme gsk annual report strategic report governance remuneration financial statements investor information pharmaceuticalsgsk annual report strategic report governance remuneration financial statements investor information pharmaceuticals business discovers develops commercialises medicines treat broad range worlds common acute chronic diseases numbers c number employeesa bn core rd spend c billion packs medicine produced around new potential medicines vaccines pipeline profiled rd eventb including gms rd dedicated support functions staff b gsk rd event november gsk annual report strategic report governance remuneration financial statements investor information pharmaceuticals pharmaceuticals portfolio performance made innovative established strengthened summary medicines hold leading global respiratory portfolio positions respiratory disease hiv underpinned innovative researching nextgeneration bn pharmaceuticals rd organisation drives discovery development treatments potential several core areas research hiv alter fundamental turnover infectious diseases oncology immunoinflammation respiratory course disease rare diseases respiratory extensive portfolio focused successfully reported sales growth cer respiratory products industry transitioning new portfolio seretideadvair remains worlds best accelerating growth products selling branded respiratory product expectation proforma sales growth cer continue lead scientific innovation nine products expected account area working ensure patients approximately sales receive effective therapy possible respiratory compared four bn convenient devices targeting research portfolio past three years potential nextgeneration treatments core operating profit significantly broadened strengthened respiratory disease beyond current respiratory portfolio launch approach inhaled medicines relvarbreo ellipta anoro ellipta launched nucala mepolizumab gsk 's incruse ellipta arnuity ellipta first injectable biologic severe asthma multiple potential medicines targeting medicines administered underlying causes respiratory disease using easy use patented dry also development powder inhaler ellipta strategy action nine products expected account approximately sales bn respiratory compared four tivicay triumeq new pharmaceutical products sales make overall pharmaceutical sales turnovergsk annual report strategic report governance remuneration financial statements investor information hiv also strong presence hiv advancing treatments benefit people global hiv business managed living hiv viiv healthcare company majority owned gsk pfizer shionogi tivicay prescribed access hiv treatments shareholders one leading people living hiv major focus reflected hiv companies world since launched august regulatory strategy taking triumeq dolutegravirbased regimen strong recent performance since august seeking regulatory approval hiv business principally led products many countries tivicay dolutegravir innovative strong sales momentum totalling possible well facilitating integrase strand transfer inhibitor bn positively supported approval process generic versions singlepill treatment triumeq pharmaceuticals business dolutegravir countries combination dolutegravir abacavir us many countries need pressing lamivudine performance overtaken previously leading third agents saw first filing generic significant hiv rd pipeline building success japan dolutegravir aurobindo supported exploring new therapies patients first country viiv healthcare viiv healthcares partnership could potentially enable longterm established leadership clinton health access initiative hiv control infrequent dosing position countrys largest viiv healthcare also signed early viiv healthcare acquired hiv company innovative manufacturing partnership bristolmyers squibbs late stage hiv continue evolve way desano pharmaceuticals enable rd assets portfolio preclinical engage healthcare professionals competitive supply dolutegravir discovery stage hiv research assets tivicay triumeq launches china number developing acquisitions expected strengthen also demonstrated digital countries end tivicay group 's leadership hiv provide communication enhance available countries us new opportunities growth interactions triumeq specialty established products rapid digital launch campaign addition respiratory hiv saw open click sell several innovative rates significantly pharmaceutical products including industry average benlysta treatment lupus digital focus positively tivicay prescribed disease tanzeumeperzan commented customers remains people living hiv type diabetes key priority since launched august established products portfolio includes mature medicines areas antiinfectives allergy central nervous system dermatology respiratory urology products important part emerging markets business sell volume second largest competitor sell volume pharmaceutical new potential products emerging medicines vaccines gsk potential markets second pipeline profiled rd event file assets largest competitor regulators believe potentially firstinclass gsk rd event november gsk annual report strategic report governance remuneration financial statements investor information pharmaceuticals continued grow deliver new pharmaceutical product sales performance summary pharmaceuticals pipeline progress new products made increasing continued progress offset contribution particularly respiratory pharmaceutical rd pipeline hiv restructuring pharmaceuticals believe offers significant opportunity drive decline seretideadvair cost base also continued longterm performance group million reported pharmaceutical sales late stage pipeline delivered new million cer primarily firstinclass medicine reflecting disposal marketed approval us europe oncology products adjusting nucala antiil monoclonal antibody disposal proforma turnover declined treatment severe asthma reflecting decline respiratory sales eosinophilic inflammation indication decline sales established breo ellipta also expanded products largely offset us approval treatment adults growth new pharmaceutical products asthma sales million rare diseases filed european increase million strong approval strimvelis gene therapy performance hiv products triumeq treat patients adenosine deaminase tivicay together acceleration severe combined immunodeficiency sales new respiratory products helped syndrome adascid approved deliver performance first corrective gene therapy new pharmaceutical product sales approved anywhere world offset decline seretideadvair immunoinflammation positive results million global seretideadvair achieved phase iii studies sales billion approximately investigating subcutaneous benlysta peak lupus sirukumab rheumatoid made significant changes arthritis regulatory filings expected modernise commercial model medicines stopped paying healthcare received data summit professionals hcps speak study understand mortality products instead recruited morbidity copd summit number inhouse medical experts achieve statistical significance addition increased digital primary endpoint data generated communications hcps study inform overall profile webinars click chat facilities medicine expected submitted enabling hcps talk real time authorities label updates gsk medical experts reactions customers positive believe changes offer gsk source competitive advantage read group financial review pages gsk annual report strategic report governance remuneration financial statements investor information began phase iii studies investigating closed triple icslama laba combination treatment copd dolutegravir combination janssen 's rilpivirine hiv infection sirukumab giant cell arteritis retosiban preterm labour stopped development losmapimod antiinflammatory agent patients acute coronary syndrome interim analysis data ongoing phase iii trial failed show efficacy signal per stepwise trial design interim review enabled us limit investment study deep portfolio innovation profiled portfolio innovative medicines focused across five core areas pharmaceuticals research hiv infectious diseases respiratory oncology immunoinflammation rare diseases vaccines rd see separate section total around new potential medicines vaccines profiled supporting groups outlook growth period significant opportunity group create value beyond believe approximately two decades innovative science delivers first medicines reviewed potential biologic treatment severe eosinophilic asthma patients firstinclass novel mechanisms action result many may offer benefits beyond current standards years us eu regulatory less asthma patients care cases could radically approvals severe asthma severe asthma proportion transform patients treated treatment nucala mepolizumab severe eosinophilic asthma key milestones long journey many struggle control asthma developing portfolio innovative discovery despite medication experiencing medicines focused targeting frequent asthma attacks regular immune mechanisms could alter nucala gsks first injectable respiratory hospitalisation fundamental course diseases modify biologic therapy identified hardest treat patients disease progression present us potential respiratory treatment condition ociden results opportunities achieve remission time considering disproportionately high burden functional cures developing treatment mild moderate asthma patients healthcare systems simplified treatment regimens however initial results patient potential new generation longacting group disappointing nine studies involving medicines provide longterm control people research allowed rd team give improve treatment outcomes patients us better understand specific role mepolizumab believed great next generation technology platforms eosinophils play severe asthma potential could use emerging also used scientists led approval firstinclass science identify patients could increase understanding fundamental approved targeted treatment severe benefit disease mechanisms develop eosinophilic asthma patients new approaches disease management aided growing understanding control causes asthma particular role eosinophil type white st blood cell cause inflammation lungs focused research look specifically severe eosinophilic firstinclass biologic asthma patients therapy targets il antibody gsk annual report strategic report governance remuneration financial statements investor information pharmaceuticals continued notable advances within scientists using pharmaceutical rd portfolio include potential leadingedge molecules next generation technology field epigenetics immunooncology platforms increase treatment cancer next generation respiratory medicines beyond understanding inhaled treatments portfolio new antibodies inflammatory diseases fundamental disease including rheumatoid arthritis autoimmune mechanisms diseases osteoarthritis investigating potential new options develop new approaches longterm control prevention hiv disease management opportunities designed cure induce longterm remission hepatitis b control c rare diseases potential total potential file breakthrough cell gene therapies assets regulators milestones additional innovative assets expect number clinical development significant development milestones pharmaceuticals rd approach pharmaceuticals vaccines pipelines ten regulatory filings including highly selective rd shingrix shingles vaccine sirukumab investing areas see rheumatoid arthritis subcutaneous best opportunities considered benlysta lupus closed triple patient need market opportunity icslamalaba combination treatment scientific understanding also copd eu committed improving rd productivity develop also expect ten phase iii starts innovative new medicines vaccines including cabotegravir hiv daprodustat greater efficiency anaemia pentavalent candidate vaccine prevention meningococcal committed publishing meningitis men abcwy estimated rd internal rate return irr phase ii starts immunoinflammation based investment made late oncology respiratory infectious stage pipeline expectations diseases regarding longterm sales performance estimated applying methodology estimated irr remained timeline development stages pharmaceutical research drug regulatory approval postmarketing preclinical clinical trials discovery review launch surveillance phase phase phase compounds compounds compounds years years years investigational new drug application submitted investigational new drug application submittedgsk annual report strategic report governance remuneration financial statements investor information collaboration external partners critical component rd strategy enabling us access increase understanding new areas science share risk development early research efforts centred around discovery performance units dpus nimble personalised units budgets greater accountability projects far removed traditional hierarchical rd business model help us maintain flexibility research investment focusing promising scientific opportunities drive accelerate drug discovery output cost savings generated today around dpus simplify pharmaceuticals restructuring support two thirds original units established progress simplifying business delivery billion annual savings group end significantly reshaped responsibility guiding pharmaceuticals business continued together improved performance investigational medicine later reduce supply chain complexity new products restructuring development stages filing regulators retaining commitment quality improve flexibility cost base rests medicines development rescaled commercial operations allow us offset headwinds teams small units six global support functions rd operating margin continued people manufacturing support business decline seretideadvair older also partnered products also supporting enhanced supply chain improvement programme organisations around world investments behind new products aims deliver industryleading levels including academic institutions growth key deliver performance since programme publicprivate partnerships expected mediumterm outlook delivered significant savings pharmaceutical biotechnology pharmaceuticals business procurement excellence companies collaboration buy logistics distribution portfolio committed meeting highest external partners critical component optimisation reducing number standards stringent quality control rd strategy enabling us access pharmaceutical pack variants quality assurance processes increase understanding new baseline medicines vaccines manufactured areas science share risk streamlining external supply according good manufacturing practice development result network cgmp regulations internal collaborative culture within gsk rd quality management system estimate around new strengthened logistics regulatory inspections molecular entities nmes currently operations establishing five regional vast majority concluded clinical development discovered supply demand hubs enabling satisfactory outcomes working internally collaborations efficient use warehouses regulators bring inspections external partners transport reducing cost serve remaining concerns acceptable million great time cost involved conclusion august following drug discovery development make ongoing rollout enterprise us food drug administration fda essential highly selective resource planning erp system across reinspection warning letter investing focusing resources commercial markets manufacturing relating cork manufacturing site rd executive team oversees strategic sites critical part transformation lifted issues overall budget management coupled new planning capabilities across rd robust governance increases endtoend visibility boards manage investment technical control helping ensure supply demand scientific commercial decisions robust aligned changes life cycle rd help improve service patients new medicine launched consumers gsk annual report strategic report governance remuneration financial statements investor information vaccinesgsk annual report strategic report governance remuneration financial statements investor information vaccines business one largest world develop make vaccines protect wide range diseases numbers c number employeesa bn core rd spend licensed vaccines protecting diseases c million vaccines delivered every day candidate vaccines pipeline including gms rd dedicated support functions staff gsk annual report strategic report governance remuneration financial statements investor information vaccines vaccines portfolio broadest performance grow vaccines company make available summary paediatric adolescent adult travel performance summary vaccines protect different reported vaccines sales grew diseases including hepatitis influenza million us europe bn pneumococcal disease rotavirus international cervical cancer business benefited sales newly turnover addition novartis portfolio acquired products proforma basis gained two vaccines prevention sales grew good contributions meningitis menveo approved rotarix fluarixflulaval boostrix us babies two months addition saw rapid sales growth marketed countries worldwide new meningitis vaccine portfolio bexsero new meningitis b vaccine menveo bexsero sales reported sales growth cer currently available countries proforma million notable decision made uk 's national health new vaccine rd pipeline brings service include bexsero national proforma sales growth cer together expertise virology bacterial immunisation programme overall growth infection different technological partly offset declines proforma platforms candidate vaccines sales hepatitis vaccines infanrix bn development diseases including pediarix sales also impacted shingles meningitis rsv group b strep year higher trade inventories core operating profit chronic obstructive pulmonary disease inherited newly acquired vaccines copd exacerbations international markets expansion portfolio boosted offering around world read group financial review pages notably us novartis strong presence track record regulatory approvals gsks significant presence emerging developing continued countries also providing new opportunities introduction make progress growth newly acquired vaccines promising pipeline many years used tiered pricing approach vaccines based support future growth gross national income enables vaccines business countries maintain expand commitment immunisation economies grow one largest contributors gavi vaccine alliance publicprivate partnership improve access vaccines developing countries efforts improve access medicines vaccines see responsible business section strategy action unique world leading expertise adjuvant technology vaccines operating could make difference margin helping protect diseases like malaria cervical cancer bexsero menveo pandemic flu combined global sales based proforma cer newly acquired meningitis portfoliogsk annual report strategic report governance remuneration financial statements investor information deliver vaccines pipeline progress vaccine rd work focuses discovering developing new prophylactic therapeutic vaccines help protect treat people serious diseases currently candidate vaccines early mid latestage development range diseases reported positive pivotal phase iii trial data adults advanced candidate shingrix prevention shingles intend file global regulatory applications shingrix second half also received positive scientific opinion european regulators malaria vaccine mosquirix children aged six weeks months mosquirix first vaccine malaria reach milestone additionally first regulatory review adjuvant technology also used shingrix two novel candidate vaccines malaria vaccine phase ii clinical development reported positive see responsible business section respiratory syncytial virus rsv common pivotal phase iii trial data cause bronchiolitis pneumonia infants lead hospitalisation adults continue progress paediatric enhanced risk severe asthma vaccine measles mumps rubella one paediatric rsv vaccine uses advanced candidate additional phase iii trial genetically engineered recombinant required achieve registration shingrix prevention chimpanzee adenovirus carrier vaccine us used ebola vaccine candidate shingles intend vaccines innovation second glycoprotein rsv vaccine file global regulatory november profiled number given pregnant women may provide promising earlier stage assets infants protective maternallyderived applications shingrix vaccines pipeline pentavalent rsvneutralising antibodies candidate vaccine prevention second half meningococcal meningitis men abcwy combines two existing gsk meningococcal meningitis vaccines advanced phase ii development phase iii studies planned start st candidate efficacy vaccines development mosquirix first malaria advanced late diseases including vaccine receive positive stage candidate vaccine shingles meningitis rsv regulatory review shingrix shingles group b strep copd two phase iii studies exacerbations gsk annual report strategic report governance remuneration financial statements investor information vaccines continued exploring maternal immunisation approach candidate vaccine phase ii development prevent group b streptococcus gbs leading cause pneumonia meningitis sepsis affects one births us addition candidate vaccine phase ii clinical proof concept study prevention exacerbations chronic obstructive pulmonary disease copd continue work partners accelerate development ebola candidate vaccine help prevent future disease outbreaks candidate vaccine tested phase ii clinical trials five countries west africa discussing potential regulatory pathways file candidate vaccine approval fda agencies investment governance highly selective invest focus resources vaccines discovery development prioritise investment meet needs patients address biggest remaining global health challenges core vaccine rd investment million impressive trial results prepare ground scientists working new shingles vaccine across vaccine rd organisation oversight key decisions make new candidate vaccine shingrix shingrix demonstrated great potential vaccines development process demonstrated longlasting effective trials involving people rests vaccine research protection pain world october pivotal development board vrdb reviews discomfort shingles pivotal phase iii study results showed rd project strategy advises phase iii studies effective shingles scientific technical matters effective phn people vaccine investment board vib shingles sufferers develop painful itchy makes final decision whether rash ociden turns blisters findings echoed earlier pivotal invest project commercial opportunity one side body also phase iii study results showing portfolio fit develop postherpetic neuralgia phn efficacy shingles intense distressing pain last phn among overs findings continue expand early stage three months acider shingles rash also showed pipeline strengthen expertise appears possible complications candidate vaccine effective ages targeted investments example include scarring eyesight problems effectiveness remained acquisition glycovaxyn february secondary infection nerve palsies constant four years acider innovative biological administered significant conjugation platform technology supports nine people improvement existing vaccine efforts develop new vaccines chicken pox risk less effective range bacterial diseases shingles however disease particularly elderly reduces efficacy time affects adults likely following successful trial results disease lifetime individuals later intend begin filing compromised immune systems applications shingrix cancer patients undergoing chemotherapy prevention shingles regulators people hiv also especially north america japan europe susceptible shingrix trials also ongoing people compromised immune systems hope able file regulatory application group patients gsk annual report strategic report governance remuneration financial statements investor information vaccines research development cycle registration identify produce preclinical phase phase ii proof phase iii file post marketing antigens antigens testing concept surveillance research including immunology preclinical development clinical development including post marketing surveillance transfer process manufacturing years years years year investing supply chain simplify gsk vaccines manufacturing progress simplifying business sites strategically positioned around world broad diversified footprint made substantial progress gives us greater manufacturing capacity integrating new novartis business efficiency flexibility acted catalyst simplify continued make significant investments vaccines operating model strengthen manufacturing network key areas manufacturing network reduce including starting construction new supply costs changes help hepatitis facility wavre belgium deliver annual cost savings set major capital investment plan help us deliver rosia italy site meningitis target operating margin least vaccines made incremental annual cost savings helped increase committed quality proforma operating profit margin vaccines manufactured vaccines cer basis highest quality standards according manufacturing sites current good manufacturing practice part complex integration cgmp regulations around world programme completed regulatory time takes produce vaccine required divestments transaction distribute million dedicated quality control including divestment meningitis vaccines nimenrix mencevax regulatory inspections vaccines every day satisfactory outcomes november also begun restructuring ste foy facilitys warning letter people across programme remove duplication us food drug administration infrastructure roles countries fda concluded fda found remediation activities completed satisfactorily gsk annual report strategic report governance remuneration financial statements investor information consumer healthcaregsk annual report strategic report governance remuneration financial statements investor information consumer healthcare business portfolio worlds trusted well loved brands brands underpinned sciencebased innovation include panadol voltaren horlicks sensodyne developed meet healthcare needs consumers worldwide numbers c number employeesa bn core rd spend specialist oral care company retail sales servings horlicks per second india nutritional supplement including gms dedicated support functions staff gsk annual report strategic report governance remuneration financial statements investor information consumer healthcare consumer healthcare business brands sold performance world leading represents countries around world summary consumer healthcare joint venture around sales emerging markets novartis together gsk consumer wellness healthcare listed businesses india wellness biggest category bn nigeria excluded overall global leader joint venture number one company countries business split almost equally retail sales leading global turnover counter otc medicines positions respiratory cold flu nasal fast moving consumer goods fmcg decongestants allergy smoking cessation brands dedicated healthcare across pain management four categories wellness oral health two top four brands one nutrition skin health systemic panadol one topical reported sales growth cer pain relief voltaren categories defined specific consumer healthcare requirements complementary ranges brands allow proforma sales growth cer us evolve consumers needs bn core operating profit strategy action consumer healthcare operating margin innovation sales one world 's leading product introductions otc companies retail within last three sales specialist years rolling basis oral care companygsk annual report strategic report governance remuneration financial statements investor information oral health power core brands top three company toothpaste power brands selected power brands selected number one specialist oral newly integrated portfolio newly integrated health leading positions sensitivity identified voltaren panadol acid erosion denture care gum sensodyne theraflu otrivin portfolio identified health sensodyne number one parodontax poligrip recommended dentists worldwide category leaders voltaren panadol sensitivity long track records higher sensodyne theraflu average gross margin skin health otrivin parodontax top three globally core brands including tums medicated skin health focusing flonase horlicks eno poligrip treating conditions affect millions many similarities power brands category leaders long people worldwide cold sores local regional opportunities dry sensitive skin abreva rather global track records higher zovirax brands hold leading positions prioritising investment worlds largest markets average gross margin rd innovation marketing nutrition commercial execution behind nutrition business particular seven power core brands focus indian subcontinent horlicks served nutritional supplement rate times per second mainly children horlicks ranked sixth trusted brand india across brands indications focused brand strategy innovation generating growth horlicks market share india sensodyne double digit growth horlicks delivered time share rd organisation three regions high trusted based emerging markets hot beverage brand india gsk annual report strategic report governance remuneration financial statements investor information consumer healthcare continued grow deliver identified dozen markets performance summary strong innovation pipeline consumer healthcare sales grew across categories prioritise investment proforma million continue prioritise investment advertising promotion note sensodyne grew rd doubledigits across regions capital expenditure close generating sales billion core rd investment consumer year also successful healthcare billion place top talent launch flonase allergy relief following million markets contribute strategy switch product integration process prescription otc investing rd two thirds growth reported growth benefited sales capabilities integrating marketing newly acquired products particularly scientific regulatory technical medical voltaren otrivin theraflu following teams colocated hubs uk formation joint venture us switzerland india china novartis proforma growth singapore going forward third predominantly driven growth rd organisation based oral health wellness categories emerging markets consumer healthcare also building new sensory sales generated innovation packaging lab capabilities ensure launched within last three years capitalise trends developments newtomarket product flavour application techniques launches throughout year present growth opportunities example developed formulation key innovation drivers year horlicks consumers mix cold included flonase us water hot water readily available sensodyne complete japan many people indian subcontinent helped sensodyne brand become example fenbid chewable leading toothpaste country launched china pain relief product need water key launches included also continue invest shopper sensodyne repair science lab stateoftheart protect whitening facility allows us research sensodyne complete innovative products simulated digital real life environments fenbid chewable mg retail partners test packaging physiogel calming relief range claims shopper materials theraflu warming syrup read group financial review pages gsk annual report strategic report governance remuneration financial statements investor information simplify progress simplifying business using integration process simplify organisation build leaner business renewed focus delivering performance increasing agility developing high performance culture personnel exits consumer healthcare joint venture completed sites consolidated making good progress changes help deliver annual cost savings expected integration enables us deliver target operating margin least cer incremental annual cost savings helped increase proforma operating profit margin cer basis careful planning enabled us maintain stable supply chain novartis integration disruptions supply time achieved net reduction pack variants within product portfolio us debut flonase allergy relief regulatory inspections satisfactory outcomes year 's top overthecounter otc launch average service levels rose launch flonase allergy relief also leading allergy brand due supply underlined effective dual capabilities recommended doctors chain improvement programme initiatives pharmaceuticals fast allergists number one investments manufacturing moving consumer goods fmcg recommended pharmacists sites enhancements systems nasal allergy brand capacity reductions singlesourced nasal spray formerly raw materials available prescription contains strong performance aided number one prescribed ingredient flonases expert digital marketing providing temporary relief hay campaign achieved striking careful planning enabled us fever upper respiratory allergies results across leading social media channels maintain stable supply reflecting heritage respiratory medicines first otc spray chain novartis relieve nasal ocular symptoms whereas allergy treatments integration target one histamine inhibits disruptions supply six key substances within months partnership retailers enabled us us launch secure strong presence store flonase captured miles shelf space almost one million pointofsale devices integrated adult allergy consumer marketing campaign worked product market simultaneously engage shoppers within months launch flonase captured adult allergy product market third leading brand category gsk annual report strategic report governance remuneration financial statements investor information gsk annual report governance remuneration financial statements investor information gsk annual report governance remuneration financial statements investor information responsible businessgsk annual report strategic report governance remuneration financial statements investor information responsible business fundamental gsk strategic priorities us business important financial results deliver numbers million people reached training frontline health workers least developed countries since million children reached lifesaving immunisation treatments interventions groundbreaking partnership save children markets operating new commercial model c employees family members countries access preventive healthcare partnership prevention programme reduction operational waste hazardous nonhazardous last five years gsk annual report strategic report governance remuneration financial statements investor information responsible business approach creating value society responsible business priorities highlights success benefits wider society gsks responsible business priorities sit developing innovative healthcare within context macroeconomic products directly benefit patients social trends affect companies consumers flexible pricing strategy wider society trends present allows prices reflect countries opportunities challenges ability pay global footprint enables global healthcare companies like gsk partnership comic relief greater access medicines see fight malaria products delivering profitable report progress across four areas sustainable business performance health behaviour people generate value returns planet identified priorities shareholders reinvest areas understanding issues business wider important business extended price freeze society benefits healthy people commitment years stakeholders essential building strong sustainable countries graduating communities longerterm commitments across gavi support four areas reflect global health needs make significant direct indirect align gsks strategic priorities economic contributions countries values many areas also communities operate support global goals sustainable tax employment development detail progress research proposals submitted people charitable support commitments access data gsk trials detail approach tax responsible business supplement also publish full details available wwwgskcomresponsibility position tax wwwgskcom assessment showed read two commitments complete responsible business commitments progressing well wwwgskcom five track one work shown table progress responsible business commitments summary commitment progress summary commitment progress health behaviour innovation unmet medical needs ethical conduct better access medicines vaccines promoting values sales marketing building products better meet needs transparency clinical research reducing child mortality rigorous patient consumer safety strengthening healthcare infrastructure minimising animal testing eliminating controlling ntds promoting human rights fighting malaria ensuring ethical interactions eradicating polio working third parties access antiretroviral treatment hiv people planet creating inspiring healthy workplaces carbon promoting inclusion diversity water community volunteering create change waste work needed track progressing well completedgsk annual report strategic report governance remuneration financial statements investor information health increasing access healthcare approach gsk developed rtss aim extend benefits supply notforprofit price recommended products people matter partnership path malaria malaria candidate live ability pay target vaccine initiative funding areas unmet medical need diseases bill melinda gates foundation vaccine rtss developing world antibiotics stimulating open innovation addition vaccines medicines introduced comprehensive approach tackle collaborating tackling barriers malaria must include wider preventative pilot programme affordability accessibility measures since supported working strengthen healthcare systems africa malaria partnership promote way seek play part use existing interventions tackling global health challenges bed nets indoor residual spraying innovation antimalarial treatments january committed innovation launched new million diseases disproportionately affect partnership comic relief worlds poorest people malaria ukbased charity fight malaria societys need greatest five endemic countries antibiotics even though may well making new discoveries offer potential commercial return adapt existing products tackle open innovation model core different health challenges october commitment submitted regulatory years research application european medicines reached two significant milestones agency antiseptic gel prevent journey develop vaccine protect umbilical cord infections newborns young children malaria july reformulated european medicines agency adopted chlorhexidine solution corsodyl positive scientific opinion malaria mouthwash see case study candidate vaccine mosquirix rtss increasing antibiotic resistance children aged six weeks months emerging urgent public health additionally world health organisation crisis research unit recommended rtss focused developing next introduced pilot generation antibiotics active rollout actively working pipeline potential new medicines financing bodies malaria development vaccine clinical trials partnership including path gsk generate support pilots finalise design pilot implementation programme helping newborns survive three million newborn babies die year infection ociden newlycut umbilical cord acts entry point bacteria issue exacerbated developing countries many births take place home working reformulate antiseptic chlorhexidine solution used corsodyl mouthwash gel prevent umbilical cord infections using insights ontheground knowledge save children european medicines agency approves regulatory application offer gel notforprofit price share knowledge others manufactured locally nerdlihc eht evas yelworc niloc otohp advanced asset topoisomerase inhibitor gepotidacin gsk developed collaboration us governments biomedical advanced research development authority barda asset novel mechanism action potential address multiple indications moving towards phase iii studies following positive phase ii results gsk annual report strategic report governance remuneration financial statements investor information health continued since open innovation model giving since capped advanced research diseases malaria tuberculosis prices patented neglected tropical diseases ntds medicines vaccines affect one billion people screened two million least developed compounds help combat deadly infectious diseases published countries ldcs data highquality hits ntds developed world prices initiating new research projects within outside gsk long manufacturing invite external researchers utilise costs covered facilities resources expertise cash open lab tres cantos spain product inkind labs recent progress ntd research time pulse included developing first preclinical management candidate treat visceral leishmaniasis promising precandidate drug combat chagas disease increasing local access supply open innovation also central africa important part commitment africa noncommunicable diseases ncds open continued evaluate lab launched lab work options manufacturing nigeria partnership major funders academic started work million groups governments conduct pharmaceutical factory india signed research ncds innovative manufacturing partnership extending affordability availability chinas desano pharmaceuticals six billion people live emerging markets allow us provide dolutegravir hiv million use healthcare treatment competitive price china first time flexible countries pricing strategy seeks meet affordability also hinder access healthcare needs providing developed countries broaden access products lower prices since products markets finding capped prices patented flexible ways price medicines medicines vaccines least retaining returns investment developed countries ldcs innovation developed world prices long manufacturing costs covered example us six also tiered pricing approach recently launched new medicines poorer countries pay less priced parity discount medicines aim supersede offer lowest vaccine prices reached agreement uk government organisations gavi vaccine make britain first country alliance supports countries nationwide vaccination programme low gross national income meningitis b agreement offers fair value froze prices countries graduate national health service gavi support continue offering us sustainable return buy vaccines discounted prices decade us offer various types patient assistance help ensure appropriate middleincome countries access medicines gsk many still live poverty flexible programmes eligible patients pricing approach enables people prescription drug coverage access products philippines medicare part prescription drug gsk introduced card coupon plan offer specialty product patient programme offering discounts assistance eligible insured patients selected products result new coverage options patients available following affordable care accessed products including antibiotics act patients insured fewer augmentin zinnat well requiring patient assistance seretide inhaler programme programmes pap however part building local capabilities improves access commitment access continue developing countries providing provide services help patients patients consumers locally relevant understand alternative coverage options products enhancing domestic manufacturing capacity capabilitygsk annual report strategic report governance remuneration financial statements investor information strengthening healthcare systems worlds least developed countries ldcs lack trained healthcare workers prevents people accessing lifesaving medicines vaccines ldcs operate reinvest ldc profits sale pharmaceutical consumer healthcare products train educate community health workers since reinvested million ldc profits countries training frontline health workers doctors midwives nurses volunteers reached million people expanded health worker training beyond ldcs countries subsaharan africa support un one million community health workers campaign funding pilot train health workers ghana apart training healthcare workers strengthen healthcare systems broadly example improving health facilities equipping training centres encouraging governments improve partnership save children complementing partnership policies increase investments groundbreaking fiveyear support broad range work reduce partnership save children childhood mortality many targeted product financial helping save one million childrens lives reinvestment programmes focus donations help provide healthcare worlds poorest countries reducing child maternal mortality vulnerable communities partnership involves combining rural communities instance nepal global community investment capabilities rd supply chain work care international totalled million compared procurement vaccines government improve maternal neonatal million charitys local expertise democratic reproductive health improving republic congo example skills frontline health workers partnership created model providing health equipment enabling essential services neonatal maternal communities feedback health centre child health replicated performance support enabled developing countries health workers nepal trained reaching one estimate reached million people million children fully immunising treating diarrhoea malaria pneumonia screening one million malnutrition strategy action published data highquality hits european medicines ntds initiating new frontline health workers agency adopted positive research projects within trained least developed scientific opinion malaria outside gsk countries since candidate vaccine mosquirix children aged six weeks months nerdlihc eht evasbbew nitram otohp gsk annual report strategic report governance remuneration financial statements investor information behaviour putting needs patients consumers first approach sales marketing practices transparency clinical trial data expect employees act line significantly changed way pioneered ways share values transparency respect sell market medicines vaccines information data clinical people integrity put patients ensure patients interests come trials providing greater access trial consumers first first better serve customers data allow others conduct believe changes provide research maximise contribution values inform approach long term commercial advantage made participants studies patient consumer safety throughout product development use january completed roll since online sell market medicines changes way sales teams clinical study register make train employees address compensated pharmaceutical medical available information trials including misconduct expectations representatives longer individual summaries results first third parties sales targets instead compensated pharmaceutical company make clinical based technical skills scientific study reports basis regulatory patient consumer safety knowledge quality service deliver submissions include detailed patient safety priority hcps broader business performance information trials publicly available development testing manufacture us approach generated use products medicines also first company sign strong customer feedback july potential risks well benefits alltrials campaigns every trial survey us healthcare professionals extensive controls detect evaluate registered results reported gsk ranked first trust customer communicate benefits risks value second time row set system researchers potential safety concerns request access detailed products remain committed ongoing anonymised patientlevel data dialogue scientific community take safety take sit behind clinical trial results peertopeer medical education part clinical trials extremely seriously wwwclinicalstudydatarequestcom modernising way engage trials conducted line lists global clinical hcps january international conference harmonisations trials conducted since formation longer pay external hcps speak good clinical practice guidelines gsk includes clinical trials prescribers medicines independent ethics committee reviews companies wellcome trust continue pay hcps nonpromotional trial protocols studies start taken management panel advisory services clinical research prevent going ahead considers applications access payments governed rigorous data initially made global risk register helps research controls based fair market value independent experts appointed gsk teams keep track emerging risks also changed support important step towards vision quality safety standards risks medical education longer choosing independent datasharing system often identified regular healthcare professionals studies across industry academia selfaudits trials sponsored attend scientific conferences end research conducted third parties behalf instead provide funding proposals submitted access performed audits trials independent professional bodies data gsk trials already core focus safety strict allocate funding individuals given research teams access quality safety standards upheld detailed trial data using multiple channels including manufacturing sites throughout digital realtime applications provide code conduct product life cycle sourcing information way time hcps code conduct online raw materials manufacturing want used effective digital resource centre guide people transportation finished products communications support interactions applying values everyday activities strive minimise risk hcps launched two new hiv employees completed counterfeit medicines medicines tivicay triumeq mandatory annual training code extended endtoend supply chain online course available healthcare professionals scientists serialisation programme fingerprint languages includes training within gsk including global medical across packaging lines values ethical leadership antibribery experts play important role informing manufacturing sites programme corruption reporting issues peers medicines applies unique serial fingerprints concerns extended responsible providing right products logs complementary information support safe governmentmanaged database workers employees complete effective use medicines verified course may face disciplinary action point supply chaingsk annual report strategic report governance remuneration financial statements investor information antibribery corruption total disciplined received employees disciplined zero tolerance bribery verbal warnings employees received breakdown types policy violations corruption however recognise documented warning exposed bribery corruption dismissed risk given global footprint particularly agreed leave company voluntarily markets government structures highest number dismissals rule law less developed related travel expense policy healthcare systems less mature violations accounted dismissals followed dismissals antibribery corruption programme related code conduct violations includes risk assessments standards attendancepayroll violations practical guidance designed prevent noncompliance working third parties employees complimentary workers expect suppliers third parties completed basic level training comply standards ethics attendancepayroll local work employees highrisk roles labour rights health safety good manufacturing regulation violations completed additional advanced training environment introduced practicesgood unauthorised distribution practices absenteeism rolling framework comprehensive programme strengthen engage train third parties based management risks travel expenses ehssafety risk profile supply chain marketing falsification promotional activities documents approach designed prevent following review suppliers code conduct training completion breaches things go wrong act identified high risk promptly decisively centralised assessed external risk review committee oversees investigations assessment experts required allegations bribery corruption complete extensive questionnaire engage artificial tax ensures prioritised consistently demonstrate policies management arrangements without business across company systems responsible business issues commercial substance additional due diligence may follow time responsibility reporting investigating shareholders financially efficient misconduct assessed around deliver sustainable tax rate centrally track misconduct allegations distributors four key risks antibribery concerns security incidents received corruption labour rights promotional details approach tax speak channels monitoring activities information protection tax disclosures found routes received also assessed group financial review reports allegations suppliers support manufacturing report responsible majority line quality management system business supplement speak channels audited environmental approach human rights offer people within outside gsk health safety management systems gsk signatory un global opportunity ask questions voice approach tax compact sets key principles concerns anonymously confidentially understand responsibility pay business human rights independent third party appropriate amount tax committed upholding universal phone online robust internal policies processes training declaration human rights concerns raised reviewed compliance programmes ensure core labour standards set formal investigations initiated alignment across business international labour organization response allegations five meet tax obligations human rights steering group provides frequent categories allegation pay significant amount tax direction oversight help ensure employee performancerelations product uk global corporate meet commitments human rights promotion interactions hcps fraud functions significant manufacturing set human rights statement antibribery corruption rd facilities located available website disciplinary action countries around world identified seven priority disciplinary action taken substantial business employment areas human rights gsk access employees fail act line presence health care air quality impact relating policies employees last years paid propellants clinical trial standards disciplined policy violations billion corporation tax globally employment practices patient safety types policy violations uk paid billion since product counterfeiting use third see chart remained broadly nearly global total party suppliers attendance payroll uk net sales global remains biggest type violation net sales total followed good manufacturing practices travel expenses violations increased due increased frequency monitoring gsk annual report strategic report governance remuneration financial statements investor information people gsks people essential success approach following steady reduction years need talented motivated resilient welcomed reportable injury illness rate workforce deliver increased slightly due large number novartis employees strategy tackle global health semicircular lipoatrophy cases brazil challenges effectively achieve gsk clear regular treatable condition associated aim create working environment localised pressure office employees feel valued respected communication crucial furniture took steps support empowered inspired affected prevent recurrence introducing new business experienced significant change global business operating particularly important us listen colleagues values markets serious incidents support people expectations occur august employee performance engagement tragically died boiler explosion global performance system site rixensart belgium underpinned set clear expectations supporting belgian authorities emphasise results also put particular emphasis leadership investigations checking every achieved line development boiler across gsk october sales values line leaders completed programmes employee india travelling help become managers also business sadly died motorcycle provide regular updates launched enterprise talent initiative collided another vehicle mission strategy progress develops leaders potential live broadcasts messages energy resilience programmes aspiration become executives ceo corporate executive team continued help employees balance since trained listening also critical personal professional responsibilities employees coaches help employees people took part others fulfil leadership potential took part employee survey providing employee survey agreed valuable feedback health wellbeing sufficient energy invest things last survey take progressive approach matter work life employee health protecting supporting people providing preventive healthcare workforce business priority restructuring complement employee healthcare refreshed simplified health welcomed novartis benefits established markets safety standards reviewed global employees gsk clear regular partnership prevention pp health well strategy setting communication crucial programme aims provide plan every gsk employee introducing new colleagues employees families access consistent comprehensive values expectations performance unprecedented access preventive health service system local employee practices healthcare services little cost programmes major reshaping continue recognised leader implementation prioritised global pharmaceuticals business health wellbeing may regions access preventive occurring time placed gsk multinational healthy services unavailable limited equal focus supporting employees workplace award global centre particularly developing markets leaving company consult healthy workplaces services including immunisations employees representatives road safety significant risk cancer screenings recommended business changes might affect employees launched driver safety world health organization talent leadership programme india plan roll available employees number graduates widely emerging markets family members countries postgraduates joining programmes places us halfway towards target increasing recruited implement pp globally graduates postgraduates onto future leaders esprit programmes globally exceeding target also welcomed apprentices uk women across volunteering number disciplines locations looking expand create change apprenticeship programme geographies pulse volunteer partnership employees use professional skills create sustainable change nonprofit partners communities serve since launch pulse enabled employees work nonprofit partners countries providing nearly million worth skilled servicesgsk annual report strategic report governance remuneration financial statements investor information diversity inclusion value diversity diverse knowledge perspectives experiences working styles global workforce strengthens business helps us meet needs patients consumers aim improve gender balance levels december women represented recruits future leaders programme management corporate executive team board female managers began accelerating difference programme high performing women leaders strive make gsk accessible people disabilities december partnered uk governments disability confident campaign raise disability awareness across business remove barriers increase understanding ensure disabilities right opportunities inspiring next generation scientists global organisation serving diverse markets six nationalities uk alone need one young told one represented corporate executive million new scientists engineers teachers study drama team board employees solve future challenges including always enjoyed sciences maths emerging markets asia pacific japan biggest health challenges ended completing phd virology represent workforce tomorrow research led immunology parttime whilst gsk aim attract develop local talent healthcare company gsk playing said partnering universities offering leading role inspiring young aim build business opportunities particular people get science technology experience uk creating global focus africa strategy new engineering maths stem stem education programmes give regional headquarters singapore well providing range career employees tools need inspire helping attract develop local people opportunities foster next generation emerging markets recruited science education early scientists engineers worldwide people countries talent team along stem future leaders graduate programme gsk offers range career opportunities ambassadors across uk engage young stem areas ranging summer people demonstrating realworld internships apprenticeships graduate science engineering schools women management positions postgraduate programmes manage graduate apprenticeship programmes apprenticeship programme offers school college leavers opportunity join svpvp rhiannon lowe heads team company variety roles director ambassadors volunteer gsk employees finance laboratory science manager site ware hertfordshire engineering apprentices learn onthejob total part programme since become valued members team began alongside job progress working towards employees gender number investigator investigative preclinical nationally recognised qualifications male female total toxicology focuses diseases ultimately transition board developing world gene therapy permanent role managementa team put expertise scheme grown steadily uk total practice inspire people ages ambition continually expand go schools demonstrate scientific programme new geographies total experiments host visits gsk labs helping nurture new generation management senior managers defined students given opportunity talent adding diversity companies act strategic report get involved science connects business directors report regulations directly work real world includes persons responsible planning directing controlling activities rhiannon encourages girls particular company strategically significant pursue subjects young age part company board women represent stem including directors undertakings included consolidated accounts professionals uk gsk annual report strategic report governance remuneration financial statements investor information planet reducing environmental impacts approach carbon emissions major environmental challenges closely linked global health concerns climate tonnes coea b change deforestation example exacerbating inequalities health scope emissions global healthcare company help scope emissions tackle effects environmental scope emissions change causes aim carbon neutral value chain intensity ratios ambitious interim goals reduce carbon scope emissions water waste past five years sales revenue tonnes made significant progress coem carbon scope fte aim reduce carbon footprint tonnes co efte across value chain baseline way carbon emissions calculated according greenhouse gas protocol goal carbon neutral value chain corporate accounting reporting standard revised edition pursue objectives reducing b data includes former novartis sites ' emissions headcount operational emissions scope engaging suppliers patients consumers cut emissions linked reducing emissions raw materials water sourcing raw materials ingredients engaging suppliers crucial aim reduce gsks water using products scope approach recognised ethical impact across value chain corporation responsible business level met volume medicines awards founded data collection milestone operations year consumer health products vaccines collaboration recognition ecodesk early reduced sent factories online platform gathers data carbon achieved higher time water waste around suppliers reductions investing watersaving value chain carbon footprint representing approximately million initiatives past five years focusing grown vs therefore half annual spend sites highest water use reduced value chain carbon footprint raw materials regions water scarcity products shipped average versus control direct around water used across emissions operations value chain comes raw materials continued growth sales reduced emissions within mainly agricultural partnered ventolin propellantbased inhalers operations million energy resources institute emit greenhouse gases tonnes co e less sustainable development ngo india administration medication cumulative saving around assess reduce water impact patients continues impact carbon million tonnes co e five years rural communities supply us footprint researching solutions achieved using energy wheat barley milk manufacture issue including changing way efficiently investing renewable horlicks manufacture reduce amount energy provides around propellant used maintaining gsk laboratories manufacturing total energy use wind turbine efficacy patients sites offices used around facility cork ireland example total water impact making major generates sites electricity investments reduce companywide delivered savings million tonnes co e strategy action reduced direct hit water target carbon emissions scope year early reducing usage since since thats reduced value chain saving million tonnes saving million carbon footprint products co e five years water use shipped average whole year versus gsk annual report strategic report governance remuneration financial statements investor information horlicks takes green leap india horlicks one bestknown constructing new mw brands used nutritional combined heat power plant supplement india provides rajahmundry also fuelled essential vitamins minerals waste biomass plant growing children improve efficiency capturing heat power generation would discovered otherwise wasted lifecycle analysis horlicks second largest carbon footprint sonepat installing photovoltaic products one reason cells generate mw power three horlicks factories india nabha solar energy investing rajahmundry sonepat powered efficient led lighting across three coal sites cut energy use investing million project since project began april green leap reduce carbon emissions cut carbon emissions water use three horlicks also installed effluent treatment factories example continue plants rainwater harvesting systems increase amount waste biomass enable water reused buy replace coal fuel disposed safely cutting water use boilers helping replenish groundwater restore local water sources consumer use accounts waste water footprint mainly cleaning aim reduce operational waste identified huge teeth continued encourage compared people leave water running last five years cut opportunity brushing sensodynes support operational waste hazardous non reduced carbon emissions turn tap campaign uk hazardous sonepat realise commitment encourage sites view waste working experts ngos resource share best practice tonnes understand best cut example facility east durham water impact across value chain us building insights combined data wwf dungarvan plant ireland install water risk filter across four areas machine recycles fibre drums used satyaprakash punia water scarcity local water quality packaging storage transportation utilities site energy manager health social risks regulatory saving us per year sonepat india reputational risks identify high produced less waste water impact hotspots previous year tonnes representing total waste sent landfill reduction tonnes compared end sites sent waste landfill gsk still pharmaceutical company hold carbon trusts since cut scored carbon standard operational waste climate change disclosure cutting carbon emissions b performance water standard cdps ftse climate reducing water use across disclosure leadership index operations globallystrategic report governance remuneration financial statements investor information group financial review ggsskk aannnnuuaall rreeppoorrtt strategic report governance remuneration financial statements investor information group financial review significant progress leaves us better positioned deliver financial architecture driving eps growth ahead sales improving cash flow generation made significant progress line prioritisation board highlights strategy including closing declared ordinary dividend pence novartis transaction accelerating per share also said delivery restructuring integration expects pay ordinary dividend programmes allowed us release pence per share bn billion incremental savings across transition groups businesses group ahead original targets deliver expectation ensure million importantly also sufficient financial flexibility continue group turnover created additional flexibility invest behind invest behind synergy benefits cer cer proforma rd pipeline new product growth opportunities well launches helping build momentum respond potential exercise put p three businesses options partners viiv healthcare group better positioned consumer healthcare joint drive sustainable growth given venture retained billion total earnings per share significant restructuring reshaping net proceeds received novartis cer cost base better placed deliver number nonstrategic asset financial architecture drive disposals billion returned p growth earnings per share ahead shareholders form special sales improving cash generation dividend pence per share paid support dividend longer term april core earnings per share cer current level dividend exceeds retention disposal proceeds cash flows generated business continued focus cash flow management strategy designed rebuild protection credit profile restructuring cash costs bn capacity transition meant year able groups business away previous fund restructuring integration reliance seretideadvair broadly programmes declare ordinary dividend based growing cash flows driven pence per share reduce net new products pharmaceuticals debt billion securing flexibility expansion vaccines consumer need complete transition healthcare businesses operating cost business deliver strategic savings arising integration objectives restructuring programme reduction viability statement level restructuring spending new requirement year assess programme comes end future prospects group period period transition longer months required forecastb said intend prioritise available going concern provisions corporate cash whether operational cash flows governance code outcome footnotes disposals return ordinary review set viability statement includes billion cash costs legacy dividends shareholders accelerate restructuring programmes completed investment behind restructuring b total charges combined restructuring integration programmes support integration programme expected rapid delivery synergy benefits approximately billion cash costs new growth opportunities expected approximately billion identified across group programme expected largely complete end ggsskk aannnnuuaall rreeppoorrtt strategic report governance remuneration financial statements investor information group financial review continued clear set priorities ensures consistency capital viability statement allocated across different businesses within gsk relative returns business benchmarked relevant accordance provision c revision code external comparatives using cash flow return investment gsk assessed prospects group longer period cfroi based framework metrics specific capital investments months required going concern provision also benchmarked similar way directors confirm reasonable expectation gsk continue operate meets liabilities fall due turnover growth next three years directors assessment made groups turnover performance reflected reference current position prospects strategy progress delivery strategic objective building boards risk appetite principal risks balanced set growth drivers across business managed detailed pages strategic report continued launch new products pharmaceuticals business board reviews internal controls risk management expanded vaccines consumer healthcare policies approves governance structure code businesses novartis transaction new sources conduct also appraises approves major financing investment growth offset decline seretideadvair licensing decisions evaluates monitors performance older products delivered overall turnover prospects gsk whole focus largely improving growth cer year proforma longterm financial performance simplifying operating sales new pharmaceutical vaccines products billion model growing diversified global business delivering year key driver consumer healthcare also made products value significant contribution proforma new products three year review considers existing strategy including recent flonase otc switch driving growth associated principal risks underpin current three year plan directors review least annually directors believe operating leverage three year assessment appropriate aligns normal ability deliver improved profitability heavily impacted well established three year business planning processes overall trend sales also affected changes three year period balances long term nature investments mix business regional product contributions growth pharmaceutical industry realistic assessment variability operating profit saw significant change mix key drivers near term business performance well external group following novartis transaction helped create factors regulation impacting business also reflects view industryleading vaccines consumer healthcare businesses access capital markets funding requirements projected alongside divestment marketed oncology products within analysis time divestment oncology business much plan stress tested series robust operational higher operating margin acquired vaccines consumer principal risk downside scenarios part boards review risk healthcare businesses particularly given heavy investment downside scenarios also consider gsks cash flows dividend cost structure inherited novartis integration cover funding strategy insurance provision recovery well plans addressing cost structure directly set key financial ratios period metrics targets significant margin improvement acquired subject sensitivity analyses involve flexing number businesses core operating margin shortterm main assumptions underlying forecasts individually affected materially transaction total impact around combination appropriate analyses stress three percentage points sales tested ensure robustness viability period evaluated potential impact material negative changes reported core operating margin declined total macroeconomic healthcare environment increased pricing percentage points substantially additional pressure us europe accelerated impact percentage point decline reflecting impact benefit generic alternative seretideadvair principal risks actually operating margin structural credit sga occurring well earliest potential exercise put options million repeated excluding effect partners three year review also makes certain assumptions proforma core operating margin broadly flat normal level capital recycling likely occur considers whether additional financing facilities required reflected delivery around billion incremental cost respective level funding flexibility headroom savings integration restructuring programmes savings contributed offset price pressures older parts based results analysis directors confirm reasonable expectation group able continue portfolio also added cost flexibility operation meet liabilities fall due three year building recent years period assessment provided greater opportunities reallocate resources across group including reinvestment support new launches rd pipeline also improvements manufacturing financial architecture capabilities capacity financial architecture designed support consistent integration restructuring programme ahead schedule execution strategy enhance returns deliver end programme delivered approximately shareholders billion annual savings remains track deliver focused delivering sustainable sales growth across billion annual savings total end company improving operating leverage profitability financial efficiency enhancing financial efficiency order drive growth continue focus improving financial efficiency overall eps ahead sales performance convert funding costs protecting credit profile particular earnings cash used invest business shortterm target credit ratings return shareholders wherever see attractive returns gsk annual report strategic report governance remuneration financial statements investor information gsk financial architecture driving improved returns shareholders sales growth operating leverage eps returns shareholders financial efficiency free cash flow cash flow growth earnings per share eps approach tax total eps saw significant increase p primarily driven profit disposal oncology business core understand responsibility pay appropriate eps declined mainly reflecting shortterm dilution amount tax group paid corporate income novartis transaction also impact continuing transition tax million million profits pharmaceuticals business particularly respiratory million million representing cash expect core eps percentage growth reach tax rate corresponding accounting double digits cer base growth core tax charge profits million million eps p tax risk managed set policies procedures free cash flow seek ensure consistency compliance tax legislation audit risk committee board responsible free cash flow generation impacted approving tax policies risk management ongoing transition pharmaceutical portfolio particularly decline seretideadvair also shortterm impact seek maintain open positive relationships governments novartis transaction particular inherited levels tax authorities worldwide welcome constructive cost investment addressed part debate taxation policy continued significant synergy integration plans international focus tax reform including oecds base erosion profit shifting beps project restructuring costs plans costs novartis european commission initiatives proposed transaction funded proceeds disposal antibeps directive increased use fiscal state aid oncology business nonstrategic assets consistent investigations oecd beps reports clarify important general approach funding costs restructuring principle tax paid profits throughout supply chain commensurate profit making activity excluding cash restructuring charges incurred year takes place gsk supports approach active billion initial tax payments due oncology providing relevant business input assist successful disposal well legal payments free cash flow generated delivery aims beps project particular support billion compared billion implementation oecds recommendations country adjusted comparable basis bycountry reporting cbcr including exchange cbcr addition rebuilding cash generation capacity continue data tax authorities key success focus improving efficiency capital investment data validated existing information held taxpayers use working capital reduce internal cash requirements support ability ensure multinational groups pay right amount tax expected allow us build operating cash flows quickly maintaining dividend returning group growth engage artificial tax arrangements without protecting credit profile business commercial substance time responsibility shareholders financially efficient returns shareholders deliver sustainable tax rate ongoing alignment group board approved ordinary dividend pence structure reflect mix operations geographies helped together special pence dividend paid net us maintain efficient effective tax rate core tax rate proceeds oncology business asset disposals similar rate however distributed april alongside regular fourth moderate upward pressure rate expected next quarter dividend also expect pay annual dividends several years given groups momentum changing earnings pence mix favour us particular core tax rate range expected fuller review financial results set pages approach tax set detail within public policy positions section website details corporate tax charges year set simon dingemans chief financial officer gsk annual report strategic report governance remuneration financial statements investor information group financial review continued proforma results reporting financial review novartis transaction completed march reported year date results include ten months turnover results reporting former novartis vaccines consumer healthcare products group financial review discusses operating financial also exclude sales former gsk oncology business performance group cash flows financial position march following completion transaction novartis resources compare results year primarily reorganised group reflect greater balance results preceding year review discusses pharmaceuticals vaccines consumer total results group also core results healthcare businesses responsibilities parts also use number adjusted measures report respective businesses realigned performance business measures used reporting three businesses separately corporate costs management planning reporting purposes reallocated accordingly profitability discussions presentations investment analysts business reflected accurately restated rating agencies defined measures segment information consistent realignment defined ifrs may comparable similarly addition presented unaudited proforma growth rates described measures used companies turnover core operating profit core operating profit cer growth business proforma growth rates calculated comparing order illustrate underlying performance practice reported turnover core operating profit year discuss results terms constant exchange rate cer december turnover core operating profit growth represents growth calculated exchange rates year december adjusted include equivalent used determine results overseas companies sterling ten months sales former novartis vaccines consumer remained unchanged used previous year healthcare products exclude sales former gsk cer represents growth constant exchange rates oncology products march december represents growth actual exchange rates free cash flow growth rates included report cer unless free cash flow net cash inflow operating activities less otherwise stated capital expenditure interest dividends paid noncontrolling interests plus proceeds sale property plant core results reporting equipment dividends received joint ventures total reported results represent groups overall performance associated undertakings free cash flow growth calculated however results contain material unusual non sterling basis reconciliation presented operational items may obscure key trends factors determining groups operational performance result adjusted free cash flow also report core results adjusted free cash flow excludes payments made settle legal disputes core results exclude following items total results amortisation impairment intangible assets excluding working capital conversion cycle computer software goodwill major restructuring costs working capital conversion cycle calculated number including costs following material acquisitions legal charges days sales outstanding plus days inventory outstanding less net insurance recoveries expenses settlement days purchases outstanding litigation government investigations acquisition rd internal rate return accounting adjustments material acquisitions disposals calculation included products launched associates products businesses operating income january december compounds royalty income items together tax phases iib iii development process calculation effects items based actual sales forecast sales core results reporting utilised one bases internal adjusted reflect expected failure rates performance reporting alongside total results cash flow broadly line standard industry failure rates cost base generation number metrics core results presented used calculation comprises estimate attributable discussed group financial review believe rd costs actual projected milestone payments core results representative performance appropriate groups operations allow key trends factors driving irr estimate factored applicable components performance easily clearly identified novartis transaction including acquisition costs forecast shareholders definition core results set also cash flows bexsero men abcwy well cash flows aligns groups results majority peer companies relevant oncology assets divested ie products launched report earnings since akt inhibitor oncology cash flows included reconciliations total core results including detailed estimated attributable rd costs estimated proportion breakdowns key noncore items set aftertax sale proceeds proceeds products launched provided shareholders ensure full visibility excluded consistency overall transparency assess groups performance methodology net impact acquisitions disposals estimated irr material gsk annual report strategic report governance remuneration financial statements investor information group turnover geographic region group turnover turnover bn restated growth growth cer bn us europe international group turnover group turnover outside us europe represented total group turnover reported proforma sales new pharmaceutical vaccine products cer growth cer growth growth growth cer respiratory operating profit bn relvarbreo ellipta anoro ellipta bn arnuity ellipta incruse ellipta nucala total operating profit cvmu eperzantanzeum global pharmaceuticals reported tivicay cer growth triumeq pharmaceuticals bexsero menveo restated growth growth vaccines cer global pharmaceuticals hiv investor day may identified series pharmaceuticals new pharmaceutical vaccine products expected vaccines deliver least billion revenues per annum cer basis products plus current clinical pipeline asset consumer healthcare shingrix set group defined segment turnover new pharmaceutical vaccine products sales new corporate pharmaceutical vaccine products expected reach unallocated turnover billion revenues per annum cer basis two years group turnover earlier cer represents growth constant exchange rates represents sales new pharmaceutical vaccine products growth actual exchange rates hiv turnover represents sales million represented approximately viiv healthcare pharmaceuticals vaccines turnover year group turnover increased reported basis million pharmaceuticals vaccines consumer healthcare reflecting impact novartis transaction proforma basis group turnover increased pharmaceuticals vaccines consumer healthcare sales new pharmaceutical vaccine products million year corporate unallocated turnover million represented sales several vaccines consumer healthcare products held sale number markets required dispose products specific markets order meet requirements antitrust approvals novartis transaction disposals completed august september gsk annual report strategic report governance remuneration financial statements investor information group financial review continued pharmaceuticals global pharmaceuticals turnover bn turnover bn group turnover group turnover reported proforma reported proforma cer growth cer growth cer growth cer growth operating profit bn operating profit bn bn bn operating profit operating profit reported proforma reported proforma cer growth cer growth cer growth cer growth pharmaceuticals turnover million global pharmaceuticals turnover reported basis primarily reflecting disposal oncology business adjusting impact disposal proforma restated growth growth turnover reflecting decline respiratory cer sales decline sales established products largely respiratory offset growth new pharmaceuticals products cardiovascular metabolic particularly hiv products tivicay triumeq urology sales new pharmaceutical products million immunoinflammation increase million offset decline oncology seretideadvair sales million global seretideadvair pharmaceuticals sales billion approximately peak established products global pharmaceuticals turnover million reported basis primarily reflecting disposal oncology business adjusting impact disposal proforma turnover reflecting decline respiratory sales decline sales established products sales new global pharmaceutical products million increase million us global pharmaceuticals reported turnover million decline year proforma basis proforma decline primarily reflected fall respiratory sales fall established products sales within respiratory advair sales million volume decline negative impact price mix flovent sales million declines partly offset sales new respiratory products breo ellipta anoro ellipta incruse ellipta arnuity ellipta combined sales million year gsk annual report strategic report governance remuneration financial statements investor information primary driver decline established products cardiovascular metabolic urology lovaza million following launch sales category declined million year generic competition april avodart declined avodart franchise fell million growth million reflecting launch generic competition sales duodartjalyn offset decline sales october relenza sales doubled million avodart reflecting patent expiry us october partly reflecting us cdc orders benlysta continued sales prolia million december strong growth sales million amgen reacquired rights prolia gsk europe global pharmaceuticals turnover declined immunoinflammation million proforma basis immunoinflammation sales grew million benlysta adjusting impact oncology disposal respiratory sales year million us benlysta sales declined million decline sales million seretide due increased generic competition ongoing oncology transition new ellipta products reported total sales sales oncology products million year million year established products sales million following disposal oncology million reflecting increased generic competition business novartis march capacity constraints supply number products pharmaceuticals international global pharmaceuticals sales million sales therapy areas fell million year reported basis proforma augmentin sales million dermatology basis sales emerging markets million declined sales declined million part adversely affected proforma emerging market respiratory sales declined supply constraints relenza sales million seretide impacted increased generic driven us cdc orders competition price pressure offset flovent ventolin avamys well million relvar ellipta sales products rare diseases declined million anoro ellipta sales established products primarily result generic competition mepron us dermatology products partly impacted established products supply constraints established products turnover fell million within emerging markets china reported year sales us million primarily proforma respiratory flat established products reflecting fall sales lovaza million primarily reflecting significantly increased pricing europe million reflecting increased pressures ongoing reshaping business including generic competition number products supply number product disposals japan global pharmaceutical constraints seroxat sales fell million sales reported basis proforma million increase respiratory sales primarily international million primarily reflecting driven relvar ellipta offset lower sales relenza reflecting lower sales seroxatpaxil million due weaker earlier flu season continued generic competition japan zeffix competitive pressures number established products million partly offset increased valtrex sales million following regaining exclusivity respiratory canada late october sales china fell respiratory sales year declined million million primarily reflecting significantly increased seretideadvair sales million pricing pressures together supply constraints zeffix flixotideflovent sales decreased million ventolin sales fell million combined total ellipta product sales million us respiratory sales declined million year volume growth negative impact price mix sales advair million volume decline negative impact price mix including benefit positive adjustments payer rebates provisions fourth quarter flovent sales million ventolin sales fell million primarily result net negative movements payer rebates provisions new ellipta products recorded sales million year european respiratory sales million seretide sales million volume decline negative impact price mix reflecting expected pressures increased competition generics transition respiratory portfolio newer products relvar ellipta recorded sales million year anoro ellipta recorded sales million respiratory sales international region flat million emerging markets japan emerging markets sales seretide declined million ventolin grew million japan sales relvar ellipta million together strong avamys xyzal sales growth offset decline adoair sales gsk annual report strategic report governance remuneration financial statements investor information group financial review continued hiv vaccines turnover bn turnover bn group turnover group turnover reported reported proforma cer growth cer growth cer growth operating profit bn operating profit bn bn bn operating profit operating profit reported reported proforma cer growth cer growth cer growth vaccines turnover hiv turnover growth growth cer growth growth combivir cer epzicomkivexa bexsero lexivatelzir infanrix pediarix selzentry boostrix tivicay fluarix flulaval hepatitis triumeq menveo trizivir rotarix synflorix worldwide hiv sales increased million us europe international vaccines sales grew million us growth three regions driven primarily europe international business benefited strong performances triumeq tivicay sales sales newly acquired products primarily meningitis million million respectively year portfolio europe us proforma growth epzicomkivexa sales declined million mainly driven bexsero sales europe strong rotarix selzentry declined million combivir lexiva fluarixflulaval boostrix sales us growth sales fell respectively partly offset decline infanrixpediarix sales due return competitor market us increased competitor activity europe supply constraints international hepatitis vaccines sales declined due supply constraints international impacted higher trade inventory newly acquired vaccines cervarix sales declined following introduction new competitor vaccine gsk annual report strategic report governance remuneration financial statements investor information us sales grew reported basis proforma consumer healthcare million proforma growth driven mainly strong performance fluarixflulaval result conversion turnover bn quadrivalent formulation rotarix benefiting cdc stockpile replenishments boostrix due market share gains meningitis portfolio driven primarily launch bexsero growth partly offset infanrixpediarix sales decline primarily result return market group turnover competitor vaccine combined lower cdc stockpile purchases europe sales grew reported basis proforma million proforma growth primarily reflected increased reported proforma sales meningitis portfolio bexsero gaining several cer growth cer growth private markets including italy spain germany portugal well uk following inclusion nhs immunisation programme menveo also delivered incremental sales result tender awards uk italy growth partly offset operating profit bn sales declines infanrixpediarix due supply constraints increased competitor activity hepatitis vaccines due supply bn constraints cervarix following introduction new competitor vaccine germany grew strongly mmrv portfolio boostrix infanrixpediarix due better operating profit supply competitor supply shortages international sales grew reported basis declined proforma basis million proforma performance mainly driven lower tender volumes latin reported proforma america particularly synflorix partly offset increased cer growth cer growth market access demand synflorix africa bangladesh cervarix sales decreased mexico south africa due lower demand infanrixpediarix hepatitis vaccines sales consumer healthcare turnover reflecting supply constraints newly acquired vaccines declined due phasing shipments higher trade inventory levels inherited part acquisition restated growth growth cer wellness oral health nutrition skin health restated growth growth cer us europe international consumer healthcare business represents consumer healthcare joint venture novartis together gsk consumer healthcare listed businesses india nigeria excluded joint venture turnover grew million benefiting significantly sales newlyacquired products included joint venture proforma basis growth volume price primarily reflecting strong growth us following launch otc flonase buoyant sales india driven horlicks well global specialist oral health growth partly due recovery supply disruptions sales new gsk innovations product introductions within last three years rolling basis represented approximately sales higher prior years primarily due flonase switch otc earlier year key launches included sensodyne repair protect whitening us germany voltaren hour rollout sensodyne mouthwash gsk annual report strategic report governance remuneration financial statements investor information group financial review continued us sales grew reported basis million total results proforma basis flonase regions principal growth driver oral health sales continued driven total results group set reconciliations sensodyne launch sensodyne repair total results core results presented protect whitening supply recovery distribution gains sensodyne pronamel excedrin grew following launch growth gel tablet format combined momentum tension turnover turnover cer headache variant theraflu posted strong growth due turnover relaunch new warming syrups format price increases cost sales nicorette lozenges nicorette mini lozenges alli returned selling general market tums impacted supply constraints increased competitive pressure year administration research sales europe grew reported basis million development grew proforma proforma performance driven royalty income oral health products reported growth reflecting operating strong performances sensodyne gum health income products following improved supply position compared operating profit new advertising key markets roll new sensodyne variants across region wellness pain relief net finance costs recorded strong doubledigit proforma performance driven profit disposal voltaren also benefited new marketing campaigns interest associates brand recorded highest market shares many major share tax european markets including germany italy poland france profits associates strong performances partly offset adverse joint ventures performances nutrition skin health categories due profit taxation realignment resources across brand portfolio following taxation integration businesses termination number total profit third party supply arrangements part supply chain taxation year simplification initiative total profit attributable international sales million grew reported basis shareholders proforma oral health sales grew strongly across earnings per share p region doubledigit growth sensodyne denture earnings per ads care products wellness sales declined proforma basis us largely result impact excess channel inventories parts acquired consumer businesses notably china cost sales russia middle east together generic competition cost sales percentage turnover impacted panadol osteo australia economic political percentage points higher percentage uncertainties venezuela india led growth amongst points higher cer basis increase reflected disposal priority markets reporting doubledigit performances eno higher margin oncology business acquisition sensodyne horlicks driven distribution gains new lower margin vaccines consumer healthcare businesses marketing campaigns relaunch improved chocolate novartis addition adverse price movements flavoured horlicks sales brazil lowsingle digits particularly us pharmaceuticals increased investments business transitioned new product formulations vaccines improve reliability capacity supply sun care business chain together increased intangible asset amortisation impairment charges higher integration restructuring costs partly offset improved product mix particularly result growth hiv sales benefits groups ongoing cost reduction programmes selling general administration sga costs percentage sales percentage points higher percentage points higher cer basis increase primarily reflected impacts novartis transaction million credit sga release reserves following simplification entity structure together higher integration restructuring costs increased promotional product support particularly new launches respiratory consumer healthcare vaccines hiv partly offset benefits pharmaceuticals cost reduction programme synergies vaccines consumer healthcare lower legal charges research development rd expenditure increased cer million turnover compared million turnover benefits cost reduction programmes pharmaceuticals vaccines consumer healthcare rd offset higher integration restructuring costs gsk annual report strategic report governance remuneration financial statements investor information operating income net finance costs net operating income million million expense included profits disposals oncology finance income business million ofatumumab million interest finance income partly offset increase liability fair value movements contingent consideration acquisition former shionogiviiv healthcare joint venture million million following improved sales performance finance expense tivicay triumeq liability million interest expense december represents present value expected future unwinding discounts liabilities payments shionogi details consideration due remeasurements fair value movements shionogi relation viiv healthcare set finance expense operating profit total operating profit million compared million increase primarily reflected profits profit disposal interest associates disposal oncology business novartis several equity profit disposal associates million investment asset disposals partly offset nil arose disposal half investment increased integration restructuring costs adverse impact aspen pharmacare remeasurement remaining margins disposal higher margin oncology business holding market value reclassification investments acquisition lower margin vaccines consumer healthcare share tax profits associates joint ventures businesses novartis increase contingent share profits associates joint ventures consideration liability payable acquisition former million million profit including million shionogiviiv healthcare joint venture gain share profit disposal investment intangible asset amortisation decreased million recognised one associates share profits million intangible asset impairments million associates principally arose holding aspen million included impairments several rd pharmacare commercial assets charges noncash items profit taxation major restructuring charges accrued year million taking account net finance costs profit disposal million reflected acceleration number interest associates share profits associates profit integration projects following completion novartis transaction taxation million compared million well charges part pharmaceuticals restructuring programme cash payments made year taxation million million programme delivered approximately billion incremental benefits compared uk current year charge charges date combined restructuring integration rest world current year charge programme billion total cash charges combined charge respect prior periods programme expected approximately billion total current taxation noncash charges billion end total deferred taxation programme delivered approximately billion annual taxation total profits savings remained track deliver billion annual savings total programme expected largely complete charge taxation total profits amounted million end represented total effective tax rate legal charges million million included gsk made payments million uk corporation settlement number existing matters litigation costs tax january gsk made payments million charge included million fine payable relation uk corporation tax amounts chinese government cash payments million corporation tax include various business million taxes borne gsk year see taxation details acquisitionrelated adjustments resulted net charge million million included remeasurements earnings per share liability unwinding discounting effects total eps p compared p increase contingent consideration acquisition former shionogi primarily reflecting profits disposal oncology viiv healthcare joint venture million million business aspen pharmacare shares partly offset contingent consideration related acquisition former increase liability contingent consideration due novartis vaccines business million net hedging gains acquisition former shionogiviiv healthcare joint venture nil consumer healthcare joint venture put option accelerated charges major restructuring expenditure million nil details consideration due dividends shionogi relation viiv healthcare set board declared four interim dividends resulting total disposals items resulted net credit million dividend year pence line dividend million charge included profit disposal addition board declared special dividend oncology business novartis million profit pence paid proceeds disposals disposal ofatumumab together equity investment oncology business assets see note financial asset disposals equity investment impairments reflecting statements dividends current market valuations oneoff required regulatory charges rd certain adjusting items gsk annual report strategic report governance remuneration financial statements investor information group financial review continued core results reconciliation december intangible intangible total asset asset major legal acquisition disposals core results amortisation impairment restructuring charges accounting results turnover cost sales gross profit selling general administration research development royalty income operating income operating profit net finance costs profit disposal associates share tax profitslosses associates joint ventures profit taxation taxation tax rate profit taxation lossprofit attributable noncontrolling interests profit attributable shareholders earnings per share p p p p p p p p weighted average number shares millions core results reconciliation december intangible intangible total asset asset major legal acquisition disposals core results amortisation impairment restructuring charges accounting results turnover cost sales gross profit selling general administration research development royalty income operating income operating profit net finance costs share tax profits associates joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolling interests profit attributable shareholders earnings per share p p p p p p p p weighted average number shares millions gsk annual report strategic report governance remuneration financial statements investor information operations pharmaceuticals rd broadly split core results discovery activities completion phase iia trials development work phase iib onwards supported use core results among metrics including total results specific common infrastructure shared services cash flow generation manage performance appropriate phase iv costs administrative group definition core results set expenses reported sga included cost sales table table analyses core rd expenditure growth categories turnover turnover cer cost sales discovery cost sales percentage turnover development percentage points higher proforma basis facilities central support functions cost sales percentage increased percentage points pharmaceuticals rd percentage points cer basis reflected adverse price movements particularly us pharmaceuticals vaccines rd increased investments vaccines improve reliability consumer healthcare rd capacity supply chain partly offset research development improved product mix particularly result growth hiv proportion pharmaceuticals rd investment made sales benefits ongoing cost reduction programmes latestage portfolio decreased pharmaceuticals rd selling general administration costs reflecting completion number latestage programmes growth royalty income turnover turnover cer royalty income million million selling general administration core operating profit business sga costs percentage sales percentage restated growth points higher percentage points higher margin margin cer basis proforma basis sga costs percentage cer sales increased percentage points percentage points global cer basis increase primarily reflected impact pharmaceuticals million credit sga release reserves hiv following simplification entity structure excluding pharmaceuticals rd sga costs percentage sales decreased percentage pharmaceuticals points cer basis driven declines global vaccines pharmaceuticals including benefits pharmaceuticals consumer cost reduction programme synergies vaccines healthcare consumer healthcare largely offset promotional product support particularly new launches respiratory consumer healthcare vaccines hiv corporate unallocated costs research development core operating profit growth core operating profit million lower turnover turnover cer cer terms turnover increase core operating research margin percentage points lower development excluding adverse impact currency movements particularly euro emerging markets currencies core rd expenditure declined cer million operating margin percentage points lower cer turnover compared million turnover basis decline included percentage point impact proforma basis rd expenditure declined novartis transaction reflecting disposal higher margin reflecting benefit cost reduction programmes oncology business acquisition lower margin pharmaceuticals vaccines consumer healthcare rd different cost structures vaccines consumer healthcare businesses novartis gsk annual report strategic report governance remuneration financial statements investor information group financial review continued proforma basis core operating profit lower net finance costs cer terms compared turnover increase primarily reflected decline proforma core operating finance income margin percentage points however decline also interest income included percentage point impact adverse fair value movements comparison included million credit sga release reserves following simplification groups entity structure trading arrangements excluding finance expense effect core operating margin declined percentage interest expense points reflecting balance continued impact unwinding discounts liabilities decline sales seretideadvair including contracting price reductions lower sales established products well remeasurements fair value movements investments required behind multiple new launches finance expense pharmaceuticals vaccines consumer healthcare transition product portfolio offset savings released restructuring integration programmes benefits net finance expense million compared improved product mix particularly growth hiv sales million pharmaceuticals share tax losses associates joint ventures pharmaceuticals operating profit million lower share losses associates joint ventures million cer terms turnover decrease million profit march reduced core operating margin percentage points lower shareholding significant associate aspen pharmacare percentage points lower cer basis holdings limited issued share capital proforma basis core operating margin decreased result longer account aspen associate percentage points cer basis reflected adverse core profit taxation price movements global pharmaceuticals particularly us respiratory products increased promotional growth manufacturing investments behind new product launches turnover turnover cer respiratory hiv well targeted investments core profit tax manufacturing capacity stability elsewhere portfolio partly offset favourable product mix primarily driven taxation growth hiv sales benefits groups cost tax core profit amounted million represented reduction programmes core operating margin global effective core tax rate reflecting pharmaceuticals hiv resolution number items benefited year noncontrolling interests vaccines allocation earnings noncontrolling interests amounted vaccines operating profit million lower million million including non cer terms turnover increase core controlling interest allocations consumer healthcare segment operating margin percentage points lower profits million million allocation percentage points lower cer basis primarily viiv healthcare profits increased million driven inclusion cost base former novartis million details economic interest vaccines business proforma core operating profit grew profits viiv healthcare set turnover increase cer basis proforma operating margin improved percentage points core earnings per share reflecting increase cost sales percentage turnover core eps p declined cer terms compared due additional supply chain investments benefit cost decline operating profit primarily reflecting greater sales number inventory adjustments contributions growth businesses offset reductions sga rd restructuring significant noncontrolling interests integration benefits consumer healthcare consumer healthcare operating profit million higher cer terms turnover increase core operating margin percentage points lower improved percentage points cer basis proforma basis operating margin increased percentage points cer basis driven reduction cost sales percentage turnover reflecting benefits improved supply pricing well delivery integration synergies together offset additional investment behind growth target power brands particularly oral health wellness gsk annual report strategic report governance remuneration financial statements investor information reconciliation net cash inflow operating activities cash generation conversion closest equivalent ifrs measure free cash flow shown summary consolidated cash flow set reconciliation free adjusted cash flow net cash inflow operating activities net cash inflowoutflow investing activities net cash inflow operating activities net cash outflow financing activities purchase property plant equipment increasedecrease cash bank overdrafts purchase intangible assets proceeds sale property plant equipment cash bank overdrafts beginning year interest paid increasedecrease cash bank overdrafts interest received exchange adjustments dividends associates joint ventures cash bank overdrafts end year distributions noncontrolling interests cash bank overdrafts end year free cash flow comprise legal payments cash cash equivalents adjusted free cash flow overdrafts investment appraisal formal process assessing potential investment adjusted net cash inflow operating activities proposals order ensure decisions aligned overall strategy process includes assessment cash flow net cash inflow operating activities year return investment cfroi well net present value million million excluding legal settlements npv internal rate return irr timeline million million adjusted net cash inflow project long term also consider impact earnings operating activities million credit profile relevant million payments noncore restructuring integration costs million million discount rate used perform financial analyses decided initial tax payments arising sale oncology business internally allow determination extent investments amounting million funded cover cost capital specific investments discount rate divestment proceeds excluding items adjusted net cash may adjusted take account country risk weightings inflow operating activities would million capital expenditure financial investment million reduction million cash payments tangible intangible fixed assets amounted decrease primarily resulted initial impact million million disposals realised novartis transaction reflecting disposal gsks higher million million cash payments acquire margin oncology business impact acquiring lower equity investments million million made margin vaccines consumer healthcare businesses well year sales equity investments realised million lower operating profits primarily global pharmaceuticals million impact negative currency movements year addition future cash flow cash payments shionogi relation viiv healthcare long term expect future cash generated contingent consideration liability recognised operating cash operations sufficient fund operating debt flows increased million total cash payments servicing costs normal levels capital expenditure obligations shionogi relation viiv healthcare contingent existing licensing agreements expenditure arising consideration liability million restructuring programmes routine outflows including tax million recognised cash flows operating activities pension contributions dividends subject risk factors million recognised purchases businesses within discussed pages may time time investing cash flows additional demands finance acquisitions share free cash flow repurchases access sources liquidity free cash flow amount cash generated business short longterm capital markets financial institutions meeting obligations interest tax dividends paid addition cash flow operations needs noncontrolling interests capital expenditure property working capital plant equipment intangible assets working capital percentage turnover working capital conversion cycle days free cash outflowinflow adjusted free cash flow working capital programme continued make progress improvements collection receivables free cash outflow million year excluding legal better inventory management payments million million adjusted free cash reported working capital conversion cycle days distorted flow million million temporary favourable impact days arising noncore restructuring integration costs initial tax novartis transaction excluding impact conversion cycle payments sale oncology business excluding around days reduction days compared items adjusted free cash inflow would million predominantly due increase million decrease reflected factors denominator increased restructuring costs offset net cash inflow operating activities described beneficial impact exchange reduced receivables improved collections reduced inventory levels gsk annual report strategic report governance remuneration financial statements investor information group financial review continued property plant equipment financial position resources business sciencebased technologyintensive highly regulated governmental authorities allocate significant financial resources renewal maintenance property assets plant equipment minimise risks interruption production noncurrent assets achieve compliance regulatory standards number property plant equipment processes use chemicals hazardous materials goodwill total cost property plant equipment intangible assets december million net book value investments associates joint ventures million land buildings represented million plant equipment million assets investments construction million invested million deferred tax assets new property plant equipment mainly related noncurrent assets large number projects renewal improvement total noncurrent assets expansion facilities various worldwide sites property mainly held freehold new investment financed current assets liquid resources december contractual inventories commitments future capital expenditure million current tax recoverable operating lease commitments million believe trade receivables facilities adequate current needs derivative financial instruments observe stringent procedures use specialist skills liquid investments manage environmental risks activities environmental cash cash equivalents issues sometimes dating operations modified assets held sale discontinued reported planet total current assets note financial statements legal proceedings total assets goodwill goodwill increased year million liabilities december million increase reflected current liabilities goodwill arising acquired novartis vaccines business shortterm borrowings creation consumer healthcare joint venture trade payables intangible assets derivative financial instruments intangible assets include cost intangibles acquired current tax payable third parties computer software net book value shortterm provisions intangible assets december total current liabilities million million increase reflected impact acquiring vaccines business noncurrent liabilities million creation consumer healthcare longterm borrowings joint venture million capitalised development costs deferred tax liabilities million partly offset amortisation impairment pensions postemployment benefits existing intangibles million million respectively provisions investments associates joint ventures derivative financial instruments held investments associates joint ventures noncurrent liabilities carrying value december million total noncurrent liabilities million market value december total liabilities million million largest net assets investments theravance inc innoviva inc book value december million market equity value december million september share capital theravance inc accounted equity investment share premium account considered group could exert significant influence company point see note retained earnings financial statements investments associates joint ventures reserves shareholders equity investments noncontrolling interests held investments carrying value december million million total equity significant investments aspen pharmacare holdings limited book value december million previously investment aspen treated associate march sold half holding aspen result longer able exert significant influence company investment reported within investments since date investments include equity stakes companies research collaborations provide access biotechnology developments potential interest interests companies arise business divestments gsk annual report strategic report governance remuneration financial statements investor information derivative financial instruments assets noncurrent liabilities current derivative financial instruments held fair value noncurrent liabilities million december million million majority amount million included million related foreign exchange contracts designated million contingent consideration payable designated accounting hedges million million respect acquisition former shionogiviiv healthcare joint inventories venture million payable novartis relation inventory million increased million vaccines acquisition addition million increase primarily reflected impact novartis related present value estimated amount payable acquisition partly offset exchange movements us event full exercise novartis right require us trade receivables acquire shareholding consumer healthcare trade receivables million increased joint venture impacted novartis acquisition partly offset net debt exchange movements derivative financial instruments liabilities held current derivative financial instruments fair value cash cash equivalents liquid investments million million current million non borrowings repayable within one year current primarily related foreign exchange contracts borrowings repayable one year designated nondesignated intercompany loans trade net debt receivables accounting hedges trade payables december net debt billion compared trade payables amounting million increased billion december comprising gross debt million reflecting effect novartis billion cash liquid investments billion acquisition increase accruals customer returns decrease net debt primarily reflected impact novartis rebates transaction sold oncology business net cash proceeds billion paid billion net cash provisions acquired purchase novartis vaccines business carried deferred tax provisions shortterm noncurrent provisions million december first tax payments novartis transaction amounting million million million made addition sold part million related legal disputes million shareholding aspen cash proceeds million million related operational excellence paid dividends shareholders million net debt also provision provision made legal disputes reflected exchange loss translation cash held indemnified disposal liabilities employee related liabilities groups venezuelan subsidiaries costs restructuring programmes extent continuing political economic uncertainties balance sheet date legal constructive obligation existed venezuela december changed could reliably estimated exchange rate used translate subsidiaries venezuela pensions postemployment benefits point applied one official rates available account pension postemployment vef us december changed arrangements accordance ias deficits vef us vef change significant net surpluses allowing deferred taxation impact group income statement gave rise million million pension arrangements exchange loss translation cash held venezuelan million million unfunded post subsidiaries million employment liabilities decreases deficits december cash liquid investments held predominantly driven higher discount rates used follows discount value liabilities partly offset increase uk inflation rate together net obligations acquired result novartis transaction bank balances deposits december uk scheme purchased insurance us treasury treasury repo contract guarantee payment specified pensioner money market funds liabilities contract valued million liquidity funds december government securities cash liquid investments billion held centrally december gsk annual report strategic report governance remuneration financial statements investor information group financial review continued maturity profile gross debt equivalent gbp bonds eur bonds usd bonds bank borrowings leases analysis cash gross debt effects hedging total equity follows december total equity increased million december million increase arose impact operating profits business asset disposal profits partly offset cash liquid investments remeasurement viiv healthcare contingent consideration gross debt fixed dividends paid year floating noninterest bearing summary movements equity set net debt total equity beginning year movements net debt total comprehensive income year dividends shareholders ordinary shares issued net debt beginning year gain transfer net assets increasedecrease cash bank overdrafts consumer healthcare jv increasedecrease liquid investments consumer healthcare jv put option net increase longterm loans loss transfer equity investment net repayment shortterm loans investment associate exchange movements changes noncontrolling interests movements forward contract relating noncontrolling net debt end year interest shares purchased cancelled held treasury shares shares acquired esop trusts sharebased incentive plans tax sharebased incentive plans distributions noncontrolling interests total equity end year gain transfer net assets consumer healthcare joint venture million reflects difference book value gsk consumer healthcare net assets contributed joint venture fair value applied consideration novartis contributed assets consumer healthcare joint venture put option million reflects recognition initial value liability group balance sheet changes non controlling interest primarily reflect recognition novartis share consumer healthcare joint venture gsk annual report strategic report governance remuneration financial statements investor information share purchases entered number research collaborations employee share ownership plan esop develop new compounds pharmaceutical companies trusts acquired million shares glaxosmithkline plc terms arrangements include upfront fees equity million shares held trusts satisfy investments loans commitments fund specified levels future exercises options awards group share research addition often agree make payments option award schemes proportion shares held future milestones achieved trusts respect awards rules scheme agreements relate compounds early require us satisfy exercises market purchases rather stages development potential obligation make milestone issue new shares shares held trusts payments continue number years compounds matched options awards granted move successfully development process generally december esop trusts held million closer product marketing approval greater million gsk shares future exercise probability success amounts shown within share options share awards carrying value intangible assets represent maximum would paid million million deducted milestones achieved include billion reserves market value shares relates externalised projects discovery portfolio million million number new commitments made licensing agreements offset amendments shares repurchased december existing agreements held million shares treasury shares million shares cost million reached agreement trustees million deducted uk pension schemes make additional contributions retained earnings three year period including eliminate pension deficit identified december actuarial funding company expect make ordinary share valuation deficit persists contributions would repurchases ordinary shares purchased payable following four years depending level deficit period january february table includes commitment excludes normal commitments contingent liabilities ongoing annual funding requirement uk approximately financial commitments summarised note financial million information pension obligations see statements commitments contingent liabilities note financial statements pensions post obligations respect short longterm debt set employment benefits note financial statements contingent liabilities contingent liabilities note financial statements net debt following table sets contingent liabilities comprising amounts provided pensions postretirement benefits discounted bills performance guarantees letters credit set note financial statements pensions items arising normal course business postemployment benefits amounts provided restructuring expected expire programmes legal environmental disputes set note financial statements provisions total yr yrs yrs yrs contractual obligations commitments guarantees following table sets contractual obligations contingent liabilities commitments december fall due payment total total yr yrs yrs yrs normal course business provided various indemnification guarantees respect business disposals loans legal disputes subsequently arisen interest loans provision made outflow resources considered finance lease obligations probable reliable estimate made likely outcome finance lease charges dispute included note financial operating lease statements provisions commitments provide outcome tax legal disputes intangible assets outflow resources considered probable reliable property plant equipment estimate outflow may made december investments disputes provision made possible make reliable estimate potential purchase commitments outflow funds might required settle disputes pensions possibility outflow remote commitments total ultimate liability matters may vary significantly amounts provided dependent upon outcome commitments respect loans future interest payable litigation proceedings negotiations relevant tax loans disclosed taking account effect authorities discussed risk factors pages derivatives notes financial statements taxation legal proceedings gsk annual report strategic report governance remuneration financial statements investor information group financial review continued however following recent review prospects viiv noncontrolling interests viiv healthcare healthcare business conclusion intended retain viiv healthcare decided put options held trading profit allocations pfizer shionogi recognised groups viiv healthcare subsidiary group balance sheet liability put options recognised operating results turnover operating profit profit tax groups balance sheet ifrs requires agreements included within group income statement portion giving us rights withhold consent changed remove earnings allocated noncontrolling interests owned rights notified pfizer shionogi shareholders line respective equity irrevocably given rights recognise shareholdings pfizer shionogi liability put options groups balance sheet shareholders including gsk also entitled preferential estimated present value liability two put options dividends determined performance certain products approximately billion adjustments value shareholder contributed relative performance preferential dividends due shareholders products changes time proportion overall earnings viiv healthcare allocated shareholder change consistent revised treatment also expect particular increasing sales tivicay triumeq recognise liabilities groups balance sheet future favourable impact proportion preferential dividends preferential dividends anticipated become payable pfizer allocated us entitled approximately shionogi estimated aggregate present value liability core earnings viiv healthcare preferential preferential dividends pfizer shionogi approximately dividends allocated pfizer shionogi included million noncontrolling interest line acquisitionrelated arrangements critical accounting policies part agreement reached acquire shionogis interest former shionogiviiv healthcare joint venture consolidated financial statements prepared accordance agreed pay additional consideration shionogi contingent ifrs adopted use european union also performance products developed joint ifrs issued iasb following accounting policies venture principally dolutegravir december fair approved board described note financial value contingent consideration due representing statements accounting principles policies discounted value total amount estimated payable required make estimates assumptions affect million recognised groups amounts assets liabilities revenue expenses reported balance sheet million shown trade payables financial statements actual amounts results could differ million noncurrent liabilities estimates payments made shionogi quarter reduce liability critical accounting policies information instalments payments calculated based sales judgements estimates made given note financial performance relevant products previous quarter statements key accounting judgements estimates reflected cash flow statement partly operating cash relevant detailed notes financial statements indicated flows partly purchases businesses within investing relate following areas activities part payment relating original estimate fair value contingent consideration acquisition turnover shionogiviiv healthcare joint venture taxation note million reported purchases businesses part legal disputes notes payment relating increase liability since goodwill intangible asset impairments notes acquisition reported within operating cash flows cash payments amounted million total business combinations note million reported operating cash flows million pensions postemployment benefits note purchases businesses information judgements estimates made areas exit rights given note financial statements key accounting certain circumstances pfizer shionogi may require us judgements estimates acquire shareholdings price based likely valuation turnover viiv healthcare conduct initial public offering respect turnover accounting policy largest business ipo pfizer may request ipo viiv healthcare time us pharmaceuticals vaccines us market either consent ipo offering complex arrangements rebates discounts completed within nine months pfizer could require us acquire allowances following briefly describes nature shareholding shionogi may also request gsk acquire arrangements existence us pharmaceuticals shareholding viiv healthcare certain circumstances six vaccines business month windows commencing arrangements certain indirect customers whereby original agreements unconditional right customer able buy products wholesalers long made subsequent distribution shareholders reduced prices chargeback represents difference withhold consent exercise either pfizer invoice price wholesaler indirect shionogi put options result accordance ifrs customers contractual discounted price accruals estimating recognise liabilities put options chargebacks calculated based terms balance sheet agreement historical experience product growth rates gsk annual report strategic report governance remuneration financial statements investor information customer rebates offered key managed care group monthly process operated monitor inventory levels purchasing organisations gpo direct indirect wholesalers abnormal movements process uses gross customers arrangements require customer achieve sales volumes prescription volumes based third party data certain performance targets relating value product sources information received key wholesalers aim purchased formulary status predetermined market shares maintain inventories consistent level year relative competitors accrual customer rebates year based pattern consumption estimated based specific terms agreement basis us pharmaceuticals vaccines inventory levels historical experience product growth rates wholesalers distribution channels december us medicaid programme stateadministered estimated amount approximately five weeks programme providing assistance certain poor vulnerable turnover calculation uses third party information accuracy patients medicaid drug rebate program totally verified believed sufficiently established reduce state federal expenditure reliable purpose prescription drugs patient protection legal disputes affordable care act became law participate providing respect accounting policy legal disputes rebates states accruals medicaid rebates calculated following briefly describes process determine based specific terms relevant regulations level provision necessary patient protection affordable care act accordance requirements ias provisions cash discounts offered customers encourage prompt contingent liabilities contingent assets provide payment accrued time invoicing anticipated settlement costs outflow resources adjusted subsequently reflect actual experience considered probable reliable estimate may made record accrual estimated sales returns applying likely outcome dispute legal expenses arising historical experience customer returns amounts invoiced claims group may become involved together market related information stock levels significant legal proceedings respect possible wholesalers anticipated price increases competitor activity make reliable estimate expected financial effect could result ultimate resolution proceedings reconciliation gross turnover net turnover us cases appropriate disclosure cases would pharmaceuticals business including puerto rico follows included annual report provision would made restated restated position could change time therefore margin margin margin assurance losses result outcome legal proceedings exceed material amount amount gross turnover provisions reported groups financial statements like many pharmaceutical companies faced various market driven complex product liability antitrust patent litigation well segments investigations operations conducted various governmental government regulatory agencies throughout year general counsel mandated state group head groups legal function programs senior vice president head global litigation group responsible litigation government investigations cash discounts routinely brief chief executive officer chief financial customer officer board directors significant litigation returns pending group governmental investigations prior year group adjustments meetings appropriate detail status significant items litigation government investigations review matters total deductions number claims notified us information potential net turnover claims yet notified assessment validity claims progress made settling claims recent settlement levels market driven segments consist primarily managed care potential reimbursement insurers medicare plans gsk negotiates contract pricing honoured via rebates chargebacks mandated segments meetings also include assessment whether consist primarily medicaid federal government programs sufficient information available us able make receive government mandated pricing via rebates reliable estimate potential outcomes disputes chargebacks often external counsel assisting us various litigation matters investigations also assist briefing board balance sheet accruals rebates discounts allowances senior management following discussions returns us pharmaceuticals vaccines business matters possible make reliable estimate managed combined basis december total amount provision may required level accrual amounted million million provision legal disputes reviewed adjusted appropriate matters discussed note financial statements legal proceedings gsk annual report strategic report governance remuneration financial statements investor information group financial review continued foreign exchange risk management treasury policies foreign currency transaction exposures arising internal external trade flows typically hedged objective report sterling pay dividends sterling profits minimise exposure overseas operating subsidiaries role corporate treasury monitor manage transaction risk matching local currency income local external internal funding requirements financial risks currency costs possible internal trading transactions support strategic objectives operate global matched centrally manage intercompany payment basis primarily subsidiary companies manage terms reduce foreign currency risk foreign currency cash flows capital ensure subsidiaries able operate hedged selectively management treasury going concerns optimise returns shareholders tmg include hedges foreign exchange risk appropriate balance debt equity treasury activities arising acquisitions disposals assets possible governed policies approved annually board directors manage cash surpluses borrowing requirements recently july treasury management group subsidiary companies centrally using forward contracts hedge tmg meeting chaired chief financial officer takes place future repayments back originating currency monthly basis review treasury activities members receive management information relating activities order reduce foreign currency translation exposure seek denominate borrowings currencies principal assets treasury operations cash flows primarily denominated us dollars objective treasury activity minimise posttax euros sterling certain borrowings swapped net cost financial operations reduce volatility order currencies required benefit earnings use variety financial instruments finance operations derivative financial instruments borrowings denominated swapped foreign currencies manage market risks operations derivatives match investments overseas group assets may treated principally comprising forward foreign currency contracts foreign hedge relevant assets forward contracts major currency options interest rate swaps used swap currencies also used reduce exposure investment borrowings liquid assets currencies required group overseas group assets tmg reviews ratio borrowings purposes manage exposure financial risks changes assets major currencies monthly foreign exchange rates interest rates counterparty risk management hold issue derivatives speculative purposes set global counterparty limits banking treasury policies specifically prohibit activity investment counterparties based longterm credit ratings transactions financial instruments undertaken manage moodys standard poors corporate treasurys usage risks arising underlying business activities limits monitored daily corporate compliance officer speculation cco operates independently corporate treasury breach limits would reported cfo immediately capital management financial strategy implemented financial cco also monitors credit rating counterparties architecture supports groups strategic priorities changes ratings occur notifies corporate treasury regularly reviewed board manage capital structure changes made investment levels authority group appropriate mix debt equity limits appropriate addition relationship banks credit ratings reviewed regularly report presented annually longterm credit rating standard poors tmg approval stable outlook moodys investor services moodys negative outlook shortterm credit ratings p standard poors moodys respectively liquidity risk management policy borrow centrally order meet anticipated strategic report funding requirements cash flow forecasts funding requirements monitored tmg monthly basis strategic report approved board directors strategy diversify liquidity sources using range march signed behalf facilities maintain broad access funding markets day sweep cash number global subsidiaries central treasury accounts liquidity management purposes interest rate risk management simon dingemans chief financial officer objective minimise effective net interest cost march balance mix debt fixed floating interest rates time policy interest rate risk management limits amount floating interest payments prescribed percentage operating profit gsk annual report gsk annual report strategic report governance remuneration financial statements investor information governance remuneration section board corporate executive team board governance corporate governance framework committee reports audit risk nominations corporate responsibility remuneration report chairmans annual statement annual report remuneration remuneration policy summary gsk annual report gsk annual report strategic report governance remuneration financial statements investor information board sir philip hampton skills experience nonexecutive chairman prior joining gsk sir philip chaired major ftse companies including royal bank scotland group plc j sainsbury plc nationality also served group finance director lloyds tsb group british bt group plc bg group plc british gas british steel plc appointment date sir philip previously appointed executive director lazards january deputy nonexecutive director rmc group plc belgacom sa chairman april chairman uk financial investments limited nonexecutive chairman manages uk governments shareholdings banks may external appointments committee membership sir philip currently senior independent director anglo nominations committee american plc chairman remuneration committee chairman finance member audit committee sir philip also chair women boards review independent review increasing representation women executive level ftse companies sir andrew witty skills experience chief executive officer sir andrew joined gsk worked uk south africa us singapore various senior roles nationality appointed president europe joined gsks corporate british executive team andrew served numerous advisory roles appointment date governments around world including south africa singapore january guangzhou china uk member chief executive officer prime ministers business advisory group may awarded knighthood services economy uk pharmaceutical industry new year honours list committee membership finance external appointments sir andrew appointed uk business ambassador group chinabritain business council advisory council school economics management advisory board sem tsinghua university beijing china sir andrew chancellor university nottingham simon dingemans skills experience chief financial officer prior joining gsk simon years experience investment banking sg warburg goldman sachs nationality time advised broad range large corporates across number british industry sectors including pharmaceuticals consumer healthcare appointment date simon advised gsk decade appointment january chief closely involved number gsks key strategic projects financial officer april external appointments committee membership simon chairman group finance directors finance dr moncef slaoui skills experience chairman global vaccines moncef joined gsk vaccines engineered development robust vaccines pipeline led worldwide nationality business development pharmaceutical products moroccan belgian american appointment lead rd given overall responsibility appointment date gsks oncology business gsk vaccines may global franchises moncef advised us presidents council advisors science technology committee membership member board agency science technology finance research astar january phd molecular biology immunology universit libre de bruxelles published scientific papers presentations prior joining gsk moncef professor immunology university mons belgium external appointments moncef member biotechnology industry organization board us member advisory committee director national institutes health also adviser qatar foundation member qatar biomedical research institute scientific advisory committee moncef serves nonexecutive director international aids vaccine initiative iavigsk annual report strategic report governance remuneration financial statements investor information sir deryck maughan skills experience senior independent sir deryck wealth international corporate investment nonexecutive director banking experience previously served chairman chief executive officer citigroup international salomon nationality brothers inc served vice chairman new york stock british exchange sir deryck former senior adviser appointment date partner kohlberg kravis roberts co previously served june senior nonexecutive director thomson reuters independent nonexecutive external appointments director may sir deryck nonexecutive director blackrock inc committee membership trustee british museum audit risk nominations remuneration finance professor sir roy anderson skills experience independent nonexecutive professor sir roy worldrenowned medical scientist advanced director scientific expert knowledge infectious disease epidemiology currently professor infectious disease faculty medicine imperial nationality college london fellow royal society academy british medical sciences royal statistical society honorary appointment date fellow institute actuaries foreign associate member october national academy medicine us national academy sciences french academy sciences professor sir roy committee membership brings scientific expertise boards deliberations nominations finance external appointments professor sir roy member international advisory board holdingham group chairman science advisory board natural history museum london also member vaccine international advisory board vacciab aj pharma holding sdn bhd malaysia manvinder singh vindi skills experience banga prior joining gsk vindi spent years unilever plc independent nonexecutive last role amongst several senior positions president global director foods home personal care businesses member unilever executive board vindi sat prime minister indias nationality council trade industry board indian governors indian institute management iim ahmedabad appointment date vindi also recipient padma bhushan one indias highest september civilian honours committee membership external appointments audit risk nominations vindi partner private equity investment firm clayton dubilier remuneration finance rice also chairman supervisory board mauser group senior independent director marks spencer group plc member nominations remuneration committees also nonexecutive director thompson reuters corp member hr committee vindi governing board indian school business isb hyderabad dr stephanie burns skills experience independent nonexecutive stephanie recognised global business leader served director chairman president ceo dow corning corporation retirement end strong scientific background nationality phd organic chemistry organosilicon speciality american advocate science education stephanie previously sat appointment date us presidents export council officer society february chemical industry american section well past honorary president ukbased parent society stephanie also committee membership officer chairman american chemistry council corporate responsibility remuneration finance external appointments stephanie nonexecutive director corning inc kellogg company appointed board hp inc november gsk annual report strategic report governance remuneration financial statements investor information board continued stacey cartwright skills experience independent nonexecutive stacey chartered accountant significant experience director global consumer businesses corporate finance served executive vice president chief financial officer burberry group plc nationality july prior joining burberry group plc stacey held british role chief financial officer egg plc appointment date worked various financerelated positions april granada group plc committee membership board determined stacey recent relevant financial audit risk finance experience agreed appropriate qualifications background audit committee financial expert external appointments stacey chief executive officer harvey nichols group companies lynn elsenhans skills experience independent nonexecutive lynn wealth experience running global business director significant knowledge global markets gsk operates served chair president chief executive officer sunoco nationality inc prior joining sunoco president american chief executive officer lynn worked royal dutch shell appointment date joined held number senior roles including july executive vice president global manufacturing committee membership external appointments corporate responsibility lynn nonexecutive director baker hughes inc committee chairman flowserve corporation director texas medical center audit risk nominations nonexecutive director first tee greater houston finance also trustee united way greater houston dr jesse goodman skills experience independent nonexecutive dr goodman previously served senior leadership positions us director scientific expert food drug administration fda including recently fdas chief scientist previously deputy commissioner science nationality public health director center biologics evaluation american research cber appointment date dr goodman played leadership role developing fdas regulatory january science medical countermeasures initiatives worked committee membership collaboratively industry academia government global public finance health regulatory partners prepare respond major public health threats including emerging infectious diseases disasters terrorism led fdas response west nile virus hn influenza pandemic served senior leadership team white house medical countermeasure review dr goodman brings scientific public health expertise boards deliberations external appointments dr goodman currently professor medicine georgetown university directs georgetown university center medical product access safety stewardship compass active clinician serves attending physician infectious diseases also serves president member board united states pharmacopeia usp judy lewent skills experience independent nonexecutive judy extensive knowledge global pharmaceutical industry director corporate finance joined merck co served chief financial officer retired judy nationality previously nonexecutive director purdue pharma inc napp american pharmaceutical holdings limited certain mundipharma international appointment date limited companies december judy previously served april nonexecutive director dell inc quaker oats company committee membership board determined judy recent relevant financial audit risk committee experience agreed appropriate qualifications chairman nominations background audit committee financial expert remuneration finance external appointments judy nonexecutive director thermo fisher scientific inc motorola solutions inc also trustee rockefeller family trust chairperson audit committee rockefeller financial services life member massachusetts institute technology corporation member american academy arts sciencesgsk annual report strategic report governance remuneration financial statements investor information dr daniel podolsky skills experience independent nonexecutive daniel worldrenowned researcher advanced knowledge director scientific expert underlying mechanisms disease new therapies gastrointestinal disorders formerly mallinckrodt professor nationality medicine chief gastroenterology massachusetts general american hospital harvard medical school previously served appointment date chief academic officer partners healthcare system daniels july current responsibilities leading large academic medical centre give relevant insight healthcare delivery daniel brings scientific committee membership expertise board audit risk committees deliberations audit risk corporate responsibility finance external appointments daniel president university texas southwestern medical center holds philip obryan montgomery jr md distinguished presidential chair academic administration doris bryan wildenthal distinguished chair medical science member national academy medicine us national academy sciences member board southwestern medical foundation director antibe therapeutics inc also member national academies sciences board army science technology urs rohner skills experience independent nonexecutive urs broad range business legal experience served director chairman number boards recently credit suisse world leading financial services company prior joining credit nationality suisse urs served chairman executive board swiss ceo prosieben prosiebensat media ag followed appointment date number years private practice major law firms switzerland january us admitted bars canton zurich state new york committee membership remuneration committee external appointments chairman finance urs currently appointed chairman board credit suisse group ag chairmans governance committee also appointed chairman member board trustees credit suisse research institute credit suisse foundation urs appointed vicechairman governing board swiss bankers association hans wijers skills experience independent nonexecutive hans broad range business economic political director experience served chief executive officer chairman akzo nobel nv hans long nationality distinguished career academia public service strategy dutch consulting served senior partner boston consulting appointment date group april external appointments committee membership hans chairman supervisory board heineken nv also corporate responsibility deputy chairman nonexecutive director royal dutch shell remuneration finance chairman supervisory board afc ajax member supervisory board hal holding nv gsk annual report strategic report governance remuneration financial statements investor information corporate executive team ceo assistance corporate executive team responsible management business developing groups strategic direction consideration approval board implementing agreed strategy sir andrew witty simon dingemans dr moncef slaoui chief executive officer chief financial officer chairman global vaccines biographical details see roger connor nick hirons abbas hussain president global manufacturing supply senior vice president global ethics president global pharmaceuticals compliance roger joined cet appointed abbas joined cet appointed president global manufacturing supply nick appointed cet september president global pharmaceuticals october gms working year senior vice president global ethics joined company president president designate gms compliance responsible emerging markets asia pacific june compliance risk management corporate joined viiv healthcare ltd board roger joined gsk astrazeneca security investigations october worked finance manufacturing strategy roles including gsk sites cork nick joined gsk international previously spent years eli lilly ireland ware uk prior auditor uk later head audit held positions including president europe position gms roger vice president assurance combined five vice president europe office ceo corporate strategy separate audit functions independent also held positions eli lilly australia february team operating common riskbased us india turkey germany several methodology june nick took roles including business development sales holds degree mechanical role china established new marketing management manufacturing engineering queens governance model china business university belfast masters degree medicinal chemistry created consistent approach compliance manufacturing leadership cambridge pharmacology loughborough university university also chartered accountant nick fellow chartered institute born madras india management accountantsgsk annual report strategic report governance remuneration financial statements investor information david redfern claire thomas phil thomson chief strategy officer senior vice president human resources senior vice president communications government affairs david joined cet chief strategy officer claire appointed cet senior vice may responsible corporate president human resources may phil joined cet appointed development strategic planning senior vice president communications claire joined company senior addition appointed chairman government affairs manager human resources sales board viiv healthcare ltd april responsibility media relations investor marketing group uk pharmaceuticals nonexecutive director aspen relations corporate responsibility internal becoming director human resources pharmacare ltd board february communications product communications uk pharmaceuticals government affairs gsks global brand previously senior vice president appointed senior vice president human northern europe responsibility gsks resources pharmaceuticals europe joined glaxo wellcome trainee pharmaceutical businesses region senior vice president human resources moving pharmaceutical brand marketing prior senior vice president international product communications became central eastern europe david joined director media relations glaxo wellcome prior joining company worked gsk finance director plc director investor relations ford motor company holding various european business returned positions human resources corporate media relations vice president david bachelor science degree claire bachelor science degree phil worked numerous corporate bristol university uk chartered economics management industrial product reputational matters gsk accountant relations university wales phil earned degree english history durham university dan troy patrick vallance emma walmsley senior vice president general counsel president pharmaceuticals rd ceo gsk consumer healthcare dan joined gsk cet senior patrick joined cet emma ceo gsk consumer healthcare vice president general counsel appointed president pharmaceuticals rd includes joint venture novartis september january prior senior listed consumer healthcare vice president medicines discovery businesses india nigeria business previously partner development split almost equally otc washington law firm sidley austin llp medicines fast moving consumer goods represented mainly pharmaceutical patrick joined company head brands across four categories wellness companies trade associations matters drug discovery prior joining gsk oral health nutrition skin health related us food drug patrick clinical academic led administration fda government division medicine university college prior emma president gsk regulations dan formerly chief counsel london years experience consumer healthcare fda served primary research clinical medicine general internal member cet since joined liaison white house us medicine cardiovascular medicine clinical gsk department health human services pharmacology elected prior emma worked loreal academy medical sciences dan graduate cornell universitys years degree classics school industrial labor relations patrick board uk modern languages oxford university earned law degree columbia office strategic coordination health emma became nonexecutive director university school law dan named research oschr since diageo plc effect january legend law burton awardsstrategic report governance remuneration financial statements investor information corporate governance board governance strategy progress towards delivery set strategic report following pages provide information board oversight groups activities board board pleased report full compliance requirements financial reporting councils frc uk corporate governance code code exception code provision c requires audit contract tenders undertaken least every years sets details years audit contract tender process copy code available frcs website wwwfrcorguk board responsible longterm success company accountable shareholders ensuring group appropriately managed governed believe governance structure provides right base help us deliver strategy grow diversified business deliver products value simplify operating model create additional longterm value shareholders board programme board met face face six times board member attended scheduled board meetings board agendas shaped create time strategic discussion debate closely managing time allocated routine items ensure focused consideration strategic priorities agendas board meetings included following business month strategy board risk oversight governance january review ceo objectives review financial results secretarys report including outlook regulatory governance updates review investor activity reappointment auditors activity novartis transaction update approval budget plan march review reshaped consumer review financial results secretarys report including healthcare global pharmaceuticals year date regulatory governance updates businesses ebola vaccines update mandatory annual corporate integrity deep dive us pharmaceuticals agreement cia training pricing formulary access may review revised plan review financial results secretarys report including long range forecasting following year date regulatory governance updates completion novartis transaction global manufacturing supply preparation agm annual update novartis transaction update review annual cia agreement compliance resolutions july annual review talent leadership r eview financial results secretarys report including development strategy year date regulatory governance updates review funding strategy vaccines annual update including treasury policy integration pipeline review pensions insurance strategies proposed agenda annual board cet strategy meeting review going concern assumptions october nnual board cet strategy meeting r eview financial results secretarys report including regulatory review output annual year date governance updates board cet strategy meeting rd annual update quality update n ew healthcare professional hcp model update december review budget r eview financial results secretarys report including regulatory plan year date governance updates supply chain update nucala launch plans pricing update uring year board members invited attend audit risk committee meetings risk matters routinely discussed gsk annual report gsk annual report strategic report governance remuneration financial statements investor information board governance continued board performance action points progress conclusions board evaluation review independently facilitated dr tracy long boardroom review limited set key findingsaction points progressachievement composition board due change next two three years board composition assessment exercise require carefully planned thoughtfully executed refreshment programme undertaken enable nominations committee plan board chairman designate together nominations committee seek enhance changes due occur next years governance processes relating board composition tenure size ensure board review seek develop objective specifications plans boards roles necessary skills alignment strategy external landscape companys evolving circumstances directors identified gaps boards current composition relating us board pleased vindi banga pricing healthcare emerging markets consumer healthcare knowledge dr jesse goodman sid designate sme respectively agreed join board closing knowledge experience gaps considered part process appointments helped fill recruitment new nonexecutive directors combined refreshment designated identified skills gaps nominations specialist roles board scientific medical expertise sme senior committee continues refresh board independent director sid meet companys future needs given speed complexity external landscape changes potential characteristics factored surprises highly experienced nonexecutive directors crucial component individual search profiles selection boards composition process recruit new nonexecutive directors critical skill sets potential candidates international markets cultural experience crisis stakeholder management considered composition choices peer group boards benchmarked replacement current sid due retire agm priority issue vindi banga whose background experience fulfilled requirements chairman designate leading search involving internal external candidates sid specification appointed sid role designate september sid specification developed balances replacement existing knowledge succeed sir deryck maughan current sid ability work well chairman designate conduct robust board evaluations conclusion agm interact well shareholders able commit necessary time role consideration given reducing size board judged board recommendation strong enough composition dynamic nominations committee agreed working towards ideal board size around aspiration considered refreshed board competenceskills matrix directors used part board refreshment programme linked companys strategy consideration given enhancing nonexecutive director evaluation process chairman concluded review agreed introduce peer evaluation chairman designate lead process consider best practice techniques inform annual review meetings combination annual individual peer evaluations board director board performance action points agreed action points arising board evaluation review internally facilitated company secretary victoria whyte progress disclosed gsks annual report set executive succession deep dives board materials strategy ned refreshment sites visits shareholders logistics assist newer directors increase focus consider deep review look continue drive make additional background executive succession dives particularly enhance boardcommittee materials briefing materials ahead plans ensure rd strategy pipeline company communicates concise also debates strategy effectiveness product launches shareholders effective highlighting disaster recovery plan us pricing joint ventures issues concerns arrange regular new business models discussion medium consider alternative aim less gms longer term strategy suggestions non presentation time fresh insights different executive director consider holding one site time discussion perspectives refreshment visit operational site debate meetings year implement suggestions allow social time enhance board members get effectiveness annual know better board cet strategy given number new meetings board members gsk annual report strategic report governance remuneration financial statements investor information corporate governance continued corporate governance framework board coherent corporate governance framework clearly defined responsibilities accountabilities designed safeguard enhance longterm shareholder value provide robust platform realise groups strategy grow deliver simplify internal control risk management arrangements described pages integral part gsks governance framework board committees board operate effectively give full consideration key matters board committees established board summary role board committee set table full terms reference committee available wwwgskcom reports membership work undertaken audit risk nominations corporate responsibility remuneration committees given pages board chief executive officer corporate executive team corporate corporate administration audit risk remuneration nominations responsibility finance transactions committee committee committee committee committee committee reviews reviews reviews reviews reviews reviews responsible recommends recommends external issues approves approves financial internal board board potential annual report matters reporting processes overall executive structure size serious impact upon form f connection integrity remuneration policy composition gsks business convening administration financial statements reference board reputation agm groups including remuneration appointment management quarterly results business annual report employees directors committee announcements certain corporate annual governance quarterly results appropriate fees members cet oversight gsks certain major transactions announcements chairman members responsible business licensing capital system internal succession commitments transactions controls determines board cet changes identification terms service groups investment management remuneration instrument risks external executive directors counterparty limits internal audit members processes cet initiating audit tenders reviews selection approves appointment remuneration external auditors report remuneration oversight workgsk annual report strategic report governance remuneration financial statements investor information leadership effectiveness chairman role chairman lead manage business board provide direction focus ensuring clear structure effective operation board committees sets agenda board discussions promote effective constructive debate support sound decisionmaking process sir philip hampton succeeded sir christopher gent chairman may works closely chief executive officer sir andrew witty ensure strategies actions agreed board effectively implemented also provides support advice sir andrew respecting executive responsibility managing group division responsibilities chairman ceo agreed board set governance section website sir philip satisfied frc codes independence test appointment board responsible shareholders performance group leads discussions nonexecutive directors nonexecutive directors provide strong independent element board well placed constructively challenge support management shape proposals strategy succession planning bring independent judgement breadth skills experience gained senior levels international business operations academia nonexecutive director letter appointment sets terms conditions directorship nonexecutive directors expected devote time necessary proper performance duties precise timings given vary year year depending companys activities expected attend board meetings additional meetings required board considers nonexecutive directors including tenure nine years demonstrate appropriate degree independence character judgement free business relationship could materially interfere exercise judgement independence commitment nonexecutive directors served board six years subjected rigorous review senior independent sir deryck maughan senior independent nonexecutive director sid since may nonexecutive director sir derycks role act sounding board chairman trusted intermediary directors sid also works process selection new chairman appropriate chairs nominations committee agreeing recommendation board chairmans successor sir deryck maintains understanding issues concerns major shareholders meetings reports investor relations team briefings company secretary corporate governance issues vindi banga succeed sir deryck sid retires board agm may ceo sir andrew responsible management business developing groups strategic direction consideration approval board implementing agreed strategy assisted members corporate executive team cet meets least times year often required short biographies members cet given corporate executive team pages company secretary company secretary victoria whyte solicitor fellow institute chartered secretaries administrators victoria formerly deputy secretary secretary remuneration committee acted secretary board boards committees since appointment company secretary january victoria whyte supports chairman designing induction new directors delivery corporate governance agenda particular planning agendas annual cycle board committee meetings ensuring information made available board members timely basis advises directors board procedures corporate governance matters arranges nonexecutive directors meet investors discuss aspects corporate governance arrangements request also arranges attend internal management meetings make visits business operations enhance knowledge understanding business company secretary responded various consultations evolving global governance corporate reporting agenda behalf group engaged shareholders ensure fully understood gsks governance remuneration arrangements request chairman undertakes evaluation board committees collaboration committee chairmen years evaluation conducted internally gsk annual report strategic report governance remuneration financial statements investor information corporate governance continued diversity experience international experience composition tenure nonexecutives scientific global executive years finance us nonexecutive years industry europe male years emap female years board addition scheduled meetings board also met board met face face six times member quorate basis five occasions consider corporate attending follows transactions including novartis transaction number board member since meetings attended board induction sir philip hampton january number new nonexecutive directors joined sir andrew witty january board year undertaken board induction programmes commenced appointed simon dingemans january programme devised new chairman based dr moncef slaoui may principles companys new nonexecutive directors sir deryck maughan june programmes outlined customised take account leadership role gsk core element professor sir roy anderson october individual meetings held listening tour gsks major vindi banga september shareholders understand firsthand views perspectives group companys strategy leadership business model dr stephanie burns february performance trading environment stacey cartwright april enhanced programme set full gsks lynn elsenhans july annual report judy lewent april induction programmes urs rohner vindi banga dr jesse goodman dr daniel podolsky july ndividually designed facilitated chairman urs rohner january company secretary hans wijers april ii designed purpose orientate familiarise sir christopher gent june industry organisation governance strategy grow deliver simplify tom de swaan january iii c ustomised take account respective experience jing ulrich july different geographical backgrounds business perspectives light particular roles would dr jesse goodman appointed nonexecutive director effect january perform committees would serve board member seeking reelection gsks agm key elements induction programmes including onetoone attended six scheduled board meetings briefings teachin sessions site visits undertaken directors retired board may urs rohner vindi banga dr jesse goodman set board composition diversity seek build effective complementary board whose executive directors discuss gsks strategic financial capability appropriate scale complexity strategic rd priorities positioning business process board appointments cet members cover principal pharmaceuticals led nominations committee described consumer healthcare vaccines businesses together pages rd gms organisations underpin operating model mindful need balance composition board committees refresh progressively time senior executives cover core operations draw upon experience longer serving directors strategic development finance tax treasury audit tapping new external perspectives insights assurance hr investor relations global ethics recent appointees bring boards deliberations compliance nonexecutive directors drawn wide range industries site visits gms vaccines rd facilities backgrounds including pharmaceutical healthcare nvestor meetings particularly customised medical research academia retail insurance financial vindi banga role sid services appropriate experience complex organisations cia new director receives two hours training global reach considerable experience cia obligations pharmaceutical industry recent appointees bring new approach group board discussions boards diversity policy set details gender diversity gsks global workforce see strategic report governance remuneration financial statements investor information board business awareness training accountability ensure nonexecutive directors develop maintain greater insight understanding business internal control framework invited attend internal management meetings including board recognises responsibilities present fair meetings cet research development executive balanced understandable assessment groups position radex product executive scientific review board prospects board accountability reviewing portfolio investment board us commercial accountability approving effectiveness internal controls operated board risk oversight compliance council rocc group including financial operational compliance controls also meet employees informally visits groups risk management operations receptions held around board meetings gsk internal control framework framework chairman also meets director annually oneto means gsk assures compliance laws one basis discuss ongoing training development regulations reliability financial reporting requirements board kept uptodate legal regulatory effectiveness risk management framework assists governance matters regular papers company ongoing process boards identification evaluation secretary presentations internal external advisers management companys principal risks required board members undertook specific refresher training frcs code designed manage rather eliminate provisions cia march new board risk achieving business objectives fitforpurpose internal member required part induction programme control framework conjunction embedding gsk values receive comprehensive training cia philip hampton speak reporting lines ensures principal risks urs rohner january vindi banga september actively effectively controlled information see jesse goodman january taken part approach risk pages training session part induction programmes framework designed ensure risks associated conducting business activities effectively controlled line internal evaluation board gsks risk appetite believe framework provides board carries evaluation performance reasonable absolute assurance material committees every year evaluation facilitated misstatement loss externally every third year progress board ensure effective governance ethical culture gsk agreed action points evaluation externally facilitated dr tracy long boardroom review limited established risk oversight compliance council rocc disclosed team senior leaders authorised board assist audit risk committee committee overseeing risk board committees evaluation process management internal control activities also provides conducted internally secretary request business framework risk management upward reporting chairman ceo significant risks gsk values policies business unit prepared surveys completed board members global support function risk board structure held interviews director reports rocc risk management compliance boards rmcb responsible local tone top risk discussed outcomes recommendations management internal controls chairman rocc rmcbs assisted global ethics following discussion board whole identified areas improvement agreed board compliance gec responsible supporting risk management development implementation amongst areas reviewed board oversight issues practices facilitate employees compliance laws shareholders stakeholder relationships board culture policy gec also provides assistance help employees meet balances challenge support ethics strategy high ethical standards operating accordance values priorities comply applicable laws regulations corporate board viewed members effective strong well responsibility able equipped navigate challenges ahead action gsks audit assurance aa provides objective view points arising evaluation disclosed ie assurance senior management board risk chairman nonexecutive director evaluation managed across group line agreed assurance senior independent nonexecutive director sid sought plan assurance helps meet oversight advisory feedback chairmans performance canvassed views responsibilities fulfilling strategic operational ambitions chairmans performance nonexecutive directors building trust patients stakeholders aa collectively results chairmans effectiveness review dual reporting line cfo committee discussed chairman sid committee receives reports business unit heads gec chairman met nonexecutive director discuss aa areas significant risk group related individual contributions performance together training internal controls reports provide summaries changes development needs also shares peer feedback control environment within principal risk area following provided part evaluation process addition consideration reports committee reports annually chairman met nonexecutive directors independently board effectiveness controls executive directors gsk annual report gsk annual report strategic report governance remuneration financial statements investor information corporate governance continued board committee conducted robust accordance provisions frcs code assessment groups principal risks framework provide board responsible determining considered effectiveness system internal nature extent principal risks willing take controls operation across group year covered achieving strategic objectives board provides oversight annual report date approval board help ensure group maintains sound risk management boards review focuses company subsidiaries internal control systems framework operation extend material associated undertakings joint whole year continues operate beyond ventures investments although considers risk date approval annual report companys participation activities established review groups risk management approach procedures controls place identify entities whose results discussed approach risk section strategic report must consolidated groups results pages management mitigation believe process followed board principal risk explained principal risks uncertainties committee reviewing regularly system internal controls pages groups viability discussed risk management arrangements accordance group financial review section strategic report guidance risk management internal control related financial business reporting issued frc ongoing review monitoring arrangements expanded year include impact novartis transaction closed march details see internal control framework e n terprise oversight b ira er cd oo rf r ofe cs op ro pn os ri ab tl ee gfo v eu rnr ny cs ete strategy risk management independent assurance financial performance disi ci epn l ni fond c e eap mn ede ntnden sb seu r ss ss mi kn ee ns ts csn ot nai tnt row lsar rr dti sten ng cou mdi mt tr ei esk r cn n oe ad ns n tp aa e roo gp ff ln ep e ss mcroi tb eiv vl nie en n gf ao e ntr sh dr see ov nai f tde eow e ru nqi rn au g r la sc ky business ot p ro ble ser sp n ding activities training c eo xerp cuor ta ivt ee team anu dp n p ago cir tn vs g ioh eue sr c uso en na itg oe rm ine gnt communication risk oversight authorised board compliance assist audit risk council committee overseeing risk management internal control activities group gsk values business units responsible identifying key assessing managing risks individual accountability within businesses line management accountability compliance business management accountability compliance risk oversight ensure appropriate audit assurance compliance internal controls effective risk council management implemented complemented country executive risk boards ensure consistent approach risk management across local geographies gnirotinom rof ytilibatnuocca gnitnemelpmi rof ytilibisnopser governance structure risk managementstrategic report governance remuneration financial statements investor information remuneration remuneration report comprises remuneration committee chairmans annual statement annual report remuneration set pages addition produced summary shareholder approved remuneration policy report set pages relations shareholders work engage effectively shareholders regular communications agm investor relations activities particularly busy year terms shareholder engagement transformational year company result novartis transaction addition continuous dialogue ceo cfo maintain institutional shareholders held individual meetings hosted group events number key shareholder engagement events year including new chairman undertaking listening tour institutional investors understand firsthand views perspectives issues challenges facing industry gsk holding investor day may ceo leaders pharmaceuticals vaccines consumer healthcare businesses outlined strategic proposition reshaped group profiled medium longterm shape opportunities gsk holding rd event november ceo leaders rd pharmaceuticals vaccines businesses profiled potential new medicines vaccines offer significant opportunity drive longterm performance deliver new benefits patients consumers also holding annual investors meetings november new chairman remuneration committee chairman audit risk committee chairman sid company secretary discussed corporate governance remuneration matters institutional investors committee reports reports audit risk nominations corporate responsibility committees describing activities committees year set pages gsk annual report gsk annual report strategic report governance remuneration financial statements investor information corporate governance continued following centres excellence established audit risk committee report g lobal risk office accountability strengthening risk management standardising methodology around managing principal risks including combined abac third party risk programme well identifying emerging risks scanning external internal environment serving steward internal control framework model proactively communicating monitoring effective judy lewent implementation audit risk committee trategy planning operations accountability chairman ensuring global system governance embedded maintaining proactively delivering standards policies dear shareholder training values assurance programme throughout gsk committees agenda continued built investigations independent business monitoring offers around usual review financial results ensuring three tiers service delivered via regional hubs provide ongoing effectiveness companys internal control risk consistent framework delivering effective independent management arrangements year however also business monitoring also aligned gsks values particular focus impact novartis transaction closed march transaction resulted related initiatives overseen committee included material change three core businesses mproved coordination investigatory efforts required significant integration restructuring efforts embed establishment enterprise investigations committee acquired businesses vaccines consumer extract accelerate management speakup antibribery oncology marketed products pharmaceuticals regular corruption abac computer security incident response reviews held committee ensure control issues assign issues investigation appropriate enable framework reporting requirements maintained greater collaboration across gec legal hr computer throughout security response teams addition committee continued monitor groups onitoring progress implementing programme actions key ongoing transformation simplification programmes underway enhance control abac risk ultimately including particular global support functions incorporate abac requirements regular business practices continuing simplify operating model employee management accountability improved programmes finance transformation well establishment network abac owners undertaking major upgrades groups systems global within business units broadening abac training processes including core erp hr supply chain platforms communications across enterprise introduction committee also regularly reviewed groups cyber periodic certifications reinforcement linkage security progress infoprotect programme gsk values performance implementation new designed address risk specifically policy senior management financial recoupment new standards introduced frcs code c ompletion general manager gm confirmations required additional focus committee year ensure operation internal control framework markets compliance requirements probably pharmaceuticals vaccines businesses excluding us significant change year new requirements different system review completed relating companys viability report assessment process become annual process first time operates standardised consistent approach finally committee approved formal commencement output reviews consolidated provide audit tender autumn result new clearer view current trends assist identification audit firm replacing pricewaterhousecoopers llp pwc potential gaps facilitate sharing good practices beginning significant important step consumer healthcare implement similar process committee board details audit tender gm confirmation operation internal control process governance timescales found framework key risks minimum controls internal framework control risk management novartis integration enhancements made internal control framework oversight novartis transaction key priority helped build stronger culture compliance enable committee given importance success transaction multifaceted approach strengthening controls around group committee received regular reports principal risks extensive training presentations integration management acquired communications implemented across compliance novartis businesses operational internal control functions turn key risk groups business accounting risk management perspective run units progress supported global ethics close transaction march regularly compliance gec function activities gec throughout year integration associated restructuring reorganised enhanced put place network programmes began implemented addition onboarded experts sitting centres excellence manage key novartis employees successfully completed mandatory elements principal risks internal control framework training code conduct abac corporate integrity new governance model designed standardise prioritise agreement obligations drive integrated compliance controls across principal risksstrategic report governance remuneration financial statements investor information global support function simplification programmes membership attendance committee continued review regularly multiyear membership committee together appointment programmes underway simplify support functions dates attendance meetings set standardise operating model around new upgraded platforms programmes well established committee attendance full peak activity currently new platforms processes members member since meetings rolled across group compounded additional judy lewent requirements integrate former novartis businesses chairman january april groups operating reporting infrastructure significant vindi banga january progress reported completion new global lynn elsenhans january hr supply chain forecasting systems multiple cut overs stacey cartwright april local operating companies onto new erp platform delivered year targeted control levels maintained throughout sir deryck maughan january committee also paid particular attention parallel dr daniel podolsky january transformation programmes underway number support tom de swaan january functions especially finance transformation initiative jing ulrich may ensure controls reporting requirements affected infoprotect tom de swaan jing ulrich retired board committee continues keep multiyear programme may enhance secure strengthen cyber security defences addition six scheduled meetings committee also met close scrutiny part review process cyber quorate basis six occasions review approve matters security report submitted chief information security associated annual report form f preliminary officer scheduled meeting pleased quarterly results announcements number key risk reduction initiatives delivered year details members financial accounting scientific experience expertise given biographies board uk corporate governance code pages following issue frcs updated code associated guidance came effect financial reporting company secretary secretary committee attends year committee devoted time satisfying meetings entire board invited attend committee internal control risk management arrangements meetings attendees include monitoring practices accord new enhanced requirements particular area investment year regular attends attendee attendee required development recommendation board new viability statement examines companys longer general counsel cid term solvency viability set agreed financial controller cid analytical assurance work management underpins head audit assurance cid statement considered three years appropriate head global ethics compliance cid timeframe base assessment longterm viability aligns regular business planning period chief medical officer cid committee also reviewed outcome stress testing chief product quality officer cid performed management recommended directors external auditor cid confirm reasonable expectation group able continue operation meet liabilities accordance frcs code board determined fall due three year period assessment stacey cartwright judy lewent recent relevant financial experience board also agreed stacey committee continue work encourage support cartwright judy lewent appropriate qualifications enhancements groups internal controls audit background audit committee financial experts defined assurance arrangements addition look forward reporting us sarbanesoxley act determined conclusion external audit tender process independent within meaning us securities exchange act explaining plan manage transition pwc amended new auditor operate addition vindi banga judy lewent sir deryck maughan also members remuneration committee allows provide input committees review groups performance oversight risk factors relevant remuneration matters judy lewent audit risk committee chairman march gsk annual report strategic report governance remuneration financial statements investor information corporate governance continued principal activities matters addressed global internal control governance month financial reporting compliance external auditors risk matters january integrity draft review risk assessment external china investigations compliance frcs financial statements management auditors effectiveness abac update code appropriateness internal control report external audit emerging risk review corporate governance accounting policies litigation report process global support update draft annual corporate integrity reappointment functions change committee evaluation report form f agreement cia auditors proposed programme impacts private meetings annual summary update reports approval agm rocc meeting update external auditors leaflet review annual audit external auditor novartis transaction head audit assurance plan yearend audit findings update assurance respectively report auditnonaudit committee members expenditure met privately february going concern sarbanesoxley auditnonaudit assumptions compliance expenditure preliminary results confirmation external auditor announcement sarbanesoxley control directors expenses findings approval external auditor annual annual report report form f f annual findings summary leaflet march approach performance china investigations audit assurance sarbanesoxley expectations abac update rating system compliance external auditors emerging risk review private meeting litigation report commercial practices external auditors cia update reports enterprise risk committee members global ethics vaccines update met privately compliance report rocc meeting update global pharma novartis transaction business unit report update may st quarter results litigation report external auditor st china investigations private meeting announcement consumer healthcare quarter results review abac update external auditors gms business unit findings novartis transaction committee members reports external audit plan update met privately fee proposal erp annual update rocc meeting update emerging risk review july going concern litigation report external auditor nd china investigations corporate governance assumptions cia update reports quarter results review abac update update including frc viability statement assessment key findings rocc meeting update code changes approach internal control cyber security report private meeting nd quarter results principal risk emerging risk review external auditors announcement vaccines business unit novartis transaction committee members review accounting report update met privately issue development ehss third party impacts oversight tpo enterprise risks treasury tax pensions insurance risk october rd quarter results litigation report external auditor rd abac update frc code announcement cia update reports quarter results review rocc meeting update guidance changes operational excellence findings cyber security report private meeting update novartis external emerging risk review external auditors rd business unit audit plan novartis transaction committee members report update met privately scientific engagement patient safety product quality tpo enterprise risks december viability statement litigation report external audit phase abac update private meetings update cia update reports results annual cyber security report external auditors management report global support report disclosure rocc meeting update corporate accounting issues functions business unit requirements novartis transaction compliance officer appropriateness report preapproval external update respectively accounting policies internal control auditor budget non emerging risk review corporate governance framework assessment audit services information protection disclosures update external terrorism risk committee members auditor fees budget assessment met privately audit tender review gsk annual report strategic report governance remuneration financial statements investor information committees financial reporting activities significant issues relating financial statements respect financial reporting activities committee reviews significant issues considered relation financial recommends board approval financial results statements year ended december set announcements considering quarterly financial results following table together summary financial announcements financial results contained outcomes appropriate addition committee annual report committee reviewed significant issues external auditors discussed significant issues addressed judgements made management determining results committee year areas particular audit committee reviewed papers prepared management setting focus described independent auditors report pages key areas risk actions undertaken quantify effects relevant issues judgements made management appropriate accounting required address issues financial statements significant issues considered committee relation financial statements issue addressed committee going concern basis committee considered outcome managements halfyearly reviews current forecast net debt preparation financial positions various financing facilities options available group following review risk statements potential impact unforeseen events committee confirmed application going concern basis preparation financial statements continued appropriate revenue recognition including committee reviewed managements approach timing recognition revenue accruals returns rebates rar customer returns rebates us pharmaceuticals vaccines accrual returns rebates accruals billion december committee reviewed basis accrual made concurred managements judgements amounts involved fuller description process operated us pharmaceuticals vaccines business determining level accrual necessary set critical accounting policies provisions legal matters committee received detailed reports actual potential litigation internal external including investigations legal counsel together number detailed updates investigations groups commercial groups commercial practices practices management outlined levels provision corresponding disclosure considered necessary respect potential adverse litigation outcomes also areas yet possible determine provision necessary amount december provision legal matters billion set note financial statements provisions provisions uncertain tax committee considered current tax disputes areas potential risk concurred positions managements judgement levels tax contingencies required december groups balance sheet included tax payable liability billion impairments intangible committee reviewed managements process reviewing testing goodwill intangible assets assets potential impairment committee accepted managements judgements intangible assets required writing resulting impairment charge million see note financial statements intangible assets details valuation contingent committee considered managements judgement following improved sales performance consideration relation tivicay triumeq necessary increase liability pay contingent consideration acquisition viiv healthcare former shionogiviiv healthcare joint venture december groups balance sheet included net contingent consideration liability billion see note financial statements acquisitions disposals details novartis transaction items committee received regular reports throughout year progress novartis transaction including vaccines contingent committee reviewed basis valuation assets liabilities acquired novartis consideration consumer particular calculations liabilities vaccines contingent consideration consumer healthcare put option healthcare put option committee concurred managements judgements amounts recognised gsk annual report strategic report governance remuneration financial statements investor information corporate governance continued audit tendering pwc auditor company group since inception performance reviewed annually audit partner rotation requirements observed time directors sought tender pwcs contract result uks implementation eus mandatory firm rotation requirements company required replace pwc another auditor later financial year commencing january january committee usual reviewed pwcs performance previous year recommended reappointment year also considered whether initiate defer external audit contract tendering process committee agreed given level change experienced business appropriate put audit tender however reviewed relative merits conducting tender recent changes regulations area committee considered best interests shareholders plan undertake tender process second half would target appointing new auditor effect january would coincide end current pwc partners five year tenure group audit engagement leader company reappoint pwc january new pwc partner would need appointed pwc would still required rotate audit consequently pwc asked participate anticipated tender exercise second half audit tender governance december committee agreed achieve move new audit firm take audit financial year audit contract tender conducted autumn final recommendation committee least two audit firms preference expressed appointment one firms anticipated made december final approval board end committee direct supervise tender process agreed implementation robust audit tender governance structure deliver successful audit contract tender process minimal disruption group main elements governance structure follows audit tender operations steering executive steering audit risk board planning team committee committee committee remit design plan remit remit leadoversee remit direct remit appoints new implement run coordinateexecute audit tender process supervise audit auditor effect audit tender process audit tender process implementation tender process january meets weekly consider shortlisting assess candidates recommend agrees seek arrangements liaise arc new auditor shareholder approval meets monthly process board appointment fortnightly towards final evaluation agm end process members arc chair cfo group financial controller company secretary meets monthly gsk annual report strategic report governance remuneration financial statements investor information ongoing effectiveness quality external audit process committee committed ensuring ongoing basis gsk receives high quality effective audit evaluating effectiveness audit process prior making recommendation reappointment external auditor committee reviews effectiveness performance criteria agrees conjunction management beginning years audit cycle activities committee typically undertakes year satisfy external audit quality effectiveness together timelines set audit reappointment auditor expectations formal auditor appointment c ommittee evaluation process setting audit planning budget setting matters addressed matters addressed matters addressed matters addressed review effectiveness external agree performance shareholders vote agm review feedback auditor expectations expectations auditor resolutions appoint committee members set previous year upcoming audit auditor fix independently part review auditors independence remuneration annual committee evaluation appropriate level review agree audit plan covering qualifications expertise upcoming audit relationship auditor resources consider auditors quality quality insights consider whether auditor control procedures provide committee exhibited appropriate level agree set statutory work challengescepticism audit fee whether work receive management sufficient access consider whether initiate feedback prior years auditor management defer audit contract tender audit process preapprove budget satisfied recommend survey covering nonaudit services ideally board auditor reappointment robustness audit statutory next agm process audit fee following year quality delivery people service january march may december detailed criteria committee uses judging effectiveness external auditor overriding responsibility deliver smooth running thorough efficiently executed audit set performance expectations gsks external auditor specific auditor responsibilities wider auditor responsibilities discuss approach areas focus advance early provide uptodate advice new viability statement engagement understanding implications gsks new requirement operating model provide uptodate knowledge technical governance ensure sarbanesoxley scope additional procedures issues providing accurate timely advice discussed endorsed management communicated serve industry resource communicating best practice timely basis within gsk pwc industry trends reporting avoid surprises timely reporting issues levels within adhere independence policies including gsks policies group financial reporting councils isa applicable ensure clarity roles responsibilities securities exchange commission standards auditor local management deliver focused consistent audit approach globally respond issues raised management timely basis reflects local risks materiality meet agreed deadlines liaise gsks audit assurance team avoid duplication work global ethics compliance team ensure provide continuity succession planning key employees common understanding audit outcomes auditor provide consistency advice levels organisation provide sufficient time management consider draft auditor ultimately provide high quality service board reports respond requests queries scrupulous scrutiny group act employ consistent communication local central utmost integrity audit teams gsk annual report strategic report governance remuneration financial statements investor information corporate governance continued nonaudit services fair balanced understandable assessment sarbanesoxley act prohibits engagement one key compliance requirements groups financial external auditor provision certain services statements annual report fair balanced legal actuarial internal audit outsourcing financial understandable coordination review groupwide information systems design external auditor contributions annual report follows well established permitted provide nonaudit services auditrelated documented process performed parallel tax services committee ensures auditor formal process undertaken external auditor objectivity independence safeguarded policy committee received summary approach taken requiring preapproval committee services management preparation gsks annual report contractual similar obligations restricting ensure met requirements frcs code groups choice external auditor enabled committee board confirm nonaudit services put competitive gsks annual report taken whole fair tender financial service providers external balanced understandable auditor line groups procurement process unless code conduct reporting lines skills experience external auditor make also number well established policies including suitable supplier nonaudit service consideration code conduct available governance section case request proposal submitted relevant website confidential speak reporting lines cet member cfo approval nonaudit services reporting investigation unlawful conduct updated spending monitored committee quarterly basis version code conduct published january discussed committee chairman cma order statement compliance following policy guidelines engaging external auditor committee confirms company provide nonaudit services observed complied mandatory audit processes audit committee ascertaining skills experience external responsibilities provisions competition markets authority auditor make suitable supplier nonaudit services statutory audit services order outlined report ensuring adequate safeguards place objectivity describes work committee discharging independence group audit threatened responsibilities compromised committee evaluation ensure total fee levels exceed annual committees annual evaluation internally facilitated audit fee except special circumstances would company secretary supplemented questionnaire clear advantage companys auditor undertaking circulated committee members behalf committee additional work chairman concluded committee continued operate effectively terms enhancements committees fees paid companys auditor associates set deliberations following improvement points agreed details given note financial statements operating profit continue improve paper content focus ensuring brevity throughout possible accounting firms engaged undertake nonaudit services increase focus setting monitoring adjusting risk appetite auditnonaudit service three year comparison graph incorporate new risk oversight compliance council reporting updates new emerging issues committees agenda aid anticipation potential risk audit issues consider division meetings two halves focusing traditional financial audit related matters committee members risk litigation serious issues facing group committee subsequently debated organisation meetings agreed board members wished continue attend entire meeting audit assurance services services including tax regulatory compliance treasuryrelated services services related novartis transaction fee audit assurance services includes million arising novartis transaction subsequent increase complexity group approximately half expected recurring gsk annual report strategic report governance remuneration financial statements investor information senior independent director sid succession nominations committee report sir deryck maughan brought style role sid discharging responsibilities great diligence including leading concluding recent chairman succession search process pleased sir deryck agreed extend tenure board step agm may brings continuity boards composition given significant knowledge experience gsks business affairs period significant change boards philip hampton membership sir deryck helped facilitate transition nominations committee sir christopher chairman addition committee member helped search recruitment successor sid committee dear shareholder pleased recommend board appointment vindi one first key priorities joined board start banga sid designate vindi joined board september year succeed sir christopher gent nominations appointed committees sir deryck committee chairman last year year significant transition january nominations audit risk remuneration meant could focus immediately tailoring working closely together ensure smooth transition refreshment board line vindi succeed sir deryck sid conclusion agreed principles actions set dr tracy longs agm may external evaluation review scientific medical expert sme succession requirements reshaped group create maximise dr daniel podolsky served boards usbased longterm value novartis transaction shareholders designated sme great distinction tenure board stepping board planned nominations committee committee busy year agm serving nine years commencing search made good progress towards aim first considering successor highly specialist role beginning board size composition replacing number year committee pleased recommend board planned retirements nonexecutive board members appointment dr jesse goodman nonexecutive addressing identified skills gaps committee also focused director sme joined board january effective management succession executive management appointed corporate responsibility committee progress respect elements set effect may board size composition details role criteria recruitment process central element current board refreshment programme sid sme roles rationale behind committee consideration appropriate size recommending vindi banga dr jesse goodmans composition board given scale complexity appointments given strategic positioning business performing analysis committee used enhanced board competence committee membership experience matrix linked companys strategy underpins lynn elsenhans appointed committee january board refreshment programme making good progress join judy lewent newer appointees ensure identifying ideal future size board likely see committee achieved good balance longer serving reduction second half part analysis committee members newer appointees support shaping committee also factored increased target size board longer term also grateful sir christopher female representation outlined lord davies sharing insights deep understanding evolution final women boards report published october board culture composition period stewardship ceo management succession committee continued scrutinise robustness committees key focus progression succession planning arrangements executive directors management succession plans working collaboration executive management role together adequacy ceo addition continue refresh nonexecutive pipeline leadership talent cet representation board aim reducing overall nearly years ceo sir andrew indicated board size around twelve members board intention retire company early board agreed retire march committee start formal search successor consider internal external candidates role end philip hampton egon zehnder korn ferry engaged nominations committee chairman march gsk annual report strategic report governance remuneration financial statements investor information corporate governance continued membership refreshment specialist roles board membership committee together appointment part orderly refreshment board dates attendance meetings set particular area focus committee searches successor sir deryck maughan sid dr daniel podolsky attendance usbased sme due retire stand committee full meetings board agm members member since sir philip hampton committee felt determining key essentials chairman january january sid desirable ukbased director failing someone travelled spent majority time professor sir roy anderson october uk also thought important individual vindi banga january strong understanding uk corporate governance lynn elsenhans january environment judy lewent may korn ferry provides recruitment services company sir deryck maughan july engaged conduct search sid provided long short list potential candidates sir christopher gent december interviewing suitable sid candidates feedback sought tom de swaan october support received certain investors committee recommended board vindi banga potential sir christopher gent committee chairman january january retired board may independent nonexecutive director sid designate appointed board september board tom de swaan retired board may considered strong operational bias bringing company secretary secretary committee attends many years commercial experience track record meetings attendees committee meetings may include delivering outstanding performance highly competitive global consumerfocused industry invaluable regular attends company currently serves nonexecutive director attendee attendee required boards two ftse companies vindi succeed chief executive officer cid sir deryck maughan sid steps board head human resources cid close agm may appropriate external advisers cid committee drawing role specification new sme role considered dr podolskys successor ideally strong business perspective usbased work committee understand us healthcare environment medic main responsibilities close patient either running operations scale main responsibilities committee set hospital institution understanding vaccines preferably respiratory considering standing gsks ceo management succession vaccines portfolio since novartis transaction completed committee ceo assistance head internal soundings taken within vaccines rd human resources working managing succession identify potential external candidates egon zehnder undertook full arrangements executive directors executive external market search suitable candidates management role secure best leadership company specification role considered detail egon zehnder provides recruitment services current future needs changing environment company engaged conduct search usbased company operates compiling succession plan internal sme role dossiers potential nonexecutive appointees external talent considered reviewed considered committee candidates shortlisted specification drawn together interview merit objective criteria assessing relevant qualifications time commitments terms executive team part ensuring focused management companys consumer healthcare vaccines interviewing suitable sme candidates committee pharmaceuticals businesses result transformational recommended board dr jesse goodman potential novartis transaction nonexecutive director sme appointed board january dr jesse goodman leader public health emma walmsley previously president consumer brings wealth expertise spanning science medicine healthcare appointed ceo consumer healthcare joint vaccines regulation public health proven record venture business became member board addressing pressing public health needs academic novartis transaction successfully completed march federal sectors invaluable gsk board following announcement deirdre connelly president north america pharmaceuticals february intention retire gsk role replaced cet addition bill louv senior vice president core business services retired planned gsk successor reports cfo member cet gsk annual report strategic report governance remuneration financial statements investor information board committee chairmen membership changes refreshment board also led following orderly changes board committee membership director committee membership appointment date retirement date sir philip hampton nominations committee chairman january na urs rohner remuneration committee member january na remuneration committee chairman may lynn elsenhans corporate responsibility committee chairman may na member since october vindi banga audit risk remuneration january na nominations committee member professor sir roy corporate responsibility committee member may na anderson dr jesse goodman corporate responsibility committee member may na sir christopher gent corporate responsibility committee chairman na may remuneration nominations committee member tom de swaan remuneration committee chairman na may audit risk nominations committee member jing ulrich audit risk committee member na may board committee changes committed diversity boardroom ongoing refreshment board resulted orderly similarly committed equal opportunities employees planned changes composition board levels organisation diversity inclusiveness committees year recommendation workforce promoted throughout gsk committee changes including planned retirements key requirement effective board comprises range dr stephanie burns sir deryck maughan dr daniel podolsky balance skills experience knowledge gender hans wijers board close agm may independence individuals prepared challenge set work team needs backed board appointments retirements diversity personal attributes including character intellect sound refreshment board led following orderly judgement honesty courage changes board members committee responsible developing measurable objectives support implementation boards diversity director appointment date retirement date policy including gender monitoring progress towards achievement objectives terms balance board sir philip hampton january na gender diversity exceeded target least urs rohner january na set may current female vindi banga september na board level representation stands noted lord dr jesse goodman january na davies new target increase female board representation least set women boards five year sir christopher gent na may summary report published october tom de swaan na may also good representation women management jing ulrich na may positions illustrated part gender dr stephanie burns na may diversity gsks global workforce continue support sir deryck maughan na may efforts increase pipeline women senior positions within gsk also support engagement dr daniel podolsky na may executive search firms mwm egon zehnder korn hans wijers na may ferry signed voluntary code conduct executive search firms gender diversity best practice board composition diversity mindful need balance composition board committee evaluation committees refresh progressively time committees annual evaluation internally facilitated draw upon experience longer serving directors company secretary behalf committee chairman tapping new external perspectives insights supplemented questionnaire circulated committee recent appointees bring boards deliberations members concluded committee continued operate effectively nonexecutive directors drawn wide range industries backgrounds including pharmaceutical healthcare terms enhancements committees work agreed medical research academia retail insurance financial focus directed forward planning services appropriate experience complex organisations executive succession replenishment board anticipation global reach considerable experience directors rotating board would also key priority pharmaceutical industry recent appointees bring new approach group board discussions gsk annual report strategic report governance remuneration financial statements investor information corporate governance continued membership corporate responsibility committee report membership committee together appointment dates attendance meetings set attendance full meetings members committee member since lynn elsenhans october chairman may lynn elsenhans corporate responsibility dr stephanie burns december committee chairman dr daniel podolsky july hans wijers october dear shareholder sir christopher gent december would like thank predecessor sir christopher gent sir christopher gent served committee chairman may strong leadership committee last years retired board may stewardship overseen development refinement gsks cr principles current responsible professor sir roy anderson dr jesse goodman business commitments addition committee acted appointed committee effect may custodian policies practices define safeguard company secretary secretary committee reputation company new chair committee attends meetings attendees committee meetings seek build legacy committee continues may include challenge shape companys responsible business agenda committee members bring wide range experience regular attends attendee attendee required insight across different sectors provide oversight companys responsible business opportunities risks chief executive officer cid invaluable relation committees assessment company chairman cid corporate responsibility challenges integrating novartis chairman global vaccines cid assets company acquired year substantial change general counsel cid particularly pleased work committee head communications government affairs cid year focused issues material gsks mission strategy values much discussions focused head pharmaceuticals cid company seeks balance need return investment head pharmaceuticals rd cid innovation need price products appropriately head human resources cid drive access broad range patients addition head external market communication cid considered ways gsk continues build commitment operating transparently integrity head global corporate responsibility cid commercial model transformation executives cid also pleased continue enjoy positive engagement independent external corporate cid investors responsible business commitments responsibility adviser included particular focus approach addressing antibribery corruption abac issues reputational independent external corporate responsibility adviser perspective changes sell market medicines healthcare professionals access innovation clinical augment engagement stakeholder opinion may trials transparency disclosures sophia tickell appointed independent external adviser committee position previously held march july ms tickell extensive experience pharmaceuticals industry improving health systems productivity lynn elsenhans sustainability energy supply distribution climate change corporate responsibility committee chairman policy shorttermism financial markets march cofounder director meteos directs pharma futures series aims align better societal shareholder value holds number board advisory roles ms tickell attended meetings committee provided independent advice guidance corporate social responsibility matters chairman ceo gsk annual report gsk annual report strategic report governance remuneration financial statements investor information main responsibilities people enabling people thrive develop main responsibilities committee set individuals deliver mission committee rolling agenda receives reports planet growing business reducing members cet senior managers ensure progress environmental impact across value chain meeting responsible business commitments within four addition meeting committee considers possible areas focus reviewed annual basis follows emerging issues may bearing companys health innovating address currently unmet health reputation interaction stakeholders committee needs improving access products irrespective also reviews approves responsible business supplement people live ability pay controlling eliminating available reference wwwgskcomresponsibility diseases affecting worlds vulnerable people behaviour putting interests patients consumers first driven values everything backed robust policies strong compliance processes work committee committee focused core remit matters set reports received highlighted evolving challenges areas including particular impact novartis transaction cr focus area committees area focus health flexible open rd approach diseases developing world areas great medical need antibiotics dementia gsks approach pricing particular balance returns investment innovation alongside need support access medicines vaccines strategy support global public health priorities including pricing models malaria vaccine ebola response behaviour global incentive compensation program selling competency model changes gsk engages healthcare professionals embedding valuesbased decision making organisation including training compliance progress work align third parties gsks standards expectations conduct public disclosure clinical research transparency detailed data behind trial results patient safety replacement refinement reduction use animals research development people organisational change employee relations inclusion diversity leadership development approach performance management employee health safety wellbeing insights staff survey employee health safety wellbeing planet environmental performance across carbon water waste impacts committee evaluation committees annual evaluation internally facilitated company secretary supplemented questionnaire circulated committee members behalf committee chairman concluded committee continued operate effectively terms enhancements committees deliberations agreed committee would regular basis look take advanced longterm perspective company may impacted external environment gsk annual report strategic report governance remuneration financial statements investor information corporate governance continued nominations committee reviewed register potential directors conflict authorisations january reported board directors powers determined uk legislation conflicts appropriately authorised articles association contain rules appointment process authorisation continues operate effectively except replacement directors provide directors may described note financial statements related party appointed ordinary resolution members transactions end financial year director resolution directors provided latter instance connected person material interest contract director appointed way retires first agm following significance group company appointment independent advice articles also provide directors normally subject company agreed procedure directors take reelection agm intervals three years annually independent legal andor financial advice companys held office continuous period nine years expense deem necessary however board agreed directors wish indemnification directors continue members board seek reelection qualifying third party indemnity provisions defined annually accordance uk corporate governance code companies act force benefit directors director may cease director former directors held office signing becomes bankrupt annual report ceases director virtue companies change control essential contracts act articles contracts arrangements individually suffers mental physical ill health board resolves fundamental ability business operate effectively shall cease director company party material agreements would take missed directors meetings continuous period six effect altered terminate upon change control following months without permission board resolves takeover bid agreements director shall cease director would provide compensation loss office employment prohibited director law resulting takeover except provisions companys resigns offers resign board accepts offer share plans may cause options awards granted plans vest takeover details termination provisions required resign board companys framework contracts executive directors directors conflicts interest given full version companys remuneration policy report directors duty companies act avoid available wwwgskcom investors section situation could direct indirect conflict interest possible conflict company articles provide general power board authorise conflicts nominations committee authorised board grant regularly review potential actual conflict authorisations recorded company secretary noted board directors counted quorum authorisation actual potential conflicts ongoing basis directors responsible informing company secretary new actual potential conflicts may arise changes circumstances may affect authorisation previously given even provided authorisation director absolved statutory duty promote success company actual conflict arises postauthorisation board may choose exclude director receipt relevant information participation debate suspend director board last resort require director resigngsk annual report strategic report governance remuneration financial statements investor information directors continued directors report purposes uk companies act directors report glaxosmithkline plc year ended december comprises pages corporate governance report directors responsibility statements pages pages investor information strategic report sets matters required disclosed directors report considered strategic importance company follows risk management objectives policies pages likely future developments company throughout strategic report research development activities pages diversity inclusion provision information consultation employees carbon emissions following information also incorporated directors report location annual report financial statements interest capitalised notes publication unaudited financial information group financial review details longterm incentive schemes remuneration report waiver emoluments director applicable waiver future emoluments director applicable non preemptive issues equity cash applicable non preemptive issues equity cash applicable unlisted major subsidiary undertaking parent company participation placing applicable listed subsidiary provision services controlling applicable shareholder financial statements shareholder waiver dividends notes financial statements shareholder waiver future dividends notes agreements controlling shareholders applicable directors report drawn presented accordance reliance upon english company law liabilities directors connection report shall subject limitations restrictions provided law directors report approved board directors march signed behalf philip hampton chairman march gsk annual report strategic report governance remuneration financial statements investor information remuneration report chairmans annual statement dear shareholder committee believes significant shareholdings remain key mechanism aligning personal interests executives following agm succeeded tom de swaan chair interests longterm shareholders sir andrews shareholding remuneration committee committee pleased times base salary gsk shares well present remuneration report would also excess share ownership requirement four times base like take opportunity thank tom behalf salary committee leadership time chairman disclosed remuneration report setting remuneration decisions respect adjusted free cash flow rd new product targets lti marked substantial progress strategy awards granted delayed pending completion creating balanced group three world leading businesses novartis transaction targets awards pharmaceuticals vaccines consumer healthcare clear agreed details adjusted free cash flow target aim deliver growth improve returns shareholders communicated via stock exchange announcement july group strong position succeed longterm business given significance transaction committee global scale less exposure risk volatility past also considered impact changes targets year accelerated new product sales growth integrated outstanding lti awards key principle new businesses vaccines consumer healthcare ensure incentives continued operate originally restructured pharmaceuticals business financial results intended committee focussed ensuring stretch ahead guidance set towards start year performance targets retained incentives continued believe well positioned return core earnings measure performance strategic objectives originally per share growth identified grant details decisions reached set background key decisions made following report committee respect remuneration follows agenda bonus outcomes executive directors material changes executive remuneration proposed determined reference performance agreed committee decided salary levels executive financial measures well committees assessment directors would increased effective january individual performance gsk achieved performance consistent salary increase budget broader excess relevant financial targets year employee populations uk us given improved performance together assessment remuneration policy expire agm year individual performance contribution resulted bonus committee undertaking review gsks remuneration awards ahead previous year would arrangements part review continue regular draw shareholders attention detailed disclosure dialogue shareholders hold annual meetings following report annual bonus plan bonuses gsks largest investors later year listen views earned enhanced reporting annual feedback meanwhile shareholders feedback bonus plan bonuses paid help shareholders current remuneration arrangements views understand awards earned hope focus review please hesitate pass shareholders join welcoming enhanced comments attention company secretary disclosures victoria whyte agm vesting performance share plan deferred annual bonus plan awards based agreed measures finally would like thank shareholders input relative tsr adjusted free cash flow rd new products engagement first year chairman committee business diversification performance three welcome shareholders feedback report look years december overall vesting level achieved forward receiving support remuneration lti awards details report agm may achievement also presented following report urs rohner remuneration committee chairman march gsk annual report strategic report governance remuneration financial statements investor information annual report remuneration executive directors remuneration summary remuneration principles policy principles committee believes pay performance executive directors remuneration designed promote longterm success company committee seeks ensure performancerelated elements executive directors remuneration transparent stretching rigorously applied policy committee considers companys shareholder approved remuneration policy executive directors pay comparator groups pay levels wider employee population group determining total individual pay packages executive directors balance fixed shortterm variable longterm variable elements pay carefully reviewed overall packages weighted heavily towards latter closely align executive directors interests shareholders table summarises committee sets element remuneration packages executive directors fixed pay base salary salaries reviewed annually supported data relevant comparator groups taking account executive directors role experience performance well average increases broader gsk workforce salary levels respect follows sir andrew witty simon dingemans dr moncef slaoui benefits principally healthcare car personal financial advice life assurance assignment travel expenses pension uk executives sir andrew witty joined group certain uk executives members legacy final salary plans closed new entrants since increases pensionable earnings limited per annum otherwise gsk operates defined contribution plan uk executives simon dingemans member plan pension contributions instead receives cash lieu contributions us executives gsk operates cash balance pension plan gsk k plan savings scheme supplemental cash balance pension plan executive supplemental savings plan essp savings scheme open dr moncef slaoui certain us executives accrue benefits us government limits imposed k plan cash balance pension plan pay performance safeguards company long standing clawback malus arrangements lti bonus plans executive risk directors executives enable company recover sums paid withhold payment management sum occurrence triggering event eg significant misconduct way violation regulation law significant gsk policy code conduct annual bonus target maximum bonus opportunities executive directors follows majority bonus based achievement target maximum challenging financial targets core groupbusiness unit operating profit core group profit interest tax salary salary agreed board committee ceo individual performance predetermined personal cfo objectives chairman global vaccines deferred individuals must defer may defer psp dapb matching awards based following annual total bonus earned three equally weighted performance measures three bonus plan deferred bonuses may matched year period dabp oneforone subject performance criteria rd new product performance adjusted free cash flow relative tsr vests threshold rising stretching performance exceeding set threshold performance performance share awards specified margin share plan executive directors follows comparator group comprising gsk nine psp salary pharmaceutical companies based vesting schedule vesting median rising ceo vesting upper quartile performance cfo psp awards subject threeyear performance period chairman global vaccines additional twoyear vesting period gsk annual report strategic report governance remuneration financial statements investor information annual report remuneration continued total remuneration audited value earned annual longterm total salary benefits pension bonus incentive remuneration awards fixed pay b pension c pay performance total remuneration executive director set table sir andrew witty simon dingemans dr moncef slaoui ceo cfo chairman global vaccines total total total total total total fixed pay salary benefits total fixed pay b pension c pay performance annual bonus including amount deferred value earned lti awards matching awards deferred annual bonus plan performance share plan total value earned lti awards total pay performance total remuneration deferral annual bonus number number number shares shares ads amount bonus deferred number shares ads purchased full details elements total remuneration given following pages report fixed pay pension pay performance base salary pages annual bonus pages benefits pages value earned lti awards pages onwards notes please note values shown differ disclosed annual report dabp value based estimated vesting price valued based fair market value closing share prices business day prior vesting date committee may specific circumstances line stated principles apply clawbackmalus determines appropriate following due consideration committee recovery sums paid clawback reduction outstanding awards vesting levels malus applied respect executive directors difference pension values dr slaoui due movements interest rate assumption ira used projection age ira decreased increased slightly gsk annual report strategic report governance remuneration financial statements investor information total remuneration fixed pay audited following sections provide details element total salary remuneration including committee implemented table sets base salaries executive approved remuneration policy applied directors last two years base salary comparator groups pay performance change committee uses two primary pay comparator groups sir andrew witty considering executive pay simon dingemans uk crossindustry global pharmaceutical dr moncef slaoui comparator group comparator group benefits audited anglo american france sanofi following table shows breakdown grossed cash astrazeneca switzerland novartis value benefits received executive directors bg group roche holdings bhp billiton uk astrazeneca sir andrew simon dr moncef bp us abbvie witty dingemans slaoui british american tobacco amgen benefits diageo bristolmyers squibb employee benefits reckitt benckiser eli lilly travel rio tinto johnson johnson benefits royal dutch shell merck co total benefits sab miller pfizer benefits tesco employee benefits unilever travel vodafone benefits total benefits amgen abbvie included remuneration benchmarking included tsr comparator group employee benefits include employee share plans healthcare car global pharmaceutical comparator group also used allowance personal financial advice life assurancedeath basis tsr comparator group features longterm service incentive awards primary pay comparator group travel expenses include car travel spousepartner costs executive directors shown table associated accompanying director gsk business primary pay comparator group deemed taxable benefits individual uk global benefits comprise expenses incurred ordinary course director crossindustry pharmaceutical business deemed taxable benefits sir andrew witty cid individual included table simon dingemans cid dr slaoui includes uk accommodation dr moncef slaoui cid reviewing ceos remuneration committee also references pay group leading european companies whose selection based size complexity summary total remuneration competitive positioning ceo total remuneration benchmarking uk crossindustry global pharmaceutical european crossindustry group group group lower quartile median median upper quartile current position benchmarking includes salary expected value incentives based committees agreed benchmarking methodology gsk annual report strategic report governance remuneration financial statements investor information annual report remuneration continued pension audited pension arrangements sir andrew sir andrew witty member glaxo wellcome defined benefit pension plan closed new entrants since witty section plan sir andrew member provides normal retirement age maximum pension value rds pensionable salary since april pensionable earnings increases limited per annum members including sir andrew simon simon dingemans member gsk pension plan pension contributions instead receives cash payment lieu dingemans pension base salary line gsks defined contribution pension plan rates simon dingemans receives death service illhealth insurance provided part pension plan included employee benefits dr moncef dr slaoui member cash balance pension plan supplemental cash balance pension plan provides slaoui executive pension credit gsk makes annual contributions dr slaouis pension plans base salary plans provide cash sum retirement fund increases interest rate set annually advance based year us treasury bond rate plan entitlement spouses pension pension increases active member belgium ag insurance exfortis plan belgian plan may deferred member since plan defined benefit plan lump sum payable normal retirement age company contributions plan dr slaoui also member k plan open us employees essp savings scheme open executives accrue benefits us government limits imposed k plan contributions plans invested range funds combined contribution rate plans core contributions plus match total base salary bonus less bonus deferred dabp following table shows breakdown pension values set sir andrew witty simon dingemans dr moncef slaoui pension remuneration values uk defined benefit us defined benefit belgian defined benefit employer cash contributions member contributions defined benefit plans total pension remuneration value pension remuneration figures calculated accordance methodology set large mediumsized companies group accounts reports amendment regulations remuneration regulations calculating defined benefit pension values difference accrued pension december accrued pension december increased inflation uk defined benefit us defined benefit belgian defined benefit multiplied results negative value deemed zero calculating total values amounts translated euros us dollars using exchange rate b sir andrew details regarding pension values set table accrued pension accrued pension pension remuneration sir andrew witty december pa december pa value uk funded uk unfunded total sir andrew joined gsk predecessor companies progressed roles increasing seniority within gsk appointed ceo may time built pensionable service different tiers glaxo wellcome pension plan current pension entitlement product service progression within gsk c dr moncef slaoui details regarding pension values set table accrued pension accrued pension pension remuneration dr moncef slaoui december pa december pa value us funded us unfunded belgium funded us k essp total dr slaoui joined gsk predecessor companies progressed number senior roles within gsk appointed chairman research development chairman global vaccines time built pensionable service belgian plan cash balance supplemental pension plans annual employer cash contributions made k plan essp current pension entitlement product service progression within gsk difference pension values due movements interest rate assumption ira used projection age ira decreased increased slightly gsk annual report strategic report governance remuneration financial statements investor information pay performance audited annual bonus majority annual bonus opportunity based formal review performance stretching financial targets outcome adjusted reflect individual performance applying individual performance multiplier ipm ipm set committee taking account performance individual objectives multiplier may set generally year executive director performed strongly objectives would expected would receive ipm towards top range annual bonus based following financial measures weightings performance targets core group operating profit core group pbit vaccines performance weighting sir andrew witty simon dingemans dr moncef slaoui performance target million million million outcome million million million core group operating profit core group pbit targets outcomes purpose annual bonuses differ core group operating profit pbit disclosed elsewhere annual report primarily target outcome numbers calculated applying gsk budget exchange rates actual exchange rates core group operating profit measure excludes corporate costs costs included core group pbit following table shows actual bonuses earned compared opportunity bonus opportunity total bonus bonus earned base salary target maximum bonus salary salary salary salary sir andrew witty simon dingemans dr moncef slaoui table sets matters committee considered respect financial measures weightings set executive directors financial performance core group group turnover increased cer reported basis million cer proforma basis core operating profit group operating profit core group profit interest tax ahead targets set profits benefited core group acceleration sales new products together cost savings released groups restructuring profit integration programmes offsetting benefits declines sales seretideadvair lower sales established interest tax products investments made support new product launches shortterm dilution novartis transaction together adverse comparison included sga credit also impacted core operating profit excluding core operating margin declined percentage points vaccines vaccines sales million cer proforma basis proforma growth performance primarily driven bexsero sales europe strong rotarix fluarixflulaval boostrix sales us vaccines operating profit million cer primarily reflecting inclusion cost base acquired former novartis vaccines business proforma basis vaccines operating profit substantial progress made integration acquired business initial restructuring integration benefits helped deliver improvement percentage points proforma core operating margin cer basis gsk annual report strategic report governance remuneration financial statements investor information annual report remuneration continued pay performance continued table sets matters committee considered respect individual objectives set executive director personal performance sir andrew witty sir andrew successfully delivered number key strategic priorities group including completing highly complex novartis transaction create group three worldleading businesses pharmaceuticals vaccines consumer healthcare significant progress integration new businesses vaccines consumer healthcare integration ahead schedule billion incremental cost savings delivered costs billion track deliver billion annual savings end restructuring pharmaceuticals business including commercial reorganisation us accelerating new product performance sales billion revised expectation achieve target billion annual sales new products two years ahead previous plan core eps p ahead financial guidance high teens decline profiling innovative rd portfolio approximately assets focused oncology immunoinflammation vaccines infectious respiratory rare diseases portfolio expected deliver multiple significant milestones next months worldwide implementation business model changes covering sales force incentivisation hcp interactions successful progress delivery responsible business commitments notable advances access medicines approval new malaria vaccine ordinary dividend p together special dividend p paid net proceeds novartis transaction expectation pay p full year ordinary dividend simon dingemans mr dingemans delivered strong financial leadership group restructuring integration ahead schedule billion incremental cost savings delivered costs billion track deliver billion annual savings end reduced net debt billion despite significant cash restructuring costs core eps p ahead financial guidance high teens decline effective core tax rate group substantial progress made deployment new core business systems supply chain improvements ordinary dividend p together special dividend p paid net proceeds novartis transaction expectation pay p full year ordinary dividend dr moncef slaoui dr slaouis leadership vaccines business delivered strong performance plan vaccines sales grew billion business benefitting sales newly acquired products primarily meningitis portfolio menveobexsero europe us well strong sales growth legacy gsk vaccines fluarixflulaval rotarix boostrix us dr slaoui also delivered number strategic priorities following completion novartis transaction march dr slaoui led effective integration gsk novartis vaccines organisations accelerated commercialisation acquired portfolio particularly meningitis portfolio significant contribution global public health agenda extensive research development progress candidate vaccines malaria ebola led successful vaccines rd organisation successes year included positive phase iii trial success candidate vaccine shinglesgsk annual report strategic report governance remuneration financial statements investor information value earned longterm incentives ltis awards performance period ended december audited committee reviewed performance psp dabp matching awards granted executive directors targets set performance achieved three years december vesting levels set table committee previously provided estimates vesting awards gsks annual reports estimates based performance achieved time following reflects performance achieved course whole performance period line committees agreed principles measure actual performance targets reviewed adjustments made appropriate reflect impact novartis transaction business ensure vesting outcome reflected genuine underlying business performance performance vesting measures relative weighting performance targets performance achieved maximum award rd new rd new product performance measure based aggregate threeyear revenue product target new product sales new products defined products launched performance performance period two preceding years therefore products launched years included aggregate sales period billion vesting schedule shown straightline vesting points vesting schedule adjusted exclude impact novartis transactions ie revenues divested oncology products removed target outcome determining performance one acquired vaccines product bexsero judged meet condition new product therefore included target outturn target vesting maximum bn bn bn threshold bn business target originally set element time grant based aggregate revenues diversification vaccines consumer healthcare emerging markets japan purpose incentivising performance rewarding growth globally diversified business remuneration committee determined original target sustainable light transformational threepart transaction novartis committee therefore reviewed original target performance light additional sales acquired vaccines business consumer healthcare joint venture overall progress made towards strategic goal diversification committee noted several strong performances business initiatives period including relation fluarixflulaval following launch quadrivalent formulation strong emerging market sales products synflorix rotarix progress japan transitioning respiratory portfolio new ellipta portfolio successful otc switch flonase consumer healthcare factors supported groups ambition creating longterm business global scale reduced exposure risk volatility consistent strategic targets identified start performance period subsequently determined light progress made performance period vesting element threshold maximum element award vest adjusted free adjusted free cash flow afcf vesting schedule disclosed time grant cash flow vesting threshold billion maximum vesting achieving billion performance committee reviewed target vesting schedule light completion novartis transaction determined adjusted reflect impact transactions restructuring adjusted vesting schedule target vesting maximum bn bn bn threshold bn afcf three years billion line committees agreed principles included adjustments number material distorting items including legal settlements exchange rate movements special pension contributions threshold level performance met element therefore lapsed relative tsr gsks tsr rank position th comparator group ten pharmaceutical companies performance gsk nine companies element therefore lapsed vesting schedule comparator group set awards adjustments made reflect novartis transaction total vesting respect awards gsk annual report strategic report governance remuneration financial statements investor information annual report remuneration continued update performance ongoing lti awards committee also reviewed performance psp dabp matching awards granted executive directors following tables provide estimate vesting taking account performance date actual vesting levels determined based performance full threeyear performance periods indications therefore regarded predictions final vesting levels line committees agreed principles measure estimates vesting include adjustments required reflect impact novartis transaction business ensure outcome reflects genuine underlying business performance details adjustments made provided time vesting awards performance period ending december performance measures relative weighting performance update rd new product rd new product sales performance measures aggregate threeyear sales new products launched performance threeyear performance period preceding two years ie threshold performance results vesting rd maximum performance threshold results vesting strong sales new products two years ending december based aggregate sales new products two years based performance measure definitions vesting currently estimated around maximum adjusted free adjusted free cash flow afcf vesting schedule disclosed time grant vesting threshold cash flow billion maximum vesting achieving billion committee reviewed target performance vesting schedule light completion novartis transaction determined adjusted reflect rd impact transactions restructuring adjusted vesting schedule threshold award vests achieving afcf billion achieving billion achieving billion maximum achieving billion straightline vesting points based afcf two years ending december performance measure definitions vesting currently estimated threshold relative tsr period january december gsks tsr rank position th comparator group performance ten pharmaceutical companies gsk nine companies vesting schedule comparator group rd set awards ranking position remains level vesting would threshold current estimate potential total vesting awards vesting awards performance period ending december performance measures relative weighting performance update rd new product rd new product sales performance measures aggregate threeyear sales new products launched performance threeyear performance period preceding two years ie threshold performance results rd vesting maximum performance threshold results vesting strong sales new products year ending december based aggregate sales new products year based performance measure definitions vesting currently estimated around maximum adjusted free adjusted free cash flow afcf vesting schedule awards determined following completion cash flow novartis transaction disclosed via announcement stock exchange july performance order fully assess disciplined use restructuring funds period committee added back rd planned restructuring costs period billion separately funded retained divestment proceeds order incentivise management deliver restructuring planned costs overspend underspend versus billion translate adjustment determining adjusted free cash flow performance relative target vesting schedule award threshold award vests achieving afcf billion achieving billion achieving billion maximum achieving billion straightline vesting points based afcf year performance measure definitions vesting currently estimated threshold maximum relative tsr period january december gsks tsr rank position th comparator group performance ten pharmaceutical companies gsk nine companies vesting schedule comparator group rd set awards ranking position remains level vesting would threshold current estimate potential total vesting awards vestinggsk annual report strategic report governance remuneration financial statements investor information executive director remuneration audited salary average salary increase budget employees level cet approximately uk us committee decided increase executive directors salaries benefits significant changes provision benefits proposed full details policy relation benefits please refer remuneration policy wwwgskcom investors section operation annual bonus plan changes proposed operation annual bonus plan inevitably targets linked directly financial strategic plan commercially sensitive committee consider appropriate disclose annual bonus targets year may result competitive harm however details performance achieved disclosed annual report longterm incentive awards levels participation deferred annual bonus plan dabp respect executive directors shown table together maximum matching awards granted respect deferrals bonuses table shows performance share plan psp award levels executive director dabp matching awards psp awards subject performance continued employment dabp matching awards psp awards matching total bonus deferred award award level award level award shares ads base salary base salary sir andrew witty shares shares simon dingemans shares shares dr moncef slaoui adss adss performance targets awards performance targets vesting schedules set table measures linked directly strategy commercially sensitive particular committee consider appropriate disclose target range rd new product performance grant may result competitive harm however target range disclosed full gsks annual report end performance period together details extent targets met committee provide updates estimated vesting targets performance period gsk annual report strategic report governance remuneration financial statements investor information annual report remuneration continued executive director remuneration continued awards performance period ending december performance measures relative weighting link strategy vesting schedule rd new recognises importance rd future business growth performance product revenue target based new product sales incentivise better threshold vesting performance rd performance commercialisation new products defined maximum rd products launched performance period two preceding years therefore performance period products threshold launched years included target adjusted use cash flow performance measure intended adjusted free free recognise importance effective working capital management cash flow vesting cash flow generating cash fund groups operations investments maximum billion performance ordinary dividends shareholders free cash flow target represents billion rd operating profit business adjusted noncash items billion deducting cost benefit working capital capital expenditure taxation adding back planned restructuring costs threshold billion period billion separately funded retained billion divestment proceeds order incentivise management deliver restructuring planned costs overspend underspend versus billion translate adjustment determining adjusted free cash flow performance relative target adjustments free cash flow used set target purpose performance measure include legal settlements special pension contributions foreign exchange divestments acquisitions measure postadjustment adjusted free cash flow relative tsr focuses delivery value shareholders tsr ranking performance relative tsr using comparator group comprising gsk nine within comparator rd global pharmaceutical companies relative tsr measured group vesting three years using twelvemonth averaging period tsr maximum st nd rd measured local currency th threshold th median th th sr comparator group astrazeneca bristolmyers squibb eli lilly gsk johnson johnson merck co novartis pfizer roche holdings sanofi vesting schedule based delivering vesting median performance comparator group ten companies median falls two companies threshold vesting therefore achieving median performancegsk annual report strategic report governance remuneration financial statements investor information remuneration performance disclosures ceo remuneration table performance graph table following graph sets performance company relative ftse index pharmaceutical performance comparator group sevenyear period december graph prepared accordance single figure remuneration regulations indication likely remuneration vesting awards granted companys incentive plans indices selected comparison purposes annual bonus reflect index gsk constituent award industry operates maximum vesting lti awards maximum bonus amounts include amounts paid operational efficiency bonus place years overall maximum bonus receivable still subject limit base salary n respect psp awards sir andrew also outstanding awards share options granted respectively lapsed full included total vesting percentage due distorting effect aggregating conditional shares share options gsk total return gsk pharma peers ftse total return index total return index index comprises astrazeneca bristolmyers squibb eli lilly johnson johnson merck co novartis pfizer roche holdings sanofi historical vesting gsks ltis following table shows historical vesting levels companys longterm incentive plans deferred annual bonus plan matching awards performance share plan share option plan respect awards made executives since share deferred annual bonus plan performance share plan option plan vesting vesting vesting vesting vesting total adjusted free rd new business total year vesting tsr cash flow product diversification vesting eps grant performance period na na na na na na na na na na na na na na na na na dabp awards subject wholly tsr performance awards subject performance measures psp awards malus clawback policy disclosure made matter subject companys policy malus clawback set public reports misconduct fully resolved companys remuneration policy report available legally permissible disclose made without wwwgskcom investors section committee unduly prejudicing company therefore shareholders line jurisdiction malus clawback respect executives disclosure guidelines neither committee event triggering event eg significant misconduct recoupment committee exercised malus clawback way violation regulation law significant gsk policy code conduct company ability claw committee determined release shares back three years annual deferred bonuses well lti plans may delayed case leavers vested unvested ltis recoupment committee exercises reinforce implementation malus clawback policy authority wider employee base comprised senior also case deferred bonus awards dabp executives relevant oversight appropriate experience granted executives retire made redundant including senior vice president global ethics compliance vesting awards normally delayed vest senior vice president general counsel original timescales rather vesting earlier end january respect financial year committee year termination date falls discloses whether recoupment committee exercised clawback malus gsk annual report strategic report governance remuneration financial statements investor information annual report remuneration continued remuneration performance disclosures continued allemployee share plans percentage change remuneration ceo executive directors participate various allemployee share sir andrew witty uk employees plans including sharesave sharereward sharesave plan hm revenue customs approved plan open uk change change employees participants may save month salary net salaries fixed term three years end benefits savings period option buy gsk shares annual bonus discount market price set launch savings contract sir andrew witty simon dingemans reflects salary earned benefits received annual contribute maximum month sharesave plan bonus earned respect compared wider uk employee population salary increase includes sharereward plan hm revenue customs approved annual salary review well additional changes year plan open uk employees terms participants eg promotion increase benefits ceo contribute month gross salaries purchase result change benefit arrangements uk employee gsk shares company matches number gsk shares benefits unchanged previous year bought month arrangement sir andrew witty changes benefit policies levels reflect simon dingemans contribute maximum month changes level benefits individual may received buy shares sharereward plan result change role eg promotion uk population dilution limits considered relevant comparison closely awards made plans incorporate dilution reflects economic environment encountered ceo limits consistent guidelines published investment external appointments executive directors association formed following merger ima board encourages executive directors hold one external abi limits rolling ten year period directorship become established plans rolling ten year period executive share roles broaden experience development help plans estimated dilution existing awards made last increase pool nonexecutive director candidates ten years december follows outside appointments considered nominations committee ensure would cause conflict interest gsk employee share plans executive share plans approved chairman behalf board companys policy remuneration earned appointments may kept individual executive director dr moncef slaoui receive fees relation membership qatar biomedical research institute scientific advisory committee meetings took place period earned honorarium attending board meeting advisory committee director national institute health external appointments receives remuneration sir andrew witty simon dingemans hold external appointments remunerated actual limit service contracts table sets relevant dates current relative importance spend pay executive directors service contracts available table shows percentage changes groups dividends review companys registered office office hours paid shareholders share buyback total employee pay date effective contract date expiry date notes change sir andrew contract amended total employee pay witty remove entitlement bonus dividends termination share buyback simon dingemans figures table set pages dividends declared respect million dr moncef contract replaced slaoui principally million ie increase given impact remove entitlement sustained strength sterling free cash flow bonus termination company suspended share repurchase programme following completion novartis transaction gsk payments past directors audited return approximately billion net proceeds way payments past directors special dividend payable time q payments loss office audited dividend special dividend included payments loss office directors amounts company expect make ordinary share repurchases total employee pay based employees average number people employed gsk annual report strategic report governance remuneration financial statements investor information overview total pay summary remuneration following shows breakdown total remuneration paid executive directors respect ceo cfo chairman global vaccines fixed pay salary benefits pension performance pay annual bonus ltis earned annual bonus lti awards summary outcomes charts illustrate annual bonus outcomes financial year ending december vesting levels psp dabp matching awards granted executive directors performance periods ending december awards based four equally weighted performance measures rd new product performance adjusted free cash flow relative tsr business diversification financial performance lti outcomes maximum business rd diversification new products target threshold adjusted relative core group core group vaccines free cash flow tsr operating pbit performance profit maximum performance target performance achieved award lapsed award vested executive directors shareholdings audited current share ownership align interests executive directors shareholders required build maintain significant ceo holdings shares gsk time executive directors required continue satisfy shareholding requirements minimum months following retirement company cfo current share ownership requirements sor follows share ownership requirement ceo x base salary chairman global vaccines executive directors x base salary cet members x base salary base x x x x x x salary current shareholdings illustrated chart opposite sor shareholding gsk annual report strategic report governance remuneration financial statements investor information annual report remuneration continued remuneration governance remuneration committee adviser committee remuneration committee chairman urs rohner joined board committee access external advice required appointed committee january committee carried formal review independent advisers appointed committee chairman effect may committee result review committee following retirement tom de swaan committee chairman reappointed deloitte llp provide independent advice nonexecutive director may executive remuneration committee chairman agrees protocols deloitte provides advice committee role committee satisfied advice received deloitte role committee set companys remuneration objective independent policy gsk able recruit retain motivate executives remuneration policy regularly reviewed deloitte member remuneration consultants group ensure consistent companys scale scope voluntarily operates code conduct relation operations supports business strategy growth plans executive remuneration consulting uk code conduct helps drive creation shareholder value found wwwremunerationconsultantsgroupcom terms reference deloitte provided independent commentary matters committees full terms reference available consideration committee updates market practice companys website terms reference reviewed legislative requirements deloittes fees advice provided least annually last revised january reflect best committee fees charged practice corporate governance developments time materials basis deloitte llp also provided consulting tax assurance services gsk year however governance committee satisfied compromise board considers members committee independence advice received deloitte independent nonexecutive directors accordance uk corporate governance code willis towers watson provided additional market data committee committee met six times scheduled meetings shareholder votes remuneration matters member attending follows votes total votes total votes total votes withheld agm cast billion million committee attendance full members member since meetings remuneration report urs rohner january chairman may votes total votes total votes total votes withheld vindi banga january agm cast billion million dr stephanie burns may remuneration report judy lewent january remuneration policy sir deryck maughan july consideration shareholder views hans wijers october committee engages regular dialogue shareholders sir christopher gent january holds annual meetings gsks largest investors discuss take feedback remuneration policy governance matters tom de swaan may chairman may annual meetings held november urs rohner committee chairman shared updates remuneration sir christopher gent tom de swaan retired board may matters last months proposals onwards addition six scheduled meetings committee met particular covered proposed enhanced annual bonus quorate basis three occasions approve formal grant disclosures inclusion annual report addition longterm incentive awards employees cet investors initial views sought future development address lti administrative matters approved remuneration policy advance anticipated submission company binding shareholder resolution committee meetings usually include closed session approve new remuneration policy agm members committee present individuals may also invited attend committee meetings committee evaluation year executives committee attendees committees annual evaluation internally facilitated involved decisions present company secretary supplemented questionnaire discussions regarding remuneration circulated committee members behalf committee chairman concluded committee continued company secretary secretary committee operate effectively terms enhancements committees attends meetings attendees committee include deliberations agreed committee would focus attention reviewing companys remuneration regular attends attendee attendee required policy ceo cid cfo cid head human resources cid head reward cid committee adviser deloitte llp cidgsk annual report strategic report governance remuneration financial statements investor information remuneration governance continued principal activities matters addressed remuneration items specific governance month overall annual bonus ltis matters january approve cet salary increase r eview approve rd annual bonus r eview draft remuneration report recommendations target metric r eview shareholder feedback r eview approve executives annual investor meetings bonuses review committee external evaluation et ceo bonus objectives report u pdate deferred annual bonus plan rules u pdate lti performance lti awards february r eceive update remuneration r eview lti performance outcomes r eview remuneration report related implications novartis approve vesting lti awards transaction cet cet review approve lti grants cet grant interim share value plan awards cet march r emuneration environment update update performance share plan update remuneration considerations employees cet grant awards certain eligible former novartis employees july review ceo cfo pay approve adjusted free cash flow target r eview agm remuneration report competitiveness awards following completion feedback external remuneration r eview remuneration benchmark novartis transaction environment performance target comparator groups disclosures incentive plans pprove committee evaluation process review chairman fees e nvironmental update august g rant interim main share value plan awards cet october c onsider remuneration u pdate lti vesting awards u pdate remuneration report report disclosures disclosures update ceo cfo review adjustment principles lti p reparation annual investor cet remuneration competitiveness measures respect novartis meetings draft plan review remuneration transaction policy agm november annual meeting investors december annual cet benchmarking grant awards certain eligible former review investment association competitiveness review novartis employees principles remuneration approve executive director salary update remuneration report increases disclosures review shareholder feedback annual investor meetings gsk annual report strategic report governance remuneration financial statements investor information annual report remuneration continued nonexecutive directors fees chairman nonexecutive directors letters appointment company aims provide chairman non terms engagement nonexecutive directors executive directors fees competitive paid set letters appointment available inspection companies equivalent size complexity subject companys registered office agm limits contained gsks articles association nonexecutive director initial appointment subsequent reappointment subject election thereafter chairmans fees periodic reelection shareholders chairman sir philip hampton appointed nonexecutive director january received standard annual nonexecutive directors letters appointment fee nonexecutive director april contain provision notice periods compensation received fees per annum deputy appointments terminated chairman since appointment chairman conclusion following table shows date initial letter agm may fees increased per appointment nonexecutive director annum elected take fees gsk shares nonexecutive director fees date letter nonexecutive director fees last increased january nonexecutive director appointment increases supplemental fees minimum sir philip hampton september fees continue delivered shares deferred professor sir roy anderson september nonexecutive director steps board vindi banga may nonexecutive directors fees applying since january dr stephanie burns february set stacey cartwright march per annum lynn elsenhans may standard annual fee dr jesse goodman december supplemental fees chairman audit risk committee judy lewent march senior independent director scientificmedical experts sir deryck maughan may chairmen remuneration corporate dr daniel podolsky july responsibility committees urs rohner october nonexecutive director undertaking intercontinental travel meetings per meeting hans wijers january table audited sets value fees benefits received nonexecutive directors form cash shares ads details nonexecutive directors share allocation plan set nonexecutive directors fees fees emoluments audited cash sharesads benefits total cash sharesads benefits total professor sir roy anderson vindi banga dr stephanie burns stacey cartwright lynn elsenhans sir christopher gent sir philip hampton judy lewent sir deryck maughan dr daniel podolsky urs rohner tom de swaan jing ulrich hans wijers sir robert wilson benefits primarily consist travel subsistence costs incurred normal course business relation meetings board committee matters gskhosted events considered taxable overseasbased nonexecutive directors includes travel meetings uk b nonexecutive directors fees paid gbp converted using exchange rate set annually based average rate last quarter year prior payment rate reviewed moves significantly year c sir philip hampton urs rohner joined board january vindi banga joined board september sir christopher gent tom de swaan jing ulrich retired board may sir robert wilson retired board may e sir christopher gents benefits number includes travel hospitality costs incurred whilst attending gsk hosted events previously agreed request company retired may gsk annual report strategic report governance remuneration financial statements investor information directors interests shares audited interests directors company office december connected persons shown tables total share plan interests december total directors interests sharesads options aunvested unvested aunvested unvested march december january subject subject subject subject vested exercised performance performance performance performance exercised year executive directors shares sir andrew wittybcdfgi simon dingemansbcdfi dr moncef slaouig ads dr moncef slaouicdeh share allocation plan nonexecutive directors total directors interests sharesads number shares ads december january march date date december dividends allocated december resignation appointment paid reinvested elected nonexecutive directors sharesj professor sir roy anderson vindi banga dr stephanie burns stacey cartwright sir christopher gentk sir philip hampton urs rohner tom de swaank hans wijers adsj dr stephanie burns lynn elsenhans judy lewent sir deryck maughan dr daniel podolsky jing ulrichk unvested shares ads unvested options held executive directors subject performance reflect bonus deferrals dabp sharesave share value plan svp awards b total directors interests march include deferred annual bonus awards related matching awards vested february awards uk participants structured nil cost options following gross interests included table tax due point exercise sir andrew witty deferred annual bonus award vested matching award mr simon dingemans deferred annual bonus award vested matching award total directors interests also includes shares purchased glaxosmithkline sharereward plan sir andrew witty simon dingemans awarded shares plan balance shares within plan follows sharereward plan shares march december january sir andrew witty simon dingemans dr moncef slaoui eligible participate sharereward plan open uk employees gsk annual report strategic report governance remuneration financial statements investor information annual report remuneration continued directors interests shares continued c total directors interests includes shares ads resulting deferral bonus subsequent reinvestment dividends dabp totals shown table include bonus deferrals exclude unvested matching awards subject ongoing performance criteria amounts represent gross share ads balances prior sale shares ads satisfy tax liabilities deferred annual bonus plan bonus deferrals march december january sir andrew witty shares simon dingemans shares dr moncef slaoui ads total directors interests march include shares ads vested due performance met elements psp awards less sold satisfy tax liabilities vested amounts see pages details e dr moncef slaoui total directors interests includes ads purchased within k plan us executive supplemental savings plan essp ads awarded dr slaouis connected person svp relevant balances follows dr moncef slaoui ads march december january us retirement savings plans share value plan executive director dr moncef slaoui eligible receive awards svp svp awards shown reflect holdings dr slaouis connected person also employee gsk awards subject threeyear vesting periods vesting contingent continued employment within gsk gains arising vesting included dr moncef slaouis total remuneration figures year connected person granted ads august grant price face value dr slaouis total share plan interests also include psp awards held connected person awards subject performance criteria relevant employees cet december connected person held ads psp comprising awards made ads ads ads amounts including dividend reinvestment f unvested options subject performance sir andrew witty simon dingemans unvested options subject performance include holdings respectively sharesave plan participate terms employees sharesave options granted sir andrew witty simon dingemans granted options plan october remainder unvested options subject performance relate bonus deferrals structured nilcost options dabp g vested exercised options executive directors following table provides details vested unexercised options december share option plan sop lapsed february gsk granted options plan executive directors annual basis share option plan number shares option date grant lapse date grant price sir andrew witty dr moncef slaoui h ads vested unexercised options totalling dr moncef slaoui represent ads options held dr moncef slaouis connected persongsk annual report strategic report governance remuneration financial statements investor information directors interests shares continued following table sets details options including nilcost options dabp exercised executive directors dr moncef slaoui exercise options year number shares market gain exercise type award date grant option date exercise grant price price exercise sir andrew witty sharesave dabp deferral dabp matching simon dingemans sharesave dabp deferral dabp matching respect options sop sharesave plans remuneration receivable executive director calculated date options first vest remuneration difference amount executive director required pay buy shares ads total value shares ads vesting date executive director chooses exercise options vesting date subsequent increase decrease amount realised due movements share ads price vesting date date exercise increase decrease value result investment decision executive director recorded remuneration options vested executive directors respect nilcost options dabp bonus deferred director recorded remuneration annual bonus year relates gain recorded exercise nilcost option comprises remuneration total amounts received reinvested dividends prior vesting gains losses resulting movements share price dates grant exercise initial bonus amount deferred dates dividend reinvestment exercise reinvested dividends matching element dabp remuneration executive director recorded year performance criteria end represents number vested shares multiplied price vesting gain recorded exercise nilcost option comprises total remuneration gain loss resulting movement share price vesting exercise sir andrew witty total gain following exercise options granted sharesave plan gain recorded following exercise nilcost options relating deferral bonus earned respect comprises remuneration recorded annual bonus net gain relating reinvestment dividends prior vesting movements share price grant dividend reinvestment dates exercise date gain recorded following exercise nilcost options relating dabp matching award comprises remuneration recorded relation dabp see investment loss relating movement share price vesting exercise dates simon dingemans total gain following exercise options granted sharesave plan gain recorded following exercise nilcost options relating deferral bonus earned respect comprises remuneration recorded annual bonus net gain relating reinvestment dividends prior vesting movements share price grant dividend reinvestment dates exercise date gain recorded following exercise nilcost options relating dabp matching award comprises remuneration recorded relation dabp see investment loss relating movement share price vesting exercise dates j nonexecutive directors total interests include shares ads received part fees nonexecutive director share allocation plan note dividends received shares ads plan converted shares ads december k ir christopher gent tom de swaan jing ulrich retired board may elected receive shares nonexecutive directors share allocation plan immediately upon retiring board dividend entitlements respect q q q dividends paid cash accordance plan rules gsk annual report strategic report governance remuneration financial statements investor information annual report remuneration continued directors interests shares continued deferred annual bonus plan matching awards deferred annual bonus plan dabp matching awards made annually executive directors based individuals mandatory deferral voluntary bonus deferral election company match shares ads oneforone depending companys performance threeyear performance period performance conditions vesting levels described pages report awards ukbased executive directors made form nilcost options award vests ukbased executive director may choose exercise award time years date grant awards usbased executive directors made conditional awards ads amount remuneration receivable respect matching shares ads calculated using share ads price date relevant award vests award vests date remuneration report calculation performed using average share ads price last quarter financial year executive director chooses exercise nilcost options vesting date subsequent increase decrease amount realised due movements share price vesting date date exercise increase decrease value result investment decision recorded remuneration dividends reinvested nilcost options conditional awards shares ads made executive directors date vesting following tables provide details executive director respect dabp matching awards market price grant vesting represent closing share prices dates performance period sir andrew witty shares market price grant unvested december granted face value grant dividends reinvested vested lapsed unvested december granted face value grant dividends reinvested vested lapsed unvested march vested shares number shares market price vesting gain remuneration remuneration value shown column award vested march valued based fair market value closing share price business day prior vesting date please note values shown differ disclosed annual report value based estimated vesting price gsk annual report strategic report governance remuneration financial statements investor information directors interests shares continued deferred annual bonus plan matching awards continued performance period simon dingemans shares market price grant unvested december granted face value grant dividends reinvested vested lapsed unvested december granted face value grant dividends reinvested vested lapsed unvested march vested shares number shares market price vesting gain remuneration remuneration value shown column award vested march valued based fair market value closing share price business day prior vesting date please note values shown differ disclosed annual report value based estimated vesting price performance period dr moncef slaoui ads market price grant unvested december granted face value grant dividends reinvested vested lapsed unvested december granted face value grant dividends reinvested vested lapsed unvested march vested ads number ads market price vesting gain remuneration remuneration value shown column award vested march valued based fair market value closing share price business day prior vesting date please note values shown differ disclosed annual report value based estimated vesting price gsk annual report strategic report governance remuneration financial statements investor information annual report remuneration continued directors interests shares continued performance share plan awards performance share plan psp awards made executive directors annual basis terms psp number shares ads vesting determined following end relevant performance period dependent gsks performance period performance conditions vesting levels described pages dividends reinvested performance shares ads awarded executives throughout performance period date vesting vesting uk participants receive relevant number shares us participants may defer receipt part vested awards amount remuneration receivable respect performance shares calculated using share ads price date relevant psp award vests psp awards made sir andrew witty threeyear performance periods however deeds award specified awards would subject twoyear vesting period five years total twoyear period additional performance criteria awards lapse sir andrew dismissed cause remuneration respect awards therefore considered realised full following determination remuneration committee vesting levels initial awards ie full remuneration recognised end threeyear performance period whole award made executive director threeyear performance period additional twoyear vesting period award therefore vest five years final two years vesting period award director lapse dismissed cause remuneration respect awards dividend equivalent point therefore recognised end threeyear performance period ie remuneration report following tables provide details executive director respect psp awards market price grant vesting represent closing share prices dates performance period sir andrew witty shares market price grant unvested december granted face value grant dividends reinvested vested lapsed unvested december granted face value grant dividends reinvested vested lapsed unvested march vested shares number shares market price vesting gain remuneration remuneration gsk annual report strategic report governance remuneration financial statements investor information directors interests shares continued performance share plan awards continued performance period simon dingemans shares market price grant unvested december granted face value grant dividends reinvested vested lapsed unvested december granted face value grant dividends reinvested vested lapsed unvested march vested shares number shares market price vesting gain remuneration remuneration performance period dr moncef slaoui ads market price grant unvested december granted face value grant dividends reinvested vested lapsed unvested december granted face value grant dividends reinvested vested lapsed unvested march vested ads number ads market price vesting gain remuneration remuneration gsk annual report strategic report governance remuneration financial statements investor information annual report remuneration continued directors senior management information provided compensation interests directors senior management group group purpose group defined nonexecutive executive directors members cet company secretary financial year following table sets aggregate remuneration group periods served capacity remuneration total compensation paid aggregate increase accrued pension benefits net inflation aggregate payments defined contribution schemes members group awarded shares ads companys various share plans set table awards dividend reinvestment awards awarded shares ads shares ads deferred annual bonus plan performance share plan deferred investment awardsa b share value planb march group following interests shares ads company holdings issued various executive share plans described note financial statements employee share schemes interests march shares ads owned unexercised options deferred annual bonus plan performance share plan deferred investment awardsa b share value planb notional shares ads b executive directors eligible receive deferred investment awards participate share value plan basis preparation remuneration report prepared accordance companies act large mediumsized companies groups accounts reports amendment regulations regulations accordance regulations following parts annual report remuneration subject audit total remuneration figures executive directors including details element remuneration salary benefits annual bonus longterm incentive awards pension nonexecutive directors fees emoluments received year directors interests shares including interests gsk share plans payments past directors payments loss office share ownership requirements holdings opinion thereon expressed remaining sections remuneration report subject audit pages referred within audited sections remuneration report approved board directors signed behalf urs rohner remuneration committee chairman march gsk annual report strategic report governance remuneration financial statements investor information remuneration policy summary executive director remuneration policy companys remuneration policy report approved may gsks annual general meeting full policy available wwwgskcom investors section annual report following summary policy value earned annual longterm total salary benefits pension bonus incentive remuneration awards fixed pay b pension c pay performance element purpose link strategy operation salary provide core reward role individuals role experience performance independently sourced data relevant comparator groups considered determining salary levels set level appropriate secure retain high calibre individuals needed deliver groups strategic priorities benefits levels set recruit retain executive directors generally eligible receive benefits line policy high calibre individuals execute employees may vary location include travel allowances business strategy including spousepartner travel healthcare life assurancedeath service provided part individuals pension arrangements personal financial advice contractual postretirement benefits pension pension arrangements provide pension arrangements structured accordance plans operated competitive level retirement country individual likely retire individual income chooses become member pension plan cash lieu relevant pension contribution paid instead new executive directors uk entitled either join defined contribution pension plan receive cash payment lieu pension contribution individual member gsk legacy defined benefit plan defined contribution plan alternative pension plan arrangement subsequently appointed board may remain member plan annual bonus incentivise recognise financial operational business targets set start year execution business strategy committee bonus levels determined committee based annual basis performance targets rewards achievement individual objectives set start year committee stretching annual financial performance objectives assessed committee strategic business targets executive directors required defer bonus earned shares delivery personal objectives ads appropriate three years may defer additional bonus earned overall maximum deferral deferred shares vest end three year performance period longterm incentivise recognise delivery deferred annual bonus plan incentive awards longer term business deferred shares may matched subject achievement performance priorities financial growth conditions three years matching awards may conditional shares increases shareholder value nilcost options eligible dividend equivalents respect compared pharmaceutical performance period companies performance share plan addition provide alignment conditional awards made annually vesting dependent shareholder interests retention achievement performance conditions three years vested awards element encourage longterm subject additional twoyear vesting period awards eligible shareholding discourage dividend equivalents date vesting excessive risk taking details policy clawbackmalus recruitment remuneration loss office termination payments please refer full remuneration policy report gsk annual report strategic report governance remuneration financial statements investor information remuneration policy summary continued nonexecutive director remuneration policy element purpose link strategy overview chairmans fee provide inclusive flat rate fee formal maximum however fees reviewed annually set competitive paid reference review chairmans performance independently companies equivalent sourced market data size complexity subject remuneration committee responsible evaluating making limits contained gsks articles recommendations board fees payable chairman association chairman participate discussions respect fees fees paid combination cash andor gsk shares ads basic fee formal maximum however fees reviewed annually set reference independently sourced market data chairman ceo responsible evaluating making recommendations board fees payable companys nonexecutive directors minimum delivered form gsk shares ads supplemental provide additional compensation additional fees committee chairmen intercontinental travel fees nonexecutive directors senior independent director medicalscientific experts current fee excluding chairman taking levels set annual report additional board responsibilities undertaking intercontinental travel meetings benefits facilitate execution travel subsistence costs nonexecutive directors incurred responsibilities duties normal course business relation meetings board committee required role matters gskhosted events includes nonexecutive directors undertaking intercontinental travel meetings nonexecutive directors may time time accompanied spouse partner meetings events costs associated met company instances deemed taxable therefore treated benefits nonexecutive director nonexecutive enhance link least nonexecutive directors total fees excluding directors share directors shareholders chairman paid form gsk shares ads allocated share allocation plan gsk requires nonexecutive ads account directors receive significant nonexecutive directors may also take opportunity invest part part fees form balance fees share ads account gsk shares ads gsk shares ads notionally awarded nonexecutive directors allocated interest accounts set directors interests table annual report accumulated balances gsk shares ads together notional dividends accrued paid nonexecutive directors leave board upon leaving nonexecutive directors receive either gsk shares ads cash amount equivalent value gsk shares ads date leaving date payment later letter nonexecutive directors nonexecutive directors subject annual election reelection appointment chairmans terms engagement normally serve longer nine years date first election set letters appointment shareholders general meeting set table chairman subject annual appointment shareholders may annual report serve longer nine years date first election shareholders general meetingstrategic report governance remuneration financial statements investor information financial statements section directors statement responsibilities independent auditors report financial statements notes financial statements financial statements glaxosmithkline plc prepared uk gaap gsk annual report gsk annual report strategic report governance remuneration financial statements investor information directors statement responsibilities directors responsible preparing annual report disclosure information auditors remuneration report group financial statements directors office date annual report accordance applicable law regulations confirmed uk company law requires directors prepare financial far aware relevant audit information statements financial year law directors companys auditors unaware required prepare group financial statements taken steps ought accordance international financial reporting standards taken director make aware ifrs adopted european union preparing group relevant audit information establish companys financial statements directors also elected comply auditors aware information ifrs issued international accounting standards board iasb company law directors must approve confirmation given interpreted accordance group financial statements unless satisfied provisions section companies act give true fair view assets liabilities financial position going concern basis profit loss group period pages contain information performance preparing financial statements directors group financial position cash flows net debt position required borrowing facilities information including treasury risk management policies exposures market credit risk select suitable accounting policies apply hedging activities given note financial statements consistently financial instruments related disclosures assessed make judgements accounting estimates principal risks matters considered connection reasonable prudent viability statement directors considered appropriate adopt going concern basis accounting preparing state group financial statements comply ifrs financial statements adopted european union ifrs issued iasb subject material departures disclosed internal control explained group financial statements board audit risk committee reviewed assessment risks internal control framework operates prepare financial statements going concern basis gsk considered effectiveness system unless inappropriate presume group internal control operation group year covered continue business annual report date approval board directors responsible keeping adequate accounting directors records sufficient show explain companys uk corporate governance code transactions disclose reasonable accuracy time board considers glaxosmithkline plc applies financial position group enable ensure principles complies provisions uk corporate group financial statements remuneration report governance code maintained financial reporting council comply companies act article ias described corporate governance section pages regulation also responsible safeguarding assets board considers annual report taken group hence taking reasonable steps whole fair balanced understandable provides prevention detection fraud irregularities information necessary shareholders assess groups group financial statements year ended december position performance business model strategy comprising principal statements supporting notes required financial conduct authoritys listing rules set financial statements pages auditors considered directors statement report responsibilities auditors relation group compliance relation points uk corporate financial statements set independent auditors report governance code specified review pages annual report group financial statements year ended december annual report year ended december included annual report published comprising report directors remuneration report printed form made available website directors financial statements additional information investors responsible maintenance integrity annual report approved board directors signed website accordance uk legislation governing behalf preparation dissemination financial statements access website available outside uk comparable legislation may different current directors whose names functions philip hampton listed corporate governance section annual report chairman confirms best knowledge march group financial statements prepared accordance ifrs adopted eu ifrs issued iasb give true fair view assets liabilities financial position profit group strategic report risk sections annual report represent management report include fair review development performance business position group together description principal risks uncertainties facesgsk annual report strategic report governance remuneration financial statements investor information independent auditors report members glaxosmithkline plc report group financial statements areas focus threepart transaction novartis opinion rebates discounts allowances returns us opinion glaxosmithkline plcs group financial statements pharmaceuticals vaccines business give true fair view state groups affairs investigations groups commercial practices december profit cash flows year ended litigation properly prepared accordance international carrying value goodwill intangible assets financial reporting standards ifrss adopted remeasurement shionogiviiv healthcare contingent european union consideration prepared accordance requirements uncertain tax positions companies act article ias regulation context separate opinion relation ifrss issued iasb context audit set groups major activities explained note group financial statements significant event last twelve months group addition applying ifrss adopted european completion groups threepart transaction union also applied ifrss issued international novartis ag therefore become new area focus accounting standards board iasb audit given number significant management opinion group financial statements comply ifrss estimates judgements required account transaction issued iasb including valuations acquired assets liabilities impact acquisition accounting recognition measurement put audited option liability certain tax judgements broad range group financial statements included within annual report financial statement line items impacted comprise time fewer markets migrated compared consolidated balance sheet december either onto groups common enterprisewide consolidated income statement consolidated statement resource planning platforms erp moved financial transaction comprehensive income year ended accounting services business process outsourcing locations bpo inhouse business service centres consolidated cash flow statement year ended bsc decision taken consciously management consolidated statement changes equity year given competing pressures organisation complete ended integrate novartis transaction result transformation groups finance processes highlighted area focus notes group financial statements include report area lower risk summary significant accounting policies included area focus report however explanatory information expect area feature area focus certain required disclosures presented elsewhere newly acquired novartis businesses start migrated onto annual report rather notes financial gsks centralised platforms statements crossreferenced financial also added new area focus groups estimation statements identified audited fair value shionogiviiv healthcare contingent financial reporting framework applied consideration reflecting significant estimation uncertainty preparation group financial statements applicable law inherent calculation balance given continued ifrss adopted european union increase size balance response changes management estimates address better expected audit approach performance acquired products revisions certain overview assumptions following resolution investigation materiality groups chinese pharmaceuticals business september overall group materiality million represents considering output audit work risk approximately profit tax adding back certain focus principally directed nonrecurring items adjusted profit tax financial reporting judgements relating active investigations audit scope department justice doj us serious fraud audit included full scope audits reporting components office sfo uk specific audit procedures performed areas focus refined reflect developments reporting components groups business including consideration expansion taken together components audit work healthcare reform continued competitive pricing pressure performed accounted consolidated revenue discounting us progress litigation consolidated profit tax adjusted profit group exposed impact changes groups segmental tax covered components individually contributed reporting following novartis transaction determination revenue profit tax adjusted profit tax cash generating units cgus impairment testing purposes managements assessment uncertain tax positions gsk annual report strategic report governance remuneration financial statements investor information independent auditors report continued scope audit areas focus procedures verify proper cutoff revenue expenses conducted audit accordance international testing existence accuracy revenue transactions standards auditing uk ireland isas uk ireland addition incorporate element unpredictability audit work year designed audit determining materiality assessing risks material misstatement financial statements risks material misstatement greatest effect particular looked directors made subjective audit including allocation resources effort judgements example respect significant accounting identified areas focus table also set estimates involved making assumptions considering future tailored audit address specific areas order events inherently uncertain audits also provide opinion group financial statements whole addressed risk management override internal controls comments make results procedures including evaluating whether evidence bias read context area focus directors represented risk material misstatement due appropriate evaluated design tested operating fraud risk fraud revenue recognition procedures effectiveness key internal controls financial reporting designed executed address risks included use data including testing operation systems financial enabled auditing techniques test journal entries postclose information generated complete list risks adjustments testing evaluating managements key accounting identified audit estimates reasonableness consistency undertaking cutoff area focus audit addressed area focus threepart transaction novartis deploying valuations specialists audited methodology refer notes group financial statements underlying assumptions mechanical accuracy valuation models significant acquired intangible assets consideration paid march group completed threepart transaction including contingent consideration settlement preexisting novartis ag group acquired novartis existing vaccines business relationships challenged cash flow projections underpinned cash consideration us billion disposed oncology valuations including consumer put option comparing business cash consideration us billion party historical cash flows understanding reasons growth contributed existing consumer healthcare business new profile projections venture group controlling interest deploying tax specialists evaluated external tax opinions focused area accounting component obtained management verify technical accuracy validate threepart transaction gave rise following significant audit risks steps taken group effecting transactions recognition goodwill million intangible assets consistent external advice opinions million acquisitions vaccines novartis consumer healthcare business instructed component teams locations undertake certain substantive procedures acquired opening balance sheets accounting establishment consumer healthcare joint vaccines consumer healthcare including attendance inventory venture complicated required fair valuing portion counts close acquisition date physical verification assets acquired gsks existing business contributed million non substantive procedures focused revenue cost cutoff controlling interest arose acquisition million result work determined provisional purchase number internal restructuring steps undertaken prior price allocations vaccines consumer healthcare acquisitions oncology disposal consumer healthcare vaccines outlined note group financial statements reasonable acquisitions order support transactions tax efficient connection oncology disposal verified cash proceeds manner reperformed managements calculation resultant gain group recognised liability present value expected disposal found pretax gain disposal oncology redemption price written put option novartis noncontrolling million associated tax charge million interest new consumer healthcare venture consumer reasonably stated latter reflecting managements best estimate put option value subject significant judgement incremental tax risk arising result threepart transaction estimation uncertainty december liability determined carrying value consumer put option carrying value million calculated accordance agreement novartis based board approved projections business reasonably stated finally found disclosures respect aspect transaction reasonable providing fair reflection accounting valuations judgementsgsk annual report strategic report governance remuneration financial statements investor information area focus audit addressed area focus rebates discounts allowances returns us obtained managements calculations accruals applicable pharmaceuticals vaccines business schemes validated assumptions used reference groups refer notes group financial statements stated commercial policies terms applicable contracts third party data related patient enrolment us government funded benefit schemes group makes sales various customers us fall historical levels product returns certain commercial government mandated contracts reimbursement arrangements significant medicaid compared assumptions contracted prices historical rebates medicare group also provides right return customers discounts allowances returns levels relevant current certain products payment trends also considered historical accuracy groups estimates previous years including certain changes made managements arrangements result deductions gross sales arriving estimates update medicaid rebates new pricing methodology turnover give rise obligations group provide customers respond impact competitive pricing pressures particularly rebates discounts allowances right return advair greater discounting us market generally formed unsettled amounts recognised accrual independent expectation largest elements accrual focused area rebates discounts allowances december using third party data compared expectation returns arrangements complex establishing appropriate actual accrual recognised group accrual requires significant judgement estimation directors based procedures performed identify material judgement particularly complex us healthcare environment differences independent expectations accrual competitive pricing pressure product discounting growing trends directors determined accrual million necessary december december million investigations groups commercial practices met directors management inhouse legal counsel spoke refer notes group financial statements groups external advisors assess risk occurrence group remains subject ongoing investigations doj similar acts previously alleged china status ongoing us sfo uk groups commercial practices investigations potential fines penalties included number markets december group concluded understanding evaluating groups internal investigations processes yet sufficient clarity likely timing assess risks allegations reported various channels completion investigations able make sufficiently including whistleblowing hotlines also evaluated ongoing reliable estimate fines penalties either doj enhancements changes made control sfo might impose group completion respective processes business practices since original allegations china investigations result group stated note unable recognise provision estimate eventual outcome deploying forensic specialists assessed scope findings either investigation investigative work performed group well risk assessment addition group carrying investigations number exercise management performed third party interaction markets ascertain activities similar previously alleged engagement broadly used output assessment instruct china occurred elsewhere ten component teams including certain markets otherwise included group audit scope undertake riskfocused audit procedures address focused following risks might material impact audit risk group financial statements might materially groups financial statements misstated due potential financial implications alleged illegal acts fines penalties might forthcoming respect ongoing respect doj sfo investigations independently circularised investigations groups commercial practices including external legal counsel engaged group obtain views status doj sfo could give rise need material investigations ascertain reasonableness managements provisions asset impairments assertions respect likely outcome investigation discussed responses received directly external legal counsel found illegal acts similar previously alleged china consistent representations received management occurred elsewhere group satisfied groups provisioning decisions december adequacy disclosures given status investigations litigation discussed status significant known actual potential litigation refer notes group financial statements inhouse legal counsel obtained substantively tested evidence support decisions rationale provisions held decisions pharmaceuticals industry heavily regulated increases record provisions including correspondence legal counsel inherent litigation risk group engaged number legal counterparties litigation also monitored considered external actions including product liability antitrust related private litigation information sources identify potential legal actions significant disclosed notes developed independent expectation litigation provisions based focused area eventual outcome claims uncertain product litigation history available evidence challenge positions taken directors based application valuation completeness provisions recognised group material judgement estimation accordingly unexpected adverse obtained confirmations external legal counsel confirm outcomes could significantly impact groups reported profit understanding settled outstanding litigation asserted claims balance sheet position evaluated significant adjustments legal provisions recorded year significant increase groups litigation year determine indicative management bias respect provisions respect paxil product liability referred increase provision paxil product liability litigation obtained notes reassessed following unsuccessful sufficient evidence conclude increase reasonable including mediation plaintiffs giving rise subsequent revision review external legal advice managements best estimate settling claims increase disclosed notes group financial statements eventual offset utilisation existing provisions million outcome legal proceedings dependent outcome future events december group held provisions million position taken group inherently judgemental found respect legal actions december million context group financial statements taken whole judgements made management reasonable disclosures made respect provisions contingent liabilities appropriate gsk annual report strategic report governance remuneration financial statements investor information independent auditors report continued area focus audit addressed area focus carrying value goodwill intangible assets deploying valuations specialists obtained groups impairment refer notes group financial statements analyses tested reasonableness key assumptions including profit cash flow growth terminal values impact expiry patents group billion intangible assets december potential product obsolescence selection discount rates billion comprising significant licenses patents acquired trade challenged management substantiate assumptions including marks excluding computer software addition group comparing relevant assumptions industry economic forecasts billion goodwill december december billion group recognised impairments intangible interrogated integrity supporting calculations corroborated assets amounting million year certain information third party sources including expectations performance certain assets components business obtained carrying values goodwill intangible assets contingent evaluated managements sensitivity analyses ascertain impact future cash flows risk cash flows meet reasonably possible changes key assumptions performed groups expectations assets impaired impairment independent sensitivity calculations quantify downside changes reviews performed group contained number significant managements models required result impairment judgements estimates including revenue growth success new product launches patent expiry dates profit margins cash conversion result work determined quantum impairment terminal values discount rate changes assumptions might recognised appropriate intangible assets including lead change carrying value intangible assets goodwill goodwill management determined impairment required found judgements supported reasonable assumptions year group reduced number individual cash would require unreasonable downside changes additional generating units cgus goodwill impairment testing purposes material impairment necessary eight four comprising global pharmaceuticals consumer healthcare vaccines viiv healthcare exercise undertaken align respect aggregation cgus confirmed lowest cgus groups operating segments changed following level management monitors goodwill internal purposes groups restructuring following novartis transaction consistent way groups leadership team exercise vaccines treated separate cgu first structured groups results financial position time global pharmaceuticals cgu aggregates pharmaceuticals reported cet cgu goodwill impairment testing businesses previously separated us europe japan emerging purposes larger groups new operating segments markets focused acquired intangible assets significant individually aggregate number indefinite lives including significant intangible assets acquired novartis group also recognised goodwill number acquisitions including threepart transaction novartis remeasurement shionogiviiv healthcare contingent deploying valuations specialists evaluated managements fair value consideration computation model including projections key assumptions used refer notes group financial statements therein also compared groups projections dolutegravir products certain third party expectations found groups subsidiary viiv healthcare acquired remaining reasonable particular considered reasonably possible alternative interest shionogiviiv healthcare joint venture scenarios comprising downside case event products launched million recognised contingent consideration competitors cannibalise groups market share anticipated represented fair value expected payments made shionogi managements base case upside case competitor contingent future sales dolutegravir products liability launches less successful scenarios result contingent required remeasured fair value reporting date consideration liabilities materially lower higher respectively since initial recognition increased response actual notwithstanding believe group reasonable basis future sales significantly exceeding original expectations determination fair value december value december associated financial liability million reflects managements best estimates december million validated methodology consistent previous years focused area fair value contingent consideration certain inputs changed discount tax rates determined number significant unobservable inputs validated appropriate triggers occurred support management judgements estimates including forecast future sales changes also verified updated assumptions reasonable tivicay triumeq overall market size hiv therapies also validated groups disclosures respect liability potential impact competitor products launched expected including disclosure estimation uncertainty impact fair launched future addition valuation sensitive value liability reasonable changes assumptions including discount tax rates revised determining valuation december uncertain tax positions conjunction uk us international tax transfer pricing refer notes group financial statements specialists evaluated challenged managements judgements respect estimates tax exposures contingencies order assess group operates complex multinational tax environment adequacy groups tax provisions included obtaining open tax transfer pricing matters uk overseas tax evaluating certain third party tax opinions group obtained authorities addition time time group enters assess appropriateness assumptions used transactions complicated accounting tax consequences including threepart transaction novartis judgement understanding evaluating managements judgements considered required assessing level provisions required respect status recent current tax authority audits enquiries outturn uncertain tax positions december group previous claims judgemental positions taken tax returns current year recognised provisions million respect uncertain tax estimates developments tax environment evidence positions million obtained considered level provisioning acceptable context group financial statements taken whole however noted assumptions judgements required formulate provisions mean range possible outcomes broadgsk annual report strategic report governance remuneration financial statements investor information tailored audit scope component teams largely focused impact threepart tailored scope audit ensure performed transaction novartis alongside planning risk enough work able give opinion group financial assessment activities addition visited four shared statements whole taking account geographic structure service centres supporting reporting components group audit group accounting processes controls scope components group audit scope site visit industry group operates undertaken involvement included regular dialogue component teams review component auditor work papers group financial statements consolidation participation certain component audit clearance meetings reporting components identified reporting components view required audit complete financial information specific audit procedures central functions group due size risk characteristics specific audit procedures consolidation areas significant judgement including taxation significant balances transactions performed goodwill intangible assets treasury postretirement benefits reporting components give appropriate coverage litigation elimination unrealised intercompany profit material balances reporting components inventory directly led group audit team supported shared financial service centres centres taken together territories functions performed also included group audit scope none reporting audit work accounted consolidated revenue components included group audit scope individually consolidated profit tax adjusted profit tax contributed consolidated revenue profit considering contribution audit evidence tax adjusted profit tax performing audit work divisional group levels work performed component auditors including testing monitoring controls disaggregated analytical determined level involvement needed audit review procedures covers significant portion groups work reporting component units result nine overseas smaller lower risk components directly included components visited senior members group audit group audit scope addition obtained audit evidence team including groups financially significant certain outofscope components procedures components us visited least annually alongside undertook groups shared service centres encompassing belgium japan switzerland germany india also held two bpos bscs centralised infrastructure day audit planning workshop london attended processes standardised materiality scope audit influenced application materiality set certain quantitative thresholds materiality together qualitative considerations helped us determine scope audit nature timing extent audit procedures individual financial statement line items disclosures evaluating effect misstatements individually financial statements whole based professional judgement determined materiality financial statements whole follows overall group materiality million million determined approximately profit tax million adding back certain nonrecurring items including remeasurement charge shionogiviiv healthcare contingent consideration million remeasurement charge consumer healthcare put option million major restructuring costs million legal costs million equity investment impairments million impairment intangible assets million deducting nonrecurring net income relating major acquisition disposal activity net million rationale benchmark applied groups principal measure earnings comprises core results adds back statutory results number items income expenditure including detailed management uses measure believes eliminates volatility inherent oneoff items took measure account determining materiality except adjust profit tax add back amortisation intangible assets certain smaller noncore items view recurring items introduce volatility groups earnings materiality lower last year primarily due effect lower profits agreed audit risk committee would report misstatements identified audit million million well misstatements amount view warranted reporting qualitative reasons going concern noted directors statement directors concluded listing rules required review directors appropriate adopt going concern basis preparing statement set relation going concern group financial statements going concern basis nothing report performed review presumes group adequate resources remain operation directors intend least one isas uk ireland also required report year date group financial statements signed anything material add draw attention relation part audit concluded directors use directors statement whether considered going concern basis appropriate appropriate adopt going concern basis preparing group financial statements nothing material add however future events conditions draw attention predicted statements guarantee groups ability continue going concern gsk annual report strategic report governance remuneration financial statements investor information independent auditors report continued required reporting consistency information companies act opinion opinion information given strategic report directors report financial year group financial statements prepared consistent group financial statements isas uk ireland reporting isas uk ireland required report opinion information annual report exceptions materially inconsistent information audited group financial statements report apparently materially incorrect based materially inconsistent knowledge group acquired course performing audit otherwise misleading statement given directors accordance provision c uk corporate governance exceptions code code consider annual report taken whole fair balanced understandable report provides information necessary members assess groups position performance business model strategy materially inconsistent knowledge group acquired course performing audit section annual report required provision c code describing work exceptions audit committee appropriately address matters communicated us audit committee report directors assessment prospects group principal risks would threaten solvency liquidity group isas uk ireland required report anything material add draw attention relation directors confirmation annual report accordance provision c code nothing material carried robust assessment principal risks facing group including would threaten add draw attention business model future performance solvency liquidity disclosures annual report describe risks explain managed mitigated nothing material add draw attention directors explanation annual report accordance provision c code nothing material assessed prospects group period done consider period add draw attention appropriate statement whether reasonable expectation group able continue operation meet liabilities fall due period assessment including related disclosures drawing attention necessary qualifications assumptions listing rules required review directors statement carried robust assessment principal risks facing group directors statement relation longerterm viability group set review substantially less scope audit consisted making enquiries considering directors process supporting statements checking statements alignment relevant provisions code considering whether statements consistent knowledge acquired us course performing audit nothing report performed review adequacy information explanations received corporate governance statement companies act required report listing rules required review part opinion received information corporate governance statement relating ten provisions explanations require audit exceptions uk corporate governance code nothing report report arising responsibility performed review directors remuneration companies act required report opinion certain disclosures directors remuneration specified law made exceptions report arising responsibilitygsk annual report strategic report governance remuneration financial statements investor information responsibilities financial statements matters audit reported separately parent company financial responsibilities directors statements glaxosmithkline plc year ended december information directors explained fully directors statement remuneration report described audited responsibilities set directors responsible preparation group financial statements company passed resolution accordance section satisfied give true fair view companies act senior statutory auditors name stated responsibility audit express opinion group financial statements accordance applicable law isas uk ireland standards require us comply auditing practices boards ethical standards auditors report including opinions prepared pricewaterhousecoopers llp companys members body accordance chartered accountants statutory auditors chapter part companies act london purpose giving opinions accept assume march responsibility purpose person report shown whose hands may come save expressly agreed prior consent writing notes audit financial statements involves maintenance integrity glaxosmithkline plc audit involves obtaining evidence amounts website responsibility directors work carried disclosures financial statements sufficient give reasonable auditors involve consideration assurance financial statements free material matters accordingly auditors accept responsibility misstatement whether caused fraud error includes changes may occurred financial assessment statements since initially presented website whether accounting policies appropriate groups b l egislation united kingdom governing preparation circumstances consistently applied dissemination financial statements may differ adequately disclosed legislation jurisdictions reasonableness significant accounting estimates made directors overall presentation financial statements primarily focus work areas assessing directors judgements available evidence forming judgements evaluating disclosures financial statements test examine information using sampling auditing techniques extent consider necessary provide reasonable basis us draw conclusions obtain audit evidence testing effectiveness controls substantive procedures combination addition read financial nonfinancial information annual report identify material inconsistencies audited financial statements identify information apparently materially incorrect based materially inconsistent knowledge acquired us course performing audit become aware apparent material misstatements inconsistencies consider implications report gsk annual report strategic report governance remuneration financial statements investor information financial statements consolidated income statement year ended december notes turnover cost sales gross profit selling general administration research development royalty income operating income operating profit finance income finance expense profit disposal interest associates share tax profits associates joint ventures profit taxation taxation profit taxation year lossprofit attributable noncontrolling interests profit attributable shareholders basic earnings per share pence p p p diluted earnings per share pence p p p consolidated statement comprehensive income year ended december profit year items may subsequently reclassified income statement exchange movements overseas net assets net investment hedges reclassification exchange liquidation disposal overseas subsidiaries deferred tax exchange movements fair value movements availableforsale investments deferred tax fair value movements availableforsale investments reclassification fair value movements availableforsale investments deferred tax reversed reclassification availableforsale investments fair value movements cash flow hedges deferred tax fair value movements cash flow hedges reclassification cash flow hedges income statement share comprehensive income associates joint ventures items reclassified income statement exchange movements overseas net assets noncontrolling interests remeasurement gainslosses defined benefit plans deferred tax remeasurement gainslosses defined benefit plans comprehensive expenseincome year total comprehensive income year total comprehensive income year attributable shareholders noncontrolling interests total comprehensive income year gsk annual report strategic report governance remuneration financial statements investor information consolidated balance sheet december notes noncurrent assets property plant equipment goodwill intangible assets investments associates joint ventures investments deferred tax assets noncurrent assets total noncurrent assets current assets inventories current tax recoverable trade receivables derivative financial instruments liquid investments cash cash equivalents assets held sale total current assets total assets current liabilities shortterm borrowings trade payables derivative financial instruments current tax payable shortterm provisions total current liabilities noncurrent liabilities longterm borrowings deferred tax liabilities pensions postemployment benefits provisions derivative financial instruments noncurrent liabilities total noncurrent liabilities total liabilities net assets equity share capital share premium account retained earnings reserves shareholders equity noncontrolling interests total equity financial statements pages approved board march signed behalf philip hampton chairman gsk annual report strategic report governance remuneration financial statements investor information financial statements continued consolidated statement changes equity year ended december shareholders equity non share share retained controlling total capital premium earnings reserves total interests equity january profit year comprehensive incomeexpense year total comprehensive income year distributions noncontrolling interests dividends shareholders changes noncontrolling interests ordinary shares issued ordinary shares purchased cancelled held treasury shares ordinary shares acquired esop trusts writedown shares held esop trusts sharebased incentive plans tax sharebased incentive plans december profit year comprehensive expenseincome year total comprehensive incomeexpense year distributions noncontrolling interests dividends shareholders changes noncontrolling interests forward contract relating noncontrolling interest ordinary shares issued ordinary shares purchased cancelled held treasury shares ordinary shares acquired esop trusts writedown shares held esop trusts sharebased incentive plans tax sharebased incentive plans december profitloss year comprehensive expenseincome year total comprehensive incomeexpense year distributions noncontrolling interests dividends shareholders gains transfer net assets consumer healthcare joint venture consumer healthcare joint venture put option changes noncontrolling interests loss transfer equity investment investment associate ordinary shares issued ordinary shares acquired esop trusts writedown shares held esop trusts sharebased incentive plans tax sharebased incentive plans december gsk annual report strategic report governance remuneration financial statements investor information consolidated cash flow statement year ended december notes cash flow operating activities profit taxation year adjustments reconciling profit tax operating cash flows cash generated operations taxation paid net cash inflow operating activities cash flow investing activities purchase property plant equipment proceeds sale property plant equipment purchase intangible assets proceeds sale intangible assets purchase equity investments proceeds sale equity investments purchase businesses net cash acquired disposal businesses investments associates joint ventures proceeds disposal subsidiary interest associate increasedecrease liquid investments interest received dividends associates joint ventures net cash inflowoutflow investing activities cash flow financing activities shares acquired esop trusts issue share capital purchase shares cancellation held treasury shares purchase noncontrolling interests increase longterm loans repayment shortterm loans net repayment obligations finance leases interest paid dividends paid shareholders distributions noncontrolling interests financing cash flows net cash outflow financing activities increasedecrease cash bank overdrafts cash bank overdrafts beginning year exchange adjustments increasedecrease cash bank overdrafts cash bank overdrafts end year cash bank overdrafts end year comprise cash cash equivalents overdrafts gsk annual report strategic report governance remuneration financial statements investor information notes financial statements presentation financial statements implementation new accounting standards amendment ias defined benefit plans employee description business contribution issued november implemented gsk major global healthcare group engaged gsk january amendment provides additional creation discovery development manufacture marketing guidance treatment contributions defined benefit pharmaceutical products including vaccines overthecounter plans employees third parties material impact otc medicines healthrelated consumer products gsks current period principal pharmaceutical products include medicines financial period following therapeutic areas respiratory antivirals central nervous system cardiovascular urogenital metabolic antibacterials financial statements cover financial year january dermatology rare diseases immunoinflammation vaccines december comparative figures financial hiv years january december appropriate january december compliance applicable law ifrs parent company financial statements financial statements prepared accordance companies act article ias regulation financial statements parent company glaxosmithkline international accounting standards ias international plc prepared accordance uk gaap uk financial reporting standards ifrs related interpretations accounting presentation company balance sheet presented adopted european union accounting policies given financial statements also compliance ifrs issued international accounting standards board accounting principles policies composition financial statements consolidation consolidated financial statements drawn sterling consolidated financial statements include functional currency glaxosmithkline plc accordance assets liabilities results cash flows ifrs accounting presentation financial statements company subsidiaries including esop trusts comprise groups share results net assets associates consolidated income statement joint ventures consolidated statement comprehensive income groups share assets liabilities revenue expenses consolidated balance sheet joint operations consolidated statement changes equity financial statements entities consolidated made december year consolidated cash flow statement entities group power direct relevant notes financial statements activities affect returns group generally composition group control financial operating policies accounted list subsidiary associated undertakings subsidiaries group ability exercise joint opinion directors principally affected amount profit control rights net assets entities entities net assets group given note principal accounted joint ventures group group companies ability exercise joint control arrangement rights specified assets obligations specified liabilities accounting principles policies arrangement arrangement accounted joint financial statements prepared using historical operation group ability exercise significant cost convention modified revaluation certain items influence entities accounted associates stated accounting policies going concern basis results assets liabilities associates joint financial statements prepared accordance ventures incorporated consolidated financial groups accounting policies approved board statements using equity method accounting described note accounting principles policies groups rights assets liabilities revenue expenses information application accounting policies joint operations included consolidated financial including areas estimation judgement given note statements accordance rights obligations key accounting judgements estimates interests acquired entities consolidated date preparation financial statements conformity group acquires control interests sold deconsolidated generally accepted accounting principles requires management date control ceases make estimates assumptions affect reported amounts assets liabilities disclosure contingent assets liabilities date financial statements reported amounts revenues expenses reporting period actual results could differ estimatesgsk annual report strategic report governance remuneration financial statements investor information accounting principles policies continued revenue revenue recognised income statement goods transactions balances subsidiaries eliminated services supplied made available external customers profit tax taken sales subsidiaries orders received title risk loss passed products sold customers outside group customer reliable estimates made relevant deductions relevant proportion profits transactions joint ventures relevant obligations fulfilled joint operations associates also deferred products earnings process regarded complete sold third parties transactions noncontrolling interests recorded directly equity deferred tax relief unrealised turnover represents net invoice value deduction intragroup profit accounted extent discounts allowances given accruals estimated future considered recoverable rebates returns methodology assumptions used estimate rebates returns monitored adjusted regularly goodwill capitalised separate item case light contractual legal obligations historical trends subsidiaries part cost investment case past experience projected market conditions market joint ventures associates goodwill denominated conditions evaluated using wholesaler thirdparty currency operation acquired analyses market research data internally generated cost acquisition fair value information value added tax sales taxes excluded net assets acquired difference recognised directly revenue income statement group copromotes product counterparty business combinations records sale group records share revenue business combinations accounted using acquisition copromotion income within turnover nature copromotion accounting method identifiable assets liabilities contingent activities group records costs sales liabilities acquired measured fair value acquisition date pharmaceutical turnover includes copromotion revenue consideration transferred measured fair value million million million addition includes fair value contingent consideration initial eventbased milestone income excluding royalty income consideration transferred together noncontrolling arising development marketing collaborations groups interest exceeds fair value net assets liabilities compounds products parties recognised contingent liabilities acquired excess recorded goodwill turnover milestone income nil included turnover costs acquisition charged income statement million million period incurred royalty income recognised accruals basis accordance equity subsidiary acquired non terms relevant licensing agreements controlling interest recognised either fair value expenditure noncontrolling interests share net assets subsidiary expenditure recognised respect goods services casebycase basis changes groups ownership received supplied accordance contractual terms percentage subsidiaries accounted within equity provision made obligation exists future liability foreign currency translation respect past event amount obligation foreign currency transactions booked functional reliably estimated manufacturing startup costs currency group company exchange rate ruling validation achievement normal production expensed date transaction foreign currency monetary assets incurred advertising promotion expenditure charged liabilities retranslated functional currency rates income statement incurred shipment costs inter exchange ruling balance sheet date exchange differences company transfers charged cost sales distribution included income statement costs sales customers included selling general administrative expenditure consolidation assets liabilities including related goodwill overseas subsidiaries associates joint ventures restructuring costs recognised provided translated sterling rates exchange ruling balance appropriate respect direct expenditure business sheet date results cash flows overseas subsidiaries reorganisation plans sufficiently detailed associates joint ventures translated sterling using well advanced appropriate communication average rates exchange affected undertaken exchange adjustments arising opening net assets profits year retained overseas subsidiaries associates joint ventures translated sterling less exchange differences arising related foreign currency borrowings hedge groups net investment operations taken separate component equity translating sterling assets liabilities results cash flows overseas subsidiaries associates joint ventures reported currencies hyperinflationary economies adjustments made material reflect current price levels loss net monetary assets charged consolidated income statement gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued accounting principles policies continued employee share plans incentives form shares provided employees research development share option share award schemes research development expenditure charged income statement period incurred development fair values options awards calculated expenditure capitalised criteria recognising grant dates using blackscholes option pricing model asset met usually regulatory filing made charged income statement relevant vesting periods major market approval considered highly probable property group provides finance esop trusts purchase company plant equipment used research development shares meet obligation provide shares employees capitalised depreciated accordance groups policy exercise options awards costs running esop environmental expenditure trusts charged income statement shares held environmental expenditure related existing conditions resulting esop trusts deducted reserves transfer made past current operations current reserves retained earnings vesting future benefit discernible charged income statement periods related share options awards reflect group recognises liability sitebysite basis ultimate proceeds receivable employees exercise reliably estimated liability includes groups property plant equipment portion total costs also portion potentially property plant equipment ppe stated cost responsible parties costs probable purchase construction less provisions depreciation able satisfy respective shares cleanup obligation impairment financing costs capitalised within cost recoveries reimbursements recorded assets qualifying assets construction virtually certain depreciation calculated write cost less residual value legal disputes ppe excluding freehold land using straightline basis provision made anticipated settlement costs legal expected useful life residual values lives reviewed disputes group outflow resources appropriate adjusted annually normal expected considered probable reliable estimate made useful lives major categories ppe likely outcome addition provision made legal expenses arising claims received disputes freehold buildings years respect product liability claims related certain products leasehold land buildings lease term years sufficient history claims made settlements plant machinery years enable management make reliable estimate provision equipment vehicles years required cover unasserted claims certain cases incurred reported ibnr actuarial technique used determine disposal ppe cost related accumulated estimate depreciation impairments removed financial statements net amount less proceeds taken group may become involved legal proceedings respect income statement possible make reliable estimate leases expected financial effect could result ultimate resolution proceedings cases appropriate leasing agreements transfer group substantially disclosure cases would included provision benefits risks ownership asset treated would made costs associated claims made group finance leases asset purchased outright third parties charged income statement assets included ppe computer software capital incurred elements leasing commitments shown obligations finance leases assets held finance leases pensions postemployment benefits depreciated basis consistent similar owned assets costs providing pensions defined benefit schemes lease term shorter interest element lease rental calculated using projected unit credit method spread included income statement leases operating period benefit expected derived leases rental costs charged income statement employees services consistent advice qualified straightline basis lease term actuaries pension obligations measured present value goodwill estimated future cash flows discounted rates reflecting yields high quality corporate bonds pension scheme assets goodwill stated cost less impairments goodwill deemed measured fair value balance sheet date indefinite useful life tested impairment least annually costs postemployment liabilities calculated similar way defined benefit pension schemes spread fair value interest acquired entitys assets period benefit expected derived liabilities contingent liabilities exceeds consideration paid employees services accordance advice excess recognised immediately gain income qualified actuaries statement actuarial gains losses effect changes actuarial assumptions recognised statement comprehensive income year arise groups contributions defined contribution plans charged income statement incurredgsk annual report strategic report governance remuneration financial statements investor information accounting principles policies continued availableforsale investments liquid investments investments classified intangible assets availableforsale investments initially recorded fair intangible assets stated cost less provisions amortisation value plus transaction costs remeasured subsequent impairments reporting dates fair value unrealised gains losses licences patents knowhow marketing rights separately availableforsale investments recognised directly acquired acquired part business combination comprehensive income impairments arising significant amortised estimated useful lives generally exceeding prolonged decline fair value equity investment reduce years using straightline basis time carrying amount asset directly charged available use estimated useful lives determining income statement amortisation charge take account patent lives disposal impairment investments gains applicable well value obtained periods non losses deferred comprehensive income exclusivity asset lives reviewed appropriate reclassified income statement dividends equity adjusted annually contingent milestone payments recognised investments recognised income statement point contingent event becomes probable groups right receive payment established equity investments development costs incurred group associated recorded noncurrent assets unless expected acquired licences patents knowhow marketing rights sold within one year written income statement incurred unless criteria recognition internally generated intangible asset purchases sales equity investments accounted met usually regulatory filing made major trade date purchases sales availableforsale market approval considered highly probable investments accounted settlement date inventories acquired brands valued independently part fair value businesses acquired third parties brand inventories included financial statements lower value substantial long term brands cost including raw materials direct labour direct costs either contractual legal nature sold separately related production overheads net realisable value cost rest businesses acquired brands amortised generally determined first first basis prelaunch estimated useful lives years except inventory held asset high probability considered useful economic life indefinite regulatory approval product point provision made carrying value recoverable amount costs acquiring developing computer software provision reversed point high probability internal use internet sites external use capitalised regulatory approval determined intangible fixed assets software site supports trade receivables significant business system expenditure leads creation durable asset erp systems software amortised trade receivables carried original invoice amount less seven ten years computer software three provisions doubtful debts provisions made five years evidence risk nonpayment taking account ageing previous experience general economic conditions impairment noncurrent assets trade receivable determined uncollectable written carrying values noncurrent assets reviewed firstly provision available income impairment either standalone basis part larger statement cash generating unit indication assets might impaired additionally goodwill intangible assets subsequent recoveries amounts previously provided indefinite useful lives intangible assets yet credited income statement longterm receivables available use tested impairment annually provision discounted effect material impairment charged income statement year borrowings concerned borrowings initially recorded amount proceeds impairments goodwill reversed impairment losses received net transaction costs borrowings subsequently noncurrent assets reversed carried amortised cost difference change estimates used determine recoverable amounts proceeds net transaction costs amount due extent revised recoverable amounts redemption recognised charge income exceed carrying values would existed net statement period relevant borrowing depreciation amortisation impairments recognised investments associates joint ventures joint operations investments associates joint ventures carried consolidated balance sheet groups share net assets date acquisition postacquisition retained profits losses together goodwill arising acquisition group recognises rights assets liabilities revenue expenses joint operations gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued accounting principles policies continued key accounting judgements estimates taxation preparing financial statements management required current tax provided amounts expected paid make estimates assumptions affect amounts applying tax rates enacted substantively enacted assets liabilities revenue expenses reported financial balance sheet date statements actual amounts results could differ estimates following considered key accounting deferred tax provided full temporary differences arising judgements estimates made tax bases assets liabilities carrying amounts financial statements deferred tax assets turnover recognised extent probable future taxable revenue recognised title risk loss passed profits available temporary differences customer reliable estimates made relevant deductions utilised deferred tax provided temporary differences relevant obligations fulfilled arising investments subsidiaries associates joint earnings process regarded complete ventures except timing reversal temporary gross turnover reduced rebates discounts allowances difference controlled probable temporary product returns given expected given vary difference reverse foreseeable future deferred tax product arrangements buying groups arrangements provided using rates tax enacted substantively purchasing organisations dependent upon submission enacted balance sheet date claims time initial recognition derivative financial instruments hedging sale accruals made time sale estimated derivative financial instruments used manage exposure rebates discounts allowances payable returns made market risks principal derivative instruments used gsk based available market information historical experience foreign currency swaps interest rate swaps foreign exchange amounts estimated may fully reflect forward contracts options group hold issue final outcome amounts subject change dependent derivative financial instruments trading speculative upon amongst things types buying group product purposes sales mix derivative financial instruments classified heldfortrading level accrual reviewed adjusted regularly carried balance sheet fair value derivatives light contractual legal obligations historical trends past designated hedging instruments classified inception experience projected market conditions market conditions cash flow hedges net investment hedges fair value hedges evaluated using wholesaler thirdparty analyses changes fair value derivatives designated cash flow market research data internally generated information hedges recognised comprehensive income future events could cause assumptions extent hedges effective ineffective portions accruals based change could affect future recognised profit loss immediately amounts deferred results group comprehensive income reclassified income statement hedged item affects profit loss taxation current tax provided amounts expected paid net investment hedges accounted similar way deferred tax provided temporary differences cash flow hedges tax bases assets liabilities carrying amounts changes fair value derivatives designated fair value rates enacted substantively enacted hedges recorded income statement together balance sheet date changes fair value hedged asset liability deferred tax assets recognised extent changes fair value derivative instruments probable future taxable profits available qualify hedge accounting recognised immediately temporary differences utilised based income statement managements assumptions relating amounts timing future taxable profits factors affecting tax charge discounting future years set note taxation change time value money material balances groups effective tax rate would changed discounted current values using appropriate rates interest total tax charge year approximately million unwinding discounts recorded finance income finance expense group open tax issues number revenue authorities outflow funds believed probable reliable estimate outcome dispute made management provides best estimate liability calculating liability gsk applies risk based approach takes account appropriate probability group would able obtain compensatory adjustments international tax treaties estimates take account specific circumstances dispute relevant external advice inherently judgemental could change substantially time new facts emerge dispute progresses gsk continues believe made adequate provision liabilities likely arise open assessments open issues exist ultimate liability matters may vary amounts provided dependent upon outcome negotiations relevant tax authorities necessary litigation proceedingsgsk annual report strategic report governance remuneration financial statements investor information key accounting judgements estimates business combinations contingent consideration included consideration continued payable business combination recorded fair value legal disputes date acquisition fair values generally based group provides anticipated settlement costs riskadjusted future cash flows discounted using appropriate outflow resources considered probable reliable interest rates fair values reviewed regular basis estimate may made likely outcome dispute least annually changes reflected income legal expenses arising claims group statement estimates take account specific circumstances december liability contingent consideration dispute relevant external advice inherently amounted million million see note judgmental could change substantially time new acquisitions disposals amount million facts emerge dispute progresses details status million arose acquisition former various uncertainties involved significant unresolved shionogiviiv healthcare joint venture million disputes set note legal proceedings arose acquisition vaccines business novartis companys directors taken legal advice established provisions taking account relevant group granted put option novartis facts circumstances matter accordance respect novartis shareholding consumer healthcare accounting requirements respect product liability claims joint venture certain circumstances novartis right related certain products sufficient history claims require gsk acquire shareholding consumer made settlements enable management make reliable healthcare joint venture marketbased valuation right estimate provision required cover unasserted claims exercisable certain windows may group may become involved legal proceedings respect exercised either respect novartis entire shareholding possible make reliable estimate four instalments gsk recognised financial liability expected financial effect result ultimate million noncurrent liabilities december resolution proceedings cases appropriate represents present value estimated amount disclosure cases would included provision payable gsk event full exercise right novartis would made contingent liability quantified calculated applying marketbased multiples forecast december provisions legal disputes future profits accordance shareholder agreements amounted billion billion sensitivity analysis given note noncurrent ultimate liability legal claims may vary amounts liabilities provided dependent upon outcome litigation assumptions relating future cash flows discount rates proceedings investigations possible settlement negotiations based business forecasts therefore inherently position could change time therefore judgemental future events could cause assumptions used assurance losses result outcome projections marketbased multiples change legal proceedings exceed amount provisions consequent adverse effect future results group reported groups financial statements material amount pensions postemployment benefits goodwill intangible asset impairments costs providing pensions postemployment goodwill deemed indefinite life benefits charged income statement accordance amortised annual impairment tests cash generating ias employee benefits period benefit units goodwill allocated performed impairment derived employees services costs assessed tests based established market multiples riskadjusted basis assumptions selected management future cash flows discounted using appropriate interest rates assumptions include future earnings pension increases assumptions used impairment tests set discount rates expected longterm rates return assets note goodwill mortality rates disclosed note pensions case valuations indicate sufficient headroom postemployment benefits surplus defined benefit reasonably possible change key assumptions unlikely scheme arises potential surplus arise result impairment related goodwill committed future contributions rights trustees prevent group obtaining refund surplus future impairment tests intangible assets undertaken considered determining whether necessary restrict events occur call question carrying values amount surplus recognised assets brands intangible assets yet available use amortised subject annual expected longterm rates return bonds determined impairment tests valuations impairment tests based based portfolio mix indexlinked government established market multiples riskadjusted future cash flows corporate bonds equity risk premium added estimated useful life asset limited equities discounted using appropriate interest rates set discount rates derived aa rated corporate bond yields note intangible assets except countries deep market corporate assumptions relating future cash flows estimated useful bonds government bond yields used sensitivity analysis lives discount rates based business forecasts provided note pensions postemployment therefore inherently judgemental future events could cause benefits reduction discount rate would lead assumptions used impairment tests change increase net pension deficit approximately million consequent adverse effect future results group increase annual pension cost approximately million selection different assumptions could affect future results group gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued new accounting requirements exchange rates following new amended accounting standards group uses average exchange rates prevailing issued iasb likely affect future annual reports period translate results cash flows overseas amendment ifrs expected material subsidiaries joint ventures associated undertakings impact results financial position group sterling period end rates translate net assets impacts ifrs ifrs ifrs results undertakings currencies influence financial position group currently assessed translations relevant exchange rates amendment ifrs joint arrangements issued may implemented group january average rates amendment requires acquisition joint operation us meets definition business accounted euro accordance ifrs business combinations yen ifrs revenue contracts customers issued may implemented group january period end rates standard provides single principlesbased approach us recognition revenue contracts customers euro focuses identification performance obligations yen contract requires revenue recognised performance obligations satisfied ifrs financial instruments issued final form july implemented group january standard replace majority ias covers classification measurement derecognition financial assets financial liabilities impairment financial assets provides new hedge accounting model ifrs leases issued january implemented group january standard replace ias leases require lease liabilities right use assets recognised balance sheet almost leasesgsk annual report strategic report governance remuneration financial statements investor information segment information operating segments reported based financial information provided chief executive officer responsibilities corporate executive team cet completion novartis transaction march changed balance group gsk changed segment reporting reflect effect january gsk reported results five segments global pharmaceuticals hiv pharmaceuticals rd vaccines consumer healthcare individual members cet responsible segment comparative information restated accordingly addition segment turnover profit restated exclude divestments completed groups management reporting process allocates intragroup profit product sale market sale recorded profit analyses presented basis pharmaceuticals rd segment responsibility head research development reported separate segment corporate unallocated turnover costs include results several vaccines consumer healthcare products held sale number markets order meet antitrust approval requirements together costs corporate functions january global pharmaceuticals hiv segments combined one operating segment pharmaceuticals restated restated turnover segment global pharmaceuticals hiv pharmaceuticals vaccines consumer healthcare segment turnover corporate unallocated turnover divestments completed restated restated global pharmaceuticals turnover therapeutic area respiratory cardiovascular metabolic urology immunoinflammation oncology pharmaceuticals established products gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued segment information continued restated restated consumer healthcare turnover category wellness oral care nutrition skin health us elements global pharmaceuticals hiv vaccines made sales three wholesalers approximately million million million million million million million million million respectively allocating finalcustomer discounts wholesalers segment profit restated restated global pharmaceuticals hiv pharmaceuticals rd pharmaceuticals vaccines consumer healthcare segment profit corporate unallocated costs reconciling items segment profit operating profit operating profit finance income finance costs profit disposal interest associates share tax profits associates joint ventures profit taxation taxation profit taxation year reconciling items segment profit operating profit comprise items specifically allocated segment profit include impairment amortisation intangible assets major restructuring charges legal charges expenses settlement litigation government investigations disposals businesses products associates certain items related major acquisition disposal activity depreciation amortisation segment restated restated global pharmaceuticals hiv pharmaceuticals rd pharmaceuticals vaccines consumer healthcare segment depreciation amortisation corporate unallocated depreciation amortisation reconciling items segment depreciation amortisation total depreciation amortisation total depreciation amortisation gsk annual report strategic report governance remuneration financial statements investor information segment information continued ppe intangible asset goodwill impairment segment restated restated global pharmaceuticals hiv pharmaceuticals rd pharmaceuticals vaccines consumer healthcare segment impairment corporate unallocated impairment reconciling items segment impairment total impairment total impairment ppe intangible asset impairment reversals segment restated restated global pharmaceuticals hiv pharmaceuticals rd pharmaceuticals vaccines consumer healthcare segment impairment reversals corporate unallocated impairment reversals total impairment reversals restated net assets segment global pharmaceuticals hiv pharmaceuticals rd pharmaceuticals vaccines consumer healthcare segment net operating assets corporate unallocated net operating assets net operating assets net debt investments associates joint ventures derivative financial instruments current deferred taxation assets held sale net assets hiv segment includes shionogiviiv healthcare contingent consideration liability million million consumer healthcare segment includes put option liability million nil gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued segment information continued geographical information uk regarded groups country domicile restated restated turnover location customer uk us international external turnover turnover location subsidiary uk us international turnover including intersegment turnover uk us international intersegment turnover uk us international external turnover operating profit location uk us international total operating profit noncurrent assets location uk us international noncurrent assets noncurrent assets location excludes amounts relating investments deferred tax assets derivative financial instruments pension assets amounts receivable insurance contracts certain noncurrent receivablesgsk annual report strategic report governance remuneration financial statements investor information operating income impairment equity investments disposal equity investments disposal businesses assets fair value remeasurements contingent consideration recognised business combinations remeasurement consumer healthcare put option liability fair value adjustments derivative financial instruments incomeexpense disposal businesses assets included disposal oncology business novartis million million divestment ofatumumab included gain disposal treximet fair value remeasurements contingent consideration recognised business combinations comprised million related acquisition former shionogiviiv healthcare joint venture million net hedging gains related acquisition vaccines business novartis fair value adjustments derivative financial instruments arise foreign exchange forward contracts options taken hedge foreign currency movements sales purchases denominated foreign currencies see note financial instruments related disclosures included unrealised loss million arising number forward exchange contracts entered following announcement proposed novartis transaction protect sterling value net us dollar proceeds due group completion transaction gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued operating profit following items included operating profit employee costs note advertising distribution costs depreciation property plant equipment impairment property plant equipment net reversals amortisation intangible assets impairment intangible assets net reversals net foreign exchange lossesgains inventories cost inventories included cost sales writedown inventories reversal prior year writedown inventories operating lease rentals minimum lease payments contingent rents sublease payments fees payable companys auditor associates relation group see reversals prior year writedowns inventories principally arise reassessment usage demand expectations prior inventory expiration included within operating profit major restructuring charges million million million see note major restructuring costs fees payable companys auditor associates audit parent company consolidated financial statements audit companys subsidiaries auditrelated assurance services including attestation sarbanesoxley act audit auditrelated services taxation compliance taxation advice assurance services services addition fees paid respect gsk pension schemes audit services gsk annual report strategic report governance remuneration financial statements investor information employee costs wages salaries social security costs pension postemployment costs including augmentations note cost sharebased incentive plans severance costs integration restructuring activities group provides benefits employees commensurate local practice individual countries including markets healthcare insurance subsidised car schemes personal life assurance charge pension postemployment costs includes credit million following restructuring us postretirement medical obligations set note pensions postemployment benefits cost sharebased incentive plans analysed follows share value plan performance share plan share option plans plans average number persons employed group including directors year number number number manufacturing selling general administration research development average number group employees excludes temporary contract staff numbers group employees end financial year given financial record average number persons employed glaxosmithkline plc nil nil compensation directors senior management members cet aggregate follows wages salaries social security costs pension postemployment costs cost sharebased incentive plans gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued major restructuring costs major restructuring costs charged arriving operating profit include restructuring costs arising major change programme initiated pharmaceuticals restructuring programme announced october following novartis transaction completed gsk reporting programmes together one combined programme total restructuring costs billion incurred following areas restructuring pharmaceuticals business north america emerging markets europe leading staff reductions sales force administration restructuring rd organisation predominantly united kingdom north america japan projects simplify eliminate processes leading staff reductions support functions transformation manufacturing vaccines businesses deliver step change quality cost productivity integration novartis consumer healthcare business new consumer healthcare joint venture analysis costs charged operating profit programmes follows increase provision major restructuring programmes see note amount provision reversed unused see note impairment losses recognised noncash charges cash costs asset impairments million nil million noncash charges totalling million million million noncash items principally fixed asset write downs manufacturing research facilities accelerated depreciation asset lives rd shortened result major restructuring programmes charges settled cash include termination leases site closure costs consultancy project management fees finance income interest income arising cash cash equivalents availableforsale investments derivatives fair value profit loss loans receivables fair value adjustments derivatives fair value profit loss derivatives fair value profit loss designated effective hedging instruments see note financial instruments related disclosures classified heldfortrading financial instruments ias gsk annual report strategic report governance remuneration financial statements investor information finance expense interest expense arising financial liabilities amortised cost derivatives fair value profit loss fair value hedges fair value movements derivatives designated hedging instruments fair value adjustments hedged items fair value movements derivatives fair value profit loss reclassification cash flow hedge comprehensive income unwinding discounts provisions movements amounts owed noncontrolling interests finance expense derivatives fair value profit loss designated effective hedging instruments see note financial instruments related disclosures classified heldfortrading financial instruments ias interest expense arising derivatives fair value profit loss relates swap interest expense associates joint ventures groups share tax profits losses associates joint ventures set share tax profits associates share tax losses joint ventures december group held one significant associate theravance inc innoviva inc investment accounted investment associate since september described note investments associates joint ventures previously included investments groups share tax profits associates includes loss million respect theravance innoviva march group divested half shareholding aspen pharmacare holdings limited ceased account remaining investment associate investment aspen included investments note aspen groups significant associate summarised income statement information respect aspen set periods group accounted investment aspen associate groups share tax profits associates comprehensive income includes profit million comprehensive income million respect aspen march turnover profit taxation comprehensive income total comprehensive income results aspen included summarised income statement information represent estimated earnings aspen group relevant periods adjusted transactions gsk aspen aggregated financial information respect associated undertakings joint ventures set share turnover share tax profitslosses share comprehensive income share total comprehensive income groups sales associates joint ventures million million million profit disposal interest associates million year arose groups divestment one half shareholding aspen pharmacare holdings limited march included gain million resulting change measurement basis groups retained investment aspen reclassification investment following divestment retained investment transferred investments associates equity accounted investments measured fair value gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued taxation taxation charge based profits year uk current year charge rest world current year charge charge respect prior periods total current taxation total deferred taxation gsk made payments million uk corporation tax january gsk made payments million relation uk corporation tax amounts corporation tax include various business taxes borne gsk year significant component deferred tax credit prior periods arose respect remeasurement contingent consideration relation former shionogiviiv healthcare joint venture credit also included unwind deferred tax liabilities disposal groups oncology business novartis credit also included recognition deferred tax asset capital losses anticipated utilised completion novartis transaction following table reconciles tax charge calculated uk statutory rate group profit tax actual tax charge year reconciliation taxation group profits profit tax uk statutory rate taxation differences overseas taxation rates benefit intellectual property incentives rd credits intercompany inventory profit impact sharebased payments losses recognisedpreviously unrecognised losses permanent differences disposals acquisitions permanent differences reassessments prior year estimates disposal associate tax unremitted earnings deferred tax adjustments restructuring tax charge tax rate gsk substantial business presence many countries around globe impact differences overseas taxation rates arose profits earned countries tax rates higher uk statutory rate significant us india france germany partially offset increased benefit intellectual property incentives uk patent box belgian patent income deduction regimes regimes provide reduced rate corporate income tax profits earned qualifying patents impact overseas tax rates offset permanent differences disposals subject uk substantial shareholdings exemption tax anticipated oncology disposal resulted recognition deferred tax assets capital losses subsequently utilised reduction benefit provided rd credits reflects change uk regime record benefit within rd expense income statement reassessments prior year estimates include benefit million resolution number tax matters various countries future tax charges therefore effective tax rate may affected factors acquisitions disposals restructurings location research development activity tax regime reforms resolution open matters continue bring tax affairs date around world tax items charged equity statement comprehensive income current taxation sharebased payments defined benefit plans deferred taxation sharebased payments defined benefit plans exchange movements fair value movements cash flow hedges fair value movements availableforsale investments total chargecredit equity statement comprehensive income items charged statement comprehensive income except tax share based paymentsgsk annual report strategic report governance remuneration financial statements investor information taxation continued issues relating taxation integrated nature groups worldwide operations involves significant investment research strategic manufacture limited number locations consequential crossborder supply routes numerous endmarkets gsks biggest risk respect taxation different tax authorities seek attribute profit activities undertaken jurisdiction potentially resulting double taxation gsk applies oecd established principles matching profit generated legal entity risk borne value added part value chain inherently subjective challenged tax authorities gives rise complexity delay resolving audits revenue authorities profits individual group companies liable tax calculating tax liability group gsk applies risk based approach determine transactions likely subject challenge probability group would able obtain compensatory adjustments international tax treaties continues significant international focus tax reform including oecds beps project european commission initiatives proposed antibeps directive increased use fiscal state aid investigations together domestic initiatives around world may result significant changes established tax principles increase tax authority disputes turn could affect adversely effective tax rate result higher cash tax liabilities group continues believe made adequate provision liabilities likely arise periods open yet agreed tax authorities ultimate liability matters may vary amounts provided dependent upon outcome agreements relevant tax authorities litigation appropriate aggregate amount unremitted profits balance sheet date approximately billion billion uk legislation relating company distributions provides exemption tax overseas profits subject certain exceptions provision deferred tax liabilities million million made respect withholding taxation would arise distribution profits certain overseas subsidiaries unremitted profits deferred tax provided billion billion deferred tax distribution profits provided grounds group able control timing reversal remaining temporary differences probable reverse foreseeable future ovement deferred tax assets liabilities pensions share accelerated post option net capital intangible contingent intragroup employment tax award temporary allowances assets consideration profit benefits losses schemes differences total january exchange adjustments creditcharge income statement charge equity charge statement comprehensive income acquisitions disposals december recognised tax losses comprise million trading losses million trading losses million capital losses net temporary differences include accrued expenses tax deduction available paid basis deferred tax assets recognised territories probable group continue generate taxable profits future assets utilised offsetting deferred tax assets liabilities appropriate within territories net deferred tax asset comprises deferred tax assets deferred tax liabilities gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued taxation continued unrecognised tax losses trading losses expiring within years years available indefinitely december capital losses december deferred tax assets recognised probable future taxable profit available utilise losses amount unrecognised capital losses revised following reassessment available losses deferred tax recognised earnings per share pence pence pence basic earnings per share diluted earnings per share basic earnings per share calculated dividing profit attributable shareholders weighted average number shares issue period deducting shares held esop trusts treasury shares trustees waived rights dividends shares held esop trusts diluted earnings per share calculated adjusting weighted average number shares used basic calculation assume conversion potentially dilutive shares potentially dilutive share forms part employee share schemes exercise price average market price gsk shares period performance conditions attaching scheme met balance sheet date numbers shares used calculating basic diluted earnings per share reconciled weighted average number shares issue millions millions millions basic dilution share options awards diluted dividends dividend total dividend total dividend total per share dividend per share dividend per share dividend paidpayable pence paid pence paid pence first interim july july july second interim october october october third interim january january january fourth interim april april april total special dividend april ifrs interim dividends recognised financial statements paid declared gsk normally pays dividend two quarters quarter relates one quarter declared financial statements recognise dividends paid namely third fourth interim dividends first second interim dividends amounts recognised year follows dividends shareholders gsk annual report strategic report governance remuneration financial statements investor information property plant equipment plant land equipment assets buildings vehicles construction total cost january exchange adjustments additions capitalised borrowing costs disposals writeoffs reclassifications transfer assets held sale cost december exchange adjustments additions business combinations additions capitalised borrowing costs disposals writeoffs reclassifications transfer assets held sale cost december depreciation january exchange adjustments charge year disposals writeoffs transfer assets held sale depreciation december exchange adjustments charge year disposals writeoffs transfer tofrom assets held sale depreciation december impairment january exchange adjustments disposals writeoffs impairment losses reversal impairments impairment december exchange adjustments disposals writeoffs impairment losses reversal impairments transfer assets held sale impairment december total depreciation impairment december total depreciation impairment december net book value january net book value december net book value december following completion novartis transaction group revised segmental reporting allocation costs assets part process review conducted ensure consistent appropriate classification reporting across group segments resulted number classification adjustments within property plant equipment reclassification impact net book value property plant equipment reported yearend income statement year within stated total ppe reduced opening balance assets construction january million increased opening balances land buildings plant equipment vehicles million million respectively equivalent adjustments reclassifications reported gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued property plant equipment continued net book value december groups land buildings comprises freehold properties million million properties leases years million million properties leases less years million million included land buildings december leased assets cost million million accumulated depreciation million million impairment nil million net book value million million included plant equipment vehicles december leased assets cost million million accumulated depreciation million million impairment nil million net book value million million lease agreements include renewal purchase options escalation clauses impairment losses principally arise decisions rationalise facilities calculated based either fair value less costs disposal value use fair value less costs disposal valuation methodology uses significant inputs based observable market data therefore valuation technique classified level fair value hierarchy calculations determine net present value projected riskadjusted posttax cash flows relevant asset cash generating unit applying discount rate group posttax weighted average cost capital wacc adjusted appropriate relevant specific risks value use calculations impairment indicated pretax cash flow calculation expected give materially different result test would reperformed using pretax cash flows pretax discount rate group wacc equivalent pretax discount rate approximately net impairment losses charged cost sales million million rd million million sga million million include million nil arising major restructuring programmes reversals impairment arise subsequent reviews impaired assets conditions gave rise original impairments deemed longer apply reversals credited cost sales carrying value december assets impairments charged reversed year million million goodwill cost january exchange adjustments additions business combinations note transfer assets held sale movements contingent consideration balances cost december net book value january net book value december gsk divested novartis marketed oncology portfolio acquired novartis vaccines business excluding influenza vaccines created consumer healthcare joint venture novartis gsk control equity interest acquisitions resulted recognition additional goodwill allocated vaccines million consumer healthcare million disposal oncology business resulted transfer goodwill assets held sale reduction goodwill global pharmaceuticals million disposal completed carrying value goodwill translated yearend exchange rates allocated following cash generating units global pharmaceuticals hiv vaccines consumer healthcare net book value december goodwill balance december reallocated reflect revised cash generating units gsk annual report strategic report governance remuneration financial statements investor information goodwill continued recoverable amounts cash generating units assessed using fair value less costs disposal model fair value less costs disposal calculated using discounted cash flow approach posttax discount rate applied projected riskadjusted posttax cash flows terminal value discount rate used based group wacc cash generating units integrated operations across large parts group discount rate adjusted appropriate specific country currency risks valuation methodology uses significant inputs based observable market data therefore valuation technique classified level fair value hierarchy details relating discounted cash flow models used impairment tests global pharmaceuticals hiv vaccines consumer healthcare cash generating units follows valuation basis fair value less costs disposal key assumptions sales growth rates profit margins terminal growth rate discount rate taxation rate determination assumptions growth rates internal forecasts based internal external market information margins reflect past experience adjusted expected changes terminal growth rates based managements estimate future longterm average growth rates discount rates based group wacc adjusted appropriate taxation rates based appropriate rates region period specific projected cash flows five years terminal growth rate discount rate terminal growth rate discount rate global pharmaceuticals pa hiv pa vaccines pa consumer healthcare pa terminal growth rates exceed longterm projected growth rates relevant markets reflect impact future generic competition take account new product launches case valuations indicate sufficient headroom reasonably possible change key assumptions unlikely result impairment related goodwill goodwill monitored segmental level global pharmaceuticals cash generating unit comprises collection smaller cash generating units including assets indefinite lives carrying value million million consumer healthcare cash generating unit also comprises collection smaller cash generating units including brands indefinite lives carrying value billion billion details indefinite life brands given note intangible assets gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued intangible assets computer licences amortised indefinite life software patents etc brands brands total cost january exchange adjustments capitalised development costs capitalised borrowing costs additions reclassifications disposals asset writeoffs transfer assets held sale cost december exchange adjustments capitalised development costs capitalised borrowing costs additions business combinations additions reclassifications disposals asset writeoffs transfer assets held sale cost december amortisation january exchange adjustments charge year disposals asset writeoffs amortisation december exchange adjustments charge year disposals asset writeoffs transfer assets held sale amortisation december impairment january exchange adjustments impairment losses disposals asset writeoffs impairment december exchange adjustments impairment losses disposals asset writeoffs transfer assets held sale impairment december total amortisation impairment december total amortisation impairment december net book value january net book value december net book value december net book value computer software includes million million internally generated costs charge impairments year includes impairments magea asset maxinutrition carrying value december intangible assets impairments charged reversed year following impairments reversals million milliongsk annual report strategic report governance remuneration financial statements investor information intangible assets continued amortisation impairment losses net reversals charged income statement follows amortisation net impairment losses cost sales selling general administration research development licences patents etc includes large number acquired licences patents knowhow agreements marketing rights either marketed use still development note acquisitions disposals gives details additions business combinations year book values largest individual items follows dolutegravir benlysta menveo bexsero men abcwy fluarixflulaval selzentry okairos technology platform others indefinite life brands comprise portfolio consumer healthcare products primarily acquired acquisitions sterling winthrop inc block drug company inc cns inc novartis consumer healthcare business together number pharmaceutical brands acquisition stiefel laboratories inc book values major brands follows voltaren otrivin fenistil theraflu panadol sensodyne lamisil breathe right stiefel trade name excedrin physiogel polident others brands considered indefinite life given strength durability brand level marketing support brands relatively similar stable profitable market sectors similar risk profiles size diversification market shares mean risk marketrelated factors causing reduction lives brands considered relatively low group aware material legal regulatory contractual competitive economic factor could limit useful lives accordingly amortised brand tested annually impairment amortised intangible assets tested indicators impairment arise testing applies fair value less costs disposal methodology generally using posttax cash flow forecasts terminal value calculation discount rate equal group posttax wacc adjusted appropriate country currency specific risks valuation methodology uses significant inputs based observable market data therefore valuation technique classified level fair value hierarchy main assumptions include future sales price volume growth product contribution future expenditure required maintain products marketability registration relevant jurisdictions assumptions based past experience reviewed part managements budgeting strategic planning cycle changes market conditions sales erosion competition terminal growth rates applied nil managements estimates future longterm average growth rates relevant markets case valuations indicate sufficient headroom reasonably possible change key assumptions unlikely result impairment intangible assets gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued investments associates joint ventures joint joint ventures associates total ventures associates total january exchange adjustments additions disposals transfer fromto investments distributions received movements profitloss tax recognised consolidated income statement comprehensive income recognised consolidated statement comprehensive income december group held one significant associate december theravance inc changed name innoviva inc january december group owned million shares theravance inc innoviva inc biopharmaceutical company listed nasdaq company partnered gsk development relvarbreo ellipta anoro ellipta receives royalty income sales products also eligible receive royalty income sales vilanterol monotherapy approved commercialised retains economic interest future payments made gsk earlierstage programmes partnered theravance biopharma inc gsk recognised theravance associate september following expiry governance agreement related groups investment company terms governance agreement group required certain limited exceptions vote shares either support recommendation independent directors board proportion shareholders votes cast expiry governance agreement removal voting rights restriction considered provide group ability exert significant influence activities company investment market value million december movements primarily reflect recognition gsks share theravances past losses transfer theravance investments associates december groups significant investment associate holding aspen pharmacare holdings limited march group sold half holding aspen result group longer ability exert significant influence aspen groups remaining investment aspen accounted investments summarised balance sheet information based preliminary results information respect theravance innoviva december aspen december set theravance aspen december december noncurrent assets current assets current liabilities noncurrent liabilities net liabilitiesassets interest associated undertaking goodwill fair value adjustments carrying value december gsk annual report strategic report governance remuneration financial statements investor information investments january exchange adjustments additions fair value gain reclassification investment associate net fair value movements impairment losses transfer investments associates joint ventures disposals december investments comprise noncurrent equity investments availableforsale investments recorded fair value balance sheet date investments traded active market fair value determined reference relevant stock exchange quoted bid price investments fair value estimated management reference relevant available information including current market value similar instruments discounted cash flows underlying net assets group holds number equity investments entities group entered research collaborations investments include listed investments million million increase arising additions fair value adjustments transfer groups investment aspen pharmacare holdings limited investments associates investments offset transfer groups investment theravance inc investments associates disposals impairments principally relating aspen december group held common stock theravance biopharma inc groups investment theravance biopharma accounted equity investment group power exert significant influence activities company group theravance biopharma entered governance agreement expires agreement group right appoint director theravance biopharma board must certain limited exceptions vote shares either support recommendation independent directors board proportion shareholders votes cast september similar governance agreement another investee theravance inc innoviva inc expired expiry agreement considered provide group ability exert significant influence activities company group therefore accounted shareholding investment associate since date march group sold half shareholding aspen pharmacare holdings limited investment previously accounted associate result sale group longer considered ability exert significant influence aspen groups remaining investment transferred investments associates investments december investment fair value million disposal investments fair value movements reclassified equity income statement based average cost shares acquired different times impairment losses recorded recognised income statement year within operating income together amounts reclassified fair value reserve recognition impairments impairments initially result prolonged significant declines fair value equity investments acquisition cost subsequent declines fair value immediately taken income statement carrying value december investments impaired follows original cost cumulative impairments recognised income statement subsequent fair value increases carrying value december noncurrent assets amounts receivable insurance contracts pension schemes surplus receivables gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued inventories raw materials consumables work progress finished goods trade receivables trade receivables net provision bad doubtful debts accrued income prepayments interest receivable employee loans advances receivables trade receivables included million million due associates joint ventures receivables included nil million due associates joint ventures increase receivables primarily arises novartis transaction bad doubtful debt provision january exchange adjustments charge year subsequent recoveries amounts provided utilised december cash cash equivalents cash bank hand shortterm deposits assets held sale property plant equipment goodwill intangibles inventory noncurrent assets disposal groups transferred assets held sale expected carrying amounts recovered principally disposal sale considered highly probable held lower carrying amount fair value less costs sell included within assets held sale assets written fair value less costs sell million million valuation methodology uses significant inputs based observable market data therefore valuation classified level fair value hierarchygsk annual report strategic report governance remuneration financial statements investor information trade payables trade payables wages salaries social security payables deferred income customer return rebate accruals contingent consideration accruals customer return rebate accruals provided group point sale respect estimated rebates discounts allowances payable customers including million million respect us pharmaceuticals vaccines accruals made time sale actual amounts paid based claims made time initial recognition sale amounts estimated may fully reflect final outcome subject change dependent upon amongst things types buying group product sales mix level accrual reviewed adjusted quarterly light historical experience actual rebates discounts allowances given returns made changes arrangements future events could cause assumptions accruals based change could affect future results group trade payables include million million due associates joint ventures pensions postemployment benefits pension postemployment costs uk pension schemes us pension schemes overseas pension schemes unfunded postretirement healthcare schemes analysed funded defined benefithybrid pension schemes unfunded defined benefit pension schemes unfunded postretirement healthcare schemes defined benefit schemes defined contribution pension schemes net reduction postretirement healthcare schemes cost arises restructuring us postretirement medical obligations details see costs defined benefit pension postretirement healthcare schemes charged income statement follows cost sales selling general administration research development gsk entities operate pension arrangements cover groups material obligations provide pensions retired employees arrangements developed accordance local practices countries concerned pension benefits provided state schemes defined contribution schemes whereby retirement benefits determined value funds arising contributions paid respect employee defined benefit schemes whereby retirement benefits based employee pensionable remuneration length service hybrid defined benefit schemes also include defined contribution sections gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued pensions postemployment benefits continued pension costs defined benefit schemes accounting purposes calculated using projected unit method certain countries pension benefits provided unfunded basis administered trustee companies formal independent actuarial valuations groups main plans undertaken regularly normally least every three years actuarial movements year recognised statement comprehensive income discount rates derived aa rated corporate bond yields except countries deep market corporate bonds government bond yields used discount rates selected reflect term expected benefit payments projected inflation rate pension increases longterm predictions based yield gap longterm indexlinked fixed interest gilts uk mortality rates determined adjusting saps standard mortality tables reflect recent scheme experience rates projected reflect improvements life expectancy line cmi projections longterm rate improvement per year males females us mortality rates calculated using rp white collar table adjusted reflect recent experience rates projected using scale bbd allow future improvements life expectancy average life expectancy assumed individual age projected apply individual age follows uk us male female male female years years years years current projected assets funded schemes generally held separately administered trusts either specific assets proportion general fund insurance contracts assets invested different classes order maintain balance risk return investments diversified limit financial effect failure individual investment group reviewed investment strategy uk plans asset allocation uk plans adjusted approximately return seeking assets liability matching assets target asset allocation us plans also updated return seeking assets liability matching assets pension plans exposed risk arises estimated market value plans assets might decline investment returns might reduce estimated value plans liabilities might increase line agreed mix return seeking assets generate future returns liability matching assets better match future pension obligations group defined overall longterm investment strategy plans investments across broad range assets main market risks within asset hedging portfolio credit risk interest rates longterm inflation equities property bank counterparty risk plan liabilities series future cash flows relatively long duration ias r basis cash flows sensitive changes expected longterm inflation rate discount rate aa corporate bond yield curve increase longterm inflation corresponds increase liabilities increase discount rate corresponds decrease liabilities uk defined benefit pension schemes operated benefit former glaxo wellcome employees former smithkline beecham employees remain separate schemes closed new entrants subsequent uk employees entitled join defined contribution scheme us former glaxo wellcome smithkline beecham defined benefit schemes merged addition group operates number postretirement healthcare schemes principal one us group applied following financial assumptions assessing defined benefit liabilities uk us rest world pa pa pa pa pa pa pa pa pa rate increase future earnings discount rate expected pension increases na na na cash balance creditconversion rate na na na inflation rate gsk annual report strategic report governance remuneration financial statements investor information pensions postemployment benefits continued amounts recorded income statement statement comprehensive income three years ended december relation defined benefit pension postretirement healthcare schemes follows postretirement pensions benefits uk us rest world group group amounts charged operating profit current service cost past service costcredit net interest cost gains settlements expenses remeasurements recorded statement comprehensive income postretirement pensions benefits uk us rest world group group amounts charged operating profit current service cost past service costcredit net interest creditcost gains settlements expenses remeasurements recorded statement comprehensive income postretirement pensions benefits uk us rest world group group amounts charged operating profit current service cost past service costcredit net interest cost expenses remeasurements recorded statement comprehensive income past service credit million includes amount million relation restructuring us postretirement medical obligations active retired members age amounts included within past service costs include million million nil augmentation costs arising major restructuring programmes see note provisions gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued pensions postemployment benefits continued summarised balance sheet presentation group defined benefit pension schemes postretirement benefits set table recognised noncurrent assets pension schemes surplus recognised pensions postemployment benefits pension schemes deficit postretirement benefits fair values assets liabilities uk us defined benefit pension schemes together aggregated data defined benefit pension schemes group follows uk us rest world group december equities listed unlisted property unlisted corporate bonds listed unlisted government bonds listed insurance contracts assets fair value assets present value scheme obligations net obligation included noncurrent assets included pensions postemployment benefits actual return plan assets indexlinked gilts held part uk repo programme included government bonds related loan included within assets value million illion million uk us rest world group december equities listed unlisted property unlisted corporate bonds listed unlisted government bonds listed insurance contracts assets fair value assets present value scheme obligations net obligation included noncurrent assets included pensions postemployment benefits actual return plan assets gsk annual report strategic report governance remuneration financial statements investor information pensions postemployment benefits continued uk us rest world group december equities listed unlisted property unlisted corporate bonds listed unlisted government bonds listed insurance contracts assets fair value assets present value scheme obligations net assetobligation included noncurrent assets included pensions postemployment benefits actual return plan assets postretirement pensions benefits uk us rest world group group movements fair values assets assets january exchange adjustments interest income expenses remeasurement employer contributions scheme participants contributions benefits paid assets december exchange adjustments interest income expenses settlements curtailments remeasurement employer contributions scheme participants contributions benefits paid assets december exchange adjustments additions business combinations interest income expenses settlements curtailments remeasurement employer contributions scheme participants contributions benefits paid assets december uk defined benefit schemes include defined contribution sections account balances totalling million december million million group made special funding contributions uk pension schemes totalling million million million million nil nil us scheme gsk reached agreement trustees uk pension schemes make additional contributions eliminate pension deficit identified december actuarial funding valuation based funding agreements following valuation additional contributions expected million contributions based government bond yield curve approach selecting discount rate rate chosen included allowance expected investment returns reflected asset mix schemes employer contributions including special funding contributions estimated approximately million respect defined benefit pension schemes million respect postretirement benefits gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued pensions postemployment benefits continued postretirement pensions benefits uk us rest world group group movements defined benefit obligations obligations january exchange adjustments service cost past service cost interest cost movements remeasurement scheme participants contributions benefits paid obligations december exchange adjustments service cost past service cost interest cost settlements curtailments movements remeasurement scheme participants contributions benefits paid obligations december exchange adjustments additions business combinations service cost past service cost interest cost settlements curtailments remeasurement scheme participants contributions benefits paid obligations december uk defined benefit schemes include defined contribution sections obligations totalling million december million million defined benefit pension obligation analysed follows funded unfunded liability us postretirement healthcare scheme assessed using assumptions us pension scheme together assumption future medical inflation grading thereafter december us postretirement healthcare scheme obligation million million million postretirement benefits unfundedgsk annual report strategic report governance remuneration financial statements investor information pensions postemployment benefits continued movement net defined benefit liability follows january exchange adjustments additions business combinations service cost past service cost interest incomecost settlements curtailments remeasurements return plan assets excluding amounts included interest gainloss change demographic assumptions gainloss change financial assumptions experience losses employer contributions expensesother movements december remeasurements included within postretirement benefits detailed gainloss change demographic assumptions gainloss change financial assumptions experience lossesgains gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued pensions postemployment benefits continued defined benefit pension obligation analysed membership category follows active retired deferred postretirement benefit obligation analysed membership category follows active retired deferred weighted average duration defined benefit obligation follows years years years pension benefits postretirement benefits sensitivity analysis effect changes assumptions used benefit obligations annual defined benefit pension post retirement costs decrease discount rate would following approximate effect increase annual pension cost decrease annual postretirement benefits cost increase pension obligation increase postretirement benefits obligation one year increase life expectancy would following approximate effect increase annual pension cost increase annual postretirement benefits cost increase pension obligation increase postretirement benefits obligation increase rate future healthcare inflation would following approximate effect increase annual postretirement benefits cost increase postretirement benefits obligation increase inflation would following approximate effect increase annual pension cost increase pension obligation gsk annual report strategic report governance remuneration financial statements investor information provisions legal major employee restructuring related disputes programmes provisions provisions total january exchange adjustments charge year reversed unused unwinding discount utilised reclassifications movements transfer pension obligations december settled within one year settled one year december legal disputes major restructuring programmes group involved substantial number legal group initiated major change restructuring disputes including notification possible claims set programme focused opportunities simplify supply chain note legal proceedings provisions legal processes build groups capabilities manufacturing disputes include amounts relating product liability antitrust rd restructure european pharmaceuticals business government investigations principally relating secdoj pharmaceuticals restructuring programme announced sfo related investigations contract terminations self october rescale commercial operations global support insurance environmental cleanup functions relevant rdmanufacturing operations across charge year million million net pharmaceuticals addition integration restructuring programme reversals estimated insurance recoveries primarily related initiated following completion novartis provisions product liability cases regarding paxil transaction restructuring integration programmes products commercial disputes various government reported together one combined major restructuring investigations programme discount provisions decreased million provisions staff severance payments made nil calculated using riskadjusted projected management made formal decision eliminate certain cash flows riskfree rates return movement positions communicated groups includes increase million million arising employees affected appropriate consultation procedures change discount rate year completed appropriate provision made staff severance payments made immediately respect product liability claims related certain products sufficient history claims made settlements enable pension augmentations arising staff redundancies management make reliable estimate provision required million million charged year cover unasserted claims ultimate liability matters transferred pension obligations provision shown may vary amounts provided dependent upon note pensions postemployment benefits outcome litigation proceedings investigations possible asset writedowns recognised impairments settlement negotiations property plant equipment note property plant equipment majority amounts provided expected nature groups business number utilised next two years matters may subject negotiation litigation many years litigation proceedings including various employee related provisions appeal procedures often take many years reach resolution employee related provisions include obligations certain outofcourt settlement discussions also often protracted medical benefits disabled employees spouses us december provision benefits group potential settlement discussions number amounted million million employee disputes amounts provided based benefits reflect variety provisions severance costs jubilee current assessment progress disputes awards longservice benefits estimates billion amount provided december settled within one year december provisions expected none nil provision made legal included provisions insurance provisions disputes reimbursed third party insurers million million onerous property lease discussion legal issues see note legal proceedings provisions million million number provisions including vehicle insurance regulatory matters gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued noncurrent liabilities accruals deferred income contingent consideration note consumer healthcare put option liability payables consumer healthcare put option liability relates ability novartis put shares consumer healthcare joint venture gsk certain points future commencing liability recorded present value expected redemption amount calculated using multiples approach based forecast revenue earnings consumer healthcare joint venture table shows indicative basis income statement balance sheet sensitivity reasonably possible changes either sales forecasts sales multiples used valuation liability increasedecrease financial liability lossgain income statement changes key inputs increase sales forecasts sales multiple applied decrease sales forecasts sales multiple applied net debt listing exchange current assets liquid investments cash cash equivalents shortterm borrowings commercial paper bank loans overdrafts obligations finance leases us us medium term note new york stock exchange us us medium term note new york stock exchange european medium term note london stock exchange longterm borrowings us us medium term note new york stock exchange us us medium term note new york stock exchange european medium term note london stock exchange us us medium term note new york stock exchange european medium term note london stock exchange us us medium term note new york stock exchange us us medium term note new york stock exchange european medium term note london stock exchange european medium term note london stock exchange european medium term note london stock exchange european medium term note london stock exchange us us medium term note london stock exchange us us medium term note new york stock exchange european medium term note london stock exchange european medium term note london stock exchange us us medium term note new york stock exchange european medium term note london stock exchange obligations finance leases net debt gsk annual report strategic report governance remuneration financial statements investor information net debt continued current assets longterm borrowings liquid investments classified availableforsale investments yearend gsk longterm borrowings billion december included us treasury notes billion billion billion government bonds effective interest rate liquid falls due five years average effective preswap investments december approximately interest rate notes issue december approximately liquid investment balances approximately approximately december earning interest floating rates amount longterm borrowings repayable five years carry interest million million liquid investment balances effective rates repayment december earning interest fixed rates amount dates range million nil pledged assets effective interest rate cash cash equivalents group pledged investments us treasury notes december approximately par value million million million approximately cash cash equivalents million security irrevocable letters credit december earning interest floating fixed rates issued groups behalf respect groups self amount million nil respectively insurance activity provisions respect selfinsurance million million included within provisions legal disputes gsks policy regarding credit quality cash cash discussed note provisions addition million equivalents referred note financial instruments million assets included note related disclosures noncurrent assets form part net debt pledged collateral future rental payments shortterm borrowings operating lease arrangements entered human genome gsk billion billion us commercial paper sciences inc prior acquisition group programme undrawn december billion billion drawn gsk also billion five year committed mediumterm facilities billion billion day committed facilities facilities put place september undrawn december liquid investments cash cash equivalents shown table weighted average interest rate current bank loans overdrafts december finance lease obligations rental payments due within one year rental payments due one two years rental payments due two three years rental payments due three four years rental payments due four five years rental payments due five years total future rental payments future finance charges total finance lease obligations contingent liabilities december contingent liabilities comprising guarantees discounted bills items arising normal course business amounted million million december nil nil financial assets pledged collateral contingent liabilities provision made outcome tax legal disputes probable group suffer outflow funds possible make reliable estimate outflow december disputes provision made possible make reliable estimate potential outflow funds might required settle disputes possibility outflow remote descriptions significant tax legal disputes group party set note taxation note legal proceedings gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued share capital share premium account share ordinary shares p premium number share capital authorised december december december share capital issued fully paid january issued employee share schemes share capital cancelled december issued employee share schemes december issued employee share schemes december december december number shares issuable employee share schemes number unissued shares option december issued share capital shares held esop trusts shares held treasury shares shares free issue issued shares fully paid nominal carrying market values shares held esop trusts disclosed note employee share schemesgsk annual report strategic report governance remuneration financial statements investor information movements equity retained earnings reserves amounted million december million million million million million relates joint ventures associated undertakings cumulative translation exchange equity follows net translation exchange included non total retained fair value controlling translation earnings reserve interests exchange january exchange movements overseas net assets december exchange movements overseas net assets reclassification exchange liquidation disposal overseas subsidiaries december exchange movements overseas net assets december analysis comprehensive income equity category follows non retained controlling earnings reserves interests total items may subsequently reclassified income statement exchange movements overseas net assets net investment hedges fair value movements availableforsale investments deferred tax fair value movements availableforsale investments reclassification fair value movements availableforsale investments deferred tax reclassification fair value movements availableforsale investments reclassification cash flow hedges income statement fair value movements cash flow hedges share comprehensive income associates joint ventures items reclassified income statement exchange movements overseas net assets noncontrolling interests remeasurement gains defined benefit plans deferred tax remeasurement gains defined benefit plans comprehensive expenseincome year non retained controlling earnings reserves interests total items may subsequently reclassified income statement exchange movements overseas net assets net investment hedges reclassification exchange liquidation disposal overseas subsidiaries deferred tax exchange movements fair value movements availableforsale investments deferred tax fair value movements availableforsale investments reclassification fair value movements availableforsale investments deferred tax reclassification fair value movements availableforsale investments reclassification cash flow hedges income statement fair value movements cash flow hedges deferred tax fair value movements cash flow hedges share comprehensive income associates joint ventures items reclassified income statement exchange movements overseas net assets noncontrolling interests remeasurement losses defined benefit plans deferred tax remeasurement losses defined benefit plans comprehensive expenseincome year gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued movements equity continued non retained controlling earnings reserves interests total items may subsequently reclassified income statement exchange movements overseas net assets net investment hedges fair value movements availableforsale investments deferred tax fair value movements availableforsale investments reclassification fair value movements availableforsale investments deferred tax reclassification fair value movements availableforsale investments reclassification cash flow hedges income statement fair value movements cash flow hedges deferred tax fair value movements cash flow hedges share comprehensive income associates joint ventures items reclassified income statement exchange movements overseas net assets noncontrolling interests remeasurement gains defined benefit plans deferred tax remeasurement gains defined benefit plans comprehensive incomeexpense year analysis reserves follows esop trust fair value cash flow shares reserve hedge reserve reserves total january transferred income expense year disposals transferred income expense year impairment net fair value movement year ordinary shares purchased cancelled ordinary shares acquired esop trusts writedown shares held esop trusts december transferred income expense year disposals net fair value movement year ordinary shares acquired esop trusts writedown shares held esop trusts forward contract noncontrolling interest december transferred income expense year disposals transferred income expense year impairments net fair value movement year ordinary shares acquired esop trusts writedown shares held esop trusts december reserves include various nondistributable merger premerger reserves amounting million december million million reserves also include capital redemption reserve created result share buyback programme amounting million december million milliongsk annual report strategic report governance remuneration financial statements investor information related party transactions gsk held interest aspen pharmacare holdings limited december following sale half groups holding aspen march investment longer accounted associate december gsk owned million shares theravance inc innoviva inc biopharmaceutical company listed nasdaq gsk began recognising theravance associate september royalty revenues paid gsk theravance period september december million nil december balance payable gsk theravance million december gsk held interest japan vaccine co ltd jvc subsidiary glaxosmithkline kk joint venture daiichi sankyo co ltd primarily responsible development marketing certain prophylactic vaccines japan gsk sold million million vaccine products joint venture december trading balance due gsk jvc million balance payable gsk jvc nil addition loan million made jvc year amount remained due gsk december aggregate compensation directors cet given note employee costs adjustments reconciling profit tax operating cash flows profit tax tax profits share tax profits associates joint ventures finance income net finance expense depreciation amortisation intangible assets impairment assets written profit sale businesses profit sale intangible assets profit sale investments associates profit sale equity investments changes working capital increase inventories decrease trade receivables increasedecrease receivables increase trade payables increase payables increasedecrease pension provisions sharebased incentive plans fair value adjustments cash generated operations gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued reconciliation net cash flow movement net debt net debt beginning year increasedecrease cash bank overdrafts decreaseincrease liquid investments net increase longterm loans net repayment shortterm loans net repayment obligations finance leases net noncash funds subsidiary undertakings acquired exchange adjustments noncash movements movement net debt net debt end year january reclass december exchange ifications cash flow analysis changes net debt liquid investments cash cash equivalents overdrafts debt due within one year commercial paper european us medium term notes debt due one year european us medium term notes net debt information significant changes net debt see note net debtgsk annual report strategic report governance remuneration financial statements investor information acquisitions disposals details acquisition disposal significant subsidiaries associates joint ventures businesses given acquisitions novartis consumer healthcare vaccines businesses threepart interconditional transaction novartis ag involving consumer healthcare vaccines oncology businesses completed march gsk novartis contributed respective consumer healthcare businesses consumer healthcare joint venture noncash transaction gsk equity interest majority control joint venture addition gsk acquired novartis global vaccines business excluding influenza vaccines initial cash consideration billion billion contingent consideration representing subsequent potential milestone payments billion billion arising achievement specified development targets ongoing royalties based future sales performance certain products total amount payable unlimited first milestone million million paid march business acquisitions addition gsk completed one smaller vaccines business acquisition cash consideration million net cash acquired fair value existing investments million represented goodwill million intangible assets million less net liabilities million fair values assets acquired business combinations including goodwill set table amounts provisional subject change novartis consumer novartis healthcare vaccines business business net assets acquired intangible assets property plant equipment inventory trade receivables assets including cash cash equivalents trade payables deferred tax liabilities liabilities noncontrolling interest goodwill consideration settled shares gsk consumer healthcare holdings cash consideration paid purchase adjustments fair value equity investment disposal contingent consideration deferred tax contingent consideration loss settlement preexisting relationships total consideration noncontrolling interest consumer healthcare joint venture calculated applying full goodwill method represents novartis share net assets joint venture together attributable goodwill goodwill businesses acquired represents potential synergies arising combining acquired businesses gsks existing businesses together value workforce acquired majority goodwill recognised expected deductible tax purposes total transaction costs recognised acquisitions novartis amounted million since acquisition march turnover million arising novartis consumer healthcare vaccines businesses included group turnover businesses acquired beginning year estimated group turnover would approximately million higher businesses integrated groups existing activities practicable identify impact group profit period disposals oncology gsk divested marketed oncology business related rd activities rights akt inhibitor also granted commercialisation partner rights future oncology products novartis consideration billion million purchase adjustments gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued acquisitions disposals continued business disposals gsk also made number small business disposals period net cash consideration million profit disposal businesses determined follows oncology cash consideration including currency forwards purchase adjustments net assets sold goodwill intangible assets property plant equipment inventory cash net assets loss currency forwards booked disposal costs profit disposal investments associates joint ventures march gsk sold half shareholding aspen representing issued share capital company million cash result sale group longer considered ability exert significant influence aspen groups remaining investment transferred investments associates investments cash consideration net book value shares reclassification exchange comprehensive income transaction fees items profit disposal associates business business jv acquisitions disposals disposals total cash flows cash consideration paidreceived purchase adjustments cash cash equivalents acquireddivested deferred cash proceeds contingent consideration paid transaction costs cash outflowinflow addition gsk made cash investments million associates joint ventures contingent consideration payable consideration certain acquisitions includes amounts contingent future events development milestones sales performance group provided fair value contingent consideration follows shionogi viiv novartis healthcare vaccines total january remeasurement goodwill remeasurement income statement settlement december additions business combinations remeasurement income statement settlement movements december million contingent consideration payable december expected paid within one year million consideration payable acquisition shionogiviiv healthcare joint venture novartis vaccines business expected paid number years information sensitivity income statement balance sheet reasonably possible changes key inputs valuations contingent consideration payable shionogiviiv healthcare business novartis vaccines business provided note financial instruments related disclosuresgsk annual report strategic report governance remuneration financial statements investor information acquisitions disposals continued cash payments settle shionogiviiv healthcare joint venture contingent consideration payable amounted million total million reported operating cash flows million cash flow purchases business acquisitions acquisitions acquisition integration costs million arising proposed threepart interconditional transaction novartis ag expensed million paid cash year disposals year million received deferred consideration sale anticoagulant business completed million disposal associate gsk also made cash investments million associates business associates acquisitions joint disposals ventures total cash flows cash consideration paid transaction costs paid purchases businesses associates net cash proceeds disposals acquisitions gsk completed acquisition three businesses cash including okairos ag european based biopharmaceutical company focused development specific vaccine technology prophylactic therapeutic fields acquired may total purchase price businesses million included million cash acquired million contingent consideration fair value net assets acquired intangibles property plant equipment inventory trade receivables assets including cash cash equivalents deferred tax provision trade payables goodwill cash consideration paid contingent consideration total consideration acquisitions made beginning year estimated group turnover would increased approximately million year okairos fully integrated gsk business practicable separately identify impact group profit year acquisitions occurred shortly end year material impact group profit year goodwill arising acquisitions reflects potential business synergies value workforce acquired majority goodwill expected deductible income tax purposes results acquisitions reported within us europe emerging markets japan trading unallocated pharmaceuticals vaccines consumer healthcare operating segments transactions accounted using acquisition accounting method acquisition costs expensed totalled million gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued acquisitions disposals continued disposals lucozade ribena december gsk completed sale lucozade ribena business including manufacturing site related inventory suntory beverage food ltd million cash recognised profit disposal operating income million lucozade ribena sales excluding retained markets totalled million year ending december cash consideration net assets sold inventory property plant equipment goodwill disposal costs profit disposal anticoagulant business december gsk completed sale anticoagulant business comprising worldwide intellectual property rights excluding china india pakistan fraxiparine arixtra together related inventory manufacturing site aspen group consideration million million received cash million deferred profit disposal million recognised operating income worldwide sales fraxiparine arixtra excluding retained markets million year ending december cash consideration cash consideration receivable net assets sold inventory property plant equipment intangible assets goodwill disposal costs total profit disposal deferral profit profit recognised year investments associates joint ventures november gsk sold one third shareholding aspen representing issued share capital company million cash december gsk held aspen continued recognise investment aspen associate cash consideration net book value shares reclassification exchange comprehensive income reclassification fair value movements comprehensive income profit disposal gsk annual report strategic report governance remuneration financial statements investor information acquisitions disposals continued business associates acquisitions joint disposals ventures total cash flows cash consideration paid cash cash equivalents acquired cash consideration paid net cash acquired total cash consideration payable net cash acquired contingent consideration cash consideration paid net cash acquired total cash proceeds receivable cash proceeds deferred net cash proceeds disposals noncontrolling interests group two subgroups material noncontrolling interests viiv healthcare limited subsidiaries gsk consumer healthcare holdings limited subsidiaries summarised financial information respect viiv healthcare group gsk consumer healthcare joint venture set viiv healthcare turnover lossprofit taxation comprehensive incomeexpense total comprehensive expenseincome noncurrent assets current assets total assets current liabilities noncurrent liabilities total liabilities net liabilities net cash inflow operating activities net cash outflow investing activities net cash outflow financing activities increasedecrease cash bank overdrafts year financial information relates viiv healthcare group standalone basis impact grouprelated adjustments primarily related recognition preferential dividends loss taxation million loss taxation million profit taxation million stated charge million million million remeasurement contingent consideration payable acquisition former shionogiviiv healthcare joint venture consideration expected paid number years following amounts attributable viiv healthcare group included gsks consolidated statement comprehensive income consolidated statement changes equity consolidated balance sheet total comprehensive expenseincome year attributable noncontrolling interests dividends paid noncontrolling interests noncontrolling interests consolidated balance sheet gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued noncontrolling interests continued consumer healthcare joint venture turnover loss taxation comprehensive income total comprehensive income noncurrent assets current assets total assets current liabilities noncurrent liabilities total liabilities net assets net cash inflow operating activities net cash outflow investing activities net cash outflow financing activities decrease cash bank overdrafts year financial information relates consumer healthcare joint venture standalone basis since formation march impact grouprelated adjustments following amounts attributable consumer healthcare joint venture included gsks consolidated statement comprehensive income consolidated statement changes equity consolidated balance sheet total comprehensive income year attributable noncontrolling interests noncontrolling interests consolidated balance sheet gsk annual report strategic report governance remuneration financial statements investor information commitments contractual obligations commitments contracted provided financial statements intangible assets property plant equipment investments purchase commitments pensions commitments interest loans finance lease charges commitments related intangible assets include milestone payments dependent successful clinical development meeting specified sales targets represent maximum would paid milestones however unlikely achieved amounts riskadjusted discounted number commitments made licensing agreements new arrangements offset reduced commitments due prior year transactions including amendments agreement ionis shionogi gsk reached agreement trustees uk pension schemes make additional contributions eliminate pension deficit identified december actuarial funding valuation payment million due future payments based deficit position scheme maximum million table includes commitment excludes normal ongoing annual funding requirement uk approximately million group also commitments principally relate revenue payments made licences alliances commitments respect future interest payable loans disclosed taking account effect interest rate swaps commitments noncancellable operating leases disclosed million million provided commitments groups balance sheet commitments noncancellable operating leases rental payments due within one year rental payments due one two years rental payments due two three years rental payments due three four years rental payments due four five years rental payments due five years total commitments noncancellable operating leases gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued f inancial instruments related market risk disclosures interest rate risk management gsks objective minimise effective net interest cost gsk uses variety financial instruments finance balance mix debt fixed floating interest rates operations derivative financial instruments manage market time policy interest rate risk management limits amount risks operations derivatives principally floating interest payments prescribed percentage comprising forward foreign currency contracts foreign currency operating profit options interest rate swaps used swap borrowings foreign exchange risk management liquid assets currencies required group purposes foreign currency transaction exposures arising internal manage exposure financial risks changes foreign external trade flows typically hedged groups exchange rates interest rates objective minimise exposure overseas operating gsk hold issue derivatives speculative purposes subsidiaries transaction risk matching local currency income treasury policies specifically prohibit activity local currency costs possible gsks internal trading transactions financial instruments undertaken manage transactions matched centrally intercompany payment risks arising underlying business activities terms managed reduce foreign currency risk foreign speculation currency cash flows hedged selectively including hedges foreign exchange risk arising acquisitions disposals capital management assets gsks financial strategy supports groups strategic priorities regularly reviewed board gsk manages capital possible gsk manages cash surpluses borrowing structure group appropriate mix debt requirements subsidiary companies centrally using forward equity contracts hedge future repayments back originating currency order reduce foreign currency translation exposure capital structure group consists net debt group seeks denominate borrowings currencies billion see note net debt shareholders equity principal assets cash flows primarily billion see consolidated statement changes equity denominated us dollars euros sterling certain borrowings total capital including provided noncontrolling swapped currencies required borrowings interests billion denominated swapped foreign currencies match longterm credit rating standard poors investments group overseas assets may treated hedge stable outlook moodys investor services moodys relevant assets forward contracts major currencies negative outlook groups shortterm credit ratings also used reduce exposure groups investment p standard poors moodys overseas assets see net investment hedges section note respectively details liquidity risk management gsks policy borrow centrally order meet anticipated funding requirements strategy diversify liquidity sources using range facilities maintain broad access funding markets december gsk billion borrowings repayable within one year held billion cash cash equivalents liquid investments billion held centrally gsk access shortterm finance billion billion us commercial paper programme gsk also billion five year committed mediumterm facilities billion billion day committed facilities facilities put place september undrawn december gsk considers level committed facilities adequate given current liquidity requirements gsk billion european medium term note programme december billion notes issue programme group also us shelf registration statement december billion billion notes issue programme gsks longterm borrowings mature dates gsk annual report strategic report governance remuneration financial statements investor information f inancial instruments related following completion novartis transaction march disclosures continued gsks cash liquid investment balances increased materially significant proportion funds placed credit risk number aaaaaa rated us treasury treasury repo group considers maximum credit risk december money market funds aaaaaa rated liquidity funds million december million credit ratings number groups total groups financial assets exception relationship banks downgraded notably deutsche investments comprising equity investments bear bank downgraded bbbbaa aa equity risk rather credit risk see details possible measures taken reduce exposure groups total financial assets december gsks lower rated counterparties including active management greatest concentration credit risk billion citibank cash balances within gsks european cash pool aa billion hsbc aaaa december million cash categorised held treasuryrelated credit risk unrated subinvestment grade rated counterparties lower gsk sets global counterparty limits gsks banking bbbbaa million cash transit investment counterparties based longterm credit ratings remaining exposure concentrated overseas banks used moodys standard poors usage limits monitored local cash management investment purposes including daily million nigeria held zenith bank united bank gsk actively manages exposure credit risk reducing surplus africa million btv austria million cash balances wherever possible part gsks strategy islandsbanki iceland regionalise cash management concentrate cash centrally million bank balances deposits held much possible table sets credit exposure bbbbaa rated counterparties million held counterparties rating liquid investments cash cash bbbbaa rated counterparties includes bank balances equivalents derivatives gross asset position deposits million state bank india million derivative contract considered purpose table hdfc bank india banks used either local although isda agreements amount risk net cash management purposes local investment purposes position counterparty table e sets groups financial assets liabilities offset basis bbba aaaaaa aaaa aa bbbbaa unrated total bank balances deposits us treasury treasury repo money market funds liquidity funds government securities rd party financial derivatives total bbba aaaaaa aaaa aa bbbbaa unrated total bank balances deposits us treasury treasury repo money market funds government securities rd party financial derivatives total table restated include detail regarding counterparty credit ratings credit ratings assigned standard poors moodys respectively opinion two rating agencies differ gsk assigns lower rating two counterparty local rating agency fitch data source available ratings converted global ratings equivalent standard poors moodys using published conversion tables gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued f inancial instruments related following methods assumptions used estimate disclosures continued fair values cash cash equivalents approximates carrying gsks centrally managed cash reserves amounted billion amount december available within three months excludes billion centrally managed cash held viiv liquid investments based quoted market prices healthcare owned subsidiary group invested calculated based observable inputs case marketable centrally managed liquid assets bank deposits aaaaaa rated securities based principal amounts case non us treasury treasury repo money market funds marketable securities short repricing periods aaaaaa rated liquidity funds investments equity investments traded active wholesale retail credit risk market determined reference relevant stock exchange outside us customer accounts quoted bid price equity investments determined groups trade receivables balance reference current market value similar instruments reference discounted cash flows underlying net us line pharmaceutical companies group assets sells products small number wholesalers addition hospitals pharmacies physicians groups shortterm loans overdrafts commercial paper sales three largest wholesalers amount approximately approximates carrying amount short sales us elements global maturity instruments pharmaceuticals hiv vaccines segments december longterm loans based quoted market prices case group trade receivables due three european us medium term notes fixed rate wholesalers totalling million million borrowings level fair value measurement approximates group exposed concentration credit risk respect carrying amount case floating rate bank loans wholesalers one encounters loans financial difficulty could materially adversely affect groups financial results contingent consideration business acquisitions based present values expected future cash flows groups credit risk monitoring activities relating wholesalers include review quarterly financial information interest rate swaps foreign exchange forward contracts standard poors credit ratings development gsk internal options based present value contractual cash flows risk ratings establishment periodic review credit limits option valuation models using market sourced data exchange however group believes credit risk rates interest rates balance sheet date provision required excess normal provision bad receivables payables approximates carrying doubtful debts see note trade receivables amount fair value financial assets liabilities companyowned life insurance policies based cash table presents carrying amounts surrender value fair values groups financial assets liabilities december december lease obligations approximates carrying amount fair values financial assets liabilities included fair value investments gsk shares price would received sell asset paid transfer december employee share ownership plan liability orderly transaction market participants esop trusts held gsk shares carrying value measurement date million million fair value million million based quoted market price shares held esop trusts satisfy future exercises options awards employee incentive schemes carrying value lower cost expected proceeds shares recognised deduction reserves december gsk held treasury shares cost million million deducted retained earningsgsk annual report strategic report governance remuneration financial statements investor information financial instruments related disclosures continued carrying fair carrying fair value value value value notes cash cash equivalents e availableforsale investments liquid investments government bonds investments loans receivables trade receivables certain noncurrent assets scope ias b financial assets fair value profit loss noncurrent assets scope ias ab derivatives designated fair value profit loss ade derivatives classified held trading ias ade total financial assets financial liabilities measured amortised cost borrowings excluding obligations finance leases bonds designated hedging relationship bonds bank loans overdrafts e commercial paper total borrowings excluding obligations finance leases f obligations finance leases total borrowings trade payables provisions certain noncurrent liabilities scope ias c financial liabilities fair value profit loss trade payables provisions certain noncurrent liabilities scope ias ac derivatives designated fair value profit loss ade derivatives classified held trading ias ade total financial liabilities net financial assets financial liabilities valuation methodology used measure fair value table described categorised trade receivables noncurrent assets trade payables provisions noncurrent liabilities reconciled relevant notes pages gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued financial instruments related disclosures continued financial instruments held fair value following tables categorise groups financial assets liabilities held fair value valuation methodology applied determining fair value possible quoted prices active markets used level prices available asset liability classified level provided significant inputs valuation model used based observable market data one significant inputs valuation model based observable market data instrument classified level investments classified level tables comprise equity investments unlisted entities group entered research collaborations also investments emerging life science companies trade payables noncurrent liabilities classified level comprise contingent consideration business acquisitions level level level total december financial assets fair value availableforsale financial assets liquid investments investments financial assets fair value profit loss noncurrent assets derivatives designated fair value profit loss derivatives classified held trading ias financial liabilities fair value financial liabilities fair value profit loss trade payables noncurrent liabilities derivatives designated fair value profit loss derivatives classified held trading ias level level level total december financial assets fair value availableforsale financial assets liquid investments investments financial assets fair value profit loss noncurrent assets derivatives designated fair value profit loss derivatives classified held trading ias financial liabilities fair value financial liabilities fair value profit loss trade payables noncurrent liabilities derivatives designated fair value profit loss derivatives classified held trading ias movements year financial instruments measured using level valuation methods presented january net losses recognised income statement net gains recognised comprehensive income contingent consideration liabilities businesses acquired year payment contingent consideration liabilities additions disposals transfers level exchange december gsk annual report strategic report governance remuneration financial statements investor information financial instruments related disclosures continued included net losses million million attributable level financial instruments recognised income statement net losses million million respect financial instruments held end year net losses reported operating income million million arose remeasurement contingent consideration payable acquisition former shionogiviiv healthcare joint venture million arose remeasurement contingent consideration payable acquisition novartis vaccines business net gains million million attributable level equity investments reported comprehensive income fair value movements availableforsale investments included net losses million net gains million respect equity investments held end year financial liabilities measured using level valuation methods december include million million respect contingent consideration payable acquisition former shionogiviiv healthcare joint venture increase fair value included impacts revisions discount rate tax rate year consideration expected paid number years vary line future performance specified products also include million respect contingent consideration acquisition novartis vaccines business consideration expected paid number years vary line future performance specified products achievement certain milestone targets table shows indicative basis income statement balance sheet sensitivity reasonably possible changes key inputs valuations liabilities shionogi viiv novartis healthcare vaccines increasedecrease financial liability lossgain income statement change key inputs increase sales forecasts decrease sales forecasts increase market interest rates decrease market interest rates increase probability milestone success decrease probability milestone success b trade receivables noncurrent assets scope ias following table reconciles financial instruments within trade receivables noncurrent assets fall within scope ias relevant balance sheet amounts financial assets predominantly noninterest earning financial instruments within noncurrent assets balance include companyowned life insurance policies nonfinancial instruments include tax receivables pension surplus balances prepayments outside scope ias fair value non fair value non loans financial financial loans financial financial profit loss receivables instruments instruments total profit loss receivables instruments instruments total trade receivables note noncurrent assets note following table shows age financial assets past due provision bad doubtful debts made past due days past due days past due days past due days past due days gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued financial instruments related disclosures continued c trade payables provisions noncurrent liabilities scope ias following table reconciles financial instruments within trade payables provisions noncurrent liabilities fall within scope ias relevant balance sheet amounts financial liabilities predominantly noninterest bearing accrued wages salaries included within financial liabilities nonfinancial instruments includes payments account tax social security payables provisions arise contractual obligations deliver cash another financial asset outside scope ias fair value non fair value non financial financial financial financial profit loss liabilities instruments instruments total profit loss liabilities instruments instruments total trade payables note provisions note noncurrent liabilities note derivative financial instruments hedging programmes following table sets fair values derivatives held gsk fair value fair value assets liabilities assets liabilities net investment hedges foreign exchange contracts principal amount million million cash flow hedges foreign exchange contracts principal amount million million derivatives designated fair value profit loss foreign exchange contracts principal amount million million embedded derivatives derivatives classified held trading ias total derivative instruments analysed current noncurrent total foreign exchange contracts classified held trading ias principal amount foreign exchange contracts absolute total outstanding positions balance sheet date groups foreign exchange contracts periods months less december group held outstanding foreign exchange contracts net asset fair value million million asset less million liability december fair value million net liability million asset less million liability following announcement novartis transaction april gsk entered number forward exchange contracts protect sterling value net us dollar proceeds due group completion transaction december contracts loss position resulted liability million unrealised loss million maturity march contracts loss position million resulted realised loss million year loss partly offset gain sterling value proceeds received group divestment oncology business result favourable exchange movements since inception forward contracts overall increase net asset fair value due maturity hedge year increased hedging intercompany loans designated accounting hedges fair value movements taken income statement period offset exchange gains losses related intercompany loan balancesgsk annual report strategic report governance remuneration financial statements investor information financial instruments related disclosures continued fair value hedges december group designated fair value hedges net investment hedges year certain foreign exchange contracts designated net investment hedges respect foreign currency translation risk arising consolidation groups net investment european euro japanese yen foreign operations shown table net assets swiss franc south african rand foreign operations also designated net investment hedges although none remained outstanding december carrying value bonds includes million million designated hedging instruments net investment hedges cash flow hedges group entered forward foreign exchange contracts designated cash flow hedges foreign exchange exposure arising euro us dollar denominated coupon payments relating groups european us medium term notes addition group carries balance reserves arose prehedging fluctuations longterm interest rates pricing bonds issued prior years balance reclassified finance costs life bonds e offsetting financial assets liabilities following tables set financial assets financial liabilities subject offsetting enforceable master netting arrangements similar agreements amounts set financial assets liabilities groups balance sheet set trade receivables trade payables derivative financial assets derivative financial liabilities amounts offset balance sheet could offset certain circumstances also set gross net financial gross financial assets related financial liabilities liabilities amounts assets assets per balance set liabilities set sheet balance sheet net december trade receivables derivative financial assets cash cash equivalents trade payables derivative financial liabilities bank loans overdrafts gross net financial gross financial assets related financial liabilities liabilities amounts assets assets per balance set liabilities set sheet balance sheet net december trade receivables derivative financial assets cash cash equivalents trade payables derivative financial liabilities bank loans overdrafts gross financial assets liabilities set balance sheet primarily relate cash pooling arrangements banks amounts meet criteria offsetting balance sheet could settled net certain circumstances principally relate derivative transactions isda international swaps derivatives association agreements party option settle amounts net basis event default party gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued financial instruments related disclosures continued f debt interest rate repricing table following table sets exposure group interest rates debt including commercial paper maturity analysis fixed rate debt stated contractual maturity floating rate debt interest rate repricing dates purpose table debt defined classes borrowings obligations finance leases total debt total floating fixed rate debt less one year one two years two three years three four years four five years five ten years greater ten years total original issuance profile fixed rate interest floating rate interest total interest bearing noninterest bearing g sensitivity analysis foreign exchange interest rate sensitivity analysis prepared assumption amount net debt ratio fixed floating interest rates debt derivatives portfolio proportion financial instruments foreign currencies constant basis hedge designations december financial instruments affected market risk include cash cash equivalents borrowings trade receivables payables derivative financial instruments following analyses intended illustrate sensitivity financial instruments changes foreign exchange interest rates foreign exchange sensitivity foreign currency exposures arise translation financial assets liabilities functional currency entity holds cash cash equivalents bank loans overdrafts intercompany loans deposits receivables payables trade receivables payables derivative financial instruments hedging legal provisions activities arising acquisitions disposals assets group primarily exposed foreign exchange risk relation sterling movements us dollar euro japanese yen based groups net financial assets liabilities december weakening sterling currencies variables held constant illustrated table table excludes financial instruments expose group foreign exchange risk risk fully hedged another financial instrument increasedecrease increasedecrease income income income statement impact nonfunctional currency foreign exchange exposures cent appreciation us dollar cent cent appreciation euro cent yen appreciation yen yen equivalent depreciation currencies would cause following increasedecrease income million million million million million nil us dollar euro yen exchange rates respectivelygsk annual report strategic report governance remuneration financial statements investor information financial instruments related disclosures continued equity impact shown foreign exchange sensitivity relates derivative nonderivative financial instruments hedging groups net investments european euro japanese yen foreign operations cash flow hedges foreign exchange exposure arising euro dominated coupon payments relating groups european medium term notes increasedecrease increasedecrease equity equity equity impact nonfunctional currency foreign exchange exposures cent appreciation us dollar cent cent appreciation euro cent yen appreciation yen yen equivalent depreciation currencies would cause following increasedecrease equity nil million million million million million us dollar euro yen exchange rates respectively table presents groups sensitivity foreign exchange rates based composition net debt shown note adjusting effects foreign exchange derivatives part net debt affect future foreign currency cash flows increasedecrease increasedecrease net debt net debt impact foreign exchange movements net debt cent appreciation us dollar cent cent appreciation euro cent yen appreciation yen yen equivalent depreciation currencies would following impact net debt million million million us dollar euro yen exchange rates respectively million million million interest rate sensitivity group exposed interest rate risk outstanding borrowings investments changes interest rates affect future cash flows fair values financial instruments majority debt issued fixed interest rates changes floating rates interest significantly affect groups net interest charge although majority cash liquid investments earn floating rates interest table hypothetically shows groups sensitivity changes interest rates relation sterling us dollar euro variable rate financial assets liabilities interest rates applicable floating rate financial assets liabilities increased basis points assuming variables remained constant estimated groups finance income would increased approximately million million increase basis points movement interest rates deemed material effect equity increasedecrease increasedecrease income income income statement impact interest rate movements basis points increase sterling interest rates basis points increase us dollar interest rates basis points increase euro interest rates h contractual cash flows nonderivative financial liabilities derivative instruments following tables provides analysis anticipated contractual cash flows including interest payable groups non derivative financial liabilities undiscounted basis impact interest rate swaps excluded purpose table debt defined classes borrowings except obligations finance leases interest calculated based debt held december without taking account future issuance floating rate interest estimated using prevailing interest rate balance sheet date cash flows foreign currencies translated using spot rates december contractual cash flows respect operating lease vacant space provisions excluded table included commitments non cancellable operating leases table note commitments finance charge trade payables obligations obligations interest finance finance liabilities debt debt leases leases net debt total december due less one year one two years two three years three four years four five years five ten years greater ten years gross contractual cash flows gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued financial instruments related disclosures continued contractual cash flows nonderivative financial liabilities derivative instruments finance charge trade payables obligations obligations interest finance finance liabilities debt debt leases leases net debt total december due less one year one two years two three years three four years four five years five ten years greater ten years gross contractual cash flows increase contractual cash flows nonderivative financial liabilities billion year results principally addition consumer healthcare put option liability contingent consideration payable novartis vaccines business acquired year addition increase billion forecast future cash flows respect contingent consideration payable acquisition former shionogiviiv healthcare joint venture increases partially offset reduction billion forecast future cash flows repayment debt debt interest table provides analysis anticipated contractual cash flows groups derivative instruments excluding embedded derivatives equity options material using undiscounted cash flows cash flows foreign currencies translated using spot rates december gross cash flows foreign exchange contracts presented purposes table although practice group uses standard settlement arrangements reduce liquidity requirements instruments amounts receivable payable less one year decreased compared december due maturity foreign exchange contracts hedging us dollar proceeds novartis transaction receivables payables receivables payables due less one year one two years gross contractual cash flows employee share schemes gsk operates several employee share schemes including share value plan whereby awards granted employees acquire shares ads glaxosmithkline plc cost three year vesting period performance share plan whereby awards granted employees acquire shares ads glaxosmithkline plc cost subject achievement group specified performance targets granting restricted share awards replaced granting options employees cost schemes readily equates potential gain made employee group also operates savings related share option schemes whereby options granted employees acquire shares glaxosmithkline plc discounted price grants restricted share awards normally exercisable end three year vesting performance period awards performance share plan normally granted employees acquire shares ads glaxosmithkline plc circumstances may settled cash grants savingsrelated share option schemes normally exercisable three years saving accordance uk practice majority options savingsrelated share option schemes granted price market price ruling date grant options historical share option schemes granted market price ruling date grant total charge sharebased incentive plans million million million amount million million million arose share value plan see note employee costs detailsgsk annual report strategic report governance remuneration financial statements investor information employee share schemes continued glaxosmithkline share award schemes share value plan share value plan share awards granted certain employees cost awards vest two half three years performance criteria attached fair value awards determined based closing share price day grant deducting expected future dividend yield duration award shares weighted ads weighted number shares ads issuable number fair value number fair value january awards granted awards exercised awards cancelled december awards granted awards exercised awards cancelled december awards granted awards exercised awards cancelled december performance share plan performance share plan share awards granted directors senior executives cost percentage award vests based upon performance group defined measurement period dividends reinvested period awards granted directors members cet performance conditions based three equally weighted measures three year performance period adjusted free cash flow tsr rd new product performance awards made eligible employees performance conditions based gsks eps growth compared increase uk retail prices index three year measurement period adjusted free cash flow addition businesses element award based strategic operational business measure three year measurement period specific employees business area fair value awards determined based closing share price day grant tsr performance elements adjusted likelihood condition met assessed time grant awards made million shares weighted fair value million ads weighted fair value december outstanding awards million shares million ads share options savingsrelated options purposes valuing options savingsrelated options arrive share based payment charge blackscholes option pricing model used assumptions used model follows riskfree interest rate dividend yield volatility expected life years years years savingsrelated options grant price including discount gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued employee share schemes continued share option share option savingsrelated options outstanding schemes shares schemes ads share option schemes weighted weighted weighted number exercise number exercise number exercise price price price december range exercise prices options outstanding year end weighted average market price exercise year weighted average remaining contractual life years years years options million shares granted year savingsrelated share option scheme weighted average fair value december million savingsrelated share options exercisable share options ads options currently exercisable expire exercised july change effective exercise price outstanding options year employee share ownership plan trusts group sponsors employee share ownership plan esop trusts acquire hold shares glaxosmithkline plc satisfy awards made employee incentive plans options granted employee share option schemes trustees esop trusts purchase shares finance provided group way loans contributions treasury shares carrying value million purchased uk esop trust satisfy future awards shareholder approved performance share plan costs running esop trusts charged income statement shares held esop trusts deducted reserves amortised value proceeds receivable employees exercise transfer retained earnings trustees waived rights dividends shares held esop trusts shares held share award schemes number shares nominal value carrying value market value shares held share option schemes number shares nominal value carrying value market value post balance sheet events certain circumstances pfizer shionogi gsks partners viiv healthcare historically able require gsk acquire shareholdings price based likely valuation viiv healthcare conduct initial public offering original agreements gsk unconditional right long made subsequent distribution shareholders withhold consent exercise either put option february gsk notified pfizer shionogi irrevocably given right lead recognition liability put options groups balance sheet estimated present value liability two put options approximately billion adjustments value preferential dividends due shareholders consistent revised treatment gsk also recognise liabilities groups balance sheet future preferential dividends anticipated become payable pfizer shionogi estimated aggregate present value liability preferential dividends pfizer shionogi approximately million february viiv healthcare completed two previously announced transactions bristolmyers squibb bms viiv healthcare acquired latestage rd assets bms initial upfront payment million followed development first commercial sale milestones million tiered royalties sales viiv healthcare also acquired bmss preclinical discovery stage hiv research business upfront payment million followed development first commercial sales milestones million consideration contingent future sales performancegsk annual report strategic report governance remuneration financial statements investor information principal group companies following represent principal subsidiaries countries incorporation group december equity share capital entities wholly owned group except percentage interest shown otherwise companies incorporated principal country operation except stated england us glaxo group limited block drug company inc glaxo operations uk limited corixa corporation glaxosmithkline capital plc glaxosmithkline capital inc glaxosmithkline consumer healthcare holdings limited glaxosmithkline consumer healthcare lp glaxosmithkline consumer healthcare uk trading limited glaxosmithkline holdings americas inc glaxosmithkline export limited glaxosmithkline llc glaxosmithkline finance plc human genome sciences inc glaxosmithkline holdings limited novartis consumer health inc glaxosmithkline research development limited stiefel laboratories inc glaxosmithkline services unlimited viiv healthcare company glaxosmithkline uk limited setfirst limited smithkline beecham limited viiv healthcare limited viiv healthcare uk limited europe others glaxosmithkline biologicals sa belgium glaxosmithkline argentina sa argentina glaxosmithkline pharmaceuticals sa belgium glaxosmithkline australia pty ltd australia glaxosmithkline biologicals sas france glaxosmithkline brasil limitada brazil groupe glaxosmithkline sas france glaxosmithkline inc canada laboratoire glaxosmithkline sas france id biomedical corporation quebec canada viiv healthcare sas france glaxosmithkline china investment co ltd china glaxosmithkline consumer healthcare gmbh co kg glaxosmithkline limited china germany glaxosmithkline pharmaceuticals suzhou limited china glaxosmithkline gmbh co kg germany sinoamerican tianjin smith kline french laboratories ltd china novartis consumer health gmbh germany glaxosmithkline consumer healthcare limited india glaxosmithkline consumer healthcare spa italy glaxosmithkline pharmaceuticals limited india glaxosmithkline spa italy glaxosmithkline consumer healthcare japan kk japan glaxosmithkline bv netherlands glaxosmithkline kk japan glaxosmithkline pharmaceuticals sa poland glaxosmithkline mexico sa de cv mexico gsk services spzoo poland glaxosmithkline pakistan limited pakistan glaxosmithkline trading services limited republic ireland glaxo wellcome manufacturing pte ltd singapore glaxosmithkline sa spain glaxosmithkline pte ltd singapore novartis consumer health sa switzerland glaxosmithkline korea limited south korea glaxosmithkline llaclari sanayi ticaret turkey exempt provisions section companies act ireland accordance exemptions noted section act subsidiaries disclosed pages exempt provisions also consolidated group financial statements directly held wholly owned subsidiary glaxosmithkline plc subsidiaries associates listed principally affect figures groups financial statements glaxosmithkline capital inc glaxosmithkline capital plc whollyowned finance subsidiary company company fully unconditionally guaranteed securities issued glaxosmithkline capital inc glaxosmithkline capital plc see pages complete list subsidiary undertakings associates joint ventures form part financial statements gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued legal proceedings intellectual property advair hfa flovent hfa ventolin hfa group involved significant legal administrative september mylan pharmaceuticals mylan filed proceedings principally product liability intellectual property petition inter partes review ipr united states tax antitrust governmental investigations well related patent trademark office uspto seeking invalidate private litigation group makes provision proceedings patent covering surfactantfree formulation use regular basis summarised note accounting principles hydrofluoroalkane hfa metered dose inhalers advair flovent policies note provisions group may ventolin group exclusively licenses patent become involved significant legal proceedings respect first right enforce defend patent possible make reliable estimate expected expires december listed orange book financial effect could result ultimate resolution group filed patent owners preliminary response opposing proceedings cases appropriate disclosures institution ipr january decision institution cases would included provision would made due april patent mylan challenged respect legal proceedings described one number patents covering advair flovent ventolin provision made group use hfa metered dose inhalers unable make reliable estimate expected financial men b vaccinesbexsero effect stage group believe information following acquisition novartis vaccine business amount sought plaintiffs known would group taken litigation originally filed novartis meaningful respect legal proceedings due pfizer inc pfizer uk italy united states related number factors including limited stage meningococcal b men b vaccines february proceedings entitlement parties appeal decision novartis filed suit pfizer uk high court patents clarity theories liability damages governing law court declaration european patent owned pfizer intellectual property claims include challenges validity infringed bexsero invalid group assumed enforceability groups patents various products responsibility matter april pfizer filed processes well assertions noninfringement statement defence may counterclaimed patents loss cases could result loss patent infringement trial matter commenced march protection product issue consequences february novartis filed suit pfizer loss could significant decrease sales product court rome declaration european patent owned could materially affect future results operations group pfizer infringed bexsero invalid group legal expenses incurred provisions related legal claims assumed responsibility matter group also charged selling general administration costs provisions prosecuting lawsuit pfizer originally filed novartis made taking appropriate legal specialist declaration european patent issued pfizer related advice outflow resources considered probable meningitis b vaccines infringed bexsero reliable estimate made likely outcome february novartis filed suit pfizer dispute certain product liability claims group make us district court district new jersey patent provision sufficient history claims made infringement complaint asserts six patents pfizer settlements enable management make reliable estimate alleging pfizers sale trumenba infringes patents provision required cover unasserted claims december trumenba indicated active immunization prevent invasive groups aggregate provision legal disputes disease caused neisseria meningitidis serogroup b including tax matters described note taxation april group filed first amended complaint billion ultimate liability legal claims may vary pfizer reasserting six patents originally asserted novartis amounts provided dependent upon outcome litigation also asserting one additional recentlygranted patent proceedings investigations possible settlement negotiations infringement contentions served group october groups position could change time therefore pfizer served noninfringement invalidity contentions assurance losses result december group responded pfizers invalidity outcome legal proceedings exceed material contentions february dates set amount amount provisions reported groups summary judgment motions trial financial statements happen could material adverse impact results operations group reporting period judgments incurred settlements entered significant matters described belowgsk annual report strategic report governance remuneration financial statements investor information legal proceedings continued may mylan filed action uk patents court alleging patent covering combination lamivudine coreg cr abacavir kivexa invalid also allege spc based mylan sent paragraph iv certification dated august upon patent invalid first marketing group flamel ireland ltd flamel stating authorisation combination alleging instead prior submitted abbreviated new drug application anda approval trizivir first trial scheduled may us food drug administration fda seeking approval addition mylan challenged combination patent generic version coreg cr notice asserted patents associated spc france italy portugal trial dates listed orange book coreg cr either invalid set jurisdictions infringed mylans product october flamel filed lexiva civil complaint us district court northern district west virginia alleging mylans product infringes flamels december lupin filed petition uspto orange booklisted extended release formulation patent ipr alleging patent covering active ingredient expires march group exclusive licensee lexiva invalid viiv healthcare filed patent owners preliminary patent coreg cr mylan answered december response opposing petition april july asserting flamels patent invalid infringed mylan uspto granted inpart denied inpart petition also filed third party complaint group requesting ipr significantly uspto denied petition basic declaration groups patent carvedilol phosphate compound claims covering lexiva granting petition hemihydrate invalid infringed scheduling conference claims patent july lupin requested set may reconsideration decision initiate review claims specifically covering lexiva october viiv healthcare epzicomkivexatrizivir requested adverse judgment claims upon review february viiv healthcare received notice lupin granted effectively cancelling claims november limited lupin filed anda containing paragraph iv uspto denied lupins motion reconsideration certification epzicom alleging three patents listed november uspto cancelled requested claims orange book epzicom either invalid unenforceable terminated ipr leaving claims covering lexiva intact infringed viiv healthcare filed suit lupin march february lupin filed new petition ipr alleging infringement patent covering remaining claims patent owners preliminary response due combination lamivudine abacavir patent covering may hemisulfate salt abacavir viiv healthcare settled lupin product liability june case dismissed august preclinical clinical trials conducted june apotex filed petition requesting inter partes development potential products determine safety review ipr combination patent covering epzicom efficacy products use humans following approval trizivir uspto granted petition december regulatory bodies notwithstanding efforts drugs initiated ipr january teva filed petition vaccines introduced marketplace unanticipated safety uspto join proceeding viiv healthcare filed issues may become claimed evident opposition tevas joinder motion april tevas group currently defendant number product liability motion join denied june july lawsuits related groups pharmaceutical vaccine viiv healthcare apotex settled case uspto consumer healthcare products significant terminated ipr august matters described teva canada apotex filed notices allegation group able make reliable estimate challenging patents kivexa lamivudineabacavir listed expected financial effect matters discussed category canadian patent register viiv healthcare filed suit included provision appropriate matters infringement teva september provision legal disputes matters patents covering abacavir hemisulfate combination group made provision also noted note lamivudine abacavir viiv healthcare filed suit apotex provisions january patent covering abacavir hemisulfate march infringement patent covering combination lamivudine abacavir viiv healthcare settled case teva april apotex july teva also challenged claims combination patent covering kivexa germany france italy united kingdom combination patent expires across europe addition viiv healthcare corresponding supplementary protection certificate spc kivexa expire late teva also challenged validity spc viiv healthcare reached settlement teva may litigation terminated gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued legal proceedings continued acts violence february six pending matters concerning avandia allegations patients took paroxetine paxil committed group named product liability lawsuits behalf attempted commit suicide acts violence trial one individuals asserting personal injury claims arising use cases scheduled september avandia federal cases filed group part multidistrict litigation proceeding pending us district court discontinuation eastern district pennsylvania mdl court cases uk late due poor prospects success also filed number state courts public funding seroxat claimants alleged withdrawal reactions ceased majority claimants discontinued february group reached agreements settle claims claimants appealed decision substantial majority federal state cases pending special cases review panel special cases review us fifteen purported class actions avandia pending panel denied appeal public funding certificate canada discharged legal aid agency january one four purported class actions seeking economic damages hundred three cases remain subject behalf third party payers tpps asserting claims arising hearing held december judgement various state federal laws including racketeer hearing published february allowed influenced corrupt organizations act rico state unfair remaining claims continue court management trade practices andor consumer protection laws mdl court case management conference expected summer consolidated four actions pretrial proceedings zofran appointed plaintiffs steering committee group filing plaintiffs allege children suffered birth defects result petition writ certiorari united states supreme court mothers ingestion zofran andor generic ondansetron seeking review third circuits decision tpps state pregnancyrelated nausea vomiting plaintiffs assert valid cause action group sold zofran knowing unsafe pregnant women sole remaining consumer class action brought behalf failed warn risks illegally marketed zofran offlabel missouri residents dismissed mdl court third use pregnant women february group circuit affirmed mdls decision dismissing action defendant personal injury lawsuits brought behalf result consumer class actions remain individual plaintiffs us federal cases part multidistrict litigation proceeding mdl district seroxatpaxil paxil cr massachusetts group also defendant four proposed group received numerous lawsuits claims alleging class actions canada early stages class use paxil paroxetine caused variety injuries certification issues cases yet addressed lawsuits contain one following january mdl court issued order denying allegations use paxil pregnancy caused groups motion dismiss claims grounds congenital malformations persistent pulmonary hypertension preempted federal law group may renew motion ii paxil treatment caused patients commit suicidal later date mdl continues monthly status conferences violent acts iii group failed warn patients issues sufficiency pleadings could experience certain symptoms discontinuing paxil scope discovery addressed treatment pregnancy group reached agreements settle majority us claims relating use paxil pregnancy february number claims related use pregnancy still pending various courts us matters dismissed without payment currently twelve trials scheduled two proposed one certified class actions canada action certified national class action british columbia relates cardiovascular defects appeal certification decision dismissed october case scheduled tried october gsk annual report strategic report governance remuneration financial statements investor information legal proceedings average wholesale price continued state attorneys general wisconsin illinois filed suit sales marketing regulation group number pharmaceutical group able make reliable estimate companies claiming damages restitution due average expected financial effect matters discussed category wholesale price awp andor wholesale acquisition cost wac included provision matters provision price reporting pharmaceutical products covered states legal disputes except noted matters medicaid programmes cases allege group group made provision also noted note reported caused reported false awp wac prices provisions turn allegedly caused state medicaid agencies secdoj sfo anticorruption enquiries reimburse providers money covered medicines us securities exchange commission sec us agencies intended states sought recovery behalf department justice doj initiated industrywide enquiry states payers cases behalf instate whether pharmaceutical companies may engaged patients consumers group reached settlement violations us foreign corrupt practices act fcpa relating state wisconsin resolving claims matter sale pharmaceuticals including argentina brazil illinois case ongoing trial date yet set canada china germany italy poland russia saudi arabia cidra thirdparty payer litigation group one companies asked respond july number major us healthcare insurers enquiry cooperating sec doj filed suit group philadelphia pennsylvania group informed doj sec investigation county court common pleas seeking compensation china operations chinese government initiated reimbursements made medicines manufactured outcome investigation group also groups former cidra plant puerto rico insurers briefed doj sec regarding countries issues claim group knowingly illegally marketed sold group also advised uk serious fraud office sfo adulterated drugs manufactured conditions noncompliant regarding investigation china operations chinese cgmp current good manufacturing practices government outcome investigation sfo thirdparty insurers unlawfully induced pay requested information group commercial suit alleges us federal various state law causes operations number countries may action sfo informed group formally opened criminal case stayed pending decision us court investigation groups practices group responding appeals third circuit overlapping potentially sfos requests group unable make reliable dispositive issue groups thirdparty payer litigation estimate expected financial effect investigations regarding avandia result third circuits denial provision made groups petition judge litigation lifted stay us vaccines subpoena parties filed supplemental briefings groups february group received subpoena motion dismiss await ruling court group us attorneys office southern district new york made provision matter requesting documents relating groups vaccines business antitrustcompetition group responding subpoena group unable group able make reliable estimate make reliable estimate expected financial effect expected financial effect matters discussed category matter provision made included provision matters provision us subpoena relating imitrex amerge legal disputes except noted matters march group received subpoena us group made provision also noted note attorneys office southern district new york requesting provisions documents relating groups us contracts imitrex uk competition markets authority investigation amerge group responding subpoena group february uk competition markets authority unable make reliable estimate expected financial effect cma issued decision fining group two matter provision made pharmaceutical companies infringement competition avandia act cma imposed fine million group group defending action county santa clara well fines totalling million companies california brought californias consumer relates agreements settle patent disputes protection laws seeking civil penalties restitution result group potential suppliers generic paroxetine formulations groups marketing avandia group filed number entered group terminated dispositive motions pending mdl court agreements issue group believes strong county santa clara recently filed motion dismiss arguments defend actions currently examining action federal court lack federal jurisdiction cmas finding legal advisors view appeal motion briefed argued parties competition appeal tribunal fine overturned substantially reduced accordingly provision made matter gsk annual report strategic report governance remuneration financial statements investor information legal proceedings continued addition private litigant suits december us securities exchange commission sec filed formal lamictal complaint stiefel charles stiefel us district purported classes direct indirect purchasers filed suit court district florida alleging stiefel us district court district new jersey alleging principals violated federal securities laws inducing stiefel group teva pharmaceuticals unlawfully conspired delay employees sell shares employee stock plan back generic competition lamictal resulting overcharges company greatly undervalued price without disclosing purchasers entering allegedly anticompetitive reverse employees company sold case payment settlement resolve patent infringement litigation stayed returned active status early summer separate count accuses group monopolising market november court entered orders asking june court appeals reversed trial courts parties rebrief summary judgment motions setting decision dismiss case remanded action back pretrial conference august group made trial court october trial court denied groups provision stiefel litigation motion stay set schedule early dispositive motions environmental matters discovery group filed petition certiorari united states supreme court february group notified potential responsibility relating past operations past waste disposal practices certain wellbutrin xl sites primarily us matters subject plaintiffs claimed antitrust injury related allegedly sham patent litigation including proceedings initiated us federal state litigation filed biovail generic companies pursuing governments waste disposal site remediation costs tort andas generic wellbutrin xl group named actions brought private parties party plaintiff two patent infringement actions later withdrew matters group party remaining group advised may responsible party two patent infringement actions relating wellbutrin xl plaintiffs approximately sites appear national alleged conspiracy delay generic approval existed priority list created comprehensive environmental biovail group court granted summary response compensation liability act superfund judgment favour group claims proceedings seek require operators hazardous waste facilities transporters waste sites generators sole remaining claim related plaintiffs allegations hazardous waste disposed sites clean sites group entered anticompetitive reverse payment settlement reimburse us government cleanup costs resolve patent infringement litigation court granted instances group involved alleged generator summary judgment favour group claims hazardous waste matter currently pending appeal us court appeals third circuit court although superfund provides defendants jointly severally liable cleanup costs proceedings commercial corporate frequently resolved basis nature quantity group able make reliable estimate waste disposed generator site groups expected financial effect matters discussed proportionate liability cleanup costs substantially category included provision respect matters determined sites referred provision legal disputes set note provisions groups potential liability varies greatly site site cost investigation study remediation securitieserisa class actions stiefel sites could time significant group routinely accrues currently three outstanding lawsuits brought former amounts related share liability matters stiefel laboratories inc stiefel employees alleging stiefel officers directors violated us employee retirement income security act erisa federal state securities laws inducing stiefel employees sell shares employee stock plan back stiefel greatly undervalued price without disclosing employees stiefel sold group fried case currently appeal us court appeals eleventh circuit oral argument taken place february stiefel complete defence verdict matter jury trial federal court florida october plaintiff appealed trial second florida case stayed pending resolution fried matter discovery also continues case pending new york federal courtgsk annual report strategic report governance remuneration financial statements investor information financial statements glaxosmithkline plc prepared uk gaap including frs reduced disclosure framework directors statement responsibilities disclosure information auditors relation companys financial directors office date annual report confirmed statements far aware relevant audit information directors responsible preparing parent company companys auditors unaware glaxosmithkline plc financial statements remuneration taken steps ought report accordance applicable law regulations taken director make aware uk company law requires directors prepare financial relevant audit information establish companys statements financial year law directors auditors aware information elected prepare parent company financial statements confirmation given interpreted accordance accordance united kingdom accounting standards provisions section companies act applicable law united kingdom generally accepted accounting practice company law directors must approve going concern basis parent company financial statements unless satisfied assessed principal risks matters considered give true fair view assets liabilities financial connection viability statement directors considered position profit loss company period appropriate adopt going concern basis accounting preparing financial statements preparing financial statements directors required uk corporate governance code board considers glaxosmithkline plc applies select suitable accounting policies apply principles complies provisions uk corporate consistently governance code maintained financial reporting council make judgements accounting estimates reasonable described corporate governance section pages prudent board considers annual report taken whole fair balanced understandable provides state regard parent company financial statements information necessary shareholders assess groups applicable uk accounting standards followed position performance business model strategy subject material departures disclosed explained parent company financial statements required financial conduct authoritys listing rules auditors considered directors statement prepare financial statements going concern basis compliance relation points uk corporate unless inappropriate presume group continue governance code specified review business directors responsible keeping adequate accounting records sufficient show explain companys transactions disclose reasonable accuracy time financial position company enable ensure philip hampton parent company financial statements remuneration report chairman comply companies act also responsible march safeguarding assets company hence taking reasonable steps prevention detection fraud irregularities parent company financial statements year ended december comprising balance sheet year ended december supporting notes set pages report responsibilities auditors relation parent company financial statements set independent auditors report financial statements year ended december included annual report published printed form made available website directors responsible maintenance integrity annual report website accordance uk legislation governing preparation dissemination financial statements access website available outside uk comparable legislation may different strategic report risk sections annual report represent management report include fair review development performance business position company group taken whole together description principal risks uncertainties faces gsk annual report strategic report governance remuneration financial statements investor information independent auditors report members glaxosmithkline plc report parent company financial companies act reporting statements companies act required report opinion certain disclosures directors remuneration opinion specified law made exceptions report opinion glaxosmithkline plcs parent company financial arising responsibility statements financial statements give true fair view state parent companys responsibilities financial statements affairs december audit properly prepared accordance united kingdom generally accepted accounting practice responsibilities directors prepared accordance requirements explained fully directors statement companies act responsibilities set directors responsible preparation financial statements audited satisfied give true fair view financial statements included within annual report comprise responsibility audit express opinion financial statements accordance applicable law isas company balance sheet december uk ireland standards require us comply company statement changes equity year auditing practices boards ethical standards auditors ended notes financial statements include summary report including opinions prepared significant accounting policies explanatory information companys members body accordance chapter part companies act purpose certain required disclosures presented elsewhere giving opinions accept assume annual report rather notes financial responsibility purpose person statements crossreferenced financial report shown whose hands may come save statements identified audited financial reporting expressly agreed prior consent writing framework applied preparation financial statements applicable law united kingdom accounting audit financial statements involves standards united kingdom generally accepted accounting conducted audit accordance isas uk ireland practice including frs reduced disclosure framework audit involves obtaining evidence amounts disclosures financial statements sufficient give reasonable assurance required reporting financial statements free material misstatement whether caused fraud error includes assessment consistency information companies act opinion whether accounting policies appropriate parent opinion information given strategic report companys circumstances consistently applied directors report financial year adequately disclosed financial statements prepared consistent reasonableness significant accounting estimates made financial statements directors isas uk ireland reporting overall presentation financial statements international standards auditing uk ireland primarily focus work areas assessing directors isas uk ireland required report judgements available evidence forming judgements opinion information annual report evaluating disclosures financial statements materially inconsistent information audited financial statements test examine information using sampling apparently materially incorrect based materially auditing techniques extent consider necessary inconsistent knowledge company acquired provide reasonable basis us draw conclusions obtain course performing audit audit evidence testing effectiveness controls otherwise misleading substantive procedures combination exceptions report arising responsibility addition read financial nonfinancial information annual report identify material inconsistencies adequacy accounting records information audited financial statements identify information explanations received apparently materially incorrect based materially inconsistent companies act required report knowledge acquired us course performing opinion audit become aware apparent material misstatements received information explanations inconsistencies consider implications report require audit adequate accounting records kept parent matter company returns adequate audit reported separately group financial statements received branches visited us glaxosmithkline plc year ended december financial statements part directors remuneration report audited agreement company passed resolution accordance section accounting records returns companies act senior statutory auditors name stated exceptions report arising responsibility directors remuneration directors remuneration report companies act opinion pricewaterhousecoopers llp opinion part directors remuneration report chartered accountants statutory auditors audited properly prepared accordance london companies act march gsk annual report strategic report governance remuneration financial statements investor information company balance sheet uk gaap including frs reduced disclosure framework december notes fixed assets investments f current assets trade receivables g cash bank total current assets trade payables h net current assets total assets less current liabilities provisions noncurrent liabilities j net assets capital reserves called share capital k share premium account k reserves retained earnings l equity shareholders funds financial statements pages approved board march signed behalf philip hampton chairman glaxosmithkline plc registered number company statement changes equity share share premium retained capital account reserves earnings total january profit attributable shareholders dividends shareholders shares issued employee share schemes shares purchased held treasury shares treasury shares transferred esot held subsidiary company december profit attributable shareholders dividends shareholders shares issued employee share schemes december gsk annual report strategic report governance remuneration financial statements investor information notes company balance sheet b accounting policies uk gaap including frs reduced foreign currency transactions disclosure framework foreign currency transactions recorded exchange rate ruling date transaction foreign currency assets presentation financial statements liabilities translated rates exchange ruling balance sheet date description business glaxosmithkline plc parent company gsk major global dividends paid received healthcare group engaged creation discovery dividends paid received included financial development manufacture marketing pharmaceutical statements period related dividends products including vaccines overthecounter otc medicines actually paid received healthrelated consumer products expenditure preparation financial statements expenditure recognised respect goods services financial statements prepared using historical received supplied accordance contractual terms cost convention going concern basis prepared provision made obligation exists future liability accordance financial reporting standard reduced respect past event amount obligation disclosure framework uk accounting presentation reliably estimated december comparative figures december investments subsidiary companies comparative figures required changing investments subsidiary companies held cost less result current year adoption frs provision impairment permitted section companies act impairment investments income statement company presented annual carrying value investments reviewed impairment report indication investment might impaired company included group financial statements provision resulting impairment review charged glaxosmithkline plc publicly available income statement year concerned following exemptions requirements ifrs share based payments applied preparation financial statements issuance company subsidiaries grant accordance frs companys shares represents additional capital contributions company subsidiaries additional investment paragraphs b ifrs sharebased subsidiaries results corresponding increase shareholders payment equity additional capital contribution based fair value ifrs financial instruments disclosures grant issued allocated underlying grants vesting paragraphs ifrs fair value measurement period paragraph ias presentation financial statements taxation comparative information requirements respect current tax provided amounts expected paid paragraph iv ias applying tax rates enacted substantively paragraphs f b enacted balance sheet date ias presentation financial statements deferred tax provided full using liability method ias statement cash flows temporary differences arising tax bases assets liabilities carrying amounts financial statements paragraph ias accounting policies changes deferred tax assets recognised extent accounting estimates errors considered recoverable future taxable profits paragraph ias related party disclosures requirement ias disclose related party deferred tax measured average tax rates expected transactions entered two members apply periods temporary differences group expected realised settled deferred tax liabilities accounting convention standards assets discounted balance sheet prepared using historical financial guarantees cost convention complies applicable uk accounting liabilities relating guarantees issued company behalf standards subsidiaries initially recognised fair value accounting principles policies amortised life guarantee preparation balance sheet conformity generally legal disputes accepted accounting principles requires management make company provides anticipated settlement costs estimates assumptions affect reported amounts outflow resources considered probable reliable assets liabilities disclosure contingent assets estimate may made likely outcome dispute liabilities date balance sheet actual amounts could legal expenses arising claims company differ estimates december provisions legal disputes balance sheet prepared accordance amounted million million companys accounting policies approved board described note bgsk annual report strategic report governance remuneration financial statements investor information notes company balance sheet uk gaap including frs reduced disclosure framework continued c key accounting judgements estimates contingent consideration contingent consideration included consideration legal disputes payable business combination recorded fair value company provides anticipated settlement costs date acquisition fair values generally based outflow resources considered probable reliable riskadjusted future cash flows discounted using appropriate estimate may made likely outcome dispute interest rates december liability contingent legal expenses arising claims company consideration amounted million acquisition estimates take account specific circumstances vaccines business novartis dispute relevant external advice inherently judgmental could change substantially time new facts assumptions relating future cash flows discount rates emerge dispute progresses based business forecasts therefore inherently judgemental future events could cause assumptions used companys directors taken legal advice projections change consequent adverse effect established provisions taking account relevant facts future results company circumstances matter accordance accounting requirements december provisions perating profit legal disputes amounted million fee relating audit million company charged operating profit ultimate liability legal claims may vary amounts e dividends provided dependent upon outcome litigation proceedings investigations possible settlement negotiations directors declared four interim dividends resulting position could change time therefore dividend year pence line dividend assurance losses result outcome legal special dividend pence also declared proceedings exceed amount provisions reported year details see note group financial companys financial statements material amount statements dividends f fixed assets investments shares glaxosmithkline services unlimited shares glaxosmithkline holdings one limited shares glaxosmithkline holdings limited shares glaxosmithkline mercury limited capital contribution relating share based payments contribution relating contingent consideration g trade receivables amounts due within one year uk corporation tax recoverable receivables deferred tax recoverable amounts owed group undertakings amounts due one year amounts due group undertakings deferred tax balance million reported reversed arose result recognition deferred tax asset tax losses expected used following completion novartis transaction march gsk annual report strategic report governance remuneration financial statements investor information notes company balance sheet uk gaap including frs reduced disclosure framework continued h trade payables amounts due within one year creditors contingent consideration payable amounts owed group undertakings company guaranteed debt issued subsidiary companies one receives annual fee aggregate company outstanding guarantees billion debt instruments amounts due subsidiary company relation guarantee fees recovered life bonds disclosed within trade receivables see note g provisions january charge year utilised movements december provisions relate number legal disputes company currently involved j noncurrent liabilities contingent consideration payable contingent consideration relates amount payable acquisition novartis vaccines portfolio current year liability included within trade payables k called share capital share premium account share premium ordinary shares p account number share capital authorised december december share capital issued fully paid january issued employee share schemes december issued employee share schemes december december december number shares issuable outstanding options number unissued shares option december issued share capital shares held esop trusts shares held treasury shares shares free issue issued shares fully paid nominal carrying market values shares held esop trusts disclosed note employee share schemes l reserves profit glaxosmithkline plc year million million dividends million million gave retained loss million million profit treasury shares purchased year million treasury shares transferred subsidiary million december retained earnings stood million million million unrealised million group companies see pages complete list subsidiaries associates joint ventures form part financial statementsgsk annual report strategic report governance remuneration financial statements investor information investor information section quarterly trend pharmaceuticals vaccines turnover five year record product development pipeline products competition intellectual property risk factors share capital share price dividends financial calendar annual general meeting tax information shareholders shareholder services contacts us law regulation group companies glossary terms gsk annual report gsk annual report strategic report governance remuneration financial statements investor information financial record quarterly trend unaudited analysis group results provided quarter sterling financial year income statement total months q reported proforma reported proforma cer cer cer cer turnover pharmaceuticals vaccines consumer healthcare corporate unallocated turnover total turnover cost sales selling general administration research development royalty income operating income operating profitloss net finance costs profitloss disposal interest associates joint ventures share tax profitslosses associates joint ventures profitloss taxation taxation tax rate profitloss taxation period lossprofit attributable noncontrolling interests profitloss attributable shareholders basic earningsloss per share pence p diluted earningsloss per share pence p income statement core total turnover cost sales selling general administration research development royalty income operating profit net finance costs share tax lossesprofits associates joint ventures profit taxation taxation tax rate profit taxation period profit attributable noncontrolling interests profit attributable shareholders adjusted earnings per share pence p p calculation core results described gsk annual report strategic report governance remuneration financial statements investor information q q q reported proforma reported proforma reported proforma cer cer cer cer cer cer p p p p p p p p p gsk annual report strategic report governance remuneration financial statements investor information financial record continued pharmaceuticals turnover therapeutic area total us europe international restated growth growth growth growth therapeutic areamajor products cer cer cer cer respiratory anoro ellipta avamysveramyst flixotideflovent relvarbreo ellipta seretideadvair ventolin cardiovascular metabolic urology cvmu avodart immunoinflammation benlysta oncology pharmaceuticals dermatology augmentin antibacterials rare diseases innovative pharmaceuticals established products coreg hepsera imigranimitrex lamictal lovaza requip serevent seroxatpaxil valtrex zeffix global pharmaceuticals hiv combivir epzicomkivexa lexivatelzir selzentry tivicay triumeq trizivir pharmaceuticals vaccines turnover total us europe international restated growth growth growth growth major products cer cer cer cer bexsero boostrix cervarix fluarix flulaval hepatitis infanrix pediarix menveo rabipurrabavert rotarix synflorix vaccines cer represents growth constant exchange rates represents growth actual exchange ratesgsk annual report strategic report governance remuneration financial statements investor information pharmaceuticals turnover therapeutic area total us europe international restated restated growth restated growth restated growth restated growth therapeutic areamajor products cer cer cer cer respiratory avamysveramyst flixotideflovent relvarbreo ellipta seretideadvair ventolin cardiovascular metabolic urology cvmu avodart immunoinflammation benlysta oncology pharmaceuticals dermatology augmentin antibacterials rare diseases innovative pharmaceuticals established products coreg hepsera imigranimitrex lamictal lovaza requip serevent seroxatpaxil valtrex zeffix global pharmaceuticals hiv combivir epzicomkivexa lexivatelzir selzentry tivicay trizivir pharmaceuticals vaccines turnover total us europe international restated growth growth growth growth major products cer cer cer cer boostrix cervarix fluarix flulaval hepatitis infanrix pediarix rotarix synflorix vaccines cer represents growth constant exchange rates represents growth actual exchange rates gsk annual report strategic report governance remuneration financial statements investor information financial record continued five year record record financial performance provided analysed accordance current reporting practice information included five year record prepared accordance ifrs adopted european union also ifrs issued international accounting standards board effect january gsk reported turnover four segments global pharmaceuticals hiv vaccines consumer healthcare comparative turnover information four years restated accordingly comparative information also restated reflect current breakdown group geographic region comparative information also reported including effect divestments completed information reported excluding effects divestments restated restated restated restated group turnover geographic region us europe international divestments total turnover including divestments group turnover segment global pharmaceuticals hiv pharmaceuticals vaccines consumer healthcare segment turnover corporate unallocated turnover divestments completed pharmaceuticals turnover therapeutic area respiratory cardiovascular metabolic urogenital immunoinflammation oncology pharmaceuticals established products global pharmaceuticals hiv pharmaceuticals vaccine turnover consumer healthcare turnover wellness oral care nutrition skin health gsk annual report strategic report governance remuneration financial statements investor information five year record continued financial results total turnover operating profit profit taxation profit taxation pence pence pence pence pence basic earnings per share diluted earnings per share millions millions millions millions millions weighted average number shares issue basic diluted financial results core turnover operating profit profit taxation profit taxation pence pence pence pence pence core earnings per share p return capital employed return capital employed calculated total profit taxation percentage average net assets year gsk annual report strategic report governance remuneration financial statements investor information financial record continued five year record continued balance sheet noncurrent assets current assets total assets current liabilities noncurrent liabilities total liabilities net assets shareholders equity noncontrolling interests total equity number employees us europe international manufacturing selling administration research development geographic distribution employees table based location gsks subsidiary companies number employees number permanent employed staff end financial period excludes employees employed managed gsk contract basis exchange rates guide holders ads following tables set periods indicated information exchange rate us dollars sterling reported bank england pm buying rate average average rate year calculated average pm buying rates day year mar feb jan dec nov oct sep high low pm buying rate march usgsk annual report strategic report governance remuneration financial statements investor information pipeline products competition pharmaceuticals vaccines product development pipeline key inlicence alliance relationship third party month first submission viiv healthcare global specialist hiv company gsk bla biological licence application pfizer inc shionogi limited shareholders responsible maa marketing authorisation application europe developing delivering hiv medicines nda new drug application us also developed indications another therapeutic area phase evaluation clinical pharmacology usually conducted volunteers optionbased alliance ionis pharmaceuticals phase ii determination dose initial evaluation efficacy conducted optionbased alliance adaptimmune ltd small number patients optionbased alliance oncomed pharmaceuticals phase iii large comparative study compound versus placebo andor established optionbased alliance telethon ospedale san raffaele treatment patients establish clinical benefit safety optionbased alliance valneva maa ndabla regulatory review milestones shown table achieved future filing dates included list achieved regulatory review milestones compound type indication phase maa ndabla hiv infectious diseases dolutegravir hiv integrase inhibitor nonnucleoside hiv infections two drug maintenance regimen iii rilpivirine reverse transcriptase inhibitor nnrti hiv attachment inhibitor hiv infections iii tafenoquine aminoquinoline plasmodium vivax malaria iii relenza iv neuraminidase inhibitor iv influenza iii cabotegravir hiv integrase inhibitor longacting hiv preexposure prophylaxis ii parenteral formulation cabotegravir hiv integrase inhibitor nonnucleoside hiv infections ii rilpivirine reverse transcriptase inhibitor nnrti longacting parenteral formulations gepotidacin type topoisomerase inhibitor bacterial infections ii danirixin chemokine cxc motif receptor influenza ii cxcr antagonist hiv maturation inhibitor hiv infections ii hiv maturation inhibitor hiv infections hbv antisense oligonucleotide hepatitis b hbv lica antisense oligonucleotide hepatitis b nonstructural protein b nsb hepatitis c polymerase inhibitor respiratory fluticasone furoate glucocorticoid agonist longacting beta chronic obstructive pulmonary disease copd iii vilanterol agonist muscarinic acetylcholine antagonist umeclidinium mepolizumab interleukin il monoclonal antibody copd iii muscarinic acetylcholine antagonist beta copd ii agonist maba muscarinic acetylcholine antagonist beta copd ii fluticasone furoate agonist maba glucocorticoid agonist tolllike receptor tlr agonist asthma ii phosphatidylinositol kinase delta pikcid asthma copd ii inhibitor recombinant human angiotensin converting acute lung injury ii enzyme rhace tumour necrosis factor receptor tnfr acute lung injury ii domain antibody danirixin chemokine cxc motif receptor cxcr copd ii antagonist fluticasone furoate glucocorticoid agonist longacting beta asthma ii vilanterol agonist muscarinic acetylcholine umeclidinium antagonist losmapimod p kinase inhibitor copd ii mepolizumab interleukin il monoclonal antibody nasal polyposis ii mepolizumab interleukin il monoclonal antibody hypereosinophilic syndrome ii sirukumab interleukin il human monoclonal antibody severe asthma ii alpha v beta integrin antagonist idiopathic pulmonary fibrosis gsk annual report strategic report governance remuneration financial statements investor information pipeline products competition continued pharmaceuticals vaccines product development pipeline continued achieved regulatory review milestones compound type indication phase maa ndabla oncology nyeso autologous engineered sarcoma multiple myeloma nonsmall cell lung ii tcrt cells engineered tcr cancer melanoma ovarian cancer tarextumab notch monoclonal antibody small cell lung cancer ii brontictuzumab notch monoclonal antibody solid tumours haematological malignancies ox agonist monoclonal antibody solid tumours haematological malignancies lysinespecific demethylase lsd acute myeloid leukemia small cell lung cancer inhibitor beta cell maturation antigen antibody multiple myeloma drug conjugate erbb receptor tyrosine kinase solid tumours erbb monoclonal antibody enhancer zeste homologue solid tumours haematological malignancies ezh inhibitor phosphatidylinositol kinase castration resistant prostate cancer pik beta inhibitor focal adhesion kinase inhibitor mesothelioma bet family bromodomain inhibitor solid tumours haematological malignancies immunoinflammation sirukumab interleukin il human monoclonal rheumatoid arthritis iii antibody sirukumab interleukin il human monoclonal giant cell arteritis iii antibody benlysta b lymphocyte stimulator monoclonal systemic lupus erythematosus iii antibody sc benlysta b lymphocyte stimulator monoclonal vasculitis iii antibody iv benlysta b lymphocyte stimulator monoclonal transplant rejection ii antibody iv benlysta rituxan b lymphocyte stimulator monoclonal sjogren 's syndrome ii antibody sc cluster differentiation cd monoclonal antibody iv granulocyte macrophage colony rheumatoid arthritis ii stimulating factor monoclonal antibody oncostatin osm monoclonal antibody systemic sclerosis interleukin il receptor monoclonal sjogren 's syndrome antibody spleen tyrosine kinase syk inhibitor chronic urticaria topical lymphocyte activation gene lag autoimmune disease protein monoclonal antibody receptorinteracting protein rip psoriasis rheumatoid arthritis ulcerative colitis kinase inhibitor chemokine cc motif ligand psoriatic arthritis ccl monoclonal antibody macrophage targeted histone rheumatoid arthritis deacetylase inhibitor rearranged transfection ret inflammatory disorders bowel kinase inhibitor rare diseases exvivo stem cell gene therapy adenosine deaminase severe combined immune submitted may deficiency adascid transthyretin ttr production inhibitor transthyretinmediated amyloidosis iii mepolizumab interleukin il monoclonal antibody eosinophilic granulomatosis polyangiitis iii serum amyloid p component sap amyloidosis ii monoclonal antibody sap depleter cphpc exvivo stem cell gene therapy metachromatic leukodystrophy ii exvivo stem cell gene therapy wiscottaldrich syndrome ii exvivo stem cell gene therapy betathalassemia igsk annual report strategic report governance remuneration financial statements investor information pharmaceuticals vaccines product development pipeline continued achieved regulatory review milestones compound type indication phase maa ndabla vaccines shingrix recombinant herpes zoster prophylaxis iii zoster vaccine mmr live attenuated measles mumps rubella prophylaxis iii us na ebola recombinant viral vector ebola haemorrhagic fever prophylaxis ii group b conjugated group b streptococcus prophylaxis ii streptococcus maternal immunisation pneumoniae next recombinant conjugated streptococcus pneumoniae disease prophylaxis ii generation copd recombinant reduction frequency copd exacerbations ii associated nontypeable haemophilus influenzae moraxella catarrhalis hepatitis c recombinant viral vector hepatitis c virus prophylaxis ii malaria next generation recombinant malaria prophylaxis plasmodium falciparum ii men abcwy recombinant conjugated meningococcal abcw disease prophylaxis ii adolescents pseudomonas recombinant pseudomonas infection prophylaxis ii shigella conjugated outer membrane shigella diarrhea prophylaxis ii tuberculosis recombinant tuberculosis prophylaxis ii rsv recombinant respiratory syncytial virus prophylaxis ii maternal immunisation rsv replicationdefective recombinant respiratory syncytial virus prophylaxis viral vector hiv recombinant proteins hiv infection prophylaxis pharmaceuticals metabolic retosiban oxytocin antagonist spontaneous preterm labour iii daprodustat prolyl hydroxylase inhibitor anaemia associated chronic renal disease ii ileal bile acid transport ibat inhibitor cholestatic pruritus ii camicinal motilin receptor agonist delayed gastric emptying ii eperzantanzeum glucagonlike peptide glp type diabetes ii albiglutide receptor agonist losmapimod p kinase inhibitor focal segmental glomerular sclerosis ii otelixizumab cluster differentiation cd new onset type diabetes ii daprodustat prolyl hydroxylase inhibitor topical wound healing monoclonal antibody transient receptor potential cation heart failure channel v trpv antagonist selective androgen receptor modulator muscle wasting oxytocin inhaled oxytocin postpartum hemorrhage dermatology chlorhexidine cationic polybiguanide topical prevention omphalitis submitted oct nonsteroidal antiinflammatory topical atopic dermatitis ii nonsteroidal antiinflammatory topical psoriasis ii ror gamma inverse agonist topical psoriasis ii umeclidinium muscarinic acetylcholine antagonist topical hyperhidrosis ii mepolizumab interleukin il monoclonal antibody severe atopic dermatitis neurosciences beta amyloid monoclonal antibody geographic retinal atrophy ii benlysta b lymphocyte stimulator monoclonal myasthenia gravis ii antibody iv rilapladib lipoproteinassociated phospholipase alzheimer 's disease ii lppla inhibitor na ocular target lica antisense geographic atrophy agerelated macular disease oligonucleotide gsk annual report strategic report governance remuneration financial statements investor information pipeline products competition continued pharmaceutical products competition intellectual property major patent expiry dates products compounds indications competitor brands us eu respiratory anoro ellipta umeclidinium bromide copd spiriva handihaler vilanterol terfenatate respimat stiolto nce nce spiolto respimat ultibro breezhaler device device duaklir genuair formulation formulation arnuity ellipta fluticasone furoate asthma qvar pulmicort na asmanex nce alvesco device formulation avamysveramyst fluticasone furoate rhinitis nasonex flixotideflovent fluticasone propionate asthmacopd qvar singulair expired diskus device diskus device hfadevice hfadevice incruse ellipta umeclidinium bromide copd spiriva handihaler respimat nce nce eklira genuair device device formulation formulation nucala mepolizumab severe eosinophilic asthma xolair relvarbreo fluticasone furoate asthmacopd symbicort foster ellipta vilanterol terfenatate flutiform dulera nce nce device device formulation formulation seretideadvair salmeterol xinafoate asthmacopd symbicort foster expired fluticasone propionate flutiform dulera diskus device diskus device hfadevice hfadevice serevent salmeterol xinafoate asthmacopd foradil spiriva expired handihalerrespimat diskus device diskus device onbrez hfadevice ventolin hfa albuterol sulphate asthmacopd generic companies hfadevice hfadevice antivirals valtrex valaciclovir genital herpes coldsores famvir expired expired shingles zeffixepivirhbv lamivudine chronic hepatitis b hepsera expired expired central nervous system lamictal lamotrigine epilepsy bipolar disorder keppra dilantin expired expired imigranimitrex sumatriptan migraine zomig maxalt relpax expired expired seroxatpaxil paroxetine depression various effexor cymbalta expired expired anxiety disorders lexapro cardiovascular urogenital eperzantanzeum albiglutide type diabetes victoza byetta bydureon lyxumia trulicity avodart dutasteride benign prostatic hyperplasia proscar flomax expired finasteride coreg cr carvedilol phosphate mildtosevere heart failure toprol xl na hypertension left ventricular formulation dysfunction post mi see risk factors details uncertainty timing followon competition see note financial statements legal proceedings generic competition possible includes supplementary protection certificates patent term extensions granted data exclusivity expires eu usgsk annual report strategic report governance remuneration financial statements investor information pharmaceutical products competition intellectual property continued major patent expiry dates products compounds indications competitor brands us eu antibacterials augmentin amoxicillinclavulanate common bacterial generic products na expired potassium infections rare diseases volibris ambrisentan pulmonary hypertension tracleer revatio na immunoinflammation benlysta belimumab systemic lupus erythematosus hiv epzicomkivexa lamivudine abacavir hivaids truvada atripla stribild combination combination compleraeviplera lexivatelzir fosamprenavir hivaids prezista kaletra reyataz selzentrycelsentri maraviroc hivaids isentress intelence prezista tivicay dolutegravir hivaids isentress prezista reyataz kaletra triumeq dolutegravir lamivudine hivaids truvada atripla abacavir stribild compleraeviplera trizivir lamivudine zidovudine hivaids truvada atripla abacavir stribild combination combination compleraeviplera vaccines products competition intellectual property patent expiry dates major products compounds indications competitor brands us eu bexsero meningococcal groupb meningitis group b prevention trumenba vaccine boostrix diphtheria tetanus acellular diphtheria tetanus acellular adacel pertussis pertussis booster vaccination infanrix hexa diphtheria tetanus pertussis prophylaxis diphtheria pentacel pediacel expired pediarix polio hepatitis b tetanus pertussis polio pentaxim pentavac haemophilus influenzae hepatitis b haemophilus hexaxim type b eu influenzae type b eu cervarix hpv virus like human papilloma virus gardasil silgard particles vlps type adjuvant mpl aluminium hydroxide fluarix tetra split inactivated influenza seasonal influenza intenza flumist qiv virus subtypes prophylaxis vaxigrip qiv subtype b antigens fluzone qiv fluzone high dose flulaval split inactivated influenza seasonal influenza vaxigrip mutagrip virus subtypes prophylaxis fluzone influvac subtype b antigens aggripal fluad intenza flumist menveo meningococcal group c w meningitis group c w mencevax menactra conjugate vaccine prophylaxis prepandrix derived split inactivated pandemic hn aflunov vepacel influenza virus antigen influenza prophylaxis adjuvant rotarix human rotavirus rix strain rotavirus prophylaxis rotateq synflorix conjugated pneumococcal prophylaxis invasive prevenar prevnar na polysaccharide disease pneumonia acute otitis media see note financial statements legal proceedings generic competition commenced includes supplementary protection certificates patent term extensions granted gsk annual report strategic report governance remuneration financial statements investor information pipeline products competition continued consumer healthcare products competition brand products application markets competition wellness panadol tablets caplets paracetamolbased global except us advil pfizer panadol cold infant syrup drops treatment headache aspirin bayer flu joint pain fever tylenol johnson johnson cold symptoms voltaren topical gel nonsteroidal diclofenac global advil pfizer based antiinflammatory aspirin bayer tylenol johnson johnson otrivin nasal spray nasal decongestant germany poland afrin merck russia sweden nasivin merck ukraine theraflu tablets syrups cold flu relief russia poland tylenol cold flu ukraine us johnson johnson mucinex reckitt benckiser lemsip reckitt benckiser flonase nasal spray allergy relief china ireland claritin bayer flixanase uk us rhinocort astra zeneca flixonase nasacort sanofi piriteze eno effervescent immediate relief antacid global except us estomazil hypermarca gelusil pfizer tums chewable tablets immediate relief antacid us alkaseltzer bayer gaviscon reckitt benckiser rolaids sanofi nicorette us lozenges gum treatment nicotine global nicorette johnson johnson nicoderm transdermal patches withdrawal aid niquitin perrigo nicotinell smoking reduction ex australia cessation oral health sensodyne toothpastes toothbrushes relief dentinal global colgate sensitive prorelief pronamel mouth rinse hypersensitivity colgatepalmolive pronamel additionally elmex colgatepalmolive protects acid oral b procter gamble erosion parodontax toothpaste helps prevent bleeding germany ireland colgate total gum health corsodyl medicated mouthwash gums treats prevents italy united kingdom colgatepalmolive gel spray gingivitis yunnan baiyao state enterprise china polident denture adhesive denture improve retention global fixodent kukident poligrip cleanser comfort dentures procter gamble corega cleans dentures steradent reckitt benckiser aquafresh toothpastes toothbrushes aids prevention dental global colgate colgatepalmolive mouthwashes cavities maintains healthy crest procter gamble teeth gums fresh breath oralb procter gamble skin health zovirax topical cream lip care treat prevent global compeed johnson johnson abreva nonmedicated patch onset cold sores carmex carma labs blistex blistex incorporated retail label nutrition horlicks malted drinks foods nutritional indian subcontinent bournvita mondelez beverages food united kingdom ireland complan heinzgsk annual report strategic report governance remuneration financial statements investor information principal risks uncertainties risk factors principal risks discussed risks uncertainties similarly business exposes us litigation government relevant business financial condition results operations investigations including limited product liability litigation patent may affect performance ability achieve objectives antitrust litigation sales marketing litigation litigation factors believe could cause actual government investigations including related provisions may make results differ materially expected historical results unfavourable outcomes increases related costs insurance premiums could materially adversely affect financial results must adapt comply broad range laws regulations requirements apply research development detail status various uncertainties involved manufacturing testing approval distribution sales marketing significant unresolved disputes potential litigation set pharmaceutical vaccine consumer healthcare products affect note legal proceedings pages cost product development also time required uk regulations require discussion mitigating activities company reach market likelihood successfully takes address principal risks uncertainties summary moreover rules regulations change governmental activities group takes manage principal risks interpretation rules regulations evolves nature accompanies description principal risk principal particular risk may change changes certain regulatory regimes risk factors uncertainties listed order significance may substantial change failure comply applicable law regulation could materially adversely affect financial results patient safety risk definition individual medical officers groups substantial global failure appropriately collect review follow report adverse safety pharmacovigilance organisation keep track adverse events potential sources act relevant findings issues reported products course clinical studies timely manner group product approved marketing group risk impact extensive postmarketing surveillance signal detection system impact risk potentially compromise ability information possible side effects medicines received conduct robust safety signal detection interpretation several sources including unsolicited reports health ensure appropriate decisions taken respect professionals patients regulatory authorities medical riskbenefit profile products including completeness scientific literature media policy employees accuracy product labels pursuit additional required report immediately issues relating safety studiesanalyses appropriate could lead potential harm quality products country managers responsible patients reputational damage product liability claims monitoring exception tracking training helps assure litigation governmental investigation regulatory action collection safety information reporting information fines penalties loss product authorisation relevant central safety department accordance group policy legal requirements context preclinical clinical trials conducted development information changes benefitrisk profile one groups investigational pharmaceutical vaccine consumer healthcare medicines result certain actions characterise communicate products determine safety efficacy products use minimise risk proposed actions discussed humans notwithstanding efforts make determine regulatory authorities include modifying prescribing safety products appropriate preclinical clinical information communications physicians healthcare trials unanticipated side effects may become evident providers restrictions product prescribingavailability help products widely introduced marketplace questions assure safe use sometimes carrying clinical trials may raised ongoing safety surveillance certain cases may appropriate stop clinical trials postmarketing studies also governmental agencies withdraw medicine market groups global safety thirdparties may analyse publicly available clinical trial results board gsb comprising senior physicians representatives supporting functions integral component system group currently defendant number product liability gsb including subsidiary boards dedicated consumer lawsuits including class actions involve significant claims healthcare products vaccines reviews safety damages related products litigation particularly us investigational marketed products across group inherently unpredictable class actions seek sweep together authority stop clinical trial continued conduct trial persons prescribed products increase potential ethically scientifically justified light information liability claims pain suffering punitive damages emerged since start trial frequently asserted product liability actions allowed represent potentially openended exposure thus could materially addition medical governance framework within group adversely affect groups financial results described group uses several mechanisms foster early evaluation mitigation resolution disputes mitigating activities arise potential claims even arise goal chief medical officer cmo responsible medical programmes create culture early identification governance group global policy policy evaluation risks claims actual potential order safeguarding human subjects clinical trials patients minimise liability litigation take products paramount importance cmo authoritative role evaluating addressing matters human safety gsk annual report strategic report governance remuneration financial statements investor information principal risks uncertainties risk factors continued intellectual property risk definition generic drug manufacturers also exhibited readiness failure appropriately secure protect intellectual property market generic versions many important products prior rights expiration patents efforts may involve challenges validity enforceability patent assertions risk impact generic product infringe patents result failure obtain subsequent loss patent protection may continue involved legal proceedings involving patent including reducing availability scope patent rights challenges may materially adversely affect financial compulsory licensing government forces manufacturer results moreover us become increasingly common license patents specific products competitor could patent infringement actions prompt claims antitrust laws materially adversely affect financial results markets violated prosecution patent litigation absence adequate patent data exclusivity protection could limit involving defence patent claims direct opportunity rely markets future sales growth indirect purchasers payers typically filed class products could also materially adversely affect actions relief sought may include treble damages restitution financial results claims similarly antitrust claims may brought government context entities private parties following settlement patent litigation innovative pharmaceutical vaccine consumer healthcare alleging settlements anticompetitive violation products company seek obtain appropriate intellectual antitrust laws successful antitrust claim private party property protection products ability obtain enforce government entity could materially adversely affect financial patents proprietary rights regard products results critical business strategy success pharmaceutical expiration dates patents major products may vaccine products usually protected copied affect dates generic versions products may generic manufacturers period exclusivity provided introduced set pages legal proceedings issued patent related intellectual property rights involving patent challenges set note financial regulatory data protection orphan drug status following statements legal proceedings expiration certain intellectual property rights generic manufacturer may lawfully produce generic version product mitigating activities global patents group focuses securing protecting operate markets intellectual property laws patent patent rights global group maintains internal processes offices still developing governments may unwilling designed seek ensure successful procurement enforcement grant enforce intellectual property rights fashion similar defence patents goal maintaining exclusive developed regions eu japan us rights markets products developing countries limited threatened limit effective patent protection pharmaceutical products order facilitate global patents group monitors new developments early competition within markets generic manufacturers international patent law seek ensure appropriate protection assets sometimes acting trade associations work face competition manufacturers proprietary generic local governments seek secure effective balanced pharmaceutical products major markets introduction intellectual property protection designed meet needs generic products particularly us highest patients payers supporting longterm investment turnover margins typically leads rapid dramatic loss innovation sales reduces revenues margins proprietary products depend certain key products significant portion sales one product respiratory pharmaceutical product seretideadvair accounts significant group sales worldwide timing impact entry us generic product containing combination active substances seretideadvair uncertain us patent compositions containing combination active substances seretideadvair expired although us patent component advair diskus device continues august generic products containing combination active substances seretide advair metered dose inhalers dry powder inhalers launched several manufacturers number european markets timing impact entry us major markets europe followon product seretideadvair uncertaingsk annual report strategic report governance remuneration financial statements investor information product quality risk definition single external global quality standard system failure comply current good manufacturing practices governs lifecycle medicinal products requirements cgmp inadequate controls governance quality often complex fragmented across national regional supply chain covering supplier standards manufacturing boundaries ich guideline q pharmaceutical quality distribution products systems provides model comprehensive quality framework takes account international quality concepts risk impact designed implemented product lifecycle failure ensure product quality could far reaching framework adopted gsk augmented implications terms patient consumer safety resulting consolidation multiple regulatory requirements across product launch delays supply interruptions product recalls world order seek ensure gsk pqs meets external would potential damage reputation expectations product quality markets supplied pqs associated regulatory legal financial consequences could regularly updated seek ensure keeps pace external materially adversely affect reputation financial results regulatory changes reflects operational improvements context new scientific understanding support delivery patients consumers healthcare professionals trust quality consistent reliable products products failure ensure product quality enterprise extensive global network quality compliance risk applicable across business activities professionals aligned business unit provide product quality may influenced many factors including oversight assist delivery quality performance product process understanding consistency manufacturing operational compliance site level senior management level components compliance gmp accuracy labelling management oversight activities accomplished reliability external supply chain embodiment hierarchy quality councils independent chief overarching quality culture internal external environment product quality officer global product quality office continues evolve new products new markets new legislation introduced increasing scrutiny supply gsk implemented riskbased approach assessing continuity focus improved distribution practice managing thirdparty suppliers provide materials used introduction novel cell gene based therapies review finished products contract manufacturers making products inspections conducted across industry national regulatory expected comply standards identified gsk authorities highlighted ongoing focus data audited help provide assurance expected standards integrity contamination prevention rigour quality met investigations including robustness decision making staff members regularly trained seek ensure timely escalation pertinent issues regulatory authorities cgmp standards behaviours based gsk values mitigating activities followed additionally advocacy communication programmes developed implemented single pharmaceutical routinely deployed seek ensure consistent messages quality system pqs defines quality standards conveyed across gsk whether originate changes systems businesses associated pharmaceuticals regulation learnings inspections regulatory submissions vaccines consumer healthcare products clinical trial continued emphasis value quality performance materials system broad scope applicable metrics facilitate improvement foster culture right throughout lifecycle products rd mature first time commercial supply gsk annual report strategic report governance remuneration financial statements investor information principal risks uncertainties risk factors continued financial control reporting risk definition third parties critical business delivery failure comply current tax law incurring significant integral part solution improve productivity quality losses due treasury activities failure report accurate financial service innovation rely thirdparties including information compliance accounting standards applicable suppliers distributors individual contractors licensees legislation failure maintain adequate governance oversight pharmaceutical biotechnology collaboration partners thirdparty relationships discovery manufacture marketing products important business processes risk impact noncompliance existing new financial reporting third party business relationships present material risk disclosure requirements changes recognition income example share critical sensitive information expenses could expose us litigation regulatory action marketing plans clinical data employee data specific could materially adversely affect financial results third parties conducting relevant outsourced business changes tax laws application respect matters operations inadequate protection misuse information transfer pricing foreign dividends controlled companies third parties could significant business impact similarly rd tax credits taxation intellectual property restriction tax use distributors agents range activities relief allowed interest intragroup debt could impact promotion tendering inherent risks effective tax rate significant losses may arise inconsistent inappropriate promotion corruption insufficient internal application treasury policies transactional settlement errors compliance controls distributors could affect counterparty defaults changes substance reputation risks increased complexities application governing tax laws failure comply tax working large numbers third parties laws significant losses due treasury activities could materially mitigating activities adversely affect financial results group maintains control environment designed identify failure adequately manage thirdparty relationships could result material errors financial reporting disclosure design business interruption exposure risk ranging suboptimal operating effectiveness key financial reporting controls contractual terms conditions severe business sanctions regularly tested management via independent business andor significant reputational damage consequences monitoring provides us assurance controls could materially adversely affect business operations key financial reporting disclosure processes operated financial results effectively context keep uptodate latest developments financial group required laws various jurisdictions reporting requirements working external auditors disclose publicly financial results events could legal advisors materially affect financial results group regulators shared accountability financial results across routinely review financial statements listed companies businesses financial results reviewed approved compliance new revised existing accounting regulatory regional management reviewed financial requirements group believes complies controller chief financial officer cfo allows appropriate regulatory requirements concerning financial financial controller cfo assess evolution statements disclosure material information including business time evaluate performance plan transactions relating business restructuring acquisitions significant judgments reviewed confirmed senior divestitures however subject investigation management business reorganisations newly acquired potential noncompliance accounting disclosure activities novartis acquired businesses oncology requirements may lead restatements previously reported divestitures integrated risk assessments appropriate results significant penalties controls reviews applied treasury group deals high value transactions mostly foreign introduced additional resources monitoring ensure exchange cash management transactions daily basis robust financial controls maintained effectively groups effective tax rate reflects rates tax managing risks initial phase integrating former jurisdictions group operates higher novartis businesses control reporting framework lower uk rate take account regimes implemented ongoing transformation upgrade encourage innovation investment science providing tax financial systems processes continued additional risk incentives changed could affect groups tax rate mitigation introduced amending programme timelines ongoing system upgrades tax charge included financial statements best estimate tax liability pending audits tax authorities group maintains disclosure committee reporting worldwide nature operations crossborder supply board reviews groups quarterly results annual routes complex lead questions tax audit report determines throughout year consultation legal advisors whether necessary disclose publicly continues significant international focus tax information group stock exchange reform including oecds beps project european announcements commission initiatives proposed antibeps directive increased use fiscal state aid investigations together treasury management group tmg meets regular domestic initiatives around world may result basis seek ensure liquidity interest rate foreign currency significant changes established tax principals increase transaction foreign currency translation risks managed tax authority disputes regardless merit line conservative approach detailed associated outcomes costly divert management attention may risk strategies policies adopted adversely impact reputation boardgsk annual report strategic report governance remuneration financial statements investor information financial control reporting continued oversight treasurys role managing counterparty risk seek guide enforce global principles interactions line agreed policy performed corporate compliance third parties place policy framework applicable officer cco operates independently treasury buying goods services managing external spend paying working third parties policy framework details mitigation treasury risks found applies employees complementary workers worldwide note financial instruments related disclosures framework complemented technical local standards tax risk managed set policies procedures seek designed seek ensure alignment nature third ensure consistency compliance tax legislation party interactions good manufacturing practice adherence local laws regulations independent business seek maintain open positive relationships governments monitoring key financial operational controls place tax authorities worldwide monitor government debate supplemented periodic checks companys tax policy key jurisdictions deal proactively independent audit assurance function potential future changes tax law engage advisors legal counsel review tax legislation implications continuous monitoring performance third parties business relevant active providing relevant enhanced third party oversight team global business input tax policy makers ethics compliance organisation team commenced implementation global programme takes enterprise centralised team dedicated specialists responsible view third party related risks programme strengthening managing transactional tax reporting compliance risk assessment due diligence efforts third parties submit tax returns according statutory time limits improving overall management third party risks engage tax authorities seek ensure tax affairs lifecycle third party engagement oversight current entering arrangements continuous audit programme provided newly created global risk office programmes advance pricing agreements provide within gsks global ethics compliance group longterm certainty tax treatment appropriate exceptional cases matters settled agreement tax authorities may resolve disputes formal appeals proceedings business unit leadership team retains ultimate accountability managing third party interactions risks working third parties gsk employees expected manage external interactions commitments responsibly expectation embedded values code conduct responsibility activities performed safely compliance applicable laws gsks values standards code conduct gsk annual report strategic report governance remuneration financial statements investor information principal risks uncertainties risk factors continued antibribery corruption risk definition mitigating activities failure prevent gsk employees third parties complying code conduct values behaviours commitment abac principles standards well zero tolerance integral mitigate risk light applicable legislation complexity geographic breadth risk constantly enhance oversight activities data reinforce risk impact employees contractors clear expectations regarding failure mitigate risk could expose group associated acceptable behaviours maintain ongoing communications persons governmental investigation regulatory action civil group centre headquarters local markets criminal liability well damage groups reputation shareholder value licence operate particular group enterprisewide abac programme designed jurisdictions could materially adversely affect respond threat risk bribery corruption financial results builds groups values existing standards form comprehensive practical approach compliance context flexible evolving nature business example exposed bribery corruption risk global scaled acquisition abac due diligence specific business operations markets government structure novartis transaction rule law less developed bearing bribery corruption risk exposure addition global abac programme supported toplevel commitment nature business healthcare sector highly competitive group board directors leadership throughout subject regulation increases instances business ongoing risk assessment global abac policy exposed activities interactions bribery written standards address commercial practices corruption risk give rise abac risk due diligence high risk third parties ongoing training communications confidential reporting line us uk authorities leading extraterritorial abac monitoring compliance investigations team addition enquiries certain groups operations programme mandates enhanced controls interactions investigations discussed note legal proceedings government officials undertaking business development transactions programme governance provided groups abac governance board includes representation key functional areas business units additionally dedicated abac team responsible implementation evolution programme response developments internal external environment complemented abac investigations abac audit independent business monitoring teams separate reporting lines continually benchmark abac programme large multinational companies use external expertise review help improve elements abac programme result china country investigations group increased resources centrally located abac team well regional abac teams also completed abac review reduced presence number highrisk marketsgsk annual report strategic report governance remuneration financial statements investor information commercialisation risk definition mitigating activities failure execute business strategies manage competitive strategic objectives designed ensure group opportunities threats effectively accordance achieves mission helping people feel better letter spirit legal industry company requirements live longer group continues transform strengthening presence key emerging markets restructuring rd simplifying risk impact core business operations reducing manufacturing failure manage risks related commercialisation could footprint recent transaction novartis helped materially adversely affect ability grow diversified accelerate pace change strengthening three global business deliver products value core businesses pharmaceuticals vaccines consumer failure comply applicable laws rules regulations may healthcare result governmental investigation regulatory action legal changes allowing us global proceedings brought group governmental relevant needs world aim reach many private plaintiffs failure provide accurate complete patients consumers improving health information related products may result incomplete wellbeing use products deliver awareness benefitrisk profile products possibly goal important achieve values provide suboptimal treatment patients consumers guide lead make decisions constantly strive consequences could materially adversely affect group right thing deliver quality products seeking ensure practices found misaligned values behaviours reflect values mission company could also result reputational damage dilute trust established key stakeholders corporate executive team set shared objectives describe important priorities need deliver context across group set enterprisewide projects operate global basis industry highly critical achieving objectives strategic objectives competitive highly regulated competitors may make cascaded throughout group ensure enterprisewide significant product innovations technical advances may alignment processes place regularly review achievement intensify price competition light competitive environment towards objectives continued development commercially viable new products development additional uses existing products critical taken action levels group enhance achieve strategic objectives improve standards procedures promotional interactions based values transparency respect integrity patient developing new pharmaceutical vaccine consumer healthcare focus policies standards governing promotional products costly lengthy uncertain process however activities undertaken group behalf product candidate may fail stage including activities conduct worldwide must conform high ethical significant group economic human resources regulatory industry standards local standards differ invested competitors products pricing strategies global standards stringent two applies failure part develop commercially successful products develop additional uses existing products could materially group harmonised policies procedures guide adversely affect ability achieve strategic objectives country commercial practices processes well clarified applicable standards engaging markets committed ethical responsible commercial practices activities oversight business commercialisation products support mission unit risk management compliance boards rmcbs improve quality human life enabling people country executive boards cebs manage risks across feel better live longer accomplish mission engage incountry business activities healthcare community various ways provide important information medicines promotional materials activities must reviewed approved according groups policies standards promotion approved products seeks ensure hcps globally conducted accordance local laws regulations seek access information need patients consumers ensure materials activities fairly represent access products need products products services group necessary prescribed recommended used manner provides disciplined including termination employees maximum healthcare benefit patients consumers engaged misconduct broadened ability claw committed communicating information related approved back remuneration senior management event products responsible legal ethical manner misconduct times researchers hcps healthcare organisations hcos gsk also implemented globally changes already made external experts engage may compensated us compensation model sales professionals services expertise provided however payments must managers interact hcps changes eliminate excessive must never perceived rewards based sales market shares individuals territories inducement reward prescribing recommending favour rewards based quality individuals products consistent abac policies also must interactions healthcare professionals starting gsk comply markets abac laws recipient payment implement prior commitment stop paying hcps deliver government official promotional presentations gsk directly sponsor paid billion billion resolve government travel medical educational conferences investigations us focused large part promotional practices paid rmb billion million resolve government investigation china focused offering money property nongovernment personnel order obtain improper commercial gains gsk annual report strategic report governance remuneration financial statements investor information principal risks uncertainties risk factors continued research practices risk definition mitigating activities failure adequately conduct ethical sound preclinical established office animal welfare ethics strategy clinical research addition failure engage scientific activities oawes led chief animal welfare ethics strategy consistent letter spirit law industry seek ensure humane responsible care animals groups requirements increase knowledge application nonanimal alternatives group oawes embeds framework animal welfare risk impact governance promotes application rs replacement refinement impacts risk include harm patients reputational damage reduction animals research explores opportunities failure obtain necessary regulatory approvals products crossindustry data sharing conducts quality assessments governmental investigation legal proceedings brought group governmental private plaintiffs product liability suits report results human subject research claims damages regulatory action fines medicines vaccines publicly accessible clinical study penalties loss product authorisation register website governmentrequired repositories consequences could materially adversely affect financial submit human research results manuscripts publication results peer reviewed scientific journals disclosed clinical study reports marketed terminated medicines context research results published scientific literature research relating animals raise ethical concerns register bringing total reports available attempt proactively address animal studies remain vital part end listed clinical trials gsk research many cases method online system wwwclinicalstudydatarequestcom used investigate effects potential new medicine living completed commitment list completed global studies body tested humans generally mandated conducted since formation gsk online system regulators ethically imperative animal research provide allows researchers request access anonymised patientlevel critical information causes diseases data groups clinical trials medicine develop countries require additional animal testing even approved terminated trial published medicines approved use elsewhere global human biological samples management hbsm clinical trials healthy volunteers patients used assess governance framework place oversee ethical lawful demonstrate investigational products efficacy safety acquisition management human biological samples evaluate product approved global hbsm network champions hbsm activities provides marketing also work human biological samples experienced group support internal sample custodians best samples fundamental discovery development safety practice monitoring products remains important priority enhance data integrity integrity data essential success stages controls began work new written standard research data lifecycle design generation recording seek ensure integrity data across research management analysis reporting storage retrieval development rd data integrity committee place research data governed legislation regulatory requirements throughout year provide oversight data integrity research data supporting documents core components quality assurance team began conducting assessments intended various stages pipeline progression decisionmaking also provide independent business monitoring internal controls form content regulatory submissions poor data integrity rd activities compromise research efforts chief regulatory officer oversees activities innate complexities interdependencies required regulatory governance board includes promoting regulatory filings particularly given global research compliance regulatory requirements groupwide development footprint rapid changes submission requirements standards making regulatory services efficient agile developing countries continue increase complexity aligning regulatory capabilities international worldwide product registration business needs enterprise local levels scientific engagement se essential part scientific group strictly prohibits promotional practices prior marketing discourse defined interaction exchange information authorisation care taken seek ensure scientific gsk external communities order advance engagement activity perceived promotional scientific medical understanding including appropriate specific accountability authorisation scientific engagement development use products nonpromotional resides within medical governance framework overseen engagement external stakeholder groups vital gsks medical governance executive committee mgec accountable mission necessary scientific medical advance chief medical officer mgec responsible oversight scope se activities includes advisory boards scientific applicable policies seeking ensure highest level integrity consultancies preplanned informal discussions healthcare continuous development scientific engagement gsk professionals hcp sharing medical information publications framework seeks ensure right level accountability clear including abstracts congresses scientific interactions programme guidance country across rd business units payers patients governments media support local operating companies loc independent medical education nonindependent educational group takes integrated approach managing scientific activities covered commercial practices cp engagement commercial practices related risks including se activities essential present legal regulatory combined guidance document promotional code scientific reputational risk sharing data invited media coverage engagement standards way considerations risks payments service providers perceived common scientific engagement commercial inappropriate promotional intent risks particularly high practices abac healthcare professionals hcp hcp engagement associated financial andor transfer engagements managed right context one place value disclosures required gsk seek ensure clarity clear lines accountabilitygsk annual report strategic report governance remuneration financial statements investor information environment health safety sustainability risk definition mitigating activities failure manage ehss risks line objectives corporate executive team responsible ehss policies relevant laws regulations governance group global policy policy cet seeks ensure control framework place risk impact manage risks impacts legal compliance issues relate failure manage ehss risks could lead significant harm ehss assigning responsibility senior managers people environment communities operate providing maintaining controls individual managers seek fines failure meet stakeholder expectations regulatory ensure ehss control framework effective well requirements litigation regulatory action damage implemented respective business area fully groups reputation could materially adversely affect compliant applicable laws regulations adequately financial results resourced maintained communicated monitored context additionally employee personally responsible ensuring group subject health safety environmental laws applicable local standard operating procedures various jurisdictions laws impose duties protect people followed expected take responsibility ehss matters environment communities operate well riskbased proactive approach articulated refreshed potential obligations remediate contaminated sites global ehs standards support ehss policy also identified potentially responsible party objective discover develop manufacture supply sell us comprehensive environmental response compensation products without harming people environment addition liability act number sites remediation costs relating design provision safe facilities plant equipment use ownership sites failure manage operate rigorous procedures help us eliminate hazards environmental risks properly could result litigation regulatory practicable protect employees health wellbeing action additional remedial costs may materially adversely affect financial results see note financial continuing efforts improve environmental statements legal proceedings discussion sustainability reduced value chain carbon intensity environmental related proceedings involved per pack water consumption waste generation actively routinely accrue amounts related liabilities matters manage environmental remediation obligations seek ensure practices environmentally sustainable compliant ehss performance results shared public year responsible business supplement information protection risk definition mitigating activities failure protect maintain access critical sensitive group global information protection policy computer systems information supported dedicated programme activity increase focus information security group established risk impact information protection privacy function provide strategy failure adequately protect critical sensitive systems direction oversight enhancing global information information may result loss commercial strategic security capabilities advantage damage reputation litigation business disruption including regulatory sanction could materially assess changes information protection risk environment adversely affect financial results briefings government agencies subscription commercial threat intelligence services knowledge sharing context pharmaceutical crossindustry companies rely critical sensitive systems data corporate strategic plans sensitive personally identifiable aim use industry best practices part information information intellectual property manufacturing systems trade security policies processes technologies invest secrets potential malicious careless actions strategies commensurate changing nature expose computer systems information misuse security threat landscape unauthorised disclosure also subject various laws govern processing several gsk employees indicted theft gsk research personally identifiable information pll groups binding information charges individuals corporate rules bcrs approved uk concerning based know believe information commissioners office human resource breach material impact companys rd activity research activities data bcrs signed european ongoing business gsk conducting full internal review states allowing us transfer pii internationally groups occurred planning continue enhance multiple entities without individual privacy agreements european layers data protection already place union country gsk annual report strategic report governance remuneration financial statements investor information principal risks uncertainties risk factors continued crisis continuity management risk definition improved linkage commercial forecasting failure deliver continuous supply compliant finished manufacturing made possible core commercial cycle product inability recover sustain critical operations methodology time decrease risk associated including key supply chains following disruption respond demand fluctuations impacting ability supply writeoffs crisis incident timely manner associated product exceeding expiry dating node supply chain optimised seek ensure risk impact adequate safety stock balancing working capital associated recognise failure supply products adversely endtoend supply chain impact consumers patients rely material interruption supply exclusion healthcare programmes safety stocks backup supply arrangements medically could expose us litigation regulatory action incurring fines critical highrevenue products place help mitigate disgorgement materially adversely affect groups risk addition compliance manufacturing external financial results groups international operations suppliers routinely monitored order identify manage partners maintain vast global footprint also expose supply base risks practical dependencies single workforce facilities operations information technology sources critical items removed reliance single potential disruption resulting natural event eg storm source components reduced certain key earthquake manmade event eg civil unrest terrorism products qualification alternative materials help global emergency eg ebola outbreak flu pandemic improve supply chain robustness cases dual sourcing important gsk robust crisis management recovery possible inventory strategy developed protect plans place manage events supply chain unanticipated disruption context continued implement anticounterfeit systems supply chain operations subject review approval product serialisation accordance emerging supply chain various regulatory agencies effectively provide licence requirements around world operate failure manufacturing distribution facilities ccm governance group set forth global policy suppliers key services materials could lead litigation policy business unit functional area head regulatory action product recalls seizures interruption bu ensures effective crisis management business supply delays approval new products suspension continuity plans place include authorised response manufacturing operations pending resolution manufacturing recovery strategies key areas responsibility clear logistics issues communication routes business disruption occurs materials services provided thirdparty suppliers additionally bu represented ccm governance board necessary commercial production products performs risk oversight provides vital information including active pharmaceutical ingredients api antigens ccm programme team regarding new threats acquisitions intermediates commodities components necessary significant business organisational changes manufacture packaging many pharmaceutical dedicated team ccm experts supports business vaccine consumer healthcare products responsibilities include chairing governance board thirdparty services procured services provided coordinating crisis management business continuity training contract manufacturing organisations clinical research facilitating exercises monitoring provide global organisations support development key products consistency alignment centrally storing monitoring important ensure continuous operation businesses updates plans supporting critical business processes although undertake business continuity planning single activities help ensure appropriate level readiness sourcing certain components bulk api finished products response capability maintained also develop maintain services creates risk failure supply event partnerships external bodies like business continuity regulatory noncompliance physical disruption institute un international strategy disaster risk manufacturing sites logistics system reduction helps improve business continuity initiatives failure small number singlesource thirdparty suppliers disaster prone areas supports development service providers fulfil contractual obligations timely community resilience disasters manner result regulatory noncompliance physical continue evaluate implications business disruption logistics manufacturing sites may result delays possible exit united kingdom european union service interruptions uk leaving eu would create uncertainty effective crisis management business continuity potentially add complexity wide range business planning committed providing health safety activities currently believe would people minimising damage impact group material adverse impact groups results longer term maintaining functional operations following natural manmade continually improve ccm risk management programme disaster public health emergency tools based learning plan activations example mitigating activities group implemented global system provides gsk supply chain model designed seek ensure supply leaders access vital information need effectively quality security products globally closely monitor respond disruptions monitoring status supply chain governance committees inventory preparedness response capability regularly solicit status delivery products seek ensure take recommendations improvements many different customers medicines vaccines products need sourcessuppliers charged responsibility assisting managing gsks risks introduce new tools improve ccm practicesgsk annual report strategic report governance remuneration financial statements investor information shareholder information share capital control share buyback programme board authorised issue allot ordinary shares details issued share capital number shares article companys articles association held treasury december found power article authority company make note financial statements share capital share purchases shares subject shareholder authorities premium account sought annual basis annual general ordinary shares listed london stock exchange meeting agm shares purchased company may also quoted new york stock exchange nyse cancelled held treasury shares used satisfying form american depositary shares ads ads share options grants group employee share plans represents two ordinary shares details listed debt programme covers purchases shares cancellation listed refer note financial statements held treasury shares accordance authority net debt renewed shareholders agm may holders ordinary shares ads entitled receive company authorised purchase maximum dividends declared companys annual report million shares details shares purchased cancelled attend speak general meetings company appoint held treasury shares disclosed note proxies exercise voting rights financial statements share capital share premium account restrictions transfer limitations determining specific share repurchase levels company holding ordinary shares ads requirements considers development free cash flow year given obtain approval prior transfers ordinary shares ads impact sustained strength sterling free cash flow carry special rights regard control company company suspended share repurchase programme restrictions voting rights major shareholders shares purchased financial year voting rights per share shareholders ended known arrangements financial rights held company confirms currently intend make person holder shares known market purchases company review agreements restrictions share transfers voting rights potential future share buybacks line shares acquired share schemes plans rank usual annual cycle subject return ratings criteria equally shares issue special rights market capitalisation trustees employee share ownership plan trusts market capitalisation based shares issue excluding waived rights dividends shares held trusts treasury shares gsk december billion exchange controls limitations affecting security date gsk third largest company market holders capitalisation ftse index certain economic sanctions may force time time currently applicable laws decrees share price regulations restricting import export capital affecting remittance dividends payments holders january companys shares nonresidents uk similarly december certain economic sanctions may force time decreaseincrease time limitations relating nonresidents uk high year english law companys articles association low year right holder vote respect companys shares table sets middle market closing prices companys share price decreased interests voting rights compares decrease ftse index stated far aware year share price march persons significant direct indirect holdings company information provided company pursuant financial conduct authoritys fca disclosure transparency rules uk us dtrs published regulatory information service companys website march company received notifications accordance fcas dtrs following notifiable interests voting rights companys issued share capital percentage issued shares capital blackrock inc legal general group plc percentage ordinary shares issue excluding treasury shares acquired disposed interests uk share price uk us ads price us shares period review gsk annual report strategic report governance remuneration financial statements investor information shareholder information continued nature trading market following tables set periods indicated high low middle market closing quotations pence shares london stock exchange high low closing prices us dollars ads nyse ordinary shares ads pence per share us dollars per share high low high low march february january december november october september august quarter ended december quarter ended september quarter ended june quarter ended march quarter ended december quarter ended september quarter ended june quarter ended march year ended december year ended december year ended december year ended december year ended december march analysis shareholdings december number total total number accounts accounts shares shares holding shares held nominee companies investment trust companies insurance companies individuals corporate bodies bny nominees limited held treasury shares glaxosmithkline bny mellon depositary companys ads listed nyse ordinary shares representing companys adr programme managed depositary registered name bny nominees limited march bny nominees limited held ordinary shares representing issued share capital excluding treasury shares date march number holders ordinary shares us holdings ordinary shares number registered holders ads holdings ads certain ordinary shares ads held brokers nominees result number holders record registered holders us representative number beneficial holders residence beneficial holdersgsk annual report strategic report governance remuneration financial statements investor information dividends financial calendar company pays dividends quarterly continues return cash event date shareholders dividend policy dividends remain quarter results announcement aprilmay essential component total shareholder return company annual general meeting may committed increasing dividend longterm details dividends declared amounts payment dates quarter results announcement july given note financial statements dividends quarter results announcement october preliminaryquarter results announcement february gsk completed transaction novartis march annual report publication februarymarch whereby gsk novartis created new worldleading annual report distribution march consumer healthcare business gsk acquired novartis global vaccines business gsk divested marketed oncology information company including share price available portfolio related rd activities website wwwgskcom information made available website constitute part annual report gsk plans use net cash transaction proceeds fund return approximately billion p per share shareholders results announcements via special dividend paid gsks q ordinary results announcements issued london stock exchange dividend payment available news service also sent us securities exchange commission nyse issued dividends per share media made available website table sets dividend per share per ads last five years dividend per ads translated us dollars financial reports applicable exchange rates company publishes annual report made available website date publication shareholders may year dividend pence us elect receive annual report contacting registrar special alternatively shareholders may elect receive notification email publication financial reports registering wwwshareviewcouk copies previous financial reports available website printed copies obtained registrar uk gsk response center us see pages supplemental contact details q interim ordinary dividend special dividend annual general meeting receivable adr holders calculated based exchange rate april cumulative dividend receivable adr pm uk time thursday may holders q q q us queen elizabeth ii conference centre broad sanctuary westminster london swp ee special dividend relates return part net cash proceeds novartis transaction agm companys principal forum communication private shareholders addition formal business supplemental dividend related disposal certain presentation ceo performance noncore otc brands north america paid group future development opportunity fourth quarter ordinary dividend questions asked board chairmen boards committees take questions relating committees dividend fee adr holders gsk introduced dividend fee adr holders effect investors holding shares nominee service arrange q dividend payment authorised terms nominee service appointed proxy respect amended restated deposit agreement notice provided shareholding order attend vote meeting registered adr holders april adr holders wishing attend meeting must obtain proxy fee introduced offset part costs related bny mellon depositary notifying request sec registration including sarbanesoxley related expenses enable attend vote business administration ads facility maintenance transacted adr holders may instruct bny mellon nyse listing fees fee expected remain place way shares represented adr voted future dividends completing returning voting card provided depositary annual fee currently set per adr per adr per quarter depositary agreement gsk documents display charge cent per adr articles association company directors service contracts applicable letters appointment dividend calendar directors company subsidiaries side ads exdividend exdividend letters relating severance terms pension arrangements quarter date date record date payment date available inspection companys registered office q made available inspection agm special dividend february february february april q may may may july q august august august october q november november november january gsk annual report strategic report governance remuneration financial statements investor information shareholder information continued tax information shareholders taxation capital gains uk shareholders may liable uk tax gains disposal summary certain uk tax us federal income tax shares adr disposals individuals subject consequences holders shares adr citizens availability exemption relief annual exempt uk us set complete analysis amount taxable capital gain accruing disposal shares possible tax consequences purchase ownership adr taxed allowable deductions sale securities intended general guide shareholders taxable income tax year exceeds basic holders advised consult advisers respect rate income tax limit cases taxable capital gain accruing tax consequences purchase ownership sale disposal shares adr may taxed shares adr consequences state local tax combination rates corporation taxpayers may entitled laws us implications current ukus tax indexation allowance applies reduce capital gains conventions extent gains arise due inflation indexation us holders adr generally treated owners allowance may reduce chargeable gain create underlying shares purposes current usuk double allowable loss taxation conventions relating income gains income tax inheritance tax convention estate gift taxes estate gift tax individual ukdomiciled otherwise shareholders may liable convention purposes internal revenue code uk inheritance tax transfer shares adr tax may amended code charged amount value shareholders uk shareholders estate reduced result transfer way lifetime gift summary applies uk resident shareholder holds disposal less full market value case shares capital assets bequest death tax may charged value shares date shareholders death gift taxation dividends disposal subject uk inheritance tax us estate different regimes apply taxation dividend income payable gift tax estate gift tax convention would generally uk resident individuals uk tax years april provide tax paid us credited tax payable tax years commencing april uk uk tax years including uk resident stamp duty stamp duty reserve tax shareholders generally subject uk income tax full uk stamp duty andor stamp duty reserve tax sdrt subject amount dividends paid grossed amount tax certain exemptions payable transfer shares credit tax credit may set individuals income tax rate rounded nearest case stamp liability respect gross dividend repayable duty consideration transfer notwithstanding shareholders tax liability less associated tax provided instrument executed pursuance credit extent individuals income exceeds basic rate agreement gave rise charge sdrt limit higher rate limit upper dividend rate applies instrument stamped within six years agreement including set grossed dividend figure stamped exempt sdrt charge cancelled whose income exceeds additional rate limit sdrt already paid repaid additional dividend rate normally apply us shareholders uk tax years onwards dividend tax credits summary applies shareholder citizen longer apply uk resident individuals entitled instead resident us domestic corporation person dividend tax allowance first otherwise subject us federal income tax net income basis dividends received tax year free tax respect shares adr holds shares adr dividends excess allowance taxed capital assets resident uk uk tax purposes basic rate taxpayers higher rate taxpayers hold shares purposes trade profession additional rate taxpayers vocation carried uk branch agency uk resident shareholders corporation taxpayers summary also address tax treatment holders note dividends payable ordinary shares generally subject special tax rules banks taxexempt entitled exemption corporation tax entities insurance companies dealers securities currencies persons hold shares adr part integrated investment including straddle comprised share adr one positions persons directly indirectly voting stock company address tax treatment may applicable result international income tax treatiesgsk annual report strategic report governance remuneration financial statements investor information taxation dividends taxation capital gains gross amount dividends received treated foreign generally us holders subject uk capital gains tax source dividend income us tax purposes eligible subject us tax capital gains realised sale dividend received deduction allowed us corporations disposal shares adr gains longterm dividends adr payable us dollars dividends shares capital gains subject reduced rates taxation individual payable pounds sterling dividends paid pounds sterling holders shares adr held one year included income us dollar amount calculated date shares vestedreleased shortterm capital reference exchange rate day dividends gains subject taxation rates whereas received holder subject certain exceptions shortterm longterm capital gains may subject rates hedged positions individual eligible us holder subject state local tax rates capital gains may also apply us taxation maximum rate respect qualified information reporting backup withholding dividends qualified dividend defined us internal dividends payments proceeds sale shares revenue service dividend meets following criteria adr paid within us certain usrelated financial must issued us corporation corporation incorporated intermediaries subject information reporting may us possession corporation eligible subject backup withholding unless us holder benefits comprehensive income tax treaty deemed corporation exempt recipient provides taxpayer satisfactory published irs identification number certifies loss exemption occurred nonus holders generally subject information dividends listed irs dividends reporting backup withholding may required provide qualify certification nonus status connection payments required dividend holding period met shares received amounts withheld allowed refund must owned days credit holders us federal income tax liability provided holding period defined day period required information furnished internal revenue begins days exdividend date day service stock trades without dividend priced example estate gift taxes stocks exdividend date october shares must held estate gift tax convention us shareholder days period august generally subject uk inheritance tax november year order count qualified dividend stamp duty uk stamp duty andor sdrt subject certain exemptions dividends qualified subject taxation us payable transfer shares adr custodian federal graduated tax rates maximum rate depository rate amount consideration types dividends automatically excluded qualified provided transferred sale value transferred dividends even meet requirements include consideration limited however stamp duty sdrt payable capital gains distributions transfer agreement transfer adr dividends bank deposits dividends held corporation employee stock ownership plan esop dividends paid taxexempt corporations us state local tax rates qualified nonqualified dividends may vary would assessed addition federal tax rates communicated gsk annual report strategic report governance remuneration financial statements investor information shareholder information continued shareholder services contacts registrar companys registrar equiniti limited aspect house spencer road lancing bn da wwwshareviewcouk tel uk tel outside uk equiniti provides range services shareholders service offers participate dividend reinvestment plan alternative receiving cash dividends may choose drip election form downloaded drip reinvest dividends buy gsk shares wwwshareviewcouk requested telephoning equiniti dividend payment direct bank account currently receive dividends cheque post dividend bank mandate form bank mandate instead paid directly bank building downloaded wwwshareviewcouk society account quicker secure avoids risk requested telephoning equiniti cheque going astray dividend payment direct bank account instead waiting sterling cheque arrive post equiniti details service costs overseas shareholders convert dividend local currency send involved please contact equiniti direct local bank account service available countries worldwide electronic communications shareholders may elect receive electronic notifications register wwwshareviewcouk company communications including annual report dividend payments paid way bank mandate access electronic tax vouchers availability online voting general meetings time gsk mails hard copy shareholder documents receive email containing link document relevant website shareview portfolio service enables create free online portfolio view register wwwshareviewcouk share balance movements update address dividend payment instructions register votes agm duplicate publications mailings receive duplicate copies report mailings please contact equiniti please contact equiniti arrange accounts merged one convenience avoid waste unnecessary costs share dealing service shareholders may trade shares either held certificated form internet transactions please log please note market trading hours held corporate sponsored nominee internet telephone wwwshareviewcoukdealing pm uk time postal dealing service provided equiniti financial monday friday excluding public holidays services limited telephone transactions please england wales call uk outside uk postal transactions please call request dealing form corporate sponsored nominee account convenient way manage shares without requiring application form requested share certificate service provides facility hold wwwshareviewcouk shares nominee company sponsored company telephoning equiniti continue receive dividend payments annual reports attend vote companys general meetings shareholders names appear publicly available share register service free join individual savings accounts isas company arranged equiniti financial services limited details available provide gsk corporate isa hold gsk ordinary shares wwwshareviewcouk requested telephoning equiniti lines open pm dealing pm enquiries monday friday excluding public holidays england wales uk lines open pm monday friday excluding public holidays england wales provision share dealing details intended invitation inducement engage investment activity advice share dealing obtained stockbroker independent financial advisergsk annual report strategic report governance remuneration financial statements investor information adr depositary contacts investor relations adr programme administered bank new york mellon investor relations may contacted follows uk bny mellon shareowner services great west road po box brentford middlesex tw gs college station tx tel overnight correspondence sent us bny mellon shareowner services crescent drive quality circle suite philadelphia pa college station tx tel us toll free wwwmybnymdrcom tel outside us tel us toll free tel outside us gsk response center email shrrelationscpushareownerservicescom tel us toll free depositary also provides global buydirect direct ads share scam alert purchasesale dividend reinvestment plan adr holders receive unsolicited telephone call offering sell buy details enrol please visit wwwmybnymdrcom shares please take extra care caller may part call helpline number obtain enrolment pack highly organised financial scam glaxo wellcome smithkline beecham uk shareholder please contact financial conduct corporate peps authority information similar activities share centre limited wwwfcaorgukconsumers consumer helpline oxford house oxford road aylesbury bucks hp sz tel uk tel tel outside uk wwwsharecom lines open pm uk time monday friday except uk public holidays donating shares save children pm saturdays gsk embarked ambitious global partnership save children share expertise resources responsible business supplement aim helping save lives one million children publishing responsible business supplement online outline gsks approach performance shareholders small number shares value key responsible business areas health behaviour makes uneconomical sell may wish consider donating people planet save children donated shares aggregated sold save children use funds raised help reach goal obtain share donation form please contact registrar equiniti managing donation sale uk shares save children free charge provision share dealing details intended invitation inducement engage investment activity advice share dealing obtained stockbroker independent financial adviser gsk annual report strategic report governance remuneration financial statements investor information statutory disclosures us law regulation disclosed annual report form f changes internal controls financial reporting number provisions us law regulation apply period covered annual report form f company shares quoted new york stock materially affected reasonably likely affect materially exchange nyse form adss companys internal control financial reporting nyse rules disclosed based recent evaluation internal general nyse rules permit company follow uk control financial reporting external auditors corporate governance practices instead applied arc significant deficiencies material weaknesses us provided explain significant variations design operation internal controls financial reporting explanation contained form f accessed reasonably likely affect adversely companys securities exchange commissions sec edgar ability record process summarise report financial database via website nyse rules came effect information fraud regardless materiality involving require us file annual interim written affirmations persons significant role companys internal concerning audit risk committee statement control financial reporting significant differences corporate governance group carried evaluation supervision sarbanesoxley act participation management including ceo following number corporate accounting scandals cfo effectiveness design operation us congress passed sarbanesoxley act groups disclosure controls procedures sarbanesoxley wideranging piece legislation concerned december largely financial reporting corporate governance inherent limitations effectiveness system recommended sec company established disclosure controls procedures including possibility disclosure committee committee reports ceo human error circumvention overriding controls cfo audit risk committee chaired procedures accordingly even effective disclosure controls company secretary members consist senior managers procedures provide reasonable assurance finance legal corporate communications investor achieving control objectives relations ceo cfo expect complete certifications external legal counsel external auditors internal experts report conclusions effectiveness disclosure controls invited attend meetings periodically responsibility procedures march following certificates considering materiality information timely basis filed sec part groups form f determining disclosure information responsibility section managements annual report internal control timely filing reports sec formal review financial reporting annual report form f committee met accordance requirements section sarbanes times oxley following report provided management respect sarbanesoxley requires annual report form f companys internal control financial reporting contain statement whether member audit risk defined rules af df us securities committee arc audit committee financial expert defined exchange act sarbanesoxley statement relevant management responsible establishing maintaining members arc stacey cartwright judy lewent adequate internal control financial reporting group included audit risk committee report internal control financial reporting designed provide biographies additional disclosure reasonable assurance regarding reliability financial requirements arise section section reporting preparation financial statements external sarbanesoxley respect disclosure controls procedures purposes accordance ifrs internal control financial reporting management conducted evaluation effectiveness section corporate responsibility financial reports internal control financial reporting based framework sarbanesoxley also introduced requirement ceo internal control integrated framework issued cfo complete formal certifications confirming committee sponsoring organisations treadway reviewed annual report form f commission coso based knowledge annual report form f changes groups internal control contains material misstatements omissions financial reporting materially affected reasonably likely affect materially groups internal based knowledge financial statements control financial reporting financial information fairly present material respects financial condition results operations cash flows management assessed effectiveness internal control dates periods presented annual report financial reporting december form f conclusion filed part groups form f responsible establishing maintaining disclosure pricewaterhousecoopers llp audited consolidated controls procedures ensure material information financial statements group year ended december made known evaluated effectiveness also assessed effectiveness groups internal controls procedures yearend results control financial reporting auditing standard evaluation contained annual report form f public company accounting oversight board united states audit report filed groups form f responsible establishing maintaining internal control financial reporting provides reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principlesgsk annual report strategic report governance remuneration financial statements investor information section r us securities exchange act donations political organisations section r us securities exchange act political expenditure amended requires issuers make specific disclosure annual reports certain types dealings iran including effect january ensure consistent approach transactions dealings governmentowned entities well political contributions across group introduced global dealings entities sanctioned activities related policy stop voluntarily corporate political contributions terrorism proliferation weapons mass destruction even period january december group activities prohibited us law make political donations eu noneu organisations involve us persons group legal entity based iran export certain pharmaceutical vaccine notwithstanding introduction policy accordance products iran via sales nonus entities two privately held federal election campaign act us continue iranian distributors group also business via nonus support employeeoperated political action committee pac entities jurisdictions targeted sanctions laws including facilitates voluntary political donations eligible gsk syria crimea north korea sudan employees believe groups direct dealings pac controlled gsk decisions amounts iran require specific disclosure requirements recipients contributions made participating employees group limits sales iran north korea syria sudan cuba exercising legal right pool resources make essential medicines determined part using criteria set political contributions subject strict limitations world health organization group direct knowledge total us us identity distributors downstream customers iran donated political organisations gsk employee pac possible customers include entities agm may shareholders first authorised governmentowned hospitals pharmacies owned company make donations eu political organisations controlled directly indirectly iranian government incur eu political expenditure provisions political persons entities sanctioned connection terrorism parties elections referendums act proliferation activities group direct year authority since renewed annually knowledge distributors customers establish companies act requires companies continue obtain proportion gross revenue sales potentially attributable shareholder approval make donations eu entities affiliated iranian government parties sanctioned political organisations incur eu political expenditure disclosable activities result group reporting entire gross revenues nil net losses million however make intend make donations groups sales iran political parties independent election candidates make donations eu political organisations incur eu group also aware hospitals medical political expenditure facilities lebanon may affiliated controlled hezbollah designated united states terrorist definitions political donations political expenditure organisation group deal directly political organisations used legislation wide facilities sells distributors group also unable particular definition eu political organisations may extend identify certainty degree nature affiliation bodies concerned policy review law reform end customers hezbollah group unable representation business community special interest establish proportion gross revenue sales potentially groups concerned environment attributable reportable entities result group company subsidiaries might wish support result reporting entire gross revenues million net profits definitions may cover legitimate business activities million groups sales lebanon ordinary sense considered political donations political expenditure activities designed support political party independent election candidate authority board sought annually precautionary measure ensure company subsidiaries inadvertently breach legislation gsk annual report strategic report governance remuneration financial statements investor information statutory disclosures continued group companies accordance section companies act full list subsidiaries associates joint ventures joint arrangements country incorporation effective percentage equity owned december disclosed unless otherwise stated share capital disclosed comprises ordinary shares indirectly held glaxosmithkline plc subsidiary companies resident tax purposes country incorporation unless otherwise stated country effective held name incorporation ownership security class share wholly owned subsidiaries alberta ulc canada common action potential venture capital limited england wales ordinary adechsa gmbh switzerland ordinary affymax research institute united states common alenfarma especialidades farmaceuticas limitada iv portugal ordinary quota allen hanburys limited iv england wales ordinary allen hanburys pharmaceutical nigeria limited nigeria ordinary allen farmaceutica sa spain ordinary allen pharmazeutika gesellschaft mbh austria ordinary aners sa iv argentina nonendorsable nominative ordinary barrier therapeutics inc united states common beecham group p l c england wales p shares ' ' p shares b beecham pharmaceuticals pte limited singapore ordinary beecham pharmaceuticals sa iv vi ecuador nominative beecham portuguesaprodutos farmaceuticos e quimicos lda portugal ordinary quota beecham sa iv belgium ordinary biddle sawyer limited india equity biovesta ilalari ltd sti turkey nominative burroughs wellcome co australia pty limited iv vi australia ordinary burroughs wellcome co bangladesh limited bangladesh ordinary burroughs wellcome international limited england wales ordinary caribbean chemical company ltd cayman islands ordinary struck cascan gmbh co kg germany ordinary castleton investment ltd vi mauritius ordinary cellzome gmbh germany ordinary cellzome limited england wales ordinary cellzome therapeutics inc iv united states ordinary cellzome inc united states ordinary series preferred series b preferred series c convertible preferred series c convertible preferred charles midgley limited iv england wales ordinary cumulative preference clarges pharmaceuticals limited england wales ordinary preference colleen corporation united states shares par value common corixa corporation united states common coulter pharmaceutical inc iv united states common dealcyber limited england wales ordinary desarrollo energia solar alternativa sl spain ordinary domantis limited england wales ordinary duncan flockhart australia pty limited iv vi australia ordinary duncan pharmaceuticals philippines inc philippines common edinburgh pharmaceutical industries limited scotland ordinary preference eskaylab limited england wales p ordinary etex farmaceutica ltda chile social capital europharm holding sa romania nominative europharm sa romania nominative fedialis medica sas france ordinary fipar thailand ltd liquidation thailand ordinary genelabs technologies inc united states common glaxo iv norway ordinary glaxo group limited england wales ordinary glaxo kabushiki kaisha iv japan ordinary gsk annual report strategic report governance remuneration financial statements investor information group companies continued country effective held name incorporation ownership security class share wholly owned subsidiaries continued glaxo laboratories nigeria limited iv nigeria ordinary glaxo laboratories limited iv england wales ordinary glaxo operations uk limited england wales ordinary glaxo properties bv netherlands ordinary glaxo verwaltungs gmbh vi germany ordinary glaxo wellcome australia pty ltd iv vi australia ordinary glaxo wellcome ceylon limited sri lanka ordinary ordinary b glaxo wellcome farmaceutica limitada portugal ordinary quota glaxo wellcome holdings limited liquidation england wales ordinary glaxo wellcome international bv v netherlands ordinary glaxo wellcome manufacturing pte ltd singapore ordinary glaxo wellcome production sas france ordinary glaxo wellcome pst pty ltd iv vi australia ordinary glaxo wellcome uk limited england wales ordinary glaxo wellcome vidhyasom limited iv thailand ordinary glaxo wellcome sa spain ordinary glaxo sa spain ordinary glaxoallenburys nigeria limited iv nigeria ordinary glaxochem uk unlimited england wales ordinary ordinary b ordinary c glaxochem pte ltd v singapore ordinary glaxosmithkline produtos farmaceuticos limitada portugal ordinary quota glaxosmithkline cambodia co ltd cambodia ordinary glaxosmithkline china investment co ltd china ordinary glaxosmithkline china rd company limited china equity glaxosmithkline cyprus limited cyprus ordinary glaxosmithkline gsk srl romania ordinary glaxosmithkline ireland limited ii ireland ordinary glaxosmithkline israel ltd israel ordinary glaxosmithkline malta limited malta ordinary glaxosmithkline private limited iv zimbabwe ordinary glaxosmithkline thailand limited thailand ordinary glaxosmithkline aebe greece ordinary glaxosmithkline ab sweden ordinary glaxosmithkline ag switzerland ordinary glaxosmithkline algrie spa algeria ordinary glaxosmithkline argentina sa argentina ordinary glaxosmithkline norway ordinary glaxosmithkline asia pvt limited india equity glaxosmithkline australia pty ltd australia ordinary glaxosmithkline bv netherlands ordinary glaxosmithkline beteiligungs gmbh germany ordinary glaxosmithkline biologicals shanghai ltd china ordinary glaxosmithkline biologicals shenzhen co ltd iv china ordinary glaxosmithkline biologicals kft hungary ordinary glaxosmithkline biologicals sas france ordinary glaxosmithkline biologicals sa belgium ordinary preference glaxosmithkline brasil limitada brazil ordinary glaxosmithkline business services sa iv vi costa rica ordinary glaxosmithkline capital inc united states ordinary glaxosmithkline capital plc england wales ordinary glaxosmithkline caribbean limited england wales ordinary glaxosmithkline chile farmaceutica limitada chile social capital glaxosmithkline colombia sa colombia ordinary glaxosmithkline consumer healthcare investments ireland ordinary ireland limited ii v glaxosmithkline consumer healthcare ireland ip limited ii v ireland ordinary glaxosmithkline consumer healthcare pakistan limited pakistan ordinary glaxosmithkline consumer healthcare sri lanka england wales ordinary holdings limited iv glaxosmithkline consumer holding bv netherlands ordinary glaxosmithkline doo bosnia euro quota herzegovina gsk annual report strategic report governance remuneration financial statements investor information statutory disclosures continued group companies continued country effective held name incorporation ownership security class share wholly owned subsidiaries continued glaxosmithkline doo croatia equity glaxosmithkline doo beograd serbia ordinary glaxosmithkline ecuador sa ecuador ordinary glaxosmithkline eesti ou estonia ordinary glaxosmithkline ehf iceland ordinary glaxosmithkline el salvador sa de cv el salvador ordinary glaxosmithkline eood bulgaria ordinary glaxosmithkline export limited england wales ordinary glaxosmithkline export panama sa panama ordinary glaxosmithkline far east bv netherlands ordinary glaxosmithkline finance plc england wales ordinary glaxosmithkline gmbh co kg germany partnership capital glaxosmithkline guatemala sa guatemala ordinary glaxosmithkline holding norway ordinary glaxosmithkline holdings americas inc united states common glaxosmithkline holdings ireland limited england wales ordinary deferred glaxosmithkline holdings one limited england wales ordinary glaxosmithkline holdings limited england wales ordinary glaxosmithkline holdings pty ltd australia ordinary glaxosmithkline honduras sa honduras ordinary glaxosmithkline ihc limited england wales ordinary glaxosmithkline ilaclari sanayi ticaret turkey nominative glaxosmithkline inc canada class common class c preference glaxosmithkline insurance ltd bermuda ordinary glaxosmithkline intellectual property limited england wales ordinary glaxosmithkline intellectual property development limited england wales ordinary glaxosmithkline intellectual property holdings limited england wales ordinary b ordinary glaxosmithkline intellectual property limited england wales ordinary deferred glaxosmithkline intellectual property management limited england wales ordinary glaxosmithkline international limited england wales ordinary glaxosmithkline investigacin desarrollo sl spain ordinary glaxosmithkline investment holdings limited england wales ordinary glaxosmithkline investment services limited england wales ordinary glaxosmithkline investments ireland limited ii v ireland ordinary glaxosmithkline investments pty ltd australia ordinary glaxosmithkline kk japan ordinary glaxosmithkline korea limited south korea ordinary glaxosmithkline latin america sa panama ordinary glaxosmithkline latvia sia latvia ordinary glaxosmithkline lietuva uab lithuania ordinary glaxosmithkline limited hong kong ordinary glaxosmithkline llc united states llc interests glaxosmithkline manufacturing spa italy ordinary glaxosmithkline maroc sa morocco ordinary glaxosmithkline medical healthcare products limited hungary ordinary quotas glaxosmithkline mercury limited england wales ordinary glaxosmithkline mexico sa de cv mexico ordinary ordinary b glaxosmithkline nz limited new zealand ordinary glaxosmithkline oy finland ordinary glaxosmithkline peru sa peru ordinary glaxosmithkline pharma denmark class glaxosmithkline pharma gmbh austria ordinary glaxosmithkline pharmaceutical kenya limited kenya ordinary glaxosmithkline pharmaceutical nigeria limited nigeria ordinary glaxosmithkline pharmaceutical sdn bhd malaysia ordinary glaxosmithkline pharmaceuticals pvt ltd iv sri lanka ordinary glaxosmithkline pharmaceuticals suzhou limited china ordinary glaxosmithkline pharmaceuticals costa rica sa costa rica ordinary glaxosmithkline pharmaceuticals sa poland ordinary ordinary b ordinary c ordinary gsk annual report strategic report governance remuneration financial statements investor information group companies continued country effective held name incorporation ownership security class share wholly owned subsidiaries continued glaxosmithkline pharmaceuticals sa belgium ordinary glaxosmithkline pharmaceuticals ukraine llc ukraine chartered capital glaxosmithkline philippines inc philippines common glaxosmithkline pte ltd singapore ordinary glaxosmithkline puerto rico inc iv puerto rico common glaxosmithkline republica dominicana sa dominican republic ordinary glaxosmithkline research development limited england wales ordinary glaxosmithkline sa spain ordinary glaxosmithkline spa italy ordinary glaxosmithkline sro czech republic ordinary glaxosmithkline services gmbh co kg vi germany partnership capital glaxosmithkline services inc iv united states common glaxosmithkline services unlimited england wales ordinary glaxosmithkline sl holdings llc united states llc interests glaxosmithkline sl llc united states llc interests glaxosmithkline sl lp iv england wales partnership glaxosmithkline slovakia sro slovakia ordinary glaxosmithkline south africa pty limited south africa ordinary glaxosmithkline superannuation company pty ltd iv vi australia ordinary glaxosmithkline trading services limited ii v ireland ordinary glaxosmithkline trading zao russia ordinary glaxosmithkline tunisia sarl tunisia ordinary glaxosmithkline uk limited england wales ordinary glaxosmithkline uruguay sa uruguay registered shares provisory stock glaxosmithkline venezuela ca venezuela ordinary glaxosmithkline vietnam limited liability company iv vietnam equity capital glycovaxyn ag iv vi switzerland common preferred preferred b preferred c group laboratories south africa pty limited iv vi south africa ordinary groupe glaxosmithkline sas france ordinary gsk business service centre sdn bhd malaysia ordinary gsk commercial sp z oo poland ordinary gsk doo ljubljana slovenia ordinary gsk employee share plan pty ltd australia ordinary gsk kazakhstan llp kazakhstan partnership interest gsk services sp z oo poland ordinary gsk vaccines gmbh germany ordinary gsk vaccines institute global health srl italy quota gsk vaccines srl italy quota gsk vaccines vertriebs gmbh germany ordinary herbridge ii iv vi ireland ordinary hgs france sarl france ordinary hgs luxembourg llc iv vi united states common interests horlicks limited england wales ordinary human genome sciences pacific pty ltd vi australia ordinary human genome sciences inc united states common id biomedical corporation quebec canada common id biomedical corporation washington iv united states common instituto luso farmaco limitada iv portugal ordinary quota interpharma dienstleistungen gmbh austria quota jj technologies lc iv united states membership interest laboratoire glaxosmithkline france ordinary laboratoire pharmaceutique algrien lpa production spa algeria ordinary laboratoire pharmaceutique algrien spa algeria ordinary laboratoires paucourt iv france ordinary laboratoires saintgermain iv france ordinary laboratorios dermatologicos darier sa de cv mexico ordinary ordinary b laboratorios farmaceuticos stiefel portugal ltda iv portugal ordinary quota laboratorios phoenix sociedad anonima industrial argentina nonendorsable nominative comercial financiera ordinary shares laboratorios stiefel de chile cia ltda chile social capital laboratorios stiefel de venezuela sa venezuela ordinary gsk annual report strategic report governance remuneration financial statements investor information statutory disclosures continued group companies continued country effective held name incorporation ownership security class share wholly owned subsidiaries continued laboratorios stiefel ltda brazil ordinary laboratorios wellcome de portugal limitada iv portugal ordinary quota laboratorios wellcome sa liquidation uruguay ordinary maxinutrition limited liquidation england wales ordinary mixis genetics limited england wales ordinary ordinary euro montrose fine chemical company ltd scotland ordinary montrose pharma company limited hungary ordinary quota montrose pharma uab iv lithuania ordinary nanjing meirui pharma co ltd china ordinary novartis vaccines diagnostics ag vi switzerland ordinary novartis vaccines diagnostics pty ltd australia ordinary novartis vaccines diagnostics sl vi spain ordinary okairos ag iv vi switzerland common preferred preferred b penn labs inc iv united states common sr one international bv netherlands ordinary sr one limited united states units common setfirst limited england wales ordinary smith kline french laboratories limited england wales ordinary smith kline french portuguesaprodutos portugal ordinary quota farmaceuticos lda iv smithkline beecham australia pty ltd iv vi australia ordinary smithkline beecham bangladesh private limited iv bangladesh ordinary smithkline beecham cork limited ii ireland ordinary smithkline beecham export limited england wales ordinary smithkline beecham h limited england wales noncumulative nonredeemable ordinary smithkline beecham investments limited england wales ordinary smithkline beecham manufacturing limited ii ireland ordinary smithkline beecham swg limited england wales ordinary smithkline beecham animal health company canada common smithkline beecham biologicals us partnership united states partnership interests smithkline beecham egypt llc egypt quotas smithkline beecham farma sa spain ordinary smithkline beecham holdings australia pty limited iv vi australia ordinary ordinary b smithkline beecham interamerican corporation iv united states shares par value common smithkline beecham limited england wales ordinary p smithkline beecham marketing technical services limited england wales ordinary smithkline beecham nominees limited england wales ordinary smithkline beecham overseas limited england wales ordinary smithkline beecham pension plan trustee limited iv england wales ordinary smithkline beecham pension trustees limited iv england wales ordinary smithkline beecham pharma gmbh co kg germany partnership capital smithkline beecham pharma verwaltungs gmbh germany ordinary smithkline beecham pharmaceuticals pty limited iv vi south africa ordinary smithkline beecham pharmaceuticals co united states shares par value common smithkline beecham port louis limited vi mauritius ordinary smithkline beecham retirement plan nominees australia ordinary pty limited iv vi smithkline beecham senior executive pension plan england wales ordinary trustee limited iv stiefel distributors ireland limited ii iv ireland ordinary stiefel dominicana srl iv dominican republic ordinary quotas stiefel farma sa spain ordinary stiefel gmbh co kg germany partnership capital stiefel india private limited india equity stiefel laboratories ireland limited ii ireland ordinary stiefel laboratories maidenhead ltd england wales ordinary stiefel laboratories thailand ltd liquidated jan thailand ordinary preference stiefel laboratories uk ltd england wales ordinary stiefel laboratories limited iv england wales ordinary gsk annual report strategic report governance remuneration financial statements investor information group companies continued country effective held name incorporation ownership security class share wholly owned subsidiaries continued stiefel laboratories pte limited singapore ordinary stiefel laboratories pty ltd iv vi australia ordinary stiefel laboratories sa pty ltd iv vi south africa ordinary stiefel laboratories taiwan ltd liquidated jan taiwan ordinary stiefel laboratories inc united states common stiefel maroc sarl morocco ordinary stiefel polska sp z oo w likwidacji liquidation poland ordinary stiefel research australia holdings pty ltd iv australia ordinary stiefel research australia pty ltd australia ordinary stiefel research institute inc vi united states common stiefel sales inc iv vi united states common stiefel west coast llc united states llc interests strebor inc united states usd par value common tempero pharmaceuticals inc united states series preference series b preference common sydney ross co iv united states ordinary wellcome foundation limited england wales ordinary ucb pharma thailand ltd liquidated jan thailand ordinary ucb pharma asia pacific sdn bhd iv malaysia ordinary webderm inc iv vi united states common wellcome consumer healthcare limited iv england wales ordinary wellcome consumer products limited iv england wales ordinary wellcome developments pty ltd iv vi australia ordinary wellcome limited england wales ordinary wellcome operations pty ltd iv vi australia ordinary subsidiaries effective interest less amoun pharmaceutical industries co sae egypt new monetary shares beecham enterprises inc iv united states common block drug company inc united states common british pharma group limited england wales capital block drug corporation iv united states common par value de micln slovakia ordinary duncan consumer healthcare philippines inc philippines common exlax inc puerto rico common fondation novartis consumer health pour i'avancement switzerland capital des sciences medicales biologiques et pharmaceutiques glaxo saudi arabia limited saudi arabia ordinary glaxosmithkline tianjin co ltd china ordinary glaxosmithkline bangladesh limited bangladesh ordinary glaxosmithkline brasil produtos para consumo e saude ltda brazil ordinary glaxosmithkline consumer healthcare china co ltd china ordinary glaxosmithkline consumer healthcare hong kong limited hong kong ordinary glaxosmithkline consumer healthcare ireland limited ii ireland ordinary glaxosmithkline consumer healthcare overseas limited england wales ordinary glaxosmithkline consumer healthcare thailand limited thailand ordinary glaxosmithkline consumer healthcare uk ip limited england wales ordinary glaxosmithkline consumer healthcare uk trading limited england wales ordinary glaxosmithkline consumer healthcare us ip llc united states llc interests glaxosmithkline consumer healthcare denmark ordinary glaxosmithkline consumer healthcare ab sweden ordinary glaxosmithkline consumer healthcare ag switzerland ordinary glaxosmithkline consumer healthcare argentina sa iv argentina nominative non endorseable ordinary glaxosmithkline consumer healthcare australia pty ltd australia ordinary glaxosmithkline consumer healthcare bv netherlands ordinary glaxosmithkline consumer healthcare canada corp canada common glaxosmithkline consumer healthcare colombia sas colombia ordinary glaxosmithkline consumer healthcare czech republic sro czech republic ordinary glaxosmithkline consumer healthcare finance limited england wales ordinary glaxosmithkline consumer healthcare finland oy finland ordinary glaxosmithkline consumer healthcare gmbh austria ordinary glaxosmithkline consumer healthcare gmbh co kg germany partnership capital gsk annual report strategic report governance remuneration financial statements investor information statutory disclosures continued group companies continued country effective held name incorporation ownership security class share subsidiaries effective interest less continued glaxosmithkline consumer healthcare greece societe greece ordinary anonyme glaxosmithkline consumer healthcare holdings us llc united states llc interests glaxosmithkline consumer healthcare holdings limited england wales ordinary ordinary b glaxosmithkline consumer healthcare inc canada common preferred glaxosmithkline consumer healthcare investments ireland ordinary ireland ii v glaxosmithkline consumer healthcare investments ireland ordinary ireland limited ii v glaxosmithkline consumer healthcare japan kk japan ordinary glaxosmithkline consumer healthcare korea co ltd korea ordinary glaxosmithkline consumer healthcare llc united states llc interests glaxosmithkline consumer healthcare limited india equity glaxosmithkline consumer healthcare mexico de rl de cv mexico ordinary glaxosmithkline consumer healthcare new zealand limited new zealand ordinary glaxosmithkline consumer healthcare norway norway ordinary glaxosmithkline consumer healthcare philippines inc philippines common glaxosmithkline consumer healthcare pte ltd singapore ordinary glaxosmithkline consumer healthcare sa belgium ordinary glaxosmithkline consumer healthcare sa spain ordinary glaxosmithkline consumer healthcare spa italy ordinary glaxosmithkline consumer healthcare sdn bhd malaysia ordinary glaxosmithkline consumer healthcare slovakia r slovakia ownership interest glaxosmithkline consumer healthcare south africa pty ltd south africa ordinary glaxosmithkline consumer healthcare spzoo poland common glaxosmithkline consumer healthcare srl romania ordinary glaxosmithkline consumer healthcare lp united states partnership interest glaxosmithkline consumer healthcare produtos para portugal ordinary quota saude e higiene lda glaxosmithkline consumer nigeria plc iii nigeria ordinary glaxosmithkline consumer private limited india equity glaxosmithkline consumer trading services limited england wales ordinary glaxosmithkline costa rica sa costa rica ordinary glaxosmithkline dungarvan limited ii ireland ordinary glaxosmithkline healthcare ao russia ordinary glaxosmithkline healthcare gmbh germany ordinary glaxosmithkline healthcare ukraine ooo ukraine ownership interest glaxosmithkline landholding company inc philippines common glaxosmithkline limited kenya ordinary glaxosmithkline otc pvt limited pakistan ordinary glaxosmithkline pakistan limited pakistan ordinary glaxosmithkline panama sa panama ordinary glaxosmithkline paraguay sa paraguay ordinary glaxosmithkline pharmaceuticals limited india equity glaxosmithkline sae egypt ordinary glaxosmithkline sante grand public sas france ordinary glaxosmithkline tuketici sagligi anonim sirketi turkey nominative glaxosmithklineconsumer hungary limited liability company hungary membership gsk consumer healthcare singapore pte ltd singapore ordinary iodosan spa italy ordinary kuhs gmbh germany equity laboratorios viiv healthcare sl spain ordinary modern pharma trading company llc egypt quotas novartis consumer health australasia pty ltd australia ordinary redeemable preference novartis consumer health canada incnovartis sante canada common familiale canada inc novartis consumer health gmbh germany ordinary novartis consumer health llc russia participation interest gsk annual report strategic report governance remuneration financial statements investor information group companies continued country effective held name incorporation ownership security class share subsidiaries effective interest less continued novartis consumer health nv belgium ordinary novartis consumer health sa spain ordinary novartis consumer health sa switzerland ordinary novartis consumer health schweiz ag switzerland ordinary novartis consumer health services sa switzerland registered shares novartis consumer health uk limited england wales ordinary novartis consumer health inc united states common novartis consumer healthgebro gmbh austria ordinary novartis sante familiale sas liquidation france ordinary pt smithkline beecham pharmaceuticals indonesia shares b shares pt sterling products indonesia indonesia shares b shares panadol gmbh germany ordinary phivco jersey ii limited iv v jersey ordinary phivco jersey limited iv v jersey ordinary phivco uk ii limited england wales ordinary phivco uk limited england wales ordinary phivco llc united states llc interests phivco llc united states llc interests pt glaxo wellcome indonesia indonesia shares b shares pt bina dentalindo liquidation indonesia ordinary shionogiviiv healthcare llc iv united states common interests sinoamerican tianjin smith kline french laboratories ltd china ordinary smithkline beecham private limited sri lanka ordinary smithkline beecham research limited england wales ordinary smithkline beecham sa spain ordinary smithkline beechambiomed ooo russia participation interest staffordmiller ireland limited ii ireland ordinary staffordmiller limited england wales ordinary noncumulative non redeemable preference sterling drug malaya sdn berhad malaysia ordinary sterling products international incorporated iv united states common stiefel consumer healthcare uk limited england wales ordinary stiefel egypt llc iv egypt quota stiefel manufacturing ireland limited ii ireland ordinary viiv healthcare south africa proprietary limited south africa ordinary viiv healthcare bv netherlands ordinary viiv healthcare company united states common viiv healthcare finance limited iv england wales ordinary viiv healthcare finance limited iv england wales ordinary viiv healthcare gmbh germany ordinary viiv healthcare gmbh switzerland ordinary viiv healthcare kabushiki kaisha japan ordinary viiv healthcare limited england wales class shares class b shares class c shares class preference class ordinary viiv healthcare overseas limited england wales ordinary viiv healthcare pty ltd australia ordinary viiv healthcare puerto rico llc puerto rico llc interests viiv healthcare srl italy quota viiv healthcare sas france ordinary viiv healthcare sprl belgium ordinary viiv healthcare trading llc russia participation interest viiv healthcare trading services uk limited england wales ordinary viiv healthcare uk limited v jersey ordinary viiv healthcare uk limited england wales ordinary viiv healthcare uk limited iv england wales ordinary viiv healthcare uk limited england wales ordinary gsk annual report strategic report governance remuneration financial statements investor information statutory disclosures continued group companies continued country effective held name incorporation ownership security class share subsidiaries effective interest less continued viiv healthcare ulc canada common viiv healthcare venture llc united states llc interests viiv hiv healthcare unipessoal lda portugal quota winster pharmaceuticals limited nigeria ordinary zhejiang tianyuan biopharmaceutical co ltd china ordinary associates calci medica inc united states series junior preferred index ventures life vi jersey lp united states partnership interest theravance inc innoviva inc united states common jcr pharmaceuticals co ltd japan common kurma biofund ii fcpr france partnership interest longwood founders fund lp united states partnership interest river vision development corp united states series preferred joint ventures chiron panacea vaccines private ltd liquidation india japan vaccine co ltd japan japan vaccine distribution co ltd japan qualivax pte limited singapore qura therapeutics llc united states key directly owned glaxosmithkline plc ii exempt provisions section companies act ireland accordance exemptions noted section act iii c onsolidated subsidiary accordance section companies act grounds dominant influence iv dormant company v tax resident uk vi entity expected disposed removed gsk annual report strategic report governance remuneration financial statements investor information glossary terms terms used annual report us equivalent brief description accelerated capital allowances ax allowance excess depreciation arising purchase fixed assets delay charging payment tax equivalent tax depreciation american depositary receipt adr r eceipt evidencing title ads gsk adr represents two ordinary shares american depositary shares ads listed new york stock exchange represents two ordinary shares basic earnings per share basic income per share called share capital ordinary shares issued fully paid cer growth growth constant exchange rates company glaxosmithkline plc corporate integrity agreement cia n company entered settlement us federal government related past sales marketing practices part settlement company entered corporate integrity agreement us department health human services improvements built existing compliance programmes currency swap exchange two currencies coupled subsequent reexchange currencies agreed exchange rates dates defined benefit plan pension plan specific employee benefits often called final salary scheme defined contribution plan p ension plan specific contributions level pension dependent upon growth pension fund derivative financial instrument financial instrument derives value price rate underlying item diluted earnings per share diluted income per share employee share ownership plan trusts trusts established group satisfy sharebased employee incentive plans equity shareholders funds shareholders equity finance lease capital lease freehold ownership absolute rights perpetuity group glaxosmithkline plc subsidiary undertakings gsk glaxosmithkline plc subsidiary undertakings hedging reduction risk normally relation foreign currency interest rate movements making offsetting commitments intangible fixed assets ssets without physical substance computer software brands licences patents knowhow marketing rights purchased outside parties novartis transaction threepart interconditional transaction novartis ag involving consumer healthcare vaccines oncology businesses completed march ordinary share fully paid ordinary share capital company profit income profit attributable shareholders net income share capital ordinary shares capital stock common stock issued fully paid share option stock option share premium account additional paidup capital paidin surplus distributable shares issue number shares outstanding subsidiary entity gsk exercises control treasury share treasury stock turnover revenue uk corporate governance code required uk listing authority company disclosed annual report applied best practice corporate governance provisions financial reporting councils uk corporate governance code gsk annual report strategic report governance remuneration financial statements investor information index accountability longterm incentive awards accounting principles policies major restructuring costs acquisitions disposals movements equity adjustments reconciling profit tax operating net debt cash flows new accounting requirements annual general meeting noncontrolling interests assets held sale noncontrolling interests viiv healthcare associates joint ventures nonexecutive directors fees board governance notes financial statements cash cash equivalents operating profit ceos statement intangible assets chairmans statement investments commitments noncurrent assets committee reports noncurrent liabilities competition operating income consolidated balance sheet provisions consolidated cash flow statement approach risk consolidated income statement behaviour consolidated statement changes equity board consolidated statement comprehensive income business consumer healthcare global marketplace consumer healthcare products competition people contingent liabilities planet corporate executive team strategy priorities corporate governance overview total pay critical accounting policies pensions postemployment benefits directors senior management pharmaceuticals directors interests shares pharmaceutical products competition directors statement responsibilities intellectual property dividends pipeline donations political organisations post balance sheet events political expenditure presentation financial statements earnings per share principal group companies employee costs property plant equipment employee share schemes quarterly trend exchange rates reconciliation net cash flow movement net debt executive director remuneration registrar finance expense related party transactions finance income relations shareholders financial instruments related disclosures remuneration governance financial position resources remuneration policy summary financial statements glaxosmithkline plc prepared remuneration report uk gaap research development five year record responsible business glossary terms risk factors goodwill segment information group companies share capital control group financial review share capital share premium account health share price independent auditors report shareholder information inventories taxation investments associates joint ventures tax information shareholders investor relations trade payables key accounting judgements estimates trade receivables key performance indicators us law regulation leadership effectiveness vaccines legal proceedings viability statement gsk glaxosmithkline plc incorporated cautionary statement regarding forwardlooking statements english public limited company december groups reports filed furnished us securities exchange commission sec including formed merger document written information released oral statements made public future behalf glaxo wellcome plc smithkline beecham group may contain forwardlooking statements forwardlooking statements give groups current plc gsk acquired two english companies expectations forecasts future events investor identify statements fact december part merger relate strictly historical current facts use words anticipate estimate expect intend arrangements project plan believe words terms similar meaning connection discussion future operating financial performance particular include statements relating future actions prospective shares listed london stock products product approvals future performance results current anticipated products sales efforts exchange new york stock exchange expenses outcome contingencies legal proceedings financial results accordance legal regulatory obligations including uk listing rules disclosure transparency read wwwgskcom rules financial conduct authority group undertakes obligation update forwardlooking statements whether result new information future events otherwise reader however consult additional disclosures group may make documents publishes andor files sec readers wherever located take note disclosures accordingly assurance given particular expectation met shareholders cautioned place undue reliance forward looking statements forwardlooking statements subject assumptions inherent risks uncertainties many relate factors beyond groups control precise estimate group cautions investors number important factors including document could cause actual results differ materially expressed implied forwardlooking statement factors include limited discussed risk find downloadable pdfs factors pages annual report forwardlooking statements made behalf annual report group speak date made based upon knowledge information available form f directors date annual report number adjusted measures used report responsible business supplement performance business measures defined reconciliation core results total results set information document constitute offer sell invitation buy shares glaxosmithkline plc invitation inducement engage investment activities past performance relied upon guide future performance nothing annual report construed profit forecast assumptions related outlook outlining expectations fiveyear period group made certain assumptions healthcare sector different markets group operates delivery revenues financial benefits current portfolio pipeline restructuring programmes group specifically period gsk brand names notice regarding limitations expects declines sales seretideadvair brand names appearing italics director liability english law introduction generic alternative advair us throughout report trade marks uk companies act safe harbour limits factored groups assessment future either owned andor licensed liability directors respect statements performance group assumes premature loss gsk associated companies omissions directors report see exclusivity key products period exception prolia owned amgen strategic report remuneration groups expectation least billion revenues per zofran owned novartis trumenba report english law directors would liable annum cer basis products launched mencevax owned pfizer treximet company third party one last three years includes contributions current owned pernix ireland lucozade reports contained errors result recklessness pipeline asset shingrix target expected ribena owned suntory nimenrix knowing misstatement dishonest concealment met two years earlier group also expects volume trade mark gsk licensed pfizer material fact would otherwise liable pages demand products increase particularly emerging inclusive comprise markets acknowledgements directors report pages inclusive comprise printing strategic report pages inclusive comprise assumptions groups revenue earnings printed pureprint group iso remuneration report drawn expectations assume material mergers acquisitions fsc certified carbon neutral presented accordance reliance upon disposals litigation costs share repurchases english company law liabilities directors company change groups shareholdings paper connection reports shall subject viiv healthcare consumer healthcare also assume annual report printed limitations restrictions provided law material changes macroeconomic healthcare environment amadeus silk recycled paper full fsc certification pulps website groups expectations assume successful delivery used made deinked gsks website wwwgskcom gives additional information groups integration restructuring plans period postconsumer waste elemental group notwithstanding references make material costs investment new product chlorine free manufacturing mill annual report gsks website none launches rd factored expectations holds iso eu ecolabel information made available website constitutes part given expectations given constant currency certificates environmental annual report shall deemed incorporated basis assume material change groups management reference herein effective tax rate gsk annual report head office registered office wwwgskcom glaxosmithkline plc great west road brentford middlesex tw gs also search us united kingdom tel registered number